{"title":"Farmaci da Banco e Senza Ricetta","description":"\u003ch2\u003eFarmaci da banco e senza obbligo di ricetta\u003c\/h2\u003e\u003cp\u003eIn questa sezione trovi i medicinali che in Italia si possono acquistare online: i farmaci da banco e quelli senza obbligo di ricetta. Ogni scheda riporta principi attivi, posologia, avvertenze e controindicazioni cosi' come sono scritti nel foglietto illustrativo.\u003c\/p\u003e\u003cp\u003eI medicinali che richiedono la ricetta medica non possono essere venduti online e non sono presenti sul sito. \u003cstrong\u003eLeggi sempre il foglietto illustrativo\u003c\/strong\u003e e rivolgiti al medico o al farmacista in caso di dubbio.\u003c\/p\u003e\u003cp\u003eSpedizione espressa in \u003cstrong\u003e24\/48 ore in Italia\u003c\/strong\u003e e \u003cstrong\u003e48\/72 ore in Europa\u003c\/strong\u003e. Per ogni dubbio puoi chiedere consiglio ai nostri farmacisti.\u003c\/p\u003e","products":[{"product_id":"tachipirina-antidolorifico-500-mg-20-compresse","title":"Tachipirina Painkiller 500 mg 20 Tablets","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAs an antipyretic: symptomatic treatment of febrile diseases such as influenza, exanthematous diseases, acute respiratory tract diseases, etc. As an analgesic: headaches, neuralgia, myalgia and other medium-level painful manifestations of various origins.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eTACHIPIRINA 500 mg tablets.\u003c\/i\u003e Each tablet contains: \u003cu\u003eactive ingredient: paracetamol 500 mg.\u003c\/u\u003e \u003ci\u003eTACHIPIRINA 500 mg effervescent granules.\u003c\/i\u003e Each sachet contains: \u003cu\u003eactive ingredient: paracetamol 500 mg.\u003c\/u\u003e \u003cu\u003eexcipients with known effects: aspartame, maltitol, 12.3 mmol sodium per sachet\u003c\/u\u003e \u003ci\u003eTACHIPIRINA 125 mg effervescent granules. \u003c\/i\u003e Each sachet contains: \u003cu\u003eactive ingredient: paracetamol 125 mg.\u003c\/u\u003e \u003cu\u003eexcipients with known effects: aspartame, maltitol, 3.07 mmol sodium per sachet\u003c\/u\u003e \u003ci\u003e \u003cu\u003eTACHIPIRINA Infants 62.5 mg suppositories.\u003c\/u\u003e \u003c\/i\u003e Each suppository contains. \u003cu\u003eactive ingredient: paracetamol 62.5 mg\u003c\/u\u003e \u003ci\u003e \u003cu\u003eTACHIPIRINA Early Childhood 125 mg suppositories.\u003c\/u\u003e \u003c\/i\u003e Each suppository contains: \u003cu\u003eactive ingredient: paracetamol 125 mg.\u003c\/u\u003e \u003ci\u003e \u003cu\u003eTACHIPIRINA Children 250 mg suppositories.\u003c\/u\u003e \u003c\/i\u003e Each suppository contains: \u003cu\u003eactive ingredient: paracetamol 250 mg.\u003c\/u\u003e \u003ci\u003e \u003cu\u003eTACHIPIRINA Children 500 mg suppositories.\u003c\/u\u003e \u003c\/i\u003e Each suppository contains: \u003cu\u003eactive ingredient: paracetamol 500 mg.\u003c\/u\u003e \u003ci\u003e \u003cu\u003eTACHIPIRINA Adults 1000 mg suppositories.\u003c\/u\u003e \u003c\/i\u003e Each suppository contains: \u003cu\u003eactive ingredient: paracetamol 1000 mg.\u003c\/u\u003e For the complete list of excipients, see par. 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e• \u003cu\u003eTablets:\u003c\/u\u003e microcrystalline cellulose, povidone, pregelatinized starch, stearic acid, croscarmellose sodium. • \u003cu\u003eEffervescent granules\u003c\/u\u003e: maltitol, mannitol, sodium bicarbonate, anhydrous citric acid, citrus flavouring, aspartame, sodium docusate. • \u003cu\u003eSuppositories\u003c\/u\u003e: solid semi-synthetic glycerides.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e• Hypersensitivity to paracetamol or to any of the excipients listed in section 6.1. • Patients suffering from severe hemolytic anemia (this contraindication does not refer to the 500mg oral formulations). • Severe hepatocellular insufficiency (this contraindication does not refer to the 500mg oral formulations).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eFor children it is essential to respect the dosage defined according to their body weight, and therefore choose the suitable formulation. Approximate ages based on body weight are indicated for information. In adults, the maximum oral dosage is 3000 mg and rectally 4000 mg of paracetamol per day (see section 4.9). The doctor must evaluate the need for treatments for more than 3 consecutive days. The dosage schedule of Tachipirina in relation to body weight and route of administration is as follows: \u003cb\u003e500 mg tablets.\u003c\/b\u003e • \u003cu\u003eChildren weighing between 21 and 25 kg\u003c\/u\u003e (approximately between 6.5 and less than 8 years): ½ tablet at a time, to be repeated if necessary after 4 hours, without exceeding 6 administrations per day (3 tablets). • \u003cu\u003eChildren weighing between 26 and 40 kg\u003c\/u\u003e (approximately between 8 and 11 years): 1 tablet at a time, to be repeated if necessary after 6 hours, without exceeding 4 doses per day. • \u003cu\u003eChildren weighing between 41 and 50 kg\u003c\/u\u003e (approximately between 12 and 15 years): 1 tablet at a time, to be repeated if necessary after 4 hours, without exceeding 6 doses per day. • \u003cu\u003eChildren weighing more than 50 kg\u003c\/u\u003e (approximately over 15 years): 1 tablet at a time, to be repeated if necessary after 4 hours, without exceeding 6 administrations per day. • \u003cu\u003eAdults\u003c\/u\u003e: 1 tablet at a time, to be repeated if necessary after 4 hours, without exceeding 6 doses per day. In case of severe pain or high fever, 2 tablets of 500 mg to be repeated if necessary after no less than 4 hours. \u003cb\u003e500 mg effervescent granules in sachets.\u003c\/b\u003e Dissolve the effervescent granules in a glass of water. • \u003cu\u003eChildren weighing between 26 and 40 kg\u003c\/u\u003e (approximately between 8 and 11 years): 1 sachet at a time, to be repeated if necessary after 6 hours, without exceeding 4 doses per day. • \u003cu\u003eChildren weighing between 41 and 50 kg\u003c\/u\u003e (approximately between 12 and 15 years): 1 sachet at a time, to be repeated if necessary after 4 hours, without exceeding 6 doses per day. • \u003cu\u003eChildren weighing more than 50 kg\u003c\/u\u003e (approximately over 15 years): 1 sachet at a time, to be repeated if necessary after 4 hours, without exceeding 6 administrations per day. • \u003cu\u003eAdults\u003c\/u\u003e: 1 sachet at a time, to be repeated if necessary after 4 hours, without exceeding 6 administrations per day. In case of severe pain or high fever, 2 sachets of 500 mg to be repeated if necessary after no less than 4 hours. \u003cb\u003e125 mg effervescent granules in sachets.\u003c\/b\u003e Dissolve the effervescent granules in a glass of water. • \u003cu\u003eChildren weighing between 7 and 10 kg\u003c\/u\u003e (approximately between 6 and 19 months): 1 sachet at a time, to be repeated if necessary after 6 hours, without exceeding 4 doses per day. • \u003cu\u003eChildren weighing between 11 and 12 kg\u003c\/u\u003e (approximately between 20 and 29 months): 1 sachet at a time, to be repeated if necessary after 4 hours, without exceeding 6 administrations per day. • \u003cu\u003eChildren weighing between 13 and 20 kg\u003c\/u\u003e (approximately between 30 months and less than 6.5 years): 2 sachets at a time (corresponding to 250 mg of paracetamol), to be repeated if necessary after 6 hours, without exceeding 4 administrations per day. • \u003cu\u003eChildren weighing between 21 and 25 kg\u003c\/u\u003e (approximately between 6.5 and less than 8 years): 2 sachets at a time (corresponding to 250 mg of paracetamol), to be repeated if necessary after 4 hours, without exceeding 6 administrations per day. \u003cb\u003e62.5 mg suppositories for newborns.\u003c\/b\u003e • \u003cu\u003eChildren weighing between 3.2 and 5 kg \u003c\/u\u003e(approximately between birth and 2 months): 1 suppository at a time, to be repeated if necessary after 6 hours, without exceeding 4 administrations per day. \u003cb\u003eEarly Childhood Suppositories 125 mg. \u003c\/b\u003e • \u003cu\u003eChildren weighing between 6 and 7 kg \u003c\/u\u003e(approximately between 3 and 5 months): 1 suppository at a time, to be repeated if necessary after 6 hours, without exceeding 4 administrations per day. • \u003cu\u003eChildren weighing between 7 and 10 kg\u003c\/u\u003e (approximately between 6 and 19 months): 1 suppository at a time, to be repeated if necessary after 4 - 6 hours, without exceeding 5 administrations per day. • \u003cu\u003eChildren weighing between 11 and 12 kg\u003c\/u\u003e (approximately between 20 and 29 months): 1 suppository at a time, to be repeated if necessary after 4 hours, without exceeding 6 administrations per day. \u003cb\u003eSuppositories Children 250 mg.\u003c\/b\u003e • \u003cu\u003eChildren weighing between 11 and 12 kg\u003c\/u\u003e (approximately between 20 and 29 months): 1 suppository at a time, to be repeated if necessary after 8 hours, without exceeding 3 doses per day. • \u003cu\u003eChildren weighing between 13 and 20 kg\u003c\/u\u003e (approximately between 30 months and less than 6.5 years): 1 suppository at a time, to be repeated if necessary after 6 hours, without exceeding 4 administrations per day. \u003cb\u003eSuppositories Children 500 mg.\u003c\/b\u003e • \u003cu\u003eChildren weighing between 21 and 25 kg\u003c\/u\u003e (approximately between 6.5 and less than 8 years): 1 suppository at a time, to be repeated if necessary after 8 hours, without exceeding 3 doses per day. • \u003cu\u003eChildren weighing between 26 and 40 kg\u003c\/u\u003e (approximately between 8 and 11 years): 1 suppository at a time, to be repeated if necessary after 6 hours, without exceeding 4 administrations per day. \u003cb\u003eSuppositories Adults of 1000 mg.\u003c\/b\u003e • \u003cu\u003eChildren weighing between 41 and 50 kg\u003c\/u\u003e (approximately between 12 and 15 years): 1 suppository at a time, to be repeated if necessary after 8 hours, without exceeding 3 doses per day. • \u003cu\u003eChildren weighing more than 50 kg\u003c\/u\u003e (approximately over 15 years): 1 suppository at a time, to be repeated if necessary after 6 hours, without exceeding 4 administrations per day. • \u003cu\u003eAdults\u003c\/u\u003e: 1 suppository at a time, to be repeated if necessary after 6 hours, without exceeding 4 doses per day. \u003ci\u003e \u003cu\u003eRenal failure.\u003c\/u\u003e \u003c\/i\u003e In case of severe renal insufficiency (creatinine clearance less than 10 ml\/min), the interval between administrations must be at least 8 hours.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eEffervescent tablets and granules\u003c\/u\u003e: no special precautions for storage. \u003cu\u003eSuppositories:\u003c\/u\u003e Store at a temperature not exceeding 25°C.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIn rare cases of allergic reactions, administration must be suspended and appropriate treatment instituted. Use with caution in cases of chronic alcoholism, excessive alcohol intake (3 or more alcoholic drinks per day), anorexia, bulimia or cachexia, chronic malnutrition (low hepatic glutathione reserves), dehydration, hypovolemia. Paracetamol should be administered with caution to patients with mild to moderate hepatocellular insufficiency (including Gilbert's syndrome), severe hepatic insufficiency (Child-Pugh\u003e9), acute hepatitis, in concomitant treatment with drugs that alter liver function, glucose-6-phosphate dehydrogenase deficiency, hemolytic anemia. High or prolonged doses of the product can cause even serious alterations to the kidney and blood, therefore administration to subjects with renal insufficiency must be carried out only if actually necessary and under direct medical supervision. In case of prolonged use it is advisable to monitor liver and kidney function and blood count. During treatment with paracetamol, before taking any other medicine, check that it does not contain the same active ingredient, since if paracetamol is taken in high doses, serious adverse reactions may occur. Invite the patient to contact the doctor before combining any other drug. See also par. 4.5. \u003cb\u003e \u003cu\u003eImportant information about some excipients.\u003c\/u\u003e \u003c\/b\u003e \u003cu\u003eTachipirina 125 mg effervescent granules contains\u003c\/u\u003e \u003cu\u003e:\u003c\/u\u003e - \u003cb\u003easpartame\u003c\/b\u003e, is a source of phenylalanine. It can be harmful in case of phenylketonuria (deficiency of the enzyme phenylalanine hydroxylase) due to the risk linked to the accumulation of the amino acid phenylalanine. - \u003cb\u003emaltitol\u003c\/b\u003e: use with caution in patients suffering from rare hereditary problems of fructose intolerance. 70.6 mg of \u003cb\u003esodium\u003c\/b\u003e per sachet equivalent to 3.53% of the maximum daily intake recommended by WHO which corresponds to 2 g of sodium for an adult: to be taken into consideration in people with reduced kidney function or who follow a low-sodium diet. \u003cu\u003eTachipirina 500 mg effervescent granules contains:\u003c\/u\u003e - \u003cb\u003easpartame\u003c\/b\u003e, is a source of phenylalanine. It can be harmful in case of phenylketonuria (deficiency of the enzyme phenylalanine hydroxylase) due to the risk linked to the accumulation of the amino acid phenylalanine. - \u003cb\u003emaltitol\u003c\/b\u003e: use with caution in patients suffering from rare hereditary problems of fructose intolerance. - 283 mg of \u003cb\u003esodium\u003c\/b\u003e per sachet equivalent to 14.1% of the WHO recommended maximum daily intake which corresponds to 2 g of sodium for an adult. The maximum dose for this product is equivalent to 84.6% of the maximum daily sodium intake recommended by the WHO: to be taken into consideration in people with reduced kidney function or who follow a low-sodium diet.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eOral absorption of paracetamol depends on the speed of gastric emptying. Therefore, concomitant administration of drugs that slow (e.g. anticholinergics, opioids) or increase (e.g. prokinetics) the rate of gastric emptying may result in a decrease or increase in the bioavailability of the product, respectively. Concomitant administration of cholestyramine reduces the absorption of paracetamol. The simultaneous intake of paracetamol and chloramphenicol can induce an increase in the half-life of chloramphenicol, with the risk of increasing its toxicity. The concomitant use of paracetamol (4 g per day for at least 4 days) with oral anticoagulants can induce slight variations in INR values. In these cases, more frequent monitoring of INR values ​​should be conducted during concomitant use and after its discontinuation. Use with extreme caution and under strict control during chronic treatment with drugs that can cause the induction of hepatic monooxygenases or in case of exposure to substances that can have this effect (for example rifampicin, cimetidine, antiepileptics such as glutetimide, phenobarbital, carbamazepine). The same applies in cases of alcoholism and in patients treated with zidovudine. The administration of paracetamol can interfere with the determination of uric acid (using the phosphotungstic acid method) and with that of blood sugar (using the glucose-oxidase-peroxidase method).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eBelow are the side effects of paracetamol organized according to the MedDRA systemic and organic classification. There is insufficient data to establish the frequency of the individual effects listed.\u003c\/p\u003e\n\u003cp\u003eBlood and lymphatic system disorders: Thrombocytopenia, leukopenia, anemia, agranulocytosis.\u003c\/p\u003e\n\u003cp\u003eImmune system disorders: Hypersensitivity reactions (urticaria, laryngeal edema, angioedema, anaphylactic shock).\u003c\/p\u003e\n\u003cp\u003eNervous system disorders: Dizziness.\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders: Gastrointestinal reaction.\u003c\/p\u003e\n\u003cp\u003eHepatobiliary disorders: Abnormal liver function, hepatitis.\u003c\/p\u003e\n\u003cp\u003eSkin and subcutaneous tissue disorders: Erythema multiforme, Stevens Johnson Syndrome, Epidermal necrolysis, rash.\u003c\/p\u003e\n\u003cp\u003eRenal and urinary disorders: Acute renal failure, interstitial nephritis, hematuria, anuria.\u003c\/p\u003e\n\u003cp\u003eVery rare cases of serious skin reactions have been reported. Reporting of suspected adverse reactions. Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eThere is a risk of intoxication, especially in patients with liver disease, in cases of chronic alcoholism, in patients suffering from chronic malnutrition, and in patients receiving enzyme inducers. In these cases, overdose can be fatal.\u003c\/u\u003e \u003cu\u003eSymptoms\u003c\/u\u003e In case of accidental intake of very high doses of paracetamol, acute intoxication manifests itself with anorexia, nausea and vomiting followed by a profound deterioration of the general conditions; these symptoms typically appear within the first 24 hours. In case of overdose, paracetamol can cause hepatic cytolysis which can progress to massive and irreversible necrosis, resulting in hepatocellular failure, metabolic acidosis and encephalopathy, which can lead to coma and death. Simultaneously, an increase in the levels of hepatic transaminases, lactic dehydrogenase, and bilirubin are observed, and a reduction in prothrombin levels, which can occur in the 12-48 hours following ingestion. \u003cu\u003eTreatment\u003c\/u\u003e The measures to be adopted consist of early gastric emptying and hospitalization for the appropriate treatment, through administration, as early as possible, of N-acetylcysteine as an antidote: the dosage is 150 mg\/kg i.v. in glucose solution in 15 minutes, then 50 mg\/kg in the following 4 hours and 100 mg\/kg in the following 16 hours, for a total of 300 mg\/kg in 20 hours.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003ePregnancy: A large amount of data on pregnant women indicates neither malformation nor fetal\/neonatal toxicity. Epidemiological studies on neurodevelopment in children exposed to paracetamol in utero show inconclusive results. If clinically necessary, paracetamol can be used during pregnancy, however it should be used at the lowest effective dose for the shortest possible time and with the lowest possible frequency. Breastfeeding: It is recommended to administer the product only in cases of actual need and under the direct supervision of a doctor.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eTachipirina does not alter the ability to drive or use machines.\u003c\/p\u003e","brand":"Angelini","offers":[{"title":"Default Title","offer_id":40207822356595,"sku":"012745093","price":5.89,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/angelini-spa-tachipirina-antidolorifico-500-mg-20-compresse-farmacia-dottor-tili-1213792780.jpg?v=1767112250"},{"product_id":"buscofen-12-capsule-molli-200mg","title":"Buscofen 12 Soft Capsules 200mg","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003ePain of various origins and nature (menstrual pain, headache, toothache, neuralgia, osteoarticular and muscular pain).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eCoated tablets\u003c\/u\u003e: 1 tablet contains: ibuprofen 200 mg \u003cu\u003eSoft gelatin capsules\u003c\/u\u003e: 1 soft capsule contains: ibuprofen 200 mg For the full list of excipients, see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eCoated tablets - blister pack of 20 tablets\u003c\/u\u003e Corn starch, sodium carboxymethyl starch, magnesium stearate, hydroxypropyl methylcellulose, polyethylene glycol 6000, talc, titanium dioxide, anti-foam emulsion. \u003cu\u003eSoft capsules - blisters of 12 or 24 capsules\u003c\/u\u003e Macrogol 600, potassium hydroxide, purified water, gelatin, partially dehydrated liquid sorbitol.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e- Hypersensitivity to the active substance or to any of the excipients. - Subjects with hypersensitivity to acetylsalicylic acid or other analgesics, antipyretics, non-steroidal anti-inflammatory drugs (NSAIDs), in particular when hypersensitivity is associated with nasal polyposis, angioedema and\/or asthma. - Severe liver failure. - Severe renal insufficiency (glomerural filtration less than 30 ml\/min). - Severe heart failure (NYHA class IV). - Subjects suffering from blood dyscrasias of unknown origin, porphyria, hypertension, severe uncontrolled coronary insufficiency. - Severe or active peptic ulcer. - History of gastrointestinal hemorrhage or perforation related to previous active treatments or history of recurrent peptic hemorrhage\/ulcer (two or more distinct episodes of demonstrated ulceration or bleeding). - Subjects with clinical conditions that cause an increased tendency to bleeding. - In conjunction with surgical interventions (including dental operations). - Subjects who have suffered significant fluid losses (due to vomiting, diarrhea or poor fluid intake). - During the third trimester of pregnancy (see par. 4.6). - Children under 12 years old.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDo not administer to children under 12 years of age. Side effects can be minimized by using the lowest effective dose for the shortest possible treatment duration needed to control symptoms (see section 4.4). \u003ci\u003e Coated tablets\u003c\/i\u003e \u003ci\u003e \u003cu\u003eAdults and adolescents over 12 years old\u003c\/u\u003e \u003c\/i\u003e 1-2 tablets, two - three times a day, preferably on a full stomach. However, do not exceed the dose of 1200 mg (6 tablets) per day. Do not exceed the recommended doses. If the use of the medicine is necessary for more than 3 days in adolescents, or in the case of worsening of symptoms, the doctor should be consulted. \u003ci\u003e \u003cu\u003eElderly\u003c\/u\u003e \u003c\/i\u003e Elderly patients must adhere to the minimum doses indicated. \u003ci\u003e \u003cu\u003ePatients with renal failure\u003c\/u\u003e \u003c\/i\u003e In the presence of renal insufficiency, elimination may be reduced and the dosage should be adjusted accordingly. \u003ci\u003e Soft capsules\u003c\/i\u003e \u003ci\u003e \u003cu\u003eAdults and adolescents over 12 years old\u003c\/u\u003e \u003c\/i\u003e 1-2 soft capsules, two - three times a day, preferably on a full stomach. However, do not exceed the dose of 1200 mg (6 soft capsules) per day. Do not exceed the recommended doses. If the use of the medicine is necessary for more than 3 days in adolescents, or in the case of worsening of symptoms, the doctor should be consulted. \u003ci\u003e \u003cu\u003eElderly\u003c\/u\u003e \u003c\/i\u003e Elderly patients must adhere to the minimum doses indicated. \u003ci\u003e \u003cu\u003ePatients with renal failure\u003c\/u\u003e \u003c\/i\u003e In the presence of renal insufficiency, elimination may be reduced and the dosage should be adjusted accordingly. Buscofen should not be used for more than 7 days. If higher doses are necessary or if longer treatment is required, then you should contact your doctor. The coated tablets and soft capsules should be swallowed without chewing, preferably with a little water. It is recommended to take it during or after meals, particularly for people with gastric disorders.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eCoated tablets - blister pack of 20 tablets\u003c\/u\u003e Store at room temperature. \u003cu\u003eSoft capsules - blisters of 12 or 24 capsules\u003c\/u\u003e No storage conditions.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe use of Buscofen concomitantly with other NSAIDs, including selective cyclooxygenase-2 (COX-2) inhibitors, should be avoided due to an increased risk of ulceration or bleeding (see section 4.5). Side effects can be minimized by using the lowest effective dose for the shortest duration of treatment needed to control symptoms (see paragraphs below on gastrointestinal and cardiovascular risks). \u003cb\u003e \u003ci\u003ePediatric population\u003c\/i\u003e \u003c\/b\u003e In dehydrated adolescents there is a risk of impaired renal function. \u003cb\u003e \u003ci\u003eElderly\u003c\/i\u003e \u003c\/b\u003e Elderly patients have an increased frequency of adverse reactions to NSAIDs, especially gastrointestinal bleeding and perforation, which may be fatal (see section 4.2). \u003cb\u003e \u003ci\u003eGastrointestinal haemorrhage, ulceration and perforation\u003c\/i\u003e \u003c\/b\u003e Gastrointestinal haemorrhage, ulceration and perforation which may be fatal have been reported during treatment with all NSAIDs, at any time, with or without warning symptoms or previous history of serious gastrointestinal events. In the elderly and in patients with a history of ulcer, especially if complicated by haemorrhage or perforation (see section 4.3), the risk of gastrointestinal haemorrhage, ulceration or perforation is higher with increased doses of NSAIDs. These patients should start treatment with the lowest available dose. For these patients and also for patients taking low doses of acetylsalicylic acid or other drugs that may increase the risk of gastrointestinal events, the concomitant use of protective agents (misoprostol or proton pump inhibitors) should be considered (see below and section 4.5). Patients with a history of gastrointestinal toxicity, particularly the elderly, should report any unusual gastrointestinal symptoms (especially gastrointestinal bleeding), particularly in the initial stages of treatment. Caution should be exercised by patients taking concomitant medications that may increase the risk of ulceration or bleeding, such as oral corticosteroids, anticoagulants such as warfarin, selective \u003ci\u003ereuptake\u003c\/i\u003e serotonin (SSRI) or antiplatelet agents such as acetylsalicylic acid (see section 4.5). When gastrointestinal bleeding or ulceration occurs in patients taking Buscofen, treatment should be discontinued. NSAIDs should be administered with caution to patients with a history of gastrointestinal disease (ulcerative colitis, Crohn's disease) as these conditions may be exacerbated (see section 4.8). Use with caution in patients with coagulation defects. \u003cb\u003e \u003ci\u003eCardiovascular and cerebrovascular effects\u003c\/i\u003e \u003c\/b\u003e Adequate monitoring and appropriate instructions are necessary in patients with a history of hypertension and\/or mild to moderate congestive heart failure since fluid retention and edema have been found in association with treatment with NSAIDs. Clinical studies suggest that the use of ibuprofen, especially at high doses (2400 mg\/day), may be associated with a modest increase in the risk of arterial thrombotic events (e.g. myocardial infarction or stroke). In general, epidemiological studies do not suggest that low doses of ibuprofen (e.g. ≤ 1200 mg\/day) are associated with an increased risk of arterial thrombotic events. Patients with uncontrolled hypertension, congestive heart failure (NYHA class II-III), established ischemic heart disease, peripheral arterial disease and\/or cerebrovascular disease should be treated with ibuprofen only after careful consideration and high doses (2400 mg\/day) should be avoided. Careful consideration must also be exercised before starting patients with risk factors for cardiovascular events (e.g. hypertension, hyperlipidemia, diabetes mellitus, cigarette smoking habit) on long-term treatment, especially if high doses (2400 mg\/day) of ibuprofen are necessary. \u003cb\u003e \u003ci\u003eSevere skin reactions\u003c\/i\u003e \u003c\/b\u003e Serious skin reactions, some of them fatal, including exfoliative dermatitis, Stevens-Johnson syndrome and toxic epidermal necrolysis have been reported very rarely in association with the use of NSAIDs (see section 4.8). In the early stages of therapy, patients appear to be exposed to higher risk; the onset of the reaction occurs in most cases within the first month of treatment. Acute generalized exanthematous pustulosis (PEAG) has been reported in connection with ibuprofen-containing medicinal products. Treatment with Buscofen should be discontinued at the first appearance of skin rash, mucosal lesions or any other sign of hypersensitivity. \u003cb\u003e \u003ci\u003eMasking of symptoms of underlying infections\u003c\/i\u003e \u003c\/b\u003e Buscofen may mask the symptoms of infection, which could delay starting appropriate treatment and therefore worsen the outcome of the infection. This has been observed in community-acquired bacterial pneumonia and bacterial complications of chickenpox. When Buscofen is administered for the relief of fever or pain related to infection, monitoring of the infection is recommended. In non-hospital settings, the patient should seek medical attention if symptoms persist or worsen. \u003cb\u003e \u003ci\u003eRenal effects\u003c\/i\u003e \u003c\/b\u003e When initiating treatment with ibuprofen, caution should be exercised in patients with considerable dehydration. Long-term use of ibuprofen, as with other NSAIDs, has led to renal papillary necrosis and other renal pathological changes. In general, the habitual use of analgesics, especially combinations of different analgesic active ingredients, can lead to permanent kidney damage with the risk of onset of renal failure (analgesic nephropathy). Renal toxicity has been reported in patients in whom renal prostaglandins have a compensatory role in maintaining renal perfusion. The administration of NSAIDs in these patients may result in a dose-dependent reduction in prostaglandin formation and, as a secondary effect, renal blood flow. This can quickly lead to renal failure. The patients most at risk of these reactions are those with reduced renal function, heart failure, liver dysfunction, the elderly and all those patients taking diuretics and ACE inhibitors. Discontinuation of NSAID therapy is usually followed by recovery to the pretreatment state. In case of prolonged use, monitor renal function, particularly in cases of diffuse lupus erythematosus. \u003cb\u003e \u003ci\u003eRespiratory disorders\u003c\/i\u003e \u003c\/b\u003e Buscofen should be prescribed with caution in patients with bronchial asthma or current or previous allergic diseases because bronchospasm could occur. The same applies to those subjects who have experienced bronchospasm after using aspirin or other NSAIDs. \u003cb\u003e \u003ci\u003eHypersensitivity reactions\u003c\/i\u003e \u003c\/b\u003e Analgesics, antipyretics, non-steroidal anti-inflammatories can cause potentially serious hypersensitivity reactions (anaphylactoid reactions), even in subjects not previously exposed to this type of drugs. The risk of hypersensitivity reactions after taking ibuprofen is greater in subjects who have experienced such reactions after the use of other analgesics, antipyretics, non-steroidal anti-inflammatory drugs and in subjects with bronchial hyperreactivity (asthma), nasal polyposis or previous episodes of angioedema (see sections 4.2 and 4.8). \u003cb\u003e \u003ci\u003eReduced cardiac, renal and hepatic function\u003c\/i\u003e \u003c\/b\u003e Particular caution should be taken when treating patients with severely reduced cardiac, hepatic or renal function. In such patients it is advisable to resort to periodic monitoring of clinical and laboratory parameters, especially in case of prolonged treatment. Ibuprofen may cause an increase in serum concentrations of aminotransferases, and other markers of liver function, in patients without previous evidence of liver function disorders. These usually include relatively modest and transient increases over the normal range. If these abnormalities are clinically significant or if they are persistent then treatment with ibuprofen should be discontinued and the response following discontinuation of treatment monitored. Ibuprofen may cause sodium, potassium and water retention in patients who have not previously shown signs of kidney disease, due to the effect on renal perfusion. This may cause edema or cause acute decompensation of cardiac function or hypertension in predisposed individuals. Patients at greatest risk of overt renal failure are elderly people, dehydrated or hypovolemic patients, patients with congestive heart failure, cirrhosis, nephrotic syndrome, renal failure, those on diuretics and patients who have recently undergone surgery. Discontinuation of treatment is usually followed by a rapid return to pre-treatment renal function. Ibuprofen may also interfere with the natriuretic effects of diuretics. \u003cb\u003e \u003ci\u003e Hematological effects\u003c\/i\u003e \u003c\/b\u003e Ibuprofen, like other NSAIDs, can inhibit platelet aggregation and has shown evidence of prolonging bleeding time in healthy subjects. \u003cb\u003e \u003ci\u003eAseptic meningitis\u003c\/i\u003e \u003c\/b\u003e On rare occasions, aseptic meningitis has been observed in patients receiving ibuprofen. Although it is more likely to occur in patients with systemic lupus erythematosus and related connective tissue diseases, it has also been observed in patients who did not have concomitant chronic diseases (see section 4.8). Since ocular alterations have been detected during animal studies with non-steroidal anti-inflammatory drugs, it is recommended, in case of prolonged treatments, to carry out periodic ophthalmological checks. The use of Buscofen, like any other drug that inhibits prostaglandin synthesis and cyclooxygenase, is not recommended in women intending to become pregnant (see also section 4.6). The administration of Buscofen should be suspended in women who have fertility problems or who are undergoing fertility investigations.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIbuprofen (like other NSAIDs) should be used with caution in association with: - \u003ci\u003e \u003cu\u003ecorticosteroids:\u003c\/u\u003e \u003c\/i\u003e increased risk of gastrointestinal ulceration or haemorrhage (see section 4.4); - \u003ci\u003e \u003cu\u003eanticoagulants:\u003c\/u\u003e \u003c\/i\u003e NSAIDs may increase the effects of anticoagulants such as warfarin (see section 4.4). It is advisable to monitor patients being treated with coumarins; - \u003ci\u003e \u003cu\u003eacetylsalicylic acid and other NSAIDs:\u003c\/u\u003e \u003c\/i\u003e these substances may increase the risk of adverse reactions affecting the gastrointestinal tract (see section 4.4). Concomitant administration of ibuprofen and acetylsalicylic acid is generally not recommended due to the potential for increased side effects. Experimental data suggest that ibuprofen can competitively inhibit the effect of low-dose acetylsalicylic acid on platelet aggregation when the two drugs are administered simultaneously. Although there are uncertainties regarding the extrapolation of these data to the clinical situation, the possibility cannot be excluded that regular, long-term use of ibuprofen may reduce the cardioprotective effect of acetylsalicylic acid at low doses. No relevant clinical effects are considered likely following occasional use of ibuprofen (see section 5.1). However, it is advisable not to combine ibuprofen with aspirin or other NSAIDs; - \u003ci\u003e \u003cu\u003eAntiplatelet agents and selective serotonin reuptake inhibitors (SSRIs):\u003c\/u\u003e \u003c\/i\u003e increased risk of gastrointestinal bleeding (see section 4.4); - \u003ci\u003e \u003cu\u003ediuretics, ACE inhibitors and angiotensin II antagonists\u003c\/u\u003e:\u003c\/i\u003e NSAIDs can reduce the effect of diuretics and other antihypertensive drugs. Diuretics may also increase the risk of NSAID-associated nephrotoxicity. In some patients with compromised renal function (e.g. dehydrated or elderly patients) co-administration of an ACE inhibitor or an angiotensin II antagonist and agents that inhibit the cyclo-oxygenase system may lead to further deterioration of renal function, including possible acute renal failure, which is usually reversible. These interactions should be considered in patients taking Buscofen concomitantly with ACE inhibitors or angiotensin II antagonists. Therefore, this combination should be administered with caution, especially in elderly patients. Patients should be adequately hydrated and consideration should be given to monitoring renal function after initiation of concomitant therapy and periodically thereafter; - \u003ci\u003e \u003cu\u003elithium:\u003c\/u\u003e \u003c\/i\u003e the simultaneous administration of lithium and NSAIDs causes an increase in lithium levels in the blood due to reduced elimination, with the possibility of reaching the toxic threshold. If this association is necessary, monitor lithium levels in order to adapt the lithium dosage during simultaneous treatment with ibuprofen; - \u003ci\u003e \u003cu\u003emethotrexate:\u003c\/u\u003e \u003c\/i\u003e NSAIDs can inhibit the tubular secretion of methotrexate and reduce its clearance with a consequent increase in the risk of toxicity; - \u003ci\u003e \u003cu\u003eaminoglycosides\u003c\/u\u003e:\u003c\/i\u003e NSAIDs can decrease the excretion of aminoglycosides; - \u003ci\u003e \u003cu\u003ecardiac glycosides\u003c\/u\u003e:\u003c\/i\u003e NSAIDs can exacerbate heart failure, reduce the glomerular filtration rate and increase plasma levels of cardiac glycosides; - \u003ci\u003e \u003cu\u003ephenytoin:\u003c\/u\u003e \u003c\/i\u003e NSAIDs may lead to an increase in plasma concentrations of phenytoin; - \u003ci\u003e \u003cu\u003echolestyramine:\u003c\/u\u003e \u003c\/i\u003e the concomitant administration of ibuprofen and cholestyramine can reduce the absorption of ibuprofen from the gastrointestinal tract. However, the clinical relevance of this interaction is unknown; - \u003ci\u003e \u003cu\u003eciclosporins:\u003c\/u\u003e \u003c\/i\u003e increase the risk of nephrotoxicity with NSAIDs. - \u003ci\u003e \u003cu\u003eCOX-2 inhibitors and other NSAIDs:\u003c\/u\u003e \u003c\/i\u003e concomitant use with other NSAIDs, including selective cyclooxygenase-2 inhibitors, must be avoided due to potential additive effect (see section 4.4); - \u003ci\u003e \u003cu\u003eplant extracts:\u003c\/u\u003e \u003c\/i\u003e Ginkgo Biloba may increase the risk of bleeding in association with NSAIDs; - \u003ci\u003e \u003cu\u003emifepristone:\u003c\/u\u003e \u003c\/i\u003e Due to the antiprostaglandin properties of NSAIDs, a decrease in the effectiveness of the medicine may theoretically occur. Limited evidence suggests that co-administration of NSAIDs on the day of prostaglandin administration does not negatively influence the effects of mifepristone or prostaglandin on cervical maturation or uterine contractility and does not reduce the clinical efficacy of the medicinal product on pregnancy termination; - \u003ci\u003e \u003cu\u003equinolone antibiotics:\u003c\/u\u003e \u003c\/i\u003e Animal data indicate that NSAIDs may increase the risk of seizures associated with quinolone antibiotics. Patients taking NSAIDs and quinolones may have an increased risk of developing seizures; - \u003ci\u003e \u003cu\u003esulfonylureas:\u003c\/u\u003e \u003c\/i\u003e NSAIDs can increase the effect of sulfonylureas. Rare cases of hypoglycemia have been reported in patients treated with sulfonylureas while taking ibuprofen; - \u003ci\u003e \u003cu\u003etacrolimus:\u003c\/u\u003e \u003c\/i\u003e possible increased risk of nephrotoxicity when NSAIDs are administered with tacrolimus; - \u003ci\u003e \u003cu\u003ezidovudine:\u003c\/u\u003e \u003c\/i\u003e increased risk of blood toxicity in case of co-administration with NSAIDs. There is evidence of an increased risk of haemarthrosis and hematoma in haemophiliac patients affected by HIV in simultaneous treatment with zidovudine and other NSAIDs; - \u003ci\u003e \u003cu\u003eritonavir\u003c\/u\u003e:\u003c\/i\u003e an increase in the concentration of NSAIDs is possible; - \u003ci\u003e \u003cu\u003eprobenecid:\u003c\/u\u003e \u003c\/i\u003e slows down the excretion of NSAIDs with possible increase in their plasma concentrations; - \u003ci\u003e \u003cu\u003esulfinpyrazone\u003c\/u\u003e \u003c\/i\u003e: may delay the excretion of ibuprofen; - \u003ci\u003e \u003cu\u003eCYP2C9 inhibitors:\u003c\/u\u003e \u003c\/i\u003e Coadministration of ibuprofen and CYP2C9 inhibitors may increase exposure to ibuprofen (CYP2C9 substrate). In a study with voriconazole and fluconazole (CYP2C9 inhibitors), increased exposure to S(+)-ibuprofen by approximately 80% to 100% was observed. Reduction of the ibuprofen dose should be considered when strong CYP2C9 inhibitors are co-administered, particularly when high doses of ibuprofen are administered with voriconazole and fluconazole.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe side effects observed with ibuprofen are generally common to other analgesics, antipyretics, non-steroidal anti-inflammatory drugs. \u003cu\u003eGastrointestinal disorders\u003c\/u\u003e: The most commonly observed adverse events are gastrointestinal in nature. Peptic ulcers, perforation or gastrointestinal haemorrhage, sometimes fatal, may occur, particularly in the elderly (see section 4.4). Gastrointestinal perforation with ibuprofen use has been observed rarely. After administration of Buscofen the following have been reported: nausea, vomiting, diarrhea, flatulence, constipation, dyspepsia, epigastric pain, heartburn, abdominal pain, melena, hematemesis, ulcerative stomatitis, exacerbation of colitis and Crohn's disease (see section 4.4). Less frequently, gastritis has been observed. Pancreatitis has also been observed very rarely. \u003cu\u003eImmune system disorders\u003c\/u\u003e: Hypersensitivity reactions have been reported following treatment with NSAIDs. These may consist of \u003ci\u003ea)\u003c\/i\u003e non-specific allergic reaction and anaphylaxis, \u003ci\u003eb)\u003c\/i\u003e reactions affecting the respiratory tract including asthma, even severe, bronchospasm or dyspnea or \u003ci\u003ec)\u003c\/i\u003e skin disorders, including rashes of various types, pruritus, urticaria, purpura, angioedema and, more rarely, exfoliative and bullous dermatitis (including Stevens - Johnson syndrome, toxic epidermal necrolysis and erythema multiforme). \u003cu\u003eCardiac and vascular pathologies\u003c\/u\u003e: Edema and fatigue, hypertension and heart failure have been reported in association with NSAID treatment. Clinical studies suggest that the use of ibuprofen, especially at high doses (2400 mg\/day), may be associated with a modest increase in the risk of arterial thrombotic events (e.g. myocardial infarction or stroke) (see section 4.4). Other adverse events reported less frequently and for which causality has not necessarily been established include: \u003cu\u003ePathologies of the blood and lymphatic system\u003c\/u\u003e: leukopenia, thrombocytopenia, neutropenia, agranulocytosis, aplastic anemia and hemolytic anemia. \u003cu\u003ePsychiatric disorders\u003c\/u\u003e: insomnia, anxiety, depression, confusional state, hallucinations. \u003cu\u003eNervous system disorders\u003c\/u\u003e: headache, paraesthesia, dizziness, drowsiness, optic neuritis. \u003cu\u003eInfections and infestations\u003c\/u\u003e: rhinitis and aseptic meningitis (especially in patients with pre-existing autoimmune disorders, such as systemic lupus erythematosus and mixed connective tissue disease) with symptoms of neck stiffness, headache, nausea, vomiting, fever or disorientation (see section 4.4). \u003cu\u003eRespiratory, thoracic and mediastinal disorders\u003c\/u\u003e: bronchospasm, dyspnea, apnea. \u003cu\u003eEye pathologies\u003c\/u\u003e: rare cases of ocular alteration resulting in visual disturbances, toxic optic neuropathy.\u003cu\u003eEar and labyrinth disorders\u003c\/u\u003e: impaired hearing, tinnitus, dizziness. \u003cu\u003eHepatobiliary disorders\u003c\/u\u003e: impaired liver function, liver failure, hepatitis and jaundice. \u003cu\u003ePathologies of the skin and subcutaneous tissue\u003c\/u\u003e: bullous reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis (very rare), photosensitivity reactions and drug reaction with eosinophilia and systemic symptoms (DRESS syndrome) (frequency not known), acute generalized exanthematous pustulosis (PEAG) (frequency not known). \u003cu\u003eRenal and urinary disorders\u003c\/u\u003e: impairment of renal function and toxic nephropathy in various forms, including interstitial nephritis, nephrotic syndrome and renal failure. \u003cu\u003eSystemic pathologies and conditions relating to the administration site\u003c\/u\u003e: malaise, fatigue. \u003cb\u003eReporting of suspected adverse reactions\u003c\/b\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eToxicity\u003c\/u\u003e Signs and symptoms of toxicity were generally not observed at doses below 100 mg\/kg in children or adults. However, in some cases supportive treatment may be necessary. Children have been observed to exhibit signs and symptoms of toxicity after ingesting ibuprofen at doses of 400 mg\/kg or greater. \u003cu\u003eSymptoms\u003c\/u\u003e Most patients who have ingested significant amounts of ibuprofen will experience symptoms within 4 to 6 hours. The most commonly reported overdose symptoms include nausea, vomiting, abdominal pain, lethargy, and drowsiness. Central nervous system (CNS) effects include headache, tinnitus, dizziness, seizures, and loss of consciousness. Nystagmus, metabolic acidosis, hypothermia, renal effects, gastrointestinal bleeding, coma, apnea, diarrhea and CNS and respiratory depression have also been reported rarely. Disorientation, arousal, fainting and cardiovascular toxicity including hypotension, bradycardia and tachycardia have been reported. In cases of significant overdose, renal failure and liver damage are possible. In cases of severe poisoning, metabolic acidosis may occur. \u003cu\u003eTreatment\u003c\/u\u003e There is no specific antidote for ibuprofen overdose. In case of overdose, symptomatic and supportive treatment is therefore indicated. Particular attention is due to the control of blood pressure, acid-base balance and any gastrointestinal bleeding. Administration of activated charcoal should be considered within 1 hour of ingestion of a potentially toxic quantity. Alternatively, in adults, gastric lavage should be considered within 1 hour of ingestion of a potentially life-threatening overdose. Adequate diuresis must be ensured and renal and hepatic functions must be closely monitored. The patient must remain under observation for at least four hours following ingestion of a potentially toxic amount of drug. Any occurrence of frequent or prolonged convulsions should be treated with intravenous diazepam. Depending on the patient's clinical condition, other support measures may be necessary. For more information, contact your local poison control center.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003e \u003cu\u003ePregnancy\u003c\/u\u003e \u003c\/i\u003e Inhibition of prostaglandin synthesis can negatively affect pregnancy and\/or embryo\/foetal development. Data obtained from epidemiological studies suggest an increased risk of miscarriage, cardiac malformation and gastroschisis after the use of a prostaglandin synthesis inhibitor during early pregnancy. The absolute risk of cardiac malformations increased from less than 1% to approximately 1.5%. The risk is thought to increase with the dose and duration of therapy. In animals, the administration of prostaglandin synthesis inhibitors has been shown to cause an increase in pre- and post-implantation loss and embryo-foetal mortality. Furthermore, an increased incidence of various malformations, including cardiovascular malformations, has been reported in animals administered prostaglandin synthesis inhibitors during the organogenetic period. During the first and second trimester of pregnancy, ibuprofen should not be administered unless strictly necessary. When used by women in the process of conceiving or during the first and second trimester of pregnancy, the dose and duration of treatment should be as low and as short as possible, respectively. During the third trimester of pregnancy, all inhibitors of prostaglandin synthesis can expose the fetus to: - cardiopulmonary toxicity (with premature closure of the ductus arteriosus and pulmonary hypertension); - renal dysfunction, which can progress to renal failure with oligo-hydramnios; the mother and the newborn, at the end of pregnancy, to: - possible prolongation of bleeding time and anti-aggregating effect which can occur even at very low doses; - inhibition of uterine contractions resulting in delayed or prolonged labor. Consequently, ibuprofen is contraindicated during the third trimester of pregnancy. \u003ci\u003e \u003cu\u003eBreastfeeding\u003c\/u\u003e \u003c\/i\u003e In the few studies available to date, NSAIDs can be found in breast milk in very low concentrations. NSAIDs, if possible, should be avoided during breastfeeding. \u003ci\u003e \u003cu\u003eFertility\u003c\/u\u003e \u003c\/i\u003e The use of ibuprofen may compromise female fertility and is not recommended in women trying to conceive. In women who have difficulty conceiving or who are undergoing fertility investigations, discontinuation of ibuprofen treatment should be considered.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eFollowing the intake of ibuprofen it is possible to experience side effects such as dizziness, drowsiness, fatigue and vision problems. This should be taken into consideration when increased vigilance is required such as when driving a car or operating machinery.\u003c\/p\u003e","brand":"Sanofi","offers":[{"title":"Default Title","offer_id":40207822389363,"sku":"029396037","price":7.91,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/sanofi-spa-buscofen-12-capsule-molli-200mg-farmacia-dottor-tili-1213792773.jpg?v=1767112233"},{"product_id":"okitask-20-bustine-granulato-40-mg","title":"Okitask 20 granulated sachets 40 mg.","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003ePain of different origins and nature, and in particular: headache, toothache, neuralgia, menstrual pain, muscular and osteoarticular pain.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eEach sachet contains: Active ingredient: ketoprofen lysine salt 40 mg (corresponding to 25 mg of ketoprofen). Excipients with known effect: aspartame, sodium dodecyl sulphate. For the full list of excipients, see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003ePovidone, colloidal silica, hydroxypropyl methylcellulose, eudragit EPO, sodium dodecyl sulphate, stearic acid, magnesium stearate, aspartame, mannitol, xylitol, talc, lime flavour, lemon flavour, frescofort flavour.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eOkitask 40 mg granules must not be administered in the following cases: • hypersensitivity to the active substance, to other non-steroidal anti-inflammatory drugs (NSAIDs) or to any of the excipients, listed in paragraph 6.1; • asthma, bronchospasm, acute rhinitis, urticaria, skin rashes, nasal polyps, angioneurotic edema or other allergic reactions caused by ketoprofen, or by medicines with a similar mechanism of action (for example acetylsalicylic acid, other NSAIDs and selective cyclo-oxygenase 2 inhibitors), see section 4.8; • previous bronchial asthma; • severe heart failure; • gastritis; • active peptic ulcer\/haemorrhage or history of recurrent peptic ulcer\/haemorrhage (two or more distinct episodes of demonstrated ulceration or haemorrhage); • previous history of gastrointestinal bleeding, ulceration or perforation, or chronic dyspepsia; • history of gastrointestinal bleeding or perforation following previous therapy with NSAIDs; • Crohn's disease or ulcerative colitis; • severe liver failure (liver cirrhosis, severe hepatitis); • severe renal failure; • leukopenia and thrombocytopenia; • haemorrhagic diathesis and other coagulation disorders, haemostatic disorders; • use of a high dosage of diuretics; • third trimester of pregnancy; • children under 15 years old.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eDosage.\u003c\/u\u003e Adults and over 15 years: the recommended dose is 40 mg (corresponding to 1 sachet), in a single dose, or repeated 2-3 times a day, in the most intense forms of pain. Do not exceed the recommended doses. \u003cb\u003eParticular populations. \u003c\/b\u003e \u003ci\u003eElderly:\u003c\/i\u003e The dosage must be carefully established taking into consideration a possible reduction in the above dosages. \u003ci\u003ePatients with hepatic or renal insufficiency: \u003c\/i\u003e Therapy at the minimum daily dosage and careful monitoring are recommended (see section 4.4). In case of renal insufficiency it is recommended to monitor the volume of urine output and renal function (see section 4.4). Okitask 40 mg granules must not be used in patients with severe hepatic or renal dysfunction (see section 4.3). \u003ci\u003ePediatric population:\u003c\/i\u003e The safety and effectiveness of Okitask 40 mg granules in children have not yet been established. \u003cu\u003eMethod of administration:\u003c\/u\u003e The contents of the sachet can be placed directly on the tongue. It dissolves with saliva: this allows it to be used without water. It is preferable to take the product on a full stomach. \u003cu\u003eTreatment duration:\u003c\/u\u003e The duration of therapy must be limited to overcoming the painful episode. The lowest effective dose should be used for the shortest period necessary to relieve symptoms (see section 4.4).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThis medicinal product does not require any special storage conditions.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eWarnings: Undesirable effects can be minimized by using the lowest effective dose for the shortest possible duration of treatment needed to control symptoms (see section 4.2 and the sections below on gastrointestinal and cardiovascular risks). The concomitant use of Okitask 40 mg granules with other NSAIDs, including selective cyclooxygenase-2 inhibitors, should be avoided. \u003cu\u003eGastrointestinal reactions:\u003c\/u\u003e Gastrointestinal haemorrhage, ulceration and perforation: Gastrointestinal haemorrhage, ulceration and perforation, which may be fatal, have been reported at any time during treatment with all NSAIDs, with or without warning symptoms or previous history of serious gastrointestinal events. In patients with a history of ulcer, especially if complicated by haemorrhage or perforation (see section 4.3), the risk of gastrointestinal haemorrhage, ulceration or perforation is higher with increased doses of NSAIDs. These patients should start treatment at the lowest possible dose. The concomitant use of protective agents (misoprostol or proton pump inhibitors) should be considered for these patients and also for patients concomitantly taking low doses of acetylsalicylic acid or other drugs that may increase the risk of gastrointestinal events (see below and section 4.5). Patients with a history of gastrointestinal toxicity, especially the elderly, should report any abdominal symptoms and\/or signs (including gastrointestinal bleeding) even at the start of treatment. Caution should be exercised in patients taking concomitant medications that may increase the risk of ulceration or haemorrhage, such as oral corticosteroids, anticoagulants such as warfarin, selective serotonin reuptake inhibitors or antiplatelet agents such as acetylsalicylic acid (see section 4.5). \u003cu\u003eElderly:\u003c\/u\u003e Elderly people have an increased frequency of adverse reactions to NSAIDs, especially gastrointestinal bleeding and perforation, which can be fatal (see section 4.2). Patients with current or previous gastrointestinal disease should be carefully monitored for the appearance of digestive disorders, especially gastrointestinal bleeding. When gastrointestinal bleeding or ulceration occurs in patients taking Okitask 40 mg granules, treatment should be suspended. \u003cu\u003ePatients with active or previous peptic ulcer:\u003c\/u\u003e Some epidemiological evidence suggests that ketoprofen may be associated with a high risk of serious gastrointestinal toxicity compared to other NSAIDs, especially at high doses (see sections 4.2 and 4.3). \u003cu\u003eSkin reactions:\u003c\/u\u003e Serious skin reactions, some of them fatal, including exfoliative dermatitis, Stevens-Johnson syndrome and toxic epidermal necrolysis, have been reported very rarely in association with the use of NSAIDs (see section 4.8). At the beginning of treatment patients appear to be at higher risk. Okitask 40 mg granules should be discontinued at the first appearance of skin rash, mucosal lesions or any other sign of hypersensitivity. Precautions. \u003cu\u003eCardiovascular, renal and hepatic dysfunction:\u003c\/u\u003e In patients with impaired renal function, the administration of ketoprofen must be carried out with particular caution given the essentially renal elimination of the drug. Renal function should be carefully monitored in patients with heart failure, cirrhosis and nephrosis, in patients receiving diuretic therapy, in patients with chronic renal impairment, particularly if patients are elderly. In these patients, administration of ketoprofen may cause a decrease in renal blood flow caused by inhibition of prostaglandins and lead to renal decompensation (see section 4.3). Caution is also required in patients subject to diuretic therapy or likely to be hypovolemic because the risk of nephrotoxicity is increased. As with all NSAIDs, Okitask 40 mg granules can increase plasma urea nitrogen and creatinine. As with other prostaglandin synthesis inhibitors, Okitas 40 mg granules may be associated with adverse effects on the renal system which may lead to glomerular nephritis, renal papillary necrosis, nephrotic syndrome and acute renal failure (see section 4.8). In patients with abnormal liver function values ​​or a history of liver disease, transaminase levels should be evaluated periodically. As with other NSAIDs, Okitask 40 mg granules can cause increases in some hepatic parameters and also significant increases in SGOT and SGPT (see section 4.8). In case of significant increase in these parameters, therapy must be interrupted. Cases of jaundice and hepatitis have been reported with the use of ketoprofen (see section 4.8). Elderly patients are more predisposed to reduced renal, cardiovascular or hepatic function. \u003cu\u003eCardiovascular and cerebrovascular effects:\u003c\/u\u003e As with other NSAIDs, patients with uncontrolled hypertension, congestive heart failure, established ischemic heart disease, peripheral arterial disease and\/or cerebrovascular disease should be treated with ketoprofen only after careful consideration. Similar considerations must be made before starting treatment in patients with risk factors for cardiovascular disease (e.g. hypertension, hyperlipidemia, diabetes mellitus, smoking). Caution is required before starting treatment in patients with a history of hypertension and\/or mild to moderate congestive heart failure as fluid retention and edema have been reported related to treatment with NSAIDs. Clinical studies and epidemiological data suggest that the use of some NSAIDs may be associated with an increased risk of arterial thrombotic events (e.g. myocardial infarction or stroke). There are insufficient data to exclude a similar risk for Okitask 40 mg granules. An increased risk of atrial fibrillation associated with the use of NSAIDs has been reported. Hyperkalaemia may occur, especially in patients with underlying diabetes, renal insufficiency, and\/or concomitant treatment with agents promoting hyperkalaemia (see section 4.5). In these circumstances potassium levels should be assessed periodically. \u003cu\u003eInfections.\u003c\/u\u003e Masking of symptoms of underlying infections: Okitask 40 mg granules may mask the symptoms of infection, which may delay the initiation of appropriate treatment and therefore worsen the outcome of the infection. This has been observed in community-acquired bacterial pneumonia and bacterial complications of chickenpox. When Okitask 40 mg granules are administered for the relief of fever or pain related to infection, monitoring of the infection is recommended. In non-hospital settings, the patient should seek medical attention if symptoms persist or worsen. \u003cu\u003eRespiratory disorders:\u003c\/u\u003e Like all non-steroidal drugs, the use of ketoprofen in patients with bronchial asthma or allergic diathesis can cause an asthma attack. Patients with asthma associated with chronic rhinitis, chronic sinusitis and\/or nasal polyposis are more exposed to the risk of allergy to acetylsalicylic acid and\/or NSAIDs than the rest of the population. The administration of this drug can cause asthmatic attacks or bronchospasm, shock and other allergic phenomena, especially in subjects allergic to acetylsalicylic acid or NSAIDs (see section 4.3). Due to the action on the metabolism of arachidonic acid, bronchospasm attacks and possibly shock and other allergic phenomena may arise in asthmatics and predisposed subjects. Administer with caution in patients with allergic manifestations or previous allergy. \u003cu\u003eVisual disturbances:\u003c\/u\u003e In case of visual disturbances, such as blurred vision, treatment should be stopped. Okitask 40 mg granules should be administered with caution in patients suffering from haematopoietic alterations, systemic lupus erythematosus or mixed connective tissue diseases. When Okitask 40 mg granules are administered to patients with hepatic porphyria, caution is required as it may trigger an attack. Important information about some excipients: Okitask 40 mg granules contains less than 1mmol (23 mg) sodium per sachet, i.e. essentially 'sodium-free'. Okitask 40 mg granules contains lemon flavoring and lime flavouring. The lemon flavor contains sucrose. Patients suffering from rare hereditary problems of fructose intolerance, glucose-galactose malabsorption, or sucrase isomaltase insufficiency should not take this medicine. The lime flavor contains glucose. Patients suffering from rare problems of glucose-galactose malabsorption should not take this medicine.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eAssociations not recommended.\u003c\/b\u003e - Other NSAIDs (including selective cyclooxygenase 2 inhibitors) and high doses of salicylates (\u003e 3 g\/day): the simultaneous administration of several NSAIDs may increase the risk of gastrointestinal ulcers and bleeding, due to a synergistic effect. - Anticoagulants (heparin and warfarin): NSAIDs can amplify the effects of anticoagulants. If coadministration cannot be avoided, the patient should be closely monitored. - Platelet aggregation inhibitors (ticlopidine and clopidogrel): concomitant administration of an NSAID may increase the risk of bleeding due to inhibition of platelet function and damage to the gastrointestinal mucosa (see section 4.4). If coadministration cannot be avoided, the patient should be closely monitored. - Lithium: the simultaneous administration of several NSAIDs can increase plasma levels of lithium, which can reach toxic values, due to reduced renal excretion. Plasma lithium levels should be carefully monitored and the lithium dosage should be adjusted during and after discontinuation of treatment with ketoprofen and other NSAIDs. - Methotrexate, at doses higher than 15 mg\/week: the simultaneous administration of an NSAID may increase the risk of blood toxicity of methotrexate, especially if administered at high doses, probably due to a displacement of plasma protein binding and a decrease in renal clearance. The intake of the two medicines must be spaced at least 12 hours apart. - Hydantoins and sulphonamides: the toxic effects of these substances may be increased; since the protein binding of ketoprofen is high, it may be necessary to reduce the dosage of diphenylhydantoin or sulphonamides, in case of concomitant administration. \u003cb\u003eAssociations requiring precaution.\u003c\/b\u003e - Drugs or therapeutic categories that can promote hyperkalemia: potassium salts, potassium-sparing diuretics, inhibitors of enzyme converters (ACE inhibitors), angiotensin II receptor blockers, NSAIDs, heparins (low molecular weight or unfractionated), ciclosporin, tacrolimus and trimethoprim. The occurrence of hyperkalemia may depend on the presence of cofactors. The risk is increased in case of simultaneous administration of the above-mentioned drugs. - Tenofovir: concomitant administration of tenofovir disoproxil fumarate and NSAIDs may increase the risk of renal failure. - Diuretics: subjects treated with diuretics, especially in case of dehydration, are at greater risk of developing renal failure secondary to the reduction in renal blood flow caused by the inhibition of prostaglandins. Hydration before starting concomitant therapy and close monitoring of renal function after initiation of treatment are recommended (see section 4.4). NSAIDs can reduce the effect of diuretics. - ACE inhibitors and angiotensin II antagonists: coadministration with cyclo-oxygenase inhibitors may lead to a further deterioration of renal function and possible acute renal failure, especially in dehydrated and elderly subjects. Caution, hydration and monitoring of renal function are recommended in case of combined therapy. -Methotrexate at doses lower than 15 mg\/week: anti-inflammatories cause a decrease in the renal clearance of methotrexate with a consequent increase in blood toxicity. In case of impaired renal function or advanced age, monitoring must be more frequent. - Corticosteroids: concomitant administration of NSAIDs may increase the risk of gastrointestinal ulceration or bleeding (see section 4.4). - Pentoxifylline: co-administration may cause an increased risk of bleeding: monitoring of bleeding time is recommended. - Zidovudine: the combination with NSAIDs increases the risk of toxicity on reticulocytes, with severe anemia occurring one week after starting treatment with NSAIDs. Complete blood cell count and reticulocyte count should be checked one week after starting treatment with the NSAID. - Sulfonylureas: NSAIDs can increase the hypoglycemic effect of sulfonylureas by displacing them from the binding sites with plasma proteins. Possible interactions with other oral hypoglycemics should also be kept in mind. - Cardiac glycosides: NSAIDs can exacerbate heart failure, reduce the glomerular filtration rate and increase levels of cardiac glycosides; however, the pharmacokinetic interaction between ketoprofen and active glycosides has not been demonstrated. \u003cb\u003eAssociations that need to be taken into consideration.\u003c\/b\u003e - Antihypertensive agents (Beta-blockers, ACE inhibitors diuretics): treatment with an NSAID can reduce the effect of antihypertensive drugs by inhibiting the synthesis of vasodilatory prostaglandins. - Mifepristone: the effectiveness of the contraceptive method may, theoretically, be reduced due to the antiprostaglandin properties of NSAIDs including acetylsalicylic acid. There is some evidence to suggest that co-administration of NSAIDs on the day of administration of the prostaglandin dose does not unfavorably influence the effects of mifepristone or prostaglandin on cervical maturation or uterine contractility and does not reduce the clinical efficacy of medical termination of pregnancy. - Intrauterine contraceptive devices (IUDs): the effectiveness of the device may be reduced resulting in pregnancy. - Ciclosporin and tacrolimus: simultaneous treatment with NSAIDs may lead to a greater risk of nephrotoxicity, especially in elderly subjects. - Thrombolytics: concomitant administration with NSAIDs may increase the risk of bleeding. - Anti-aggregating agents (ticlopidine and clopidogrel) and selective serotonin reuptake inhibitors (SSRIs): NSAIDs may increase the risk of gastrointestinal bleeding (see section 4.4). - Probenecid: the concomitant administration of probenecid can markedly reduce the plasma clearance of ketoprofen due to inhibition of tubular secretion and glucuronide conjugation, therefore an adaptation of the dose of ketoprofen is necessary. - Quinolone antibiotics: animal data indicate that NSAIDs may increase the risk of convulsions related to quinolone use. Patients being treated with NSAIDs and quinolones may have an increased risk of developing seizures. - Diphenylhydantoin and sulphonamides: since the protein binding of ketoprofen is high, it may be necessary to reduce the dosage of diphenylhydantoin or sulphonamides in case of co-administration. - Gemeprost: combined use with an NSAID may reduce its effectiveness. Alcohol intake during treatment should be avoided.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe most commonly observed adverse events are gastrointestinal in nature. Classification of expected frequencies: very common (1\/10), common (1\/100 to ≤1\/10), uncommon (1\/1000 to ≤1\/100), rare (1\/10000 to ≤1\/1000), very rare (≤1\/10000), not known (cannot be estimated from the available data). The following adverse reactions have been observed with the use of ketoprofen in adults:\u003c\/p\u003e\n\u003cp\u003eBlood and lymphatic system disorders - Rare (≥1\/10,000, \u003c1\/1,000): haemorrhagic anemia. Frequency not known: thrombocytopenia, agranulocytosis, bone marrow failure, haemolytic anemia, leucopenia, neutropenia, aplastic anemia, leukocytosis, thrombocytopenic purpura.\u003c\/p\u003e\n\u003cp\u003eImmune system disorders - Frequency not known: anaphylactic reaction (including shock), hypersensitivity\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders - Common (≥1\/100, \u003c1\/10): dyspepsia, nausea, abdominal pain, vomiting. Uncommon (≥1\/1,000, \u003c1\/100): constipation, diarrhoea, flatulence, gastritis. Rare (≥1\/10,000, \u003c1\/1,000): stomatitis, peptic ulcer. Frequency not known: exacerbation of colitis and Crohn's disease, gastrointestinal haemorrhage, gastrointestinal perforation (sometimes fatal, particularly in the elderly - see section 4.4), gastric ulcer, mouth ulceration, duodenal ulcer, duodenal perforation, melena, haematemesis, abdominal discomfort, colitis, heartburn, mouth edema, pancreatitis, hyperchlorhydria, gastric pain, erosive gastritis, mouth edema language.\u003c\/p\u003e\n\u003cp\u003eSkin and subcutaneous tissue disorders - Uncommon (≥1\/1,000, \u003c1\/100): rash, pruritus. Very rare (\u003c1\/10,000): erythema. Frequency not known: photosensitivity reaction, alopecia, urticaria, angioedema, bullous dermatitis including Stevens-Johnson syndrome and toxic epidermal necrolysis, edema, exanthema, Lyell's syndrome, maculopapular exanthema, purpura, acute generalized exanthematous pustulosis, dermatitis.\u003c\/p\u003e\n\u003cp\u003eGeneral disorders and administration site conditions - Uncommon (≥1\/1,000, \u003c1\/100): fatigue,. Very rare (\u003c1\/10,000): facial edema. Frequency not known: peripheral edema, chills, asthenia.\u003c\/p\u003e\n\u003cp\u003eNervous system disorders - Uncommon (≥1\/1,000, \u003c1\/100): headache, dizziness, drowsiness. Rare (≥1\/10,000, \u003c1\/1,000): paraesthesia. Frequency not known: seizure, dysgeusia, dizziness, dyskinesia, syncope, tremor, hyperkinesia.\u003c\/p\u003e\n\u003cp\u003eEye disorders - Rare (≥1\/10,000, \u003c1\/1,000): blurred vision (see section 4.4). Frequency not known: periorbital edema.\u003c\/p\u003e\n\u003cp\u003eEar and labyrinth disorders - Rare (≥1\/10,000, \u003c1\/1,000): tinnitus.\u003c\/p\u003e\n\u003cp\u003eHepatobiliary disorders - Rare (≥1\/10,000, \u003c1\/1,000): hepatitis, increased transaminases, increased blood bilirubin. Frequency not known: jaundice.\u003c\/p\u003e\n\u003cp\u003eRespiratory, thoracic and mediastinal disorders - Rare (≥1\/10,000, \u003c1\/1,000): asthma. Frequency not known: bronchospasm (especially in patients with known hypersensitivity to acetylsalicylic acid and other NSAIDs), rhinitis, dyspnoea, laryngeal edema, laryngospasm, acute respiratory failure (one case with fatal outcome has been reported in an asthmatic patient sensitive to acetylsalicylic acid).\u003c\/p\u003e\n\u003cp\u003eRenal and urinary disorders: - Frequency not known: acute renal failure, tubulointerstitial nephritis, nephritic syndrome, abnormal renal function test, haematuria, nephritis, nephrotic syndrome, glomerulonephritis, sodium\/water retention with possible edema, acute tubular necrosis, renal papillary necrosis, oliguria.\u003c\/p\u003e\n\u003cp\u003ePsychiatric disorders - Frequency not known: altered mood, depression, hallucination, confusional state, agitation, insomnia.\u003c\/p\u003e\n\u003cp\u003eCardiac disorders - Frequency not known: heart failure, atrial fibrillation, palpitations, tachycardia.\u003c\/p\u003e\n\u003cp\u003eVascular disorders - Frequency not known: hypertension, vasodilation, hypotension, vasculitis (including leukocytoclastic vasculitis).\u003c\/p\u003e\n\u003cp\u003eMetabolism and nutrition disorders - Frequency not known: hyperkalemia, hyponatremia.\u003c\/p\u003e\n\u003cp\u003eInfections and infestations - Frequency not known: aseptic meningitis, lymphangitis.\u003c\/p\u003e\n\u003cp\u003eInvestigations - Rare (≥1\/10,000, \u003c1\/1,000): Increased weight.\u003c\/p\u003e\n\u003cp\u003eClinical studies and epidemiological data suggest that the use of some NSAIDs (especially at high doses and for long-term treatments) may be associated with an increased risk of arterial thrombotic events (e.g. myocardial infarction or stroke) (see section 4.4). \u003cu\u003eReporting of suspected adverse reactions.\u003c\/u\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eCases of overdose have been reported with doses of up to 2.5 g of ketoprofen. In most cases, observed symptoms were limited to lethargy, confusion, loss of consciousness, drowsiness, headache, vertigo, dizziness, nausea, vomiting, epigastric pain, abdominal pain and diarrhea. In case of severe overdose, gastrointestinal bleeding, hypotension, respiratory depression and cyanosis may also occur, in which case the patient should be immediately transferred to a specialized hospital center to begin symptomatic treatment. There are no specific antidotes in case of ketoprofen overdose. In case of suspected massive overdose, gastric lavage is recommended and symptomatic and supportive treatment is advised to compensate for dehydration, monitor urinary excretion and correct acidosis, if present. In cases of renal failure, hemodialysis may be useful to remove the drug from the circulation.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003ePregnancy:\u003c\/u\u003e The use of ketoprofen during the first and second trimester of pregnancy should be avoided, the administration of ketoprofen should only be considered if the expected benefit for the mother exceeds the risk for the embryo or fetus. Inhibition of prostaglandin synthesis can negatively affect pregnancy and\/or embryo\/foetal development. Results of epidemiological studies suggest an increased risk of miscarriage and cardiac malformation and gastroschisis after the use of a prostaglandin synthesis inhibitor in early pregnancy. The absolute risk of cardiac malformations increased from less than 1% to approximately 1.5%. The risk was thought to increase with the dose and duration of therapy. In animals, the administration of prostaglandin synthesis inhibitors has been shown to cause an increase in pre- and post-implantation loss and embryo-foetal mortality. Furthermore, an increased incidence of various malformations, including cardiovascular malformations, has been reported in animals to which prostaglandin synthesis inhibitors were administered during the organogenetic period. Therefore ketoprofen should not be administered during the first and second trimester of pregnancy unless strictly necessary. If ketoprofen is used by a woman desiring to become pregnant, or during the first and second trimester of pregnancy, the dosage should be kept as low as possible for the shortest possible duration of treatment. During the third trimester of pregnancy, all inhibitors of prostaglandin synthesis can expose the fetus to: - cardiopulmonary toxicity (with premature closure of the ductus arteriosus and pulmonary hypertension); - renal dysfunction, which can progress to renal failure with oligo-hydramnios; the mother and the newborn, at the end of pregnancy, to: - possible prolongation of bleeding time and anti-aggregating effect which can occur even at very low doses; - inhibition of uterine contractions resulting in delayed or prolonged labor. The use of the medicine close to childbirth can cause alterations in the hemodynamics of the small circulation of the unborn child with serious consequences for breathing. Consequently, ketoprofen is contraindicated during the third trimester of pregnancy. \u003cu\u003eBreastfeeding:\u003c\/u\u003e There is no information available on the excretion of ketoprofen in breast milk. Ketoprofen is not recommended during breast-feeding. \u003cu\u003eFertility:\u003c\/u\u003e The use of NSAIDs can reduce female fertility and is therefore not recommended in women intending to become pregnant. The administration of NSAIDs, as well as Okitask 40 mg granules, must be suspended in women who have fertility problems or who are undergoing fertility investigations.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eFollowing the administration of ketoprofen, drowsiness, dizziness or convulsions and visual disturbances may occur. It is recommended to avoid driving, using machinery or carrying out activities requiring particular vigilance.\u003c\/p\u003e","brand":"Dompé","offers":[{"title":"Default Title","offer_id":40207822422131,"sku":"042028023","price":10.23,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/products\/dompe-farmaceutici-spa-okitask-20-bustine-granulato-40-mg-farmacia-dottor-tili-1213792778.jpg?v=1767112213"},{"product_id":"buscopan-40-compresse-rivestite-10-mg","title":"Buscopan 40 Coated Tablets 10 mg","description":"\u003cp dir=\"ltr\"\u003e\u003cspan\u003eBuscopan\u003c\/span\u003e\u003cspan\u003e is a drug used to treat cramps and abdominal pain, particularly those related to gastrointestinal and urinary tract disorders. The active ingredient, \u003c\/span\u003e\u003cspan\u003ebutylscopolamine bromide\u003c\/span\u003e\u003cspan\u003e, acts as an antispasmodic, relaxing the smooth muscles of the gastrointestinal and urinary tract, thus reducing pain and discomfort. Thanks to its localized action, Buscopan is effective in the treatment of intestinal spasms, colic and similar disorders\u003c\/span\u003e\u003c\/p\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eBuscopan is indicated for:\u003c\/span\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli dir=\"ltr\" aria-level=\"1\"\u003e\n\u003cp dir=\"ltr\" role=\"presentation\"\u003e\u003cspan\u003eSymptomatic treatment of abdominal cramps\u003c\/span\u003e\u003cspan\u003e and pain caused by gastrointestinal spasms.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli dir=\"ltr\" aria-level=\"1\"\u003e\n\u003cp dir=\"ltr\" role=\"presentation\"\u003e\u003cspan\u003eRelief of pain from renal and biliary colic\u003c\/span\u003e\u003cspan\u003e.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli dir=\"ltr\" aria-level=\"1\"\u003e\n\u003cp dir=\"ltr\" role=\"presentation\"\u003e\u003cspan\u003eTreatment of spasms and pain related to urinary tract disorders\u003c\/span\u003e\u003cspan\u003e.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eINDICATIONS\u003c\/h2\u003e\n\u003ch3\u003eWhy is Buscopan 40 Coated Tablets 10 mg used? What is it for?\u003c\/h3\u003e\u003cp dir=\"ltr\"\u003e\u003cspan\u003eSymptomatic treatment of spastic-painful manifestations of the gastrointestinal tract.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2\u003eACTIVE INGREDIENTS AND EXCIPIENTS\u003c\/h2\u003e\n\u003ch3\u003eWhat is the composition of Buscopan 40 Coated Tablets 10 mg?\u003c\/h3\u003e\u003cp dir=\"ltr\"\u003e\u003cspan\u003eCoated tablets, one coated tablet contains: Hyoscine N-butylbromide 10 mg. Excipients: sucrose. Suppositories, one suppository contains: Hyoscine N-butylbromide 10 mg. For the complete list of excipients see section 6.1.\u003c\/span\u003e\u003c\/p\u003e\u003cbr\u003e\u003cbr\u003e\u003cp dir=\"ltr\"\u003e\u003cspan\u003eCoated tablets; core: calcium hydrogen phosphate, corn starch, soluble starch, anhydrous colloidal silica, tartaric acid, stearic acid. Coating: povidone, sucrose, talc, gum arabic, titanium dioxide (E171), macrogol 6000, carnauba wax, white wax. Suppositories: solid semi-synthetic glycerides.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2\u003eDOSAGE\u003c\/h2\u003e\n\u003ch3\u003eHow is Buscopan 40 Coated Tablets 10 mg taken?\u003c\/h3\u003e\u003cp dir=\"ltr\"\u003e\u003cspan\u003eDosage: the following dosages are recommended for adults and children over 14 years of age. Coated tablets: 1-2 coated tablets 3 times a day. Suppositories: 1 suppository 3 times a day. Single doses can be increased according to the doctor's judgment. In pediatrics, children between the ages of 6 and 14 must follow the doctor's prescription exactly. Method of administration: the tablets must be taken whole with an adequate quantity of water. Buscopan should not be taken daily on a regular basis or for prolonged periods without investigating the cause of abdominal pain.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/h2\u003e\n\u003ch3\u003eWhen should Buscopan 40 Coated Tablets 10 mg not be used and what side effects can it cause?\u003c\/h3\u003e\u003cp dir=\"ltr\"\u003e\u003cspan\u003eHypersensitivity to the active substance or to any of the excipients. Acute angle glaucoma. Prostatic hypertrophy or other causes of urinary retention. Pyloric stenosis and other conditions that stenose the gastrointestinal tract. Mechanical stenosis of the gastrointestinal tract. Paralytic or obstructive ileus. Megacolon. Ulcerative colitis. Reflux esophagitis. Intestinal atony in the elderly and debilitated subjects. Myasthenia gravis. Children under 6 years of age. In case of rare hereditary conditions of incompatibility with one of the excipients (see section 4.4 \"\"Special warnings and precautions for use\"\"), the use of the medicine is contraindicated.\u003c\/span\u003e\u003c\/p\u003e\u003cbr\u003e\u003cbr\u003e\u003cp dir=\"ltr\"\u003e\u003cspan\u003eMany of the side effects listed can be attributed to the anticholinergic properties of Buscopan. The anticholinergic side effects of Buscopan are generally mild and self-limiting. Immune system disorders. Uncommon frequency: skin reactions, urticaria, itching; frequency not known*: anaphylactic shock, anaphylactic reactions, dyspnoea, skin rash, erythema and other manifestations of hypersensitivity. *These adverse reactions have been observed in post-marketing experience. At 95% probability, the frequency category is no higher than uncommon (3\/1368), but could be lower. A precise estimate of the frequency is not possible since these adverse reactions did not occur in 1368 patients in clinical trials. Cardiac diseases. Uncommon frequency: tachycardia. Gastrointestinal disorders. Uncommon frequency: dry mouth. Constipation was also observed. Pathologies of the skin and subcutaneous tissue. Uncommon frequency: alterations in sweating. Renal and urinary disorders. Rare frequency: urinary retention. The following side effects have also been observed. Eye disorders: mydriasis, accommodation disorders, increased ocular tone. Nervous system disorders: drowsiness. High doses may cause signs of central stimulation and more serious signs of interference with the nervous system, the state of consciousness and cardiorespiratory function. Reporting of suspected adverse reactions. Reporting suspected adverse reactions that occur after authorization of the medicinal product is important, as it allows continuous monitoring of the benefit\/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2\u003eINTERACTIONS\u003c\/h2\u003e\n\u003ch3\u003eWhich medicines or foods can modify the effect of Buscopan 40 Coated Tablets 10 mg?\u003c\/h3\u003e\u003cp dir=\"ltr\"\u003e\u003cspan\u003eanticholinergic drugs such as tri- and tetracyclic antidepressants, phenothiazines, butyrophenones, antihistamines, antipsychotics, quinidine, amantadine, diisopyramide and other anticholinergics (e.g. tiotropium, ipratropium and atropine-like compounds) may be accentuated by Buscopan. Concomitant treatment with dopamine antagonists, such as metoclopramide, can lead to a reduction in the impact of both drugs on the gastrointestinal tract. Tachycardia induced by beta-adrenergic drugs may be accentuated by Buscopan. Do not drink alcohol during therapy. Because antacids may reduce the intestinal absorption of anticholinergics, these drugs should not be administered simultaneously.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2\u003ePREGNANCY AND BREASTFEEDING\u003c\/h2\u003e\n\u003ch3\u003eCan Buscopan 40 Coated Tablets 10 mg be used during pregnancy and breastfeeding?\u003c\/h3\u003e\u003cp dir=\"ltr\"\u003e\u003cspan\u003eLimited data are available regarding the use of hyoscine N-butylbromide in pregnant women. Animal studies do not indicate direct or indirect harmful effects of reproductive toxicity (see section 5.3). There is insufficient information on the excretion of Buscopan and its metabolites in human milk. As a precautionary measure, it is preferable to avoid the use of Buscopan during pregnancy and breastfeeding. No studies on the effects on human fertility have been conducted (see section 5.3).\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2\u003eWARNINGS\u003c\/h2\u003e\n\u003ch3\u003eWhat are the warnings of Buscopan 40 Coated Tablets 10 mg?\u003c\/h3\u003e\u003cp dir=\"ltr\"\u003e\u003cspan\u003eIf you experience severe abdominal pain of unknown cause, that persists or worsens, or that occurs together with other symptoms such as fever, nausea, vomiting, changes in bowel movement, abdominal tenderness, decreased blood pressure, fainting or blood in the stool, you should contact your doctor immediately. Anticholinergics should be used with caution in the elderly, in patients with disorders of the autonomic nervous system, in cardiac tachyarrhythmias, in arterial hypertension, in congestive heart failure, in hyperthyroidism and in patients with liver and kidney disease. Due to the potential risk of complications related to an excessive anticholinergic effect, caution should be exercised in patients subject to acute-angle glaucoma as well as in patients susceptible to intestinal and urinary stasis and in those prone to tachyarrhythmias. Anticholinergics may prolong gastric emptying time and cause antral stasis. Because of the possibility that anticholinergics may reduce sweating, Buscopan should be administered with caution in patients with pyrexia. Treatment with high doses should not be abruptly stopped. Minor side effects can be controlled by appropriately reducing the dose; the appearance of important secondary manifestations requires the interruption of therapy. A 10 mg coated tablet contains 41.2 mg of sucrose equal to 247.2 mg per maximum recommended daily dose. Therefore patients suffering from rare hereditary problems of fructose intolerance should not take this medicine.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2\u003eCONSERVATION\u003c\/h2\u003e\n\u003ch3\u003eHow is Buscopan 40 Coated Tablets 10 mg stored?\u003c\/h3\u003e\u003cp dir=\"ltr\"\u003e\u003cspan\u003eCoated tablets: this medicine does not require any special storage conditions. Suppositories: Do not store above 30 degrees C.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2\u003eFORMAT\u003c\/h2\u003e\n\u003ch3\u003eWhat is the format of Buscopan 40 Coated Tablets 10 mg?\u003c\/h3\u003e\u003cp\u003e40 Coated Tablets 10 mg\u003c\/p\u003e\n\u003ch2\u003eDRUG LEGAL TEXT\u003c\/h2\u003e\n\u003cp\u003eContent responsibility\u003c\/p\u003e\u003cp\u003eThis sheet contains information that is not intended to replace a doctor's diagnosis or advice, as only the doctor can draw up any prescription and give therapeutic indications. All contents must be understood and are of an exclusively informative nature and aimed exclusively at bringing to the attention of customers or potential customers in the pre-purchase phase of the products sold through this site. In case of pathologies, disorders or allergies it is always best to consult your doctor first.\u003c\/p\u003e\u003cp\u003ePlease note\u003c\/p\u003e\u003cp\u003eThe product names, ingredients and percentages indicated in the descriptions are purely indicative and may be subject to changes or updates by the manufacturing companies. Due to the impossibility of adapting to these updates in real time, the photos and technical information of the products included on Dottortili.com may differ from those shown on the label or otherwise disseminated by the manufacturing companies. The only identification element appears to be the ministerial code MINSAN. The online pharmacy Dottortili.com does not guarantee the truthfulness and timeliness of the information published and declines any responsibility for any errors, omissions or failure to update the same. Dottortili.com assumes no responsibility for damages of any nature that may arise from access to the information published.\u003c\/p\u003e\u003cp\u003eData source: Farmadati Italia\u003c\/p\u003e\u003cp\u003eWebsite: www.farmadati.it\u003c\/p\u003e\u003cp\u003eThe Farmadati Italia database is used by almost all pharmacies, parapharmacies, herbalist shops, health shops, large-scale retail trade, computerized doctors, etc. thanks to the guarantee of historical reliability, seriousness and professionalism of the company on the national territory.\u003c\/p\u003e\u003cp\u003eThe Farmadati Italia S.r.l management system complies with the requirements of the UNI EN ISO 9001:2015 standards for quality management systems and UNI CEI ISO\/IEC 27001:2017 for information security management systems.\u003c\/p\u003e","brand":"Sanofi","offers":[{"title":"Default Title","offer_id":40207822454899,"sku":"006979088","price":17.01,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/sanofi-spa-buscopan-40-compresse-rivestite-10-mg-farmacia-dottor-tili-1213792764.jpg?v=1767125423"},{"product_id":"codex-30-capsule-5-miliardi-250-mg-blister","title":"Codex 30 Capsules 5 Billion 250 mg Blister","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eProphylaxis and treatment of intestinal dysmicrobism and related diarrheal syndromes.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eCodex 5 billion hard capsules\u003c\/u\u003e Each capsule contains: active ingredient: \u003ci\u003eSaccharomyces boulardii\u003c\/i\u003e 5 billion live germs (in the form of 250 mg of freeze-dried powder) Excipient with known effect: lactose. For the full list of excipients, see section 6.1\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eCodex 5 billion hard capsules\u003c\/u\u003e Each capsule contains: lactose; magnesium stearate; jelly; titanium dioxide\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to the active substance or to any of the excipients listed in paragraph 6.1. Patients with central venous catheters. Allergy to yeasts, in particular to \u003ci\u003eSaccharomyces boulardii\u003c\/i\u003e. Critically ill patients or immunocompromised patients, due to the risk of fungaemia (see section 4.4.).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAdults: 1-2 capsules 2 times a day. Unless otherwise prescribed by a doctor. We recommend administering Codex at regular intervals, possibly on an empty stomach or at least 15 minutes before meals. During therapy with antibiotics, administer Codex at the same time as these. Due to the risk of airborne contamination, the capsules should not be opened in patient environments. When handling probiotics to be administered to patients, healthcare personnel should wear disposable gloves, dispose of them immediately after use and wash their hands thoroughly (see section 4.4).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo special precautions for storage.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDo not mix Codex with too hot liquids or alcoholic solutions. In view of the fungal nature of \u003ci\u003eSaccharomyces boulardii\u003c\/i\u003e, Codex should not be administered during topical or systemic antifungal therapy. \u003ci\u003e \u003cu\u003eGeneral information\u003c\/u\u003e \u003c\/i\u003e - Treatment of diarrhea is not a substitute for rehydration, when necessary. The extent of rehydration and its route of administration must be commensurate with the severity of the diarrhea and the age and state of health of the patient. - Very rare cases of fungaemia have occurred (and positive blood cultures for strains of \u003ci\u003eSaccharomyces\u003c\/i\u003e) and sepsis mostly in patients with a central venous catheter, critically ill or immunocompromised, resulting in pyrexia in most cases. In the majority of cases the outcome was satisfactory after stopping treatment with \u003ci\u003eSaccharomyces boulardii\u003c\/i\u003e, administration of antifungal treatment and removal of the catheter where necessary. However, the outcome has been fatal in some critically ill patients (see sections 4.3 and 4.8). - As with all drugs based on live microorganisms, particular attention must be paid when handling the product, mainly in the presence of patients with a central venous catheter, but also in the presence of patients with a peripheral venous catheter, even if not treated with \u003ci\u003eSaccharomyces boulardii\u003c\/i\u003e, in order to avoid contact contamination and\/or the spread of microorganisms by air (see paragraph 4.2). \u003ci\u003e \u003cu\u003eImportant information about some excipients\u003c\/u\u003e \u003c\/i\u003e \u003ci\u003e CODEX 5 billion hard capsules \u003c\/i\u003e - contains \u003ci\u003elactose.\u003c\/i\u003e Patients suffering from rare hereditary problems of galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption should not take this medicine - it does not contain gluten.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIn view of the fungal nature of \u003ci\u003eSaccharomyces boulardii\u003c\/i\u003e, Codex should not be administered during topical or systemic antifungal therapy.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe following side effects have been reported following administration of Codex:\u003c\/p\u003e\n\u003cp\u003eSkin and subcutaneous tissue disorders - Very rare: allergic reactions: facial edema (angioedema), itching, hives (urticaria) and localized or systemic rashes.\u003c\/p\u003e\n\u003cp\u003eImmune system disorders - Very rare: Anaphylactic reaction or shock.\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders - Rare: Flatulence. Frequency not known: Constipation.\u003c\/p\u003e\n\u003cp\u003eInfections and infestations - Very rare: Fungemia in patients with central venous catheters and in critically ill or immunocompromised patients (see section 4.4). Frequency not known: Sepsis in critically ill or immunocompromised patients (see section 4.4).\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eReporting of suspected adverse reactions. \u003c\/i\u003e \u003ci\u003eReporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/i\u003e\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIn case of overdose, no special interventions are required.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo reliable information is available regarding teratogenicity in animals. Clinically, no cases of malformations and foetotoxic effects have been reported. However, since data from the monitoring of pregnant women exposed to the medicine are insufficient, it is not possible to exclude any risk. Despite the \u003ci\u003eSaccharomyces boulardii\u003c\/i\u003e is not absorbed, its administration during pregnancy and during the breastfeeding period should only be carried out in case of actual need under the direct supervision of the doctor who will evaluate the risk\/benefit ratio.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo studies on the effects on the ability to drive and use machines have been performed.\u003c\/p\u003e","brand":"Zambon","offers":[{"title":"Default Title","offer_id":40207822585971,"sku":"029032087","price":24.18,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/zambon-codex-30-capsule-5-miliardi-250-mg-blister-farmacia-dottor-tili-1254211182.jpg?v=1786732779"},{"product_id":"dicloreum-antinfiammatorio-locale-10-cerotti-medicati-180-mg","title":"Dicloreum Local Anti-inflammatory 10 Medicated Patches 180 mg","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eLocal treatment of painful and inflammatory conditions of a rheumatic or traumatic nature of joints, muscles, tendons and ligaments.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eA 180 mg medicated plaster contains: Active ingredient: Diclofenac hydroxyethylpyrrolidine 180 mg (equal to 140 mg of sodium Diclofenac) Excipients with known effects: 14 mg of methyl parahydroxybenzoate (E218), 7 mg of propyl parahydroxybenzoate (E216), 420 mg of propylene glycol and 2.8 mg of perfume (containing amyl cinnamale, amyl cinnamyl alcohol, benzyl alcohol, benzyl benzoate, benzyl salicylate, cinnammal, cinnamyl alcohol, citronellol, d-Limonene, eugenol, farinasol, geraniol, hexyl cinnamic aldehyde, hydroxycitronellal, isoeugenol, linalool, methyl heptin carbonate). For the full list of excipients, see section 6.1\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eGelatin, Povidone, D-Sorbitol 70% solution, Kaolin, Titanium dioxide, Propylene glycol, Methyl parahydroxybenzoate (E218), Propyl parahydroxybenzoate (E216), Disodium edetate, Tartaric acid, Dihydroxyaluminium aminoacetate, Sodium caramel, Sodium polyacrylate, 1,3-butylene glycol, Polysorbate 80, Perfume, Purified water, Synthetic felt, Plastic film.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e• Hypersensitivity to diclofenac, acetylsalicylic acid or other non-steroidal anti-inflammatory preparations (NSAIDs) or to any of the excipients of the finished product, as well as to isopropanol. • Patients in whom asthma attacks, urticaria or acute rhinitis have occurred after taking acetylsalicylic acid or other non-steroidal inflammatory drugs (NSAIDs). • Damaged skin, regardless of the type of lesion: exudative dermatitis, eczema, infected lesion, burns or wounds. • Third trimester of pregnancy and breastfeeding (see section 4.6). • Patients with active peptic ulcer. \u003ci\u003eChildren and adolescents:\u003c\/i\u003e Use in children and adolescents under 16 years of age is contraindicated.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eFor cutaneous use only. \u003cu\u003eDosage\u003c\/u\u003e The product should only be applied to intact, healthy skin and should not be applied when bathing or showering. The diclofenac medicated plaster must be used for the shortest time possible in relation to the indication of use. \u003ci\u003eAdults\u003c\/i\u003e The usual dosing regimen is 1 or 2 patches (or any other frequency evaluated in clinical studies for a specific product) per day (one application every 12 or 24 hours) for a period of up to 14 days (or for any other number of days the use has been evaluated in clinical studies for a specific product). If there is no improvement following the recommended treatment period, you should consult a doctor \u003ci\u003eChildren and adolescents under 16 years of age:\u003c\/i\u003e The use of this medicated plaster is not recommended in children and adolescents under 16 years of age because insufficient data are available to evaluate the safety and effectiveness of the medicine (see section 4.3). In adolescents aged 16 years and older, if the product is needed for a treatment period of more than 7 days for pain relief or if symptoms worsen, the patient or relatives of the adolescent are advised to consult a doctor. \u003ci\u003eElderly\u003c\/i\u003e This medicine should be used with caution in elderly patients as they are more predisposed to side effects (see section 4.4). \u003ci\u003ePatients with hepatic or renal insufficiency\u003c\/i\u003e For the use of diclofenac medicated plasters in patients with hepatic or renal insufficiency, consult section 4.4. \u003cu\u003eMethod of administration\u003c\/u\u003e Cut the bag containing the medicated plaster as indicated. Remove a medicated plaster, remove the plastic film used to protect the adhesive surface and apply the plaster to the joint or painful surface. If necessary, the patch can be held in place using an elastic band. Carefully close the envelope by pressing the edge where the closing cord is located. The patch must be used whole.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eStore at a temperature not exceeding 30°C.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIf diclofenac medicated plasters are used on large skin surfaces and for a prolonged period of time, the possibility of systemic adverse events cannot be excluded (see the Summary of Product Characteristics of the systemic formulations of diclofenac). The medicated plaster must be applied only to intact and healthy skin and must not be applied to damaged skin or open wounds. The patches should not come into contact with the eyes or mucous membranes. Side effects can be minimized by using the lowest effective dose for the shortest possible duration of treatment needed to control symptoms. - Do not use with an occlusive dressing that does not allow air to pass through. - Treatment must be stopped immediately if a skin rash develops after application of the medicated plaster. - Do not simultaneously administer topically or systemically another medicinal product based on diclofenac or other NSAIDs. - Although systemic effects should be limited, the medicated plaster should be used with caution in patients with renal, cardiac or hepatic impairment, history of peptic ulcer or inflammatory bowel disease or bleeding diathesis. Non-steroidal anti-inflammatory drugs should be used with particular caution in elderly patients who are more predisposed to side effects. - Patients should be advised not to expose themselves to direct sunlight or light from sunlamps for approximately one day after removal of the medicated plaster in order to reduce the risk of photosensitivity. Local anti-inflammatory Dicloreum contains: - methyl parahydroxybenzoate (E218) and propyl parahydroxybenzoate (E216) which may cause allergic reactions (even delayed). - 420 mg of propylene glycol per patch which may cause skin irritation. - a perfume containing allergens (amyl cinnamale, amyl cinnamyl alcohol, benzyl alcohol, benzyl benzoate, benzyl salicylate, cinnammal, cinnamyl alcohol, citronellol, d-Limonene, eugenol, farinasol, geraniol, hexyl cinnamic aldehyde, hydroxycitronellal, isoeugenol, linalool, methyl heptin carbonate) which may cause reactions allergic.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSince the systemic absorption of diclofenac following the use of medicated plasters is very low, the risk of developing clinically significant interactions with other medicinal products is negligible.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAdverse reactions (Table 1) are listed by frequency, the most frequent first, using the following convention: common (≥ 1\/100, \u003c 1\/10); uncommon (≥ 1\/1,000, \u003c 1\/100); rare (≥ 1\/10,000, \u003c 1\/1,000); very rare (\u003c 1\/10,000); Not known: cannot be estimated from available data.\u003c\/p\u003e\n\u003cp\u003eInfections and infestations.\u003c\/p\u003e\n\u003cp\u003eVery rare: Rash with pustules.\u003c\/p\u003e\n\u003cp\u003eImmune system disorders.\u003c\/p\u003e\n\u003cp\u003eVery rare: Hypersensitivity (including urticaria), angioneurotic edema, anaphylactoid reaction.\u003c\/p\u003e\n\u003cp\u003eRespiratory, thoracic and mediastinal disorders.\u003c\/p\u003e\n\u003cp\u003eVery rare: Asthma.\u003c\/p\u003e\n\u003cp\u003ePathologies of the skin and subcutaneous tissue.\u003c\/p\u003e\n\u003cp\u003eCommon: Rash, eczema, erythema, dermatitis (including allergic dermatitis and contact dermatitis), pruritus.\u003c\/p\u003e\n\u003cp\u003eRare: Bullous dermatitis (e.g. bullous erythema), dry skin.\u003c\/p\u003e\n\u003cp\u003eVery rare: Photosensitivity reactions\u003c\/p\u003e\n\u003cp\u003eSystemic pathologies and conditions relating to the administration site.\u003c\/p\u003e\n\u003cp\u003eCommon: Administration site reactions.\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eReporting of suspected adverse reactions\u003c\/u\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the risk\/benefit ratio of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo cases of overdose have been reported with diclofenac medicated plasters. Should systemic side effects occur due to incorrect use or accidental overdose (e.g. in children) with the product, the general supportive measures to be taken in case of intoxication with non-steroidal anti-inflammatory drugs are recommended.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003ePregnancy\u003c\/u\u003e The systemic concentration of diclofenac, compared to oral formulations, is lower after topical administration. Referring to the experience of treatment with NSAIDs for systemic administration, the following is recommended: Inhibition of prostaglandin synthesis may have negative effects on pregnancy and\/or embryo\/foetal development. Results of epidemiological studies suggest an increased risk of miscarriage and cardiac malformation and gastroschisis after the use of a prostaglandin synthesis inhibitor in the early stages of pregnancy. The absolute risk of cardiac malformations increased from less than 1% to approximately 1.5%. The risk was thought to increase with the dose and duration of therapy. In animals, the administration of prostaglandin synthesis inhibitors has been shown to cause an increase in pre- and post-implantation loss and embryo-foetal mortality. Furthermore, an increased incidence of various malformations, including cardiovascular malformations, has been reported in animals administered prostaglandin synthesis inhibitors during the organogenetic period. During the first and second trimester of pregnancy diclofenac should not be administered unless strictly necessary. If diclofenac is used by a woman attempting to conceive, or during the first and second trimester of pregnancy, the dose should be kept as low as possible and the duration of treatment as short as possible. During the third trimester of pregnancy, all inhibitors of prostaglandin synthesis can expose the fetus to: - cardiopulmonary toxicity (with premature closure of the ductus arteriosus and pulmonary hypertension); - renal dysfunction, which can progress to renal failure with oligo-hydramnios; the mother and the newborn, at the end of pregnancy, to: - possible prolongation of bleeding time, and anti-aggregating effect which can occur even at very low doses; - inhibition of uterine contractions resulting in delayed or prolonged labor. Consequently, diclofenac is contraindicated during the third trimester of pregnancy. \u003cu\u003eBreastfeeding\u003c\/u\u003e Like other NSAIDs, diclofenac passes into breast milk in small quantities. However, at therapeutic doses of diclofenac medicated plasters, no effects on the infant are expected. Due to the lack of controlled studies in breastfeeding women, the product should be used during breastfeeding only under the advice of a healthcare professional. In this circumstance, diclofenac medicated plasters should not be applied to the breasts of breastfeeding mothers, nor elsewhere on large areas of skin or for a prolonged period of time (see section 4.4).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe application of diclofenac medicated plasters does not alter the ability to drive or use machinery.\u003c\/p\u003e","brand":"Alfasigma","offers":[{"title":"Default Title","offer_id":40207822913651,"sku":"042685014","price":23.81,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/alfasigma-dicloreum-antinfiammatorio-locale-10-cerotti-medicati-180-mg-farmacia-dottor-tili-1254211180.jpg?v=1786732718"},{"product_id":"benagol-miele-e-limone-36-pastiglie-mal-di-gola","title":"Benagol Honey and Lemon 36 Tablets Sore Throat","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAntiseptic of the oral cavity.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eBENAGOL Ginger and Spice flavored tablets Active ingredients: 2,4-dichlorobenzyl alcohol 1.2 mg; amylmetacresol 0.6 mg. Excipients with known effects: liquid sucrose, liquid glucose (containing sulphites and wheat starch), spice flavoring and ginger flavoring (containing cinnamale, citral, citronellol, eugenol, farinasol, geraniol, isoeugenol and linalool). BENAGOL Honey and Lemon flavored tablets Active ingredients: 2,4-dichlorobenzil alcohol 1.2 mg; amylmetacresol 0.6 mg. Excipients with known effects: liquid glucose (containing sulphites and wheat starch), liquid sucrose, mint essence and lemon essence (containing citral, d-limonene, geraniol and linalool), honey (invert sugar). BENAGOL Sugar-Free Lemon Flavor Lozenges Active ingredients: 2,4-dichlorobenzil alcohol 1.2 mg; amylmetacresol 0.6 mg. Excipients with known effects: liquid maltitol, isomalt, lemon flavoring (containing benzyl alcohol, citral, citronellol, d-limonene, geraniol and linalool). BENAGOL Strawberry flavor tablets without sugar Active ingredients: 2,4-dichlorobenzyl alcohol 1.2 mg; amylmetacresol 0.6 mg. Excipients with known effects: liquid maltitol, isomalt, strawberry flavor (containing propylene glycol and benzyl alcohol). BENAGOL Cold Mint flavor tablets Active ingredients: 2,4-dichlorobenzyl alcohol 1.2 mg; amylmetacresol 0.6 mg. Excipients with known effects: liquid sucrose, liquid glucose (containing sulphites and wheat starch), mint flavor and eucalyptus essence (containing propylene glycol, benzyl alcohol, cinnamyl alcohol, citral, citronellol, d-limonene, eugenol and linalool). BENAGOL Menthol-Eucalyptol flavor tablets Active ingredients: 2,4-dichlorobenzil alcohol 1.2 mg; amylmetacresol 0.6 mg; menthol 8.0 mg. Excipients with known effects: liquid sucrose, liquid glucose (containing sulphites and wheat starch) and eucalyptus essence (containing d-limonene). BENAGOL Tablets with Vitamin C Orange flavor Active ingredients: 2,4-dichlorobenzil alcohol 1.2 mg; amylmetacresol 0.6 mg; sodium ascorbate 74.9 mg; ascorbic acid 33.5 mg. Excipients with known effects: liquid sucrose, liquid glucose (containing sulphites and wheat starch), orange flavor (containing citral, citronellol, d-limonene, geraniol, linalool), propylene glycol. For the full list of excipients, see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eBENAGOL Ginger and Spice flavored tablets\u003c\/u\u003e: One tablet contains: liquid sucrose, liquid glucose (containing sulphites and wheat starch), tartaric acid, anthocyanins (E163) (containing sodium), plum flavour, cream flavour, spice flavor and ginger flavor (containing cinnamale, citral, citronellol, eugenol, farfalle, geraniol, isoeugenol and linalool), medium-chain saturated triglycerides. \u003cu\u003eBENAGOL Honey and Lemon flavored tablets\u003c\/u\u003e: One tablet contains: mint essence and lemon essence (containing citral, d-limonene, geraniol and linalool), tartaric acid, honey (invert sugar), liquid glucose (containing sulphites and wheat starch), liquid sucrose. \u003cu\u003eBENAGOL Menthol-Eucalyptol flavor tablets\u003c\/u\u003e: One tablet contains: indigo carmine (E 132) (containing sodium), eucalyptus essence (containing d-limonene), tartaric acid, liquid sucrose, liquid glucose (containing sulphites and wheat starch). \u003cu\u003eBENAGOL Orange flavored tablets with Vitamin C\u003c\/u\u003e: One tablet contains: liquid sucrose, liquid glucose (containing sulphites and wheat starch), tartaric acid, orange flavor (containing citral, citronellol, d-limonene, geraniol and linalool), levomenthol, propylene glycol. \u003cu\u003eBENAGOL Lemon flavored tablets without sugar\u003c\/u\u003e: One tablet contains: lemon flavoring (containing benzyl alcohol, citral, citronellol, dlimonene, geraniol and linalool), sodium saccharin, tartaric acid, liquid maltitol, isomalt. \u003cu\u003eBENAGOL Strawberry flavored tablets without sugar\u003c\/u\u003e: One tablet contains: strawberry flavor (containing propylene glycol and benzyl alcohol), anthocyanins (E163) (containing sodium), sodium saccharin, tartaric acid, liquid maltitol, isomalt. \u003cu\u003eBENAGOL Cold Mint flavor tablets\u003c\/u\u003e: One tablet contains: xylitol, levomenthol, mint flavor and eucalyptus essence (containing propylene glycol, benzyl alcohol, cinnamyl alcohol, citral, citronellol, d-limonene, eugenol and linalool), liquid sucrose, liquid glucose (containing sulphites and wheat starch).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to the active substances or to any of the excipients listed in paragraph 6.1. Do not administer to children under 6 years of age. BENAGOL Menthol-Eucalyptol flavor is contraindicated in children with a history of epilepsy or febrile convulsions. Do not administer BENAGOL Cold Mint flavor and BENAGOL Ginger and Spice flavor to children under 12 years of age.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eDosage\u003c\/u\u003e The lowest effective dose for the shortest duration necessary to relieve symptoms should be used. \u003cb\u003eAdults and children over 6 years of age:\u003c\/b\u003e One tablet every 2 or 3 hours. In children over 6 years of age, consult your doctor for an appropriate dosage. Do not exceed the recommended doses and in particular, for BENAGOL with Vitamin C Orange flavor and BENAGOL Cold Mint flavor, do not exceed the daily maximum of 8 tablets. For all other flavors of BENAGOL, do not exceed the maximum daily dose of 12 tablets. \u003cu\u003eAdminister BENAGOL Cold Mint flavor and BENAGOL Ginger and Spice flavor to adults and children over the age of 12\u003c\/u\u003e. The duration of treatment with BENAGOL Menthol-Eucalyptol flavor must not exceed 3 days. BENAGOL Lemon flavor Without Sugar and BENAGOL Strawberry flavor Without Sugar are suitable for those patients who need to control their sugar and calorie intake. \u003ci\u003eElderly population\u003c\/i\u003e No data available. \u003cu\u003eMethod of administration\u003c\/u\u003e Oromucosal administration. The tablet should be dissolved slowly in the mouth.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDo not store above 25°C.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eBe careful with pre-school children as if the tablets are swallowed whole they may cause choking. In the event of the appearance of sensitization or irritation phenomena, administration should be discontinued and suitable treatment instituted. BENAGOL Menthol-Eucalyptol flavor contains terpene derivatives which, in excessive doses, can cause neurological disorders such as convulsions in infants and children. Treatment with BENAGOL Menthol-Eucalyptol flavor must not be prolonged for more than 3 days due to the risks associated with the accumulation of terpene derivatives, such as \u003ci\u003eexample camphor, cineol, niaouli, wild thyme, terpineol, terpine, citral, menthol and essential oils of pine needles, eucalyptus and turpentine\u003c\/i\u003e (due to their lipophilic properties the rate of metabolism and disposal is not known) in tissues and the brain, in particular neuropsychological disorders. A higher than recommended dose should not be used to avoid an increased risk of adverse drug reactions and disorders associated with overdose (see section 4.9). BENAGOL Menthol-Eucalyptol flavor is flammable, it should not be brought near flames. \u003ci\u003eImportant information about some excipients\u003c\/i\u003e \u003cu\u003eBENAGOL Ginger and Spice flavored tablets, BENAGOL Honey and Lemon flavored tablets\u003c\/u\u003e, \u003cu\u003eBENAGOL Menthol-Eucalyptol flavor tablets, BENAGOL Orange flavor tablets with Vitamin C, BENAGOL Cold Mint flavor tablets contain\u003c\/u\u003e Liquid glucose: - Patients suffering from rare hereditary problems of glucose-galactose malabsorption should not take this medicine. - To be taken into consideration in people suffering from diabetes mellitus: BENAGOL Ginger and Spice flavored tablets contains 1.10 g of glucose per tablet. BENAGOL Honey and Lemon flavored tablets contains 0.98 g of glucose per tablet. BENAGOL Menthol-Eucalyptol flavor tablets contains 1.01 g of glucose per tablet. BENAGOL Tablets with Vitamin C Orange flavor contains 0.97 g of glucose per tablet. BENAGOL Cold Mint flavor tablets contains 1.10 g of glucose per tablet. - Liquid glucose contains sulphites. These medicines can rarely cause serious hypersensitivity reactions and bronchospasm. - Liquid glucose contains wheat starch. These medicines contain only a very small amount of gluten (from wheat starch). These medicines are considered “gluten-free” and are very unlikely to cause problems if the patient has celiac disease. One tablet of BENAGOL Ginger and Spice flavored tablets contains no more than 22.04 micrograms of gluten. One tablet of BENAGOL Honey and Lemon flavored tablets contains no more than 19.52 micrograms of gluten. One tablet of BENAGOL Menthol-Eucalyptol flavor contains no more than 20.26 micrograms of gluten. One tablet of BENAGOL Tablets with Vitamin C Orange flavor contains no more than 19.38 micrograms of gluten. One tablet of BENAGOL Cold Mint flavor tablets contains no more than 22.04 micrograms of gluten. If the patient is allergic to wheat (a condition other than celiac disease) he should not take these medicines. Liquid sucrose: - Patients suffering from rare hereditary problems of fructose intolerance, glucose-galactose malabsorption, or sucrase isomaltase insufficiency should not take this medicine. - To be taken into consideration in people suffering from diabetes mellitus: BENAGOL Ginger and Spice flavored tablets contains 1.38 g of sucrose per tablet. BENAGOL Honey and Lemon flavored tablets contains 1.44 g of sucrose per tablet. BENAGOL Menthol-Eucalyptol flavor tablets contains 1.50 g of sucrose per tablet. BENAGOL Tablets with Vitamin C Orange flavor contains 1.44 g of sucrose per tablet. BENAGOL Cold Mint flavor tablets contains 1.38 g of sucrose per tablet. \u003cu\u003eBENAGOL Ginger and Spice flavored tablets, BENAGOL Menthol-Eucalyptol flavored tablets\u003c\/u\u003e, \u003cu\u003eBENAGOL Tablets with Vitamin C Orange flavor, BENAGOL Tablets Lemon flavor Without Sugar, BENAGOL Tablets Strawberry flavor Without Sugar\u003c\/u\u003e These medicines contain less than 1 mmol (23 mg) sodium per dose, i.e. essentially 'sodium-free'. \u003cu\u003eBENAGOL Lemon Flavor Tablets Without Sugar and BENAGOL Strawberry Flavor Tablets Without Sugar\u003c\/u\u003e These medicines contain liquid maltitol and isomalt. Patients with rare hereditary problems of fructose intolerance should not take this medicine. They may have a mild laxative effect. The caloric value of maltitol and isomalt is 2.3 kcal\/g. \u003cu\u003eBENAGOL Ginger and Spice flavored tablets\u003c\/u\u003e This medicine contains a flavoring which contains cinnamale, citral, citronellol, eugenol, farfalle, geraniol, isoeugenol and linalool. Cinnamale, citral, citronellol, eugenol, farfalle, geraniol, isoeugenol and linalool can cause allergic reactions. This medicine contains excipients that can cause a warm sensation in the mouth and throat when you suck the lozenge. \u003cu\u003eBENAGOL Honey and Lemon flavored tablets\u003c\/u\u003e This medicine contains a flavoring which contains citral, d-limonene, geraniol and linalool. Citral, d-limonene, geraniol and linalool can cause allergic reactions. This medicine contains honey (invert sugar). Patients suffering from rare hereditary problems of fructose intolerance, or glucose-galactose malabsorption, should not take this medicine. \u003cu\u003eBENAGOL Menthol-Eucalyptol flavor tablets\u003c\/u\u003e This medicine contains a flavoring which contains d-limonene. D-limonene can cause allergic reactions. \u003cu\u003eBENAGOL Orange flavored tablets with Vitamin C\u003c\/u\u003e This medicine contains a flavoring which contains citral, citronellol, d-limonene, geraniol and linalool. Citral, citronellol, d-limonene, geraniol and linalool can cause allergic reactions. This medicine contains 3 mg of propylene glycol per tablet. \u003cu\u003eBENAGOL Lemon flavored tablets without sugar\u003c\/u\u003e This medicine contains a flavoring which contains benzyl alcohol, citral, citronellol, d-limonene, geraniol and linalool. Benzyl alcohol, citral, citronellol, d-limonene, geraniol and linalool can cause allergic reactions. \u003cu\u003eBENAGOL Strawberry flavored tablets without sugar\u003c\/u\u003e This medicine contains a flavoring which contains benzyl alcohol. Benzyl alcohol can cause allergic reactions. This medicine contains 7.30 mg of propylene glycol in each tablet. \u003cu\u003eBENAGOL Cold Mint flavor tablets\u003c\/u\u003e This medicine contains a flavoring which contains benzyl alcohol, cinnamyl alcohol, citral, citronellol, d-limonene, eugenol and linalool. Benzyl alcohol, cinnamyl alcohol, citral, citronellol, d-limonene, eugenol and linalool can cause allergic reactions. This medicine contains 1.89 mg of propylene glycol in each tablet.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eBENAGOL Menthol-Eucalyptol flavor must not be used in conjunction with other products (medicines or cosmetics) containing terpene derivatives, regardless of the route of administration (oral, rectal, cutaneous, nasal or inhalation).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eBENAGOL Menthol - Eucalyptol flavour: due to the presence of menthol and in case of non-compliance with the recommended doses there may be a risk of convulsions in children and infants. Adverse reactions associated with the use of 2,4 dichlorobenzyl alcohol, amylmetacresol, levomenthol and ascorbic acid are listed below, divided by frequency and organ class. Frequencies are defined as: Very common (≥1\/10); Common (≥1\/100 and \u003c1\/10); Uncommon (≥1\/1000 and \u003c1\/100); Rare (≥1\/10000 and \u003c1\/1000); Very rare (\u003c1\/10000); Not known (frequency cannot be estimated from the available data). Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.\u003c\/p\u003e\n\u003cp\u003eImmune system disorders - Frequency: Rare. Adverse reactions: Hypersensitivity\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders - Frequency: Rare. Adverse reactions: Glossitis.\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders - Frequency: Not known. Adverse reactions: Abdominal pain, nausea, gastrointestinal discomfort.\u003c\/p\u003e\n\u003cp\u003eSkin and subcutaneous tissue disorders - Frequency: Not known. Adverse reactions: Skin rash.\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eReporting of suspected adverse reactions\u003c\/u\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eA possible overdose could only cause gastrointestinal disorders, for which appropriate symptomatic treatments must be adopted. BENAGOL Menthol-Eucalyptol flavour: in case of accidental oral intake or incorrect administration in infants and children there may be a risk of neurological disorders. If necessary, administer appropriate symptomatic treatment in specialized treatment centers.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIn pregnant and breastfeeding women, the product should be administered only if clearly necessary. \u003cu\u003ePregnancy\u003c\/u\u003e There are no, or limited numbers, of data relating to the use of the active ingredients of BENAGOL in pregnant women. BENAGOL Menthol-Eucalyptol flavor is not recommended during pregnancy and in women of childbearing age who do not use contraceptive measures. \u003cu\u003eBreastfeeding\u003c\/u\u003e It is not known whether the active substances or their metabolites are excreted in breast milk. The risk to newborns and infants cannot be excluded. Ascorbic acid or its metabolites are excreted in breast milk. \u003cu\u003eFertility\u003c\/u\u003e No data are available regarding the effect on fertility. BENAGOL Menthol-Eucalyptol flavor is not recommended in women of childbearing age who are not using contraceptive measures.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo effects on the ability to drive or use machines are reported.\u003c\/p\u003e","brand":"Reckitt Benckiser","offers":[{"title":"Default Title","offer_id":40207822946419,"sku":"016242149","price":15.72,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/reckitt-benckiser-benagol-miele-e-limone-36-pastiglie-mal-di-gola-farmacia-dottor-tili-1258975935.jpg?v=1789562711"},{"product_id":"moment-200mg-analgesico-36-compresse-rivestite","title":"Moment 200mg Analgesic 36 Coated Tablets","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003ePain of various origins and nature (headache, toothache, neuralgia, osteo-articular and muscular pain, menstrual pain). Adjuvant in the symptomatic treatment of fever and flu.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eEach coated tablet contains: \u003cu\u003eActive ingredient\u003c\/u\u003e: ibuprofen 200 mg. For the full list of excipients see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eCorn starch, sodium carboxymethyl starch, povidone, colloidal anhydrous silica, talc, hydroxypropyl cellulose, gum arabic, sucrose, Macrogol 6000, light magnesium carbonate, titanium dioxide.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e• Do not administer to children under 12 years of age. • Pregnancy and breastfeeding. • Hypersensitivity to the active ingredient, to other antirheumatic drugs (acetylsalicylic acid, etc.) or to any of the excipients. • Active or severe gastroduodenal ulcer or other gastropathies. • History of gastrointestinal hemorrhage or perforation related to previous active treatment or history of recurrent peptic hemorrhage\/ulcer (two or more distinct episodes of demonstrated ulceration or bleeding). • Severe hepatic or renal insufficiency. • Severe heart failure.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAdults and adolescents over 12 years: 1–2 tablets, 2–3 times a day. Do not exceed the dose of 6 tablets per day. If the use of the medicine is necessary for more than 3 days in adolescents, or in the case of worsening of symptoms, the doctor should be consulted. Do not exceed the recommended doses; in particular elderly patients should stick to the minimum dosages indicated above. Take the product on a full stomach.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThis medicine does not require any particular storage temperature.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e• In asthmatic patients the product must be used with caution, after consulting the doctor. • The use of Moment, like any drug that inhibits the synthesis of prostaglandins and cyclooxygenase, is not recommended in women who intend to become pregnant. • The administration of Moment should be suspended in women who have fertility problems or who are undergoing fertility investigations. • The use of Moment should be avoided concomitantly with NSAIDs, including selective COX-2 inhibitors. • Side effects can be minimized by using the lowest effective dose for the shortest possible duration of treatment needed to control symptoms (see paragraphs below on gastrointestinal and cardiovascular risks). • Cardiovascular and cerebrovascular effects: clinical studies and epidemiological data suggest that the use of ibuprofen, especially at high doses (2400 mg\/day) and for long-term treatments, may be associated with a modest increase in the risk of arterial thrombotic events (e.g. myocardial infarction or stroke). In general, epidemiological studies do not suggest that low doses of ibuprofen (e.g. ≤ 1200 mg\/day) are associated with an increased risk of myocardial infarction. • There is a risk of impaired renal function in dehydrated adolescents • Elderly: Elderly patients have an increased frequency of adverse reactions to NSAIDs, especially gastrointestinal haemorrhages and perforations, which may be fatal (see section 4.2). • Gastrointestinal haemorrhage, ulceration and perforation: Gastrointestinal haemorrhage, ulceration and perforation, which may be fatal, have been reported at any time during treatment with all NSAIDs, with or without warning symptoms or previous history of serious gastrointestinal events. • In the elderly and in patients with a history of ulcer, especially if complicated by haemorrhage or perforation (see section 4.3), the risk of gastrointestinal haemorrhage, ulceration or perforation is higher with increased doses of NSAIDs. These patients should start treatment with the lowest available dose. Concomitant use of protective agents (misoprostol or proton pump inhibitors) should be considered for these patients and also for patients taking low doses of aspirin or other drugs that may increase the risk of gastrointestinal events (see below and section 4.5). Patients with a history of gastrointestinal toxicity, particularly elderly, should report any unusual gastrointestinal symptoms (especially gastrointestinal haemorrhage) particularly in the initial stages of treatment. • Carefully monitor patients taking concomitant medications that may increase the risk of ulceration or bleeding, such as oral corticosteroids, anticoagulants such as warfarin, selective serotonin reuptake inhibitors or antiplatelet agents such as aspirin (see section 4.5). • When gastrointestinal bleeding or ulceration occurs in patients taking Moment, treatment should be discontinued. • NSAIDs should be administered with caution to patients with a history of gastrointestinal disease (ulcerative colitis, Crohn's disease) as these conditions may be exacerbated (see section 4.8). • Caution is required before starting treatment in patients with a positive history of hypertension and\/or heart failure since fluid retention, hypertension and edema have been reported in association with treatment with NSAIDs. • Serious skin reactions, some of them fatal, including exfoliative dermatitis, Stevens-Johnson syndrome and toxic epidermal necrolysis, have been reported very rarely in association with the use of NSAIDs (see section 4.8). In the early stages of therapy patients appear to be at higher risk: the onset of the reaction occurs in most cases within the first month of treatment. Moment should be discontinued at the first appearance of skin rash, mucosal lesions or any other sign of hypersensitivity. • Moment contains: – sucrose: patients suffering from rare hereditary problems of fructose intolerance, glucose-galactose malabsorption, or sucrase isomaltase insufficiency should not take this medicine.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e• Possible interactions with coumarin-type anticoagulants must be kept in mind: patients undergoing treatment with these drugs must consult their doctor before taking the product. It is also advisable to seek medical advice in case of any concomitant therapy before administering the product. • Corticosteroids: increased risk of gastrointestinal ulceration or haemorrhage (see section 4.4). • Anticoagulants: NSAIDs may increase the effects of anticoagulants, such as warfarin (see section 4.4). • Antiplatelet agents and selective serotonin reuptake inhibitors (SSRIs): increased risk of gastrointestinal bleeding (see section 4.4). • Diuretics, ACE inhibitors and Angiotensin II antagonists: NSAIDs can reduce the effect of diuretics and other antihypertensive drugs. In some patients with compromised renal function (e.g. dehydrated patients or elderly patients with compromised renal function) co-administration of an ACE inhibitor or an angiotensin II antagonist and agents that inhibit the cyclo-oxygenase system may lead to further deterioration of renal function, including possible acute renal failure, which is usually reversible. These interactions should be considered in patients taking Moment concomitantly with ACE inhibitors or angiotensin II antagonists. Therefore, the combination should be administered with caution, especially in elderly patients. • Patients should be adequately hydrated and consideration should be given to monitoring renal function after initiation of concomitant therapy. • Experimental data indicate that ibuprofen can inhibit the effects of low-dose acetylsalicylic acid on platelet aggregation when the drugs are administered concomitantly. However, the paucity of data and the uncertainties relating to their application to the clinical situation do not allow definitive conclusions to be drawn for the continuous use of ibuprofen; There appears to be no clinically relevant effects from occasional use of ibuprofen (see section 5.1).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eSkin effects\u003c\/u\u003e Sometimes allergic skin rashes may occur (erythema, itching, urticaria). Bullous reactions including Stevens–Johnson syndrome and toxic epidermal necrolysis (very rarely). \u003cu\u003eGastrointestinal effects\u003c\/u\u003e The most commonly observed adverse events are gastrointestinal in nature. Peptic ulcers, perforation or gastrointestinal haemorrhage, sometimes fatal, may occur, particularly in the elderly (see section 4.4). After administration of Moment the following have been reported: feeling of weight in the stomach, nausea, vomiting, diarrhoea, flatulence, constipation, dyspepsia, abdominal pain, melena, haematemesis, ulcerative stomatitis, exacerbation of colitis and Crohn's disease (see section 4.4). Less frequently, gastritis has been observed. \u003cu\u003eCardiovascular effects \u003c\/u\u003e Edema, hypertension and heart failure have been reported in association with treatment with NSAIDs. Clinical studies and epidemiological data suggest that the use of ibuprofen (especially at high doses 2400 mg\/day) and for long-term treatments, may be associated with a modest increase in the risk of arterial thrombotic events (e.g. myocardial infarction or stroke) (see Section 4.4). These phenomena rapidly regress upon suspension of treatment.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIn case of overdose, gastric lavage and correction of blood electrolytes are indicated. There is no specific antidote for ibuprofen.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003ePregnancy\u003c\/u\u003e Inhibition of prostaglandin synthesis can negatively affect pregnancy and\/or embryo\/foetal development. Results of epidemiological studies suggest an increased risk of miscarriage and cardiac malformation and gastroschisis after the use of a prostaglandin synthesis inhibitor in the early stages of pregnancy. The absolute risk of cardiac malformations increased from less than 1% to approximately 1.5%. The risk was thought to increase with the dose and duration of therapy. In animals, the administration of prostaglandin synthesis inhibitors has been shown to cause an increase in pre- and post-implantation loss and embryo-foetal mortality. Furthermore, an increased incidence of various malformations, including cardiovascular malformations, has been reported in animals to which prostaglandin synthesis inhibitors were administered during the organogenetic period. During the third trimester of pregnancy, all inhibitors of prostaglandin synthesis can expose: the fetus to: – cardiopulmonary toxicity (with premature closure of the ductus arteriosus and pulmonary hypertension); – renal dysfunction, which can progress to renal failure with oligo-hydramnios; the mother and the newborn, at the end of pregnancy, to: – possible prolongation of bleeding time, and anti-aggregating effect which can occur even at very low doses; – inhibition of uterine contractions resulting in delayed or prolonged labor.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAs a rule, the use of ibuprofen does not alter the ability to drive or use other machinery. However, patients whose activity requires vigilance should use caution if they notice drowsiness, dizziness or depression during ibuprofen therapy.\u003c\/p\u003e","brand":"Angelini","offers":[{"title":"Default Title","offer_id":40207823011955,"sku":"025669185","price":14.42,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/products\/angelini-spa-moment-200mg-analgesico-36-compresse-rivestite-farmacia-dottor-tili-1213792749.jpg?v=1767125589"},{"product_id":"mag-2-orosolubile-20-bustine-2-25-g","title":"Mag 2 Orosolubile 20 Sachets 2.25 g","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eMagnesium deficiency states.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003e \u003cu\u003eOne vial of oral solution contains\u003c\/u\u003e:\u003c\/i\u003e \u003ci\u003eactive ingredient:\u003c\/i\u003e \u003cb\u003emagnesium pidolate 1,500 g (corresponding to 122 mg of Mg ion\u003csup\u003e++\u003c\/sup\u003e).\u003c\/b\u003e Excipients with known effects: sucrose, sodium methyl parahydroxybenzoate, sodium propyl parahydroxybenzoate. \u003ci\u003e \u003cu\u003eA single-dose sachet of oral solution contains\u003c\/u\u003e:\u003c\/i\u003e\u003ci\u003eactive ingredient:\u003c\/i\u003e \u003cb\u003emagnesium pidolate 1,500 g (corresponding to 122 mg of Mg ion\u003csup\u003e++\u003c\/sup\u003e).\u003c\/b\u003e Excipients with known effects: sucrose, sodium methyl parahydroxybenzoate, sodium propyl parahydroxybenzoate. \u003ci\u003e \u003cu\u003eOne sachet of powder for oral solution contains\u003c\/u\u003e:\u003c\/i\u003e \u003ci\u003eactive ingredient:\u003c\/i\u003e \u003cb\u003emagnesium pidolate 2,250 g (corresponding to 184 mg of Mg ion\u003csup\u003e++\u003c\/sup\u003e).\u003c\/b\u003e Excipients with known effects: sucrose. For the full list of excipients, see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eMAG2 1.5 g\/10 ml oral solution\u003c\/i\u003e \u003cb\u003eSucrose\u003c\/b\u003e, orange flavour, \u003cb\u003esodium methyl parahydroxybenzoate, sodium propyl parahydroxybenzoate\u003c\/b\u003e, purified water. \u003ci\u003eMAG2 2.25 g powder for oral solution \u003c\/i\u003e Sodium saccharin, citric acid monohydrate, \u003cb\u003esucrose\u003c\/b\u003e, lemon flavour.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to the active substance or to any of the excipients listed in paragraph 6.1. Severe renal insufficiency (creatinine clearance less than 30 mL\/min). Not to be administered to subjects undergoing digitalis therapy.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eDosage\u003c\/u\u003e \u003ci\u003eFor adults only:\u003c\/i\u003e 3 vials or 3 single-dose sachets of solution or 2 sachets of powder per day. \u003ci\u003ePediatric population\u003c\/i\u003e In children, the dosage may be established by the doctor after consulting them. Warning: use only for short treatment periods. \u003ci\u003eInstructions for use\u003c\/i\u003e \u003cu\u003eMAG2 1.5 g\/10 ml oral solution\u003c\/u\u003e: It is advisable to shake before use. To open the vial, twist the top and peel it off. Take the contents of the vial as is or dilute it in water. \u003cu\u003eMAG2 2.25 g powder for oral solution\u003c\/u\u003e: Dissolve the contents of a sachet in water.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eOral solution\u003c\/u\u003e: Store below 25°C. \u003cu\u003ePowder for oral solution\u003c\/u\u003e: This medicinal product does not require any special storage conditions.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIf there is concomitant calcium deficiency, the magnesium deficiency must be corrected before administering supplemental calcium. In patients with moderate renal insufficiency it is necessary to reduce the dosage and monitor renal function and magnesemia, due to the risk associated with hypermagnesemia. It is appropriate to consider the possibility that depression of cardiovascular activity may occur during treatment. Each vial of MAG2 solution contains 3.5 g of sucrose. Each single-dose sachet of MAG2 solution contains 3.5 g of sucrose. Each sachet of MAG2 powder contains 2.985 g of sucrose. If taken in accordance with the recommended dose, the daily intake of sucrose corresponds to 10.5 g for vials and single-dose sachets of solution and 5.97 g for sachets of powder. Patients suffering from rare hereditary problems of fructose intolerance, glucose-galactose malabsorption, or sucrase-isomaltase insufficiency should not take this medicine. MAG2 oral solution contains parahydroxybenzoates (sodium methyl parahydroxybenzoate and sodium propyl parahydroxybenzoate): may cause allergic reactions (even delayed). MAG2 vials, single-dose sachets of solution and powder for oral solution contain less than 1 mmol (23 mg) sodium per vial or sachet, i.e. they are essentially “sodium-free”.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIn case of concomitant treatment with oral tetracyclines, the administration of MAG2 must be delayed for at least 3 hours. Quinolones should be administered at least 2 hours before or 6 hours after administration of magnesium products to avoid interference with their absorption. Concomitant administration of magnesium-based products and cholecalciferol (vitamin D3) can lead to the appearance of hypercalcemia. The concomitant use of preparations containing calcium or phosphate salts is not recommended as these products prevent the intestinal absorption of magnesium. The simultaneous intake of magnesium-based products with drugs that depress the Central Nervous System can enhance the effects of magnesium on the CNS and must be carefully evaluated.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe following convention has been used for the classification of undesirable effects: very common ≥ 1\/10; common ≥ 1\/100 and \u003c 1\/10; uncommon ≥ 1\/1000 and \u003c 1\/100; rare ≥ 1\/10,000 and \u003c 1\/1,000); very rare \u003c 1\/10,000 and not known (frequency cannot be estimated from the available data). \u003cu\u003eGastrointestinal disorders\u003c\/u\u003e. Frequency not known: gastrointestinal disorders, diarrhoea, abdominal pain. \u003cu\u003ePathologies of the skin and subcutaneous tissue\u003c\/u\u003e. Frequency not known: skin reactions. \u003cu\u003eImmune system disorders.\u003c\/u\u003e Frequency not known: hypersensitivity. Exceptional cases of individual intolerance to magnesium have been reported, which can be treated with oral or parenteral antihistamines. \u003cb\u003eReporting of suspected adverse reactions\u003c\/b\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/web\/guest\/content\/segnalazioni-reazioni-avverse.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eSigns and symptoms\u003c\/u\u003e Overdose of oral magnesium does not, in general, induce toxic reactions in the presence of normal renal function. Magnesium poisoning can, however, develop in cases of severe kidney failure. The toxic effect depends mainly on serum magnesium levels and the signs are as follows: drop in blood pressure, nausea, vomiting, depression of the Central Nervous System, decreased reflexes, ECG abnormalities (e.g. cardiac rhythm disturbances), onset of respiratory depression, coma, cardiac arrest, respiratory paralysis, anuric syndrome and disorders of neuromuscular transmission. \u003cu\u003eTherapy\u003c\/u\u003e Treatment must include rehydration with restoration of abundant diuresis or forced diuresis. In the presence of renal failure, hemodialysis or peritoneal dialysis is necessary.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eLimited data are available on the use of MAG2 in pregnant women. However, no conclusions can be drawn about whether the use of MAG2 is safe during pregnancy. MAG2 can be used during pregnancy only if the potential benefits to the mother outweigh the potential risks, including those to the fetus. Magnesium is considered compatible with breastfeeding.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo particular recommendations.\u003c\/p\u003e","brand":"Sanofi","offers":[{"title":"Default Title","offer_id":40207823143027,"sku":"025519048","price":16.65,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/sanofi-mag-2-orosolubile-20-bustine-2-25-g-farmacia-dottor-tili-1254211177.jpg?v=1786732630"},{"product_id":"aspirina-dolore-infiammazione-20-compresse-500-mg","title":"Aspirin Pain Inflammation 20 Tablets 500mg","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSymptomatic treatment of fever and\/or mild to moderate pain, such as headache, flu syndrome, toothache, muscle pain.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eEach tablet contains 500 mg of acetylsalicylic acid. Excipients with known effect: one coated tablet contains 3.12 mmol (or 71.7 mg) sodium. For the full list of excipients, see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eTablet core: Colloidal silicon dioxide, Sodium carbonate. Coating: Carnauba wax, Hypromellose, Zinc stearate.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e• Hypersensitivity to acetylsalicylic acid or other salicylates, or to any of the excipients listed in section 6.1, • history of asthma or hypersensitivity reactions (e.g. urticaria, angioedema, severe rhinitis, shock) induced by the administration of salicylates or substances with a similar action, in particular non-steroidal anti-inflammatory drugs (NSAIDs), • active peptic ulcer, • diathesis hemorrhagic, • severe renal failure (GFR\u003ci\u003e\u0026lt; 30\u003c\/i\u003e \u003ci\u003eml\/min\/ 1.73 m²\u003c\/i\u003e), • severe hepatic failure, • severe uncontrolled heart failure, • concomitant administration of methotrexate in doses exceeding 15 mg per week, for anti-inflammatory doses of acetylsalicylic acid, or for analgesic or antipyretic doses (see section 4.5), • concomitant administration of oral anticoagulants for anti-inflammatory doses of acetylsalicylic acid, or for analgesic or antipyretic doses and in patients with history of gastroduodenal ulcers (see section 4.5), • from the beginning of the 6th month of pregnancy (beyond the twenty-fourth week of amenorrhea) (see section 4.6), • children and young people under 16 years of age.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eDosage\u003c\/u\u003e Adults and children (from 16 years onwards): 1 to 2 tablets for each dose to be repeated as needed after a minimum period of 4 hours. The maximum daily dose should not exceed 6 tablets. Elderly (from 65 years): 1 tablet for each dose to be repeated as needed after a minimum period of 4 hours. The maximum daily dose should not exceed 4 tablets. Acetylsalicylic acid should not be taken for more than 3 days (in case of fever) or 3 - 4 days (in case of pain) unless otherwise indicated by the doctor. Pediatric population: Acetylsalicylic acid should not be used in children and adolescents under 16 years of age without a medical prescription. Acetylsalicylic acid should be used with caution in patients with abnormal liver or kidney function or circulatory problems. \u003cu\u003eMethod of administration\u003c\/u\u003e For oral use. The tablets should be taken with an adequate quantity of water. To open the strip, tear from the edge at any position.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDo not store above 30°C. Store in the original packaging to protect from light and humidity.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIn case of combination with other medicinal products, to avoid any risk of overdose, check that acetylsalicylic acid is absent from the composition of these other medicines. • Reye's syndrome, a very rare and potentially fatal disease, has been described in children with symptoms of viral infections (particularly chickenpox and flu episodes) with or without taking acetylsalicylic acid. Consequently, acetylsalicylic acid should be administered to children in these conditions only after medical advice and when other measures have proven ineffective. In case of persistent vomiting, changes in consciousness or abnormal behavior, treatment with acetylsalicylic acid should be discontinued. • In case of prolonged administration of high-dose analgesics, the headache attack should not be treated with higher doses. • Regular use of analgesics, particularly a combination of analgesics, may result in permanent kidney damage, with risk of renal failure. • The medicine must be used with particular caution in the following cases: patients with mild to moderate renal function impairment (\u003ci\u003eGFR ≥ 30 to \u003c 90 ml\/min\/ 1.73 m²\u003c\/i\u003e) or patients with impaired cardiovascular circulation (e.g. renal vascular disease, congestive heart failure, volume depletion, major surgery, sepsis or major bleeding events) as acetylsalicylic acid may further increase the risk of renal impairment and acute renal failure. • In some severe forms of G6PD deficiency, high doses of acetylsalicylic acid can cause hemolysis. In case of G6PD deficiency, acetylsalicylic acid should be administered under medical supervision. • Treatment monitoring should be intensified in the following cases: • in patients with a history of gastric or duodenal ulcer, gastrointestinal bleeding, or gastritis; • in patients with renal failure; • in patients with liver failure; • in patients with asthma: the occurrence of an asthma attack, in some patients, may be linked to an allergy to non-steroidal anti-inflammatory drugs or to acetylsalicylic acid; in this case, this medicinal product is contraindicated (see section 4.3); • in patients with metrorrhagia or menorrhagia (risk of an increase in the volume and duration of the cycle). • Gastrointestinal bleeding or ulcers\/perforations may occur at any time during treatment, without necessarily having any warning signs or history in the patient. The relative risk increases in elderly subjects, in subjects with low body weight, and in patients receiving anticoagulants or platelet aggregation inhibitors (see section 4.5). In case of gastrointestinal bleeding, treatment should be stopped immediately. • Given the inhibitory effect of acetylsalicylic acid on platelet aggregation, which occurs even at very low doses and persists for several days, the patient should be aware of the risk of bleeding in the event of surgical interventions, even minor ones (e.g. tooth extraction). • In analgesic or antipyretic doses, acetylsalicylic acid inhibits the excretion of uric acid; in the doses used in rheumatology (anti-inflammatory doses), acetylsalicylic acid has a uricosuric effect. • The use of this medicine is not recommended during breastfeeding (see section 4.6). The administration of acetylsalicylic acid is not recommended with: • Oral anticoagulants with analgesic or antipyretic doses of acetylsalicylic acid (≥500 mg per administration and\/or \u003c 3 g per day) and in patients without a history of gastroduodenal ulcers (see section 4.5); • Other non-steroidal anti-inflammatory drugs (NSAIDs) with anti-inflammatory doses of acetylsalicylic acid (≥ 1g per administration and\/or ≥ 3g per day) or with analgesic or antipyretic doses of acetylsalicylic acid (≥500 mg per administration and\/or \u003c 3 g per day) (see section 4.5); • Low molecular weight heparins (and related molecules) and unfractionated heparins with therapeutic doses or in elderly patients (\u003e65 years) regardless of the heparin dose, and for anti-inflammatory doses of acetylsalicylic acid (≥ 1g per administration and\/or ≥ 3g per day) or with analgesic or antipyretic doses of acetylsalicylic acid (≥500 mg per administration and\/or \u003c 3 g per day) (see section 4.5); • Clopidogrel (beyond the approved indications for this combination in patients with acute coronary disease) (see section 4.5); • Ticlopidine (see section 4.5); • Uricosurics (see section 4.5); • Glucocorticoids (except hydrocortisone replacement therapy) for anti-inflammatory doses of acetylsalicylic acid (≥ 1g per administration and\/or ≥ 3g per day) (see section 4.5); • Pemetrexed in patients with mildly to moderately reduced renal function (creatinine clearance between 45 ml\/min and 80 ml\/min) (see section 4.5); • Anagrelide: increased risk of bleeding and decreased antithrombotic effect (see paragraph 4.5). \u003cb\u003eImportant information about some excipients\u003c\/b\u003e This medicinal product contains 71.7 mg sodium per dose equivalent to 3.6% of the WHO recommended maximum daily intake of 2 g sodium for an adult.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIn the following text, the following definitions apply: - anti-inflammatory doses of acetylsalicylic acid are defined as “≥ 1g per administration and\/or ≥ 3g per day”; - Analgesic or antipyretic doses of acetylsalicylic acid are defined as “≥500 mg per administration and\/or \u003c3 g per day”. Various substances give rise to interactions, due to their platelet aggregation inhibitor properties: abciximab, acetylsalicylic acid, cilostazol, clopidogrel, epoprostenol, eptifibatide, iloprost, iloprost trometamol, prasugrel, ticlopidine, Tirofiban, ticagrelor. The risk of bleeding increases with the use of multiple platelet aggregation inhibitors as well as with their use in combination with heparin or related molecules, oral anticoagulants or other thrombolytics, and must be evaluated through constant clinical monitoring. Contraindicated combinations (see section 4.3): • Methotrexate in doses higher than 15 mg per week, with anti-inflammatory doses of acetylsalicylic acid, or with analgesic or antipyretic doses of acetylsalicylic acid: increased toxicity of methotrexate, in particular haematological toxicity (due to reduced renal elimination of methotrexate caused by acetylsalicylic acid). • Oral anticoagulants with anti-inflammatory doses of acetylsalicylic acid, or with analgesic or antipyretic doses of acetylsalicylic acid and in patients with a history of gastroduodenal ulcers: increased risk of hemorrhage. Combinations not recommended: • Oral anticoagulants with analgesic or antipyretic doses of acetylsalicylic acid and in patients without a history of gastroduodenal ulcers: increased risk of haemorrhage. • Other non-steroidal anti-inflammatory drugs (NSAIDs) with anti-inflammatory doses of acetylsalicylic acid, or with analgesic or antipyretic doses of acetylsalicylic acid: increased risk of gastrointestinal ulcers and haemorrhage. • Low molecular weight heparins (and related molecules) and unfractionated heparins at curative doses, or in elderly patients (≥65 years) regardless of the heparin dose, and for anti-inflammatory doses of acetylsalicylic acid or analgesic or antipyretic doses of acetylsalicylic acid: increased risk of hemorrhage (inhibition of platelet aggregation and aggression of the gastroduodenal mucosa by the acid acetylsalicylic). Another anti-inflammatory drug, or another analgesic or antipyretic should be used. • Clopidogrel (outside the approved indication for this combination in patients with acute coronary syndrome): increased risk of bleeding. If concomitant administration cannot be avoided, clinical monitoring is recommended. • Ticlopidine: increased risk of haemorrhage. If concomitant administration cannot be avoided, clinical monitoring is recommended. • Uricosurics (benzbromarone, probenecid): reduction of the uricosuric effect due to competition for the elimination of uric acid in the renal tubules. • Glucocorticoids (excluding hydrocortisone replacement therapy) for anti-inflammatory doses of acetylsalicylic acid: increased risk of bleeding. • Pemetrexed in patients with mild to moderate reduction in renal function (creatinine clearance between 45 ml\/min and 80 ml\/min); increased risk of pemetrexed toxicity (due to decreased renal elimination of pemetrexed caused by acetylsalicylic acid) with anti-inflammatory doses of acetylsalicylic acid. • Anagrelide: increased risk of hemorrhage and decreased antithrombotic effect. If concomitant administration cannot be avoided, clinical monitoring is recommended. Combinations requiring precautions for use: • Diuretics, angiotensin converting enzyme (ACE) inhibitors and angiotensin II receptor antagonists, with anti-inflammatory doses of acetylsalicylic acid or with analgesic or antipyretic doses of acetylsalicylic acid: In dehydrated patients, acute renal failure may occur caused by the reduction in the glomerular filtration rate due to the decreased synthesis of renal prostaglandins. Furthermore, there may be a reduction in the antihypertensive effect. Ensure the patient is hydrated and renal function is monitored at the start of treatment. • Methotrexate in doses ≤ 15 mg per week, with anti-inflammatory doses of acetylsalicylic acid, or with analgesic or antipyretic doses of acetylsalicylic acid: increased toxicity of methotrexate, in particular haematological toxicity (due to reduced renal elimination of methotrexate caused by acetylsalicylic acid). Complete blood counts should be monitored weekly during the first few weeks of coadministration. Patients with reduced renal function (even mild) and elderly patients should be closely monitored. • Clopidogrel (in the approved indication for this combination in patients with acute coronary syndrome): increased risk of bleeding. Clinical monitoring is recommended. • Topical gastrointestinal treatments, antacids and activated charcoal: increased renal excretion of acetylsalicylic acid due to alkalinization of the urine. It is recommended to administer antacids and topical gastrointestinal treatments at least two hours after taking acetylsalicylic acid. • Pemetrexed in patients with normal renal function: increased risk of pemetrexed toxicity (due to decreased renal elimination of pemetrexed caused by acetylsalicylic acid) with anti-inflammatory doses of acetylsalicylic acid. Renal function should be monitored. Combinations that must be taken into consideration: • Glucocorticoids (excluding hydrocortisone replacement therapy) for analgesic and antipyretic doses of acetylsalicylic acid: increased risk of haemorrhage. • Deferasirox: with anti-inflammatory doses of acetylsalicylic acid, or with analgesic or antipyretic doses of acetylsalicylic acid: increased risk of gastrointestinal ulcers and haemorrhage. • Low molecular weight heparins (and related molecules) and unfractionated heparins in preventive doses in patients under 65 years of age: influencing hemostasis at various levels, concomitant administration increases the risk of hemorrhage. Therefore, in patients under 65 years of age, the concomitant administration of heparins (or related molecules) in preventive doses, and of acetylsalicylic acid in any dose, should be taken into consideration combined with clinical and laboratory monitoring as needed. • Thrombolytics: increased risk of haemorrhage. • Selective Serotonin Reuptake Inhibitors (citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline): increased risk of bleeding.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eFrequencies: not known (cannot be estimated from available data) \u003cb\u003eBlood and lymphatic system disorders\u003c\/b\u003e Bleeding and tendency to haemorrhage (epistaxis, bleeding gums, purpura, etc.) with increased bleeding time. The risk of bleeding may persist for 4-8 days after stopping taking acetylsalicylic acid. It may cause an increased risk of bleeding during surgery. Intracranial and gastrointestinal hemorrhages may also occur. \u003cb\u003eImmune system disorders\u003c\/b\u003e Hypersensitivity reactions, anaphylactic reactions, asthma, angioedema \u003cb\u003eNervous system disorders\u003c\/b\u003e Headache, dizziness, sensation of hearing loss, tinnitus, usually indicating an overdose. Intracranial hemorrhage \u003cb\u003eGastrointestinal disorders\u003c\/b\u003e Abdominal pain Occult or overt gastrointestinal bleeding (hematemesis, melena, etc.) resulting in iron deficiency anemia. The risk of bleeding is dose related. Gastric ulcers and perforations Intestinal diaphragm disease (especially in long-term treatment) \u003cb\u003eRenal and urinary disorders\u003c\/b\u003e Renal impairment and acute kidney injury have been reported \u003cb\u003eHepatobiliary disorders\u003c\/b\u003e Elevations of liver enzymes usually reversible upon discontinuation of treatment, liver damage, mainly hepatocellular in nature \u003cb\u003ePathologies of the skin and subcutaneous tissue\u003c\/b\u003e Urticaria, skin rashes \u003cb\u003eGeneral disorders \u003c\/b\u003e Reye's syndrome (see section 4.4) \u003cb\u003eReporting of side effects \u003c\/b\u003e It is important to report side effects of the medicine after authorization. This allows continued monitoring of the risk-benefit ratio of the medicine. Healthcare professionals are asked to report any suspected adverse reaction via the Website: https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eOverdose can be harmful in elderly subjects and in particular in young children (therapeutic overdose or, more frequently, accidental intoxication) in which it can be fatal. \u003cb\u003eSymptoms\u003c\/b\u003e Moderate intoxication: Symptoms such as ringing in the ears, sensation of hearing loss, headache and dizziness are indicative of overdose and can be controlled by reducing the dosage. Severe intoxication: Symptoms include: Fever, hyperventilation, ketosis, respiratory alkalosis, metabolic acidosis, coma, cardiovascular collapse, respiratory failure, severe hypoglycemia. In children, overdose can be fatal starting from a single dose of 100 mg\/kg. \u003cb\u003eEmergency management\u003c\/b\u003e • Immediate transfer to a specialized hospital unit • Gastrointestinal lavage and administration of activated charcoal • Control of acid-base balance • Alkalinization of urine with monitoring of urinary pH • Hemodialysis in case of severe intoxication • Symptomatic treatment\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003ePregnancy\u003c\/u\u003e Inhibition of prostaglandin synthesis may have adverse effects on the course of pregnancy and\/or embryo-foetal development. Data from epidemiological studies suggest an increased risk of miscarriage, cardiac malformations and gastroschisis following the use of prostaglandin synthesis inhibitors in early pregnancy. The absolute risk of cardiovascular malformations increased from no less than 1% to approximately 1.5%. The risk appears to increase with the dose and duration of treatment. In animals, it has been demonstrated that the administration of a prostaglandin synthesis inhibitor causes an increase in pre- and post-implantation loss and embryo-foetal mortality. Furthermore, an increased incidence of various malformations, including cardiovascular malformations, has been reported in animals administered a prostaglandin synthesis inhibitor during the organogenetic period of gestation. Unless absolutely essential, acetylsalicylic acid should not be administered during the first 24 weeks of amenorrhea. If acetylsalicylic acid is administered to women who wish to become pregnant or are pregnant during the first 24 weeks of amenorrhea, the dose should be as low as possible and the duration of treatment as short as possible. Beyond the 24th week of amenorrhea, all inhibitors of prostaglandin synthesis can expose the fetus to: • cardiopulmonary toxicity (with premature closure of the ductus arteriosus and pulmonary hypertension); • renal dysfunction, which can evolve into renal failure with oligohydramniosis; In the final phase of pregnancy, the mother and newborn may experience: • Prolongation of the bleeding time, due to the inhibition of platelet aggregation which can occur even at very low doses of acetylsalicylic acid; • inhibition of uterine contractions which determines the delay or prolongation of labor. Therefore, acetylsalicylic acid is contraindicated beyond the 5th month of pregnancy (beyond 24 weeks of amenorrhea) (see section 4.3). \u003cu\u003eBreastfeeding\u003c\/u\u003e Acetylsalicylic acid passes into breast milk: therefore the use of acetylsalicylic acid is not recommended during breastfeeding (see section 4.4) Fertility There is some evidence that drugs that inhibit cyclooxygenase\/prostaglandin synthesis may cause impaired female fertility due to an effect on ovulation. This effect is reversible upon discontinuation of treatment.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAcetylsalicylic acid has no influence on the ability to drive and use machines.\u003c\/p\u003e","brand":"Bayer","offers":[{"title":"Default Title","offer_id":40207823208563,"sku":"041962034","price":9.21,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/bayer-aspirina-dolore-infiammazione-20-compresse-500-mg-farmacia-dottor-tili-1254211176.jpg?v=1786732599"},{"product_id":"tachipirina-sciroppo-bambini-paracetamolo-120-mg-5-ml","title":"Tachipirina Syrup Children Paracetamol 120 mg\/5 ml","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAs an antipyretic: symptomatic treatment of febrile diseases such as influenza, exanthematous diseases, acute respiratory tract diseases, etc. As an analgesic: headaches, neuralgia, myalgia and other medium-level painful manifestations of various origins.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003e \u003cu\u003eTACHIPIRINA 120mg\/5 ml syrup\u003c\/u\u003e \u003c\/i\u003e 5 ml of syrup contain \u003cu\u003eactive ingredient: paracetamol 120 mg\u003c\/u\u003e excipients with known effects: sucrose, methyl parahydroxybenzoate, sodium. \u003ci\u003e \u003cu\u003eTACHIPIRINA 100mg\/ ml oral drops, solution\u003c\/u\u003e \u003c\/i\u003e 1 ml of solution contains \u003cu\u003eactive ingredient: paracetamol 100 mg\u003c\/u\u003e excipients with known effects: sorbitol, propylene glycol For the complete list of excipients, see par. 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e• \u003cu\u003eSyrup\u003c\/u\u003e: sucrose, sodium citrate, sodium saccharin, methyl parahydroxybenzoate, potassium sorbate, Macrogol 6000, citric acid monohydrate, strawberry flavour, mandarin flavour, purified water. • \u003cu\u003eOral drops\u003c\/u\u003e: propylene glycol, Macrogol 6000, sorbitol, sodium saccharin, citrus vanilla flavouring, propyl gallate, caramel (E150a), sodium edetate, purified water.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e• Hypersensitivity to the active substance or to any of the excipients listed in paragraph 6.1. • Patients suffering from severe hemolytic anemia (this contraindication does not refer to the 500mg oral formulations). • Severe hepatocellular insufficiency (this contraindication does not refer to the 500mg oral formulations).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIn children up to 10 years of age it is essential to respect the dosage defined on the basis of body weight and not on the basis of age, which is approximate and indicated for information purposes only. If the child's age does not correspond to the weight shown in the table, always refer to body weight when choosing the dosage. In children weighing up to 7.2 kg it is recommended to use the formulation in drops, between 7.2 and 11 kg it is possible to use the drops or the syrup as the dosage per weight range is identical, between 12 and 32 kg it is recommended to use the syrup. The dosage scheme of Tachipirina drops is as follows.\u003c\/p\u003e\n\u003cp\u003eTACHIPIRINA DROPS.\u003c\/p\u003e\n\u003cp\u003eWeight: from 3.2 kg - Age (approximate): 0-30 days. Single dose: 8 drops. Daily dose: Up to 4 times (every 6 hours).\u003c\/p\u003e\n\u003cp\u003eWeight: from 4.3 kg - Age (approximate): 1 month. Single dose: 10 drops. Daily dose: Up to 4 times (every 6 hours).\u003c\/p\u003e\n\u003cp\u003eWeight: from 5.3 kg - Age (approximate): 2 months. Single dose: 13 drops. Daily dose: Up to 4 times (every 6 hours).\u003c\/p\u003e\n\u003cp\u003eWeight: from 6.1 kg - Age (approximate): 3 months. Single dose: 22 drops. Daily dose: Up to 4 times (every 6 hours).\u003c\/p\u003e\n\u003cp\u003eWeight: from 6.7 kg - Age (approximate): 4 months. Single dose: 25 drops. Daily dose: Up to 4 times (every 6 hours).\u003c\/p\u003e\n\u003cp\u003eWeight: from 7.2 kg - Age (approximate): 5-6 months. Single dose: 27 drops. Daily dose: Up to 4 times (every 6 hours).\u003c\/p\u003e\n\u003cp\u003eWeight: from 8 kg - Age (approximate): 7-10 months. Single dose: 30 drops. Daily dose: Up to 4 times (every 6 hours).\u003c\/p\u003e\n\u003cp\u003eWeight: from 9 kg - Age (approximate): 11-14 months. Single dose: 33 drops. Daily dose: Up to 4 times (every 6 hours).\u003c\/p\u003e\n\u003cp\u003eWeight: from 10 kg - Age (approximate): 15-19 months. Single dose: 36 drops. Daily dose: Up to 4 times (every 6 hours).\u003c\/p\u003e\n\u003cp\u003eWeight: from 11 kg - Age (approximate): 20-23 months. Single dose: 39 drops. Daily dose: Up to 4 times (every 6 hours).\u003c\/p\u003e\n\u003cp\u003eThe dosage scheme of Tachipirina syrup is as follows.\u003c\/p\u003e\n\u003cp\u003eTACHIPIRINA SYRUP.\u003c\/p\u003e\n\u003cp\u003eWeight: from 7.2 kg - Age (approximate): 5-6 months. Single dose: 4.5 ml. Daily dose: Up to 4 times (every 6 hours).\u003c\/p\u003e\n\u003cp\u003eWeight: from 8 kg - Age (approximate): 7-10 months. Single dose: 5 ml. Daily dose: Up to 4 times (every 6 hours).\u003c\/p\u003e\n\u003cp\u003eWeight: from 9 kg - Age (approximate): 11-14 months. Single dose: 5.5 ml. Daily dose: Up to 4 times (every 6 hours).\u003c\/p\u003e\n\u003cp\u003eWeight: from 10 kg - Age (approximate): 15-19 months. Single dose: 6 ml. Daily dose: Up to 4 times (every 6 hours).\u003c\/p\u003e\n\u003cp\u003eWeight: from 11 kg - Age (approximate): 20-23 months. Single dose: 6.5 ml. Daily dose: Up to 4 times (every 6 hours).\u003c\/p\u003e\n\u003cp\u003eWeight: from 12 kg - Age (approximate): 2 years. Single dose: 7.5 ml. Daily dose: Up to 4 times (every 6 hours).\u003c\/p\u003e\n\u003cp\u003eWeight: from 14 kg - Age (approximate): 3 years. Single dose: 8.5 ml. Daily dose: Up to 4 times (every 6 hours).\u003c\/p\u003e\n\u003cp\u003eWeight: from 16 kg - Age (approximate): 4 years. Single dose: 10 ml. Daily dose: Up to 4 times (every 6 hours).\u003c\/p\u003e\n\u003cp\u003eWeight: from 18 kg - Age (approximate): 5 years. Single dose: 11ml. Daily dose: Up to 4 times (every 6 hours).\u003c\/p\u003e\n\u003cp\u003eWeight: from 20 kg - Age (approximate): 6 years. Single dose: 12.5 ml. Daily dose: Up to 4 times (every 6 hours).\u003c\/p\u003e\n\u003cp\u003eWeight: from 22 kg - Age (approximate): 7 years. Single dose: 13.5 ml. Daily dose: Up to 4 times (every 6 hours).\u003c\/p\u003e\n\u003cp\u003eWeight: from 25 kg - Age (approximate): 8 years. Single dose: 15.5 ml. Daily dose: Up to 4 times (every 6 hours).\u003c\/p\u003e\n\u003cp\u003eWeight: from 28 kg - Age (approximate): 9 years. Single dose: 17.5 ml. Daily dose: Up to 4 times (every 6 hours).\u003c\/p\u003e\n\u003cp\u003eWeight: from 31 kg up to 32 kg - Age (approximate): 10 years. Single dose: 19 ml. Daily dose: Up to 4 times (every 6 hours).\u003c\/p\u003e\n\u003cp\u003eIn case of jaundice in children under three months, it is advisable to reduce the single dose. In children over 10 years of age, the relationship between weight and age becomes no longer homogeneous due to pubertal development which, at the same age, has a different impact on body weight depending on the sex and individual characteristics of the child. Therefore, above 10 years of age, the dosage of the syrup is indicated in terms of weight and age ranges, as reported below. Children weighing between 33 and 40 kg (over 10 years of age and under 12 years of age): 20 ml of syrup at a time (corresponding to 480 mg), to be repeated if necessary after 6 hours, without exceeding 4 administrations per day. Adolescents weighing more than 40 kg (aged 12 years or more) and adults: 20 ml of syrup at a time (corresponding to 480 mg), to be repeated if necessary after 4 hours, without exceeding 6 administrations per day. The doctor must evaluate the need for treatments for more than 3 consecutive days. \u003cu\u003eMethod of administration\u003c\/u\u003e The package includes a measuring syringe with indicated level marks corresponding to 1 ml, 2 ml, 3 ml, 4 ml, 4.5 ml and 5 ml and a measuring cup with indicated level marks corresponding to 5.5 ml, 6 ml, 6.5 ml, 7.5 ml, 8.5 ml, 10 ml, 11 ml, 12.5 ml, 13.5 ml, 15.5ml, 17.5ml, 19ml \u003cu\u003eSyrup\u003c\/u\u003e The syrup contains 24 mg of paracetamol per ml of product. To open the bottle, push the cap downwards and at the same time turn to the left. To use the syringe, insert the tip of the syringe fully into the hole in the undercap: For doses greater than 5 ml, withdraw the necessary quantity with the syringe and pour the contents into the glass. Repeat the process until the mark corresponding to the indicated dosage is reached, and administer to the child, inviting him to drink. For doses in children over 10 years of age and in adults, equal to 20 ml, use the glass by filling it 2 times up to the 10 ml mark. The product must be used immediately after removal from the bottle. Any residual product in the syringe or glass must be eliminated. After use, close the bottle by screwing the cap tightly and wash the syringe and the glass with hot water. Leave them to dry, keeping them out of the reach and sight of children. \u003cu\u003eDrops\u003c\/u\u003e Each drop contains 4 mg of paracetamol. Turn the bottle upside down and pour the number of drops corresponding to the dosage to be used into 25-50 ml of water, and let the child drink. \u003ci\u003e \u003cu\u003eRenal failure\u003c\/u\u003e \u003c\/i\u003e In case of severe renal insufficiency (creatinine clearance less than 10 ml\/min), the interval between administrations must be at least 8 hours.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThis medicinal product does not require any special storage conditions.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIn rare cases of allergic reactions, administration must be suspended and appropriate treatment instituted. Use with caution in cases of chronic alcoholism, excessive alcohol intake (3 or more alcoholic drinks per day), anorexia, bulimia or cachexia, chronic malnutrition (low hepatic glutathione reserves), dehydration, hypovolemia. Paracetamol should be administered with caution to patients with mild to moderate hepatocellular insufficiency (including Gilbert's syndrome), severe hepatic insufficiency (Child-Pugh\u003e9), acute hepatitis, in concomitant treatment with drugs that alter liver function, glucose-6-phosphate dehydrogenase deficiency, hemolytic anemia. High or prolonged doses of the product can cause even serious alterations to the kidney and blood, therefore administration to subjects with renal insufficiency must be carried out only if actually necessary and under direct medical supervision. In case of prolonged use it is advisable to monitor liver and kidney function and blood count. During treatment with paracetamol, before taking any other medicine, check that it does not contain the same active ingredient, since if paracetamol is taken in high doses, serious adverse reactions may occur. Invite the patient to contact the doctor before combining any other drug (see section 4.5). \u003cb\u003e \u003cu\u003eImportant information about some excipients\u003c\/u\u003e \u003c\/b\u003e \u003cu\u003eTachipirina drops, solution contains\u003c\/u\u003e: - sorbitol: patients suffering from rare hereditary problems of fructose intolerance should not take this medicine. - propylene glycol: can cause symptoms similar to those caused by alcohol. - The container of \u003cu\u003eTachipirina drops, solution\u003c\/u\u003e It is made of latex rubber. May cause serious allergic reactions. \u003cu\u003eTachipirina syrup contains\u003c\/u\u003e: - sucrose: patients suffering from rare hereditary problems of fructose intolerance, glucose-galactose malabsorption, or sucrase-isomaltase insufficiency should not take this medicine. For the 15 ml dose this medicine contains 5.25 g of sucrose, for the 16.5 ml dose it contains 5.78 g of sucrose, for the 18.5 ml dose it contains 6.48 g of sucrose and for the 20 ml dose it contains 7 g of sucrose. To be taken into consideration in people suffering from diabetes mellitus. - methyl parahydroxybenzoate: may cause allergic reactions (even delayed). - sodium: this medicine contains 1.2 mmol (or 27.6 mg) sodium per 20 ml equivalent to 1.38% of the WHO recommended maximum daily intake of 2 g sodium for an adult. To be taken into consideration by people following a low sodium diet.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eOral absorption of paracetamol depends on the speed of gastric emptying. Therefore, concomitant administration of drugs that slow (e.g. anticholinergics, opioids) or increase (e.g. prokinetics) the rate of gastric emptying may result in a decrease or increase in the bioavailability of the product, respectively. Concomitant administration of cholestyramine reduces the absorption of paracetamol. The simultaneous intake of paracetamol and chloramphenicol can induce an increase in the half-life of chloramphenicol, with the risk of increasing its toxicity. The concomitant use of paracetamol (4 g per day for at least 4 days) with oral anticoagulants can induce slight variations in INR values. In these cases, more frequent monitoring of INR values ​​should be conducted during concomitant use and after its discontinuation. Use with extreme caution and under strict control during chronic treatment with drugs that can cause the induction of hepatic monooxygenases or in case of exposure to substances that can have this effect (for example rifampicin, cimetidine, antiepileptics such as glutetimide, phenobarbital, carbamazepine). The same applies in cases of alcoholism and in patients treated with zidovudine. The administration of paracetamol can interfere with the determination of uric acid (using the phosphotungstic acid method) and with that of blood sugar (using the glucose-oxidase-peroxidase method).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eBelow are the side effects of paracetamol organized according to the MedDRA systemic and organic classification. There is insufficient data to establish the frequency of the individual effects listed.\u003c\/p\u003e\n\u003cp\u003eBlood and lymphatic system disorders: Thrombocytopenia, leukopenia, anemia, agranulocytosis.\u003c\/p\u003e\n\u003cp\u003eImmune system disorders: Hypersensitivity reactions (urticaria, laryngeal edema, angioedema, anaphylactic shock).\u003c\/p\u003e\n\u003cp\u003eNervous system disorders: Dizziness.\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders: Gastrointestinal reaction.\u003c\/p\u003e\n\u003cp\u003eHepatobiliary disorders: Abnormal liver function, hepatitis.\u003c\/p\u003e\n\u003cp\u003eSkin and subcutaneous tissue disorders: Erythema multiforme, Stevens Johnson Syndrome, Epidermal necrolysis, rash.\u003c\/p\u003e\n\u003cp\u003eRenal and urinary disorders: Acute renal failure, interstitial nephritis, hematuria, anuria.\u003c\/p\u003e\n\u003cp\u003eVery rare cases of serious skin reactions have been reported. Reporting of suspected adverse reactions Reporting suspected adverse reactions that occur after authorization of the medicinal product is important, as it allows continuous monitoring of the benefit\/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eThere is a risk of intoxication, especially in patients with liver disease, in cases of chronic alcoholism, in patients suffering from chronic malnutrition, and in patients receiving enzyme inducers. In these cases, overdose can be fatal.\u003c\/u\u003e \u003cu\u003eSymptoms\u003c\/u\u003e In case of accidental intake of very high doses of paracetamol, acute intoxication manifests itself with anorexia, nausea and vomiting followed by a profound deterioration of the general conditions; these symptoms typically appear within the first 24 hours. In case of overdose, paracetamol can cause hepatic cytolysis which can progress to massive and irreversible necrosis, resulting in hepatocellular failure, metabolic acidosis and encephalopathy, which can lead to coma and death. Simultaneously, an increase in the levels of hepatic transaminases, lactic dehydrogenase, and bilirubin are observed, and a reduction in prothrombin levels, which can occur in the 12-48 hours following ingestion. \u003cu\u003eTreatment\u003c\/u\u003e The measures to be adopted consist of early gastric emptying and hospitalization for the appropriate treatment, through administration, as early as possible, of N-acetylcysteine as an antidote: the dosage is 150 mg\/kg i.v. in glucose solution in 15 minutes, then 50 mg\/kg in the following 4 hours and 100 mg\/kg in the following 16 hours, for a total of 300 mg\/kg in 20 hours.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003ePregnancy: A large amount of data on pregnant women indicates neither malformation nor fetal\/neonatal toxicity. Epidemiological studies on neurodevelopment in children exposed to paracetamol in utero show inconclusive results. If clinically necessary, paracetamol can be used during pregnancy, however it should be used at the lowest effective dose for the shortest possible time and with the lowest possible frequency. Breastfeeding: it is recommended to take\/administer this medicine only in cases of real need and under the direct supervision of a doctor.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eTachipirina does not alter the ability to drive or use machines.\u003c\/p\u003e","brand":"Angelini","offers":[{"title":"Default Title","offer_id":40207823241331,"sku":"012745016","price":7.25,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/products\/angelini-spa-tachipirina-sciroppo-bambini-paracetamolo-120-mg-5-ml-farmacia-dottor-tili-1213792758.png?v=1767125710"},{"product_id":"pursennid-30-compresse-lassative-12-mg","title":"Pursennid 40 Laxative Tablets 12 mg","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eShort-term treatment of occasional constipation.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eOne coated tablet contains: - Active ingredient: sennosides A + B (as calcium salts) 12 mg. - Excipients with known effects: lactose monohydrate; anhydrous glucose; sucrose. For the full list of excipients, see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eLactose monohydrate\u003c\/b\u003e; stearic acid; talc; corn starch; \u003cb\u003eanhydrous glucose\u003c\/b\u003e; \u003cb\u003esucrose\u003c\/b\u003e; gum arabic; anhydrous colloidal silica; titanium dioxide; cetyl palmitate.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to the active substance or to any of the excipients listed in paragraph 6.1. Contraindicated if the following medical conditions exist: - Inflammatory diseases of the digestive system (i.e. Crohn's disease, ulcerative colitis, liver disease, peritonitis and inflammatory intestinal diseases); - Irritation or obstruction of the gastrointestinal tract (i.e. spastic constipation, obstruction of the ileum\/preileum, cramps and pain, nausea, vomiting and colic); - Abdominal symptoms that may be due to an undiagnosed underlying condition, such as acute intestinal conditions that may require surgery (i.e. acute diverticulitis, appendicitis and massive diarrhea); - states of severe dehydration, with loss of water and electrolytes, especially hypokalemia. Contraindicated in children under 10 years of age.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eDosage\u003c\/b\u003e Adults and children over 12 years of age: 2-4 coated tablets per day. Children between 10 and 12 years: 1-2 coated tablets per day. After a short period of treatment without appreciable results, consult your doctor. The correct dose is the minimum sufficient to produce an easy evacuation of loose stools. It is advisable to initially use the minimum doses provided. When necessary, the dose can then be increased, but without ever exceeding the maximum indicated. \u003cb\u003ePediatric population\u003c\/b\u003e Contraindicated in children under 10 years of age. \u003cb\u003eMethod of administration\u003c\/b\u003e Take preferably in the evening. The action of Pursennid occurs after 6-12 hours. Administered in the evening, the effect of Pursennid appears the following morning. Laxatives should be used as infrequently as possible and for no longer than seven days. Use for longer periods of time requires a doctor's prescription after adequate evaluation of the individual case. Swallow together with an adequate quantity of water (a large glass). A diet rich in liquids favors the effect of the medicine.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThis medicinal product does not require any special storage conditions.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe established dose must not be exceeded. Prolonged indiscriminate use of laxatives can lead to addiction and a deterioration of intestinal functions. The lowest effective dosage should be used to restore normal intestinal function. If no improvement has been achieved in the intestine, the dosage can be increased under medical supervision. Products containing senna and sennosides should only be used if a therapeutic effect cannot be achieved through a change in diet or the administration of bulking agents. The use of these drugs requires medical supervision: - if there are no positive effects following the treatment; - if use is prolonged beyond one week of treatment; - if symptoms persist or worsen; - after a laparotomy or abdominal surgery; - if a skin rash is present, because it can be a sign of hypersensitivity; - if nausea and vomiting are present, because these symptoms may be signs of a potential or existing intestinal blockage (ileus); - in children between 10 and 12 years old. \u003cu\u003eInformation relating to excipients\u003c\/u\u003e - Lactose: patients suffering from rare hereditary problems of galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption should not take this medicine. - Glucose: patients suffering from rare problems of glucose-galactose malabsorption should not take this medicine. - Sucrose: patients suffering from rare hereditary problems of fructose intolerance, glucose-galactose malabsorption, or sucrase isomaltase insufficiency should not take this medicine.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eConcomitant use of other drugs that induce hypokalemia (i.e. diuretics, adrenocorticosteroids and licorice) may increase electrolyte imbalance. Hypokalemia (resulting from abuse of laxatives taken for a long time) enhances the action of cardiac glycosides and interferes with antiarrhythmic drugs, with other drugs that induce the return to sinus rhythm (quinidine) and with drugs that induce prolongation of the Q-T interval.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThis medicine may cause mild abdominal discomfort such as abdominal pain, cramps, irritation of the colonic and gastric mucosa. Other effects such as dehydration, hypotension, fatigue, myopathies, stomach pain, hyponatremia, renal disorders, secondary hyperaldosteronism, hypocalcemia and hypomagnesemia have also been reported. These adverse reactions are usually reversible once you stop taking the laxative. Prolonged use or overdose of this drug may cause nausea, diarrhea with excessive loss of electrolytes, especially potassium (hypokalemia). There is also the possibility of developing megacolon. During treatment, a yellow-brownish coloration (pH-dependent) of the urine may occur due to metabolites, which has no clinical significance. Habituation has been reported after prolonged treatment. Adverse reactions are listed below by system organ class and frequency. Frequencies are defined as: \u003ci\u003every common\u003c\/i\u003e (≥ 1\/10), \u003ci\u003ecommon\u003c\/i\u003e (≥ 1\/100, \u0026lt; 1\/10); \u003ci\u003euncommon\u003c\/i\u003e (≥ 1\/1.000, \u0026lt; 1\/100); \u003ci\u003erare\u003c\/i\u003e (≥ 1\/10.000; \u0026lt; 1\/1.000); \u003ci\u003every rare\u003c\/i\u003e (\u003c 1\/10,000), or \u003ci\u003enot known\u003c\/i\u003e (frequency cannot be estimated from the available data). \u003cb\u003eTable 4-1 Undesirable effects in the post-marketing experience \u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003eImmune system disorders.\u003c\/p\u003e\n\u003cp\u003eNot known - Adverse event: Hypersensitivity reactions (itching, urticaria, local or generalized rash).\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders.\u003c\/p\u003e\n\u003cp\u003eNot known - Adverse event: Megacolon.\u003c\/p\u003e\n\u003cp\u003eNot known - Adverse event: Abdominal pain.\u003c\/p\u003e\n\u003cp\u003eNot known - Adverse event: Diarrhoea.\u003c\/p\u003e\n\u003cp\u003eNot known - Adverse event: Nausea.\u003c\/p\u003e\n\u003cp\u003eNot known - Adverse event: Abdominal discomfort.\u003c\/p\u003e\n\u003cp\u003eNot known.\u003c\/p\u003e\n\u003cp\u003eSystemic pathologies and conditions relating to the administration site.\u003c\/p\u003e\n\u003cp\u003eNot known - Adverse event: Fatigue.\u003c\/p\u003e\n\u003cp\u003eNot known - Adverse event: Drug tolerance.\u003c\/p\u003e\n\u003cp\u003ePathologies of the musculoskeletal system and connective tissue.\u003c\/p\u003e\n\u003cp\u003eNot known - Adverse event: Myopathy.\u003c\/p\u003e\n\u003cp\u003eRenal and urinary disorders.\u003c\/p\u003e\n\u003cp\u003eNot known - Adverse event: Kidney problems.\u003c\/p\u003e\n\u003cp\u003eNot known - Adverse event: Chromaturia.\u003c\/p\u003e\n\u003cp\u003eMetabolism and nutrition disorders.\u003c\/p\u003e\n\u003cp\u003eNot known - Adverse event: Hyperaldosteronism.\u003c\/p\u003e\n\u003cp\u003eNot known - Adverse event: Hypocalcemia.\u003c\/p\u003e\n\u003cp\u003eNot known - Adverse event: Hypomagnesemia.\u003c\/p\u003e\n\u003cp\u003eNot known - Adverse event: Dehydration.\u003c\/p\u003e\n\u003cp\u003eNot known - Adverse event: Hypokalemia.\u003c\/p\u003e\n\u003cp\u003eNot known - Adverse event: Hyponatremia.\u003c\/p\u003e\n\u003cp\u003eNot known - Adverse event: Decreased blood electrolytes.\u003c\/p\u003e\n\u003cp\u003eVascular pathologies.\u003c\/p\u003e\n\u003cp\u003eNot known - Adverse event: Hypotension.\u003c\/p\u003e\n\u003cp\u003eThe adverse events listed above are based on spontaneous post-marketing reports and represent a less precise estimate of the incidence that would be obtained in clinical trials. \u003cb\u003ePediatric population\u003c\/b\u003e The same frequency, type and severity of adverse events are expected in children and adults. \u003cb\u003eReporting of suspected adverse reactions\u003c\/b\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eSymptoms\u003c\/b\u003e The most important symptoms related to overdose\/excessive use are abdominal colic and severe diarrhea resulting in losses of fluids and electrolytes, which must be replaced. Diarrhea especially can cause potassium loss, which can lead to cardiac disorders and muscular asthenia, particularly when cardiac glycosides, diuretics, adrenocorticosteroids or licorice root are administered at the same time. \u003cb\u003eManagement\u003c\/b\u003e Treatment must be supportive with generous quantities of fluids. Electrolytes, especially potassium, should be monitored. This is especially important in the elderly. Chronic overdose of anthraquinone drugs can cause toxic hepatitis. Further treatment modalities should take into account clinical indications or poison control center recommendation, where available.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003ePregnancy\u003c\/u\u003e There are no adequate data on the use of sennosides in pregnant women. Animal studies have not shown reproductive toxicity. The potential risk for humans is unknown. Pregnant women should consult their doctor before taking this medicine. \u003cu\u003eBreastfeeding\u003c\/u\u003e Use during breastfeeding is not recommended as there are insufficient data on the excretion of the metabolites in breast milk. Small quantities of metabolites (rein) are excreted in breast milk. No laxative effect has been reported on breast-fed infants. \u003cu\u003eFertility\u003c\/u\u003e Preclinical studies with sennosides do not indicate particular risks for fertility at therapeutically relevant doses.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThis medicine has no or negligible influence on the ability to drive or use machinery.\u003c\/p\u003e","brand":"Gsk","offers":[{"title":"Default Title","offer_id":40207823732851,"sku":"004758025","price":12.28,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/products\/glaxosmithkline-c-health-spa-pursennid-30-compresse-lassative-12-mg-farmacia-dottor-tili-1213792748.jpg?v=1767125872"},{"product_id":"enterogermina-4-miliardi-5-ml-20-flaconcini","title":"Enterogermina 4 Billion\/5 Ml 20 Vials","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eTreatment and prophylaxis of intestinal dysmicrobism and consequent endogenous vitamin deficiency. Therapy assists the restoration of the intestinal microbial flora, altered during antibiotic or chemotherapy treatments. Acute and chronic gastrointestinal disorders in infants, attributable to intoxications or intestinal dysmicrobisms and vitamin deficiency.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eOne vial contains the active ingredient: polyantibiotic resistant Bacillus clausii spores (SIN, O\/C, T, N\/R strains) 4 billion. For the full list of excipients, see section 6.1\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eVials: Purified water.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to the active substance or to any of the excipients listed in paragraph 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDosage Adults: 1 vial per day. Infants and children: 1 vial per day. Method of administration Take the contents of the vial as is or diluted in water or other drinks (e.g. milk, tea, orange juice). This medicine is for oral use only. Do not inject or administer in any other way (see section 4.4).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eStore below 30°C.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eSpecial warnings\u003c\/i\u003e Bacteremia\/sepsis Post-marketing cases of bacteremia, septicemia and sepsis have been reported in immunocompromised or seriously ill patients and in preterm infants. In the case of some critically ill patients, the outcome was fatal. ENTEROGERMINA should be avoided in these patient groups (see section 4.8). This medicine is for oral use only. Do not inject or administer by other routes. Incorrect use of the medicine has caused serious anaphylactic reactions such as anaphylactic shock. \u003ci\u003ePrecautions for use\u003c\/i\u003e During antibiotic therapy it is advisable to administer the preparation in the interval between one antibiotic administration and the next. The possible presence of visible corpuscles in the vials of ENTEROGERMINA is due to aggregates of spores of \u003ci\u003eBacillus clausii\u003c\/i\u003e; it is therefore not an indication of an altered product. Shake the vial before use.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo interaction studies have been performed.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe following side effects have been observed during treatment with this medicine, classified according to the MedDRA classification by organ class and according to the following frequency classes: very common (≥1\/10); common (≥1\/100,\u003c1\/10); uncommon (≥1\/1,000, \u003c1\/100); rare (≥1\/10,000,\u003c1\/1,000); very rare \u003c1\/10,000); not known (frequency cannot be estimated from the available data).\u003c\/p\u003e\n\u003cp\u003eInfections and infestations - Not known: Bacteremia, septicemia and sepsis (in immunocompromised or seriously ill patients) (see section 4.4).\u003c\/p\u003e\n\u003cp\u003eSkin and subcutaneous tissue disorders - Not known: hypersensitivity reactions, including rash, urticaria and angioedema.\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eReporting of suspected adverse reactions. \u003c\/u\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at \u003cu\u003ehttps:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse\u003c\/u\u003e.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo cases of overdose have been reported.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003ePregnancy\u003c\/u\u003e There are no data available regarding the use of Enterogermina in pregnant women; therefore it is not possible to draw conclusions on the safety of the use of Enterogermina during pregnancy. Enterogermina should be used during pregnancy only if the potential benefits to the mother outweigh the potential risks, including those to the fetus. \u003cu\u003eBreastfeeding\u003c\/u\u003e There are no data available regarding the use of Enterogermina during breastfeeding regarding the composition of breast milk and the effects on the baby. It is not possible to draw any conclusions about the safety of using Enterogermina during breastfeeding. Enterogermina should be used during breastfeeding only if the potential benefits to the mother outweigh the potential risks, including those to the breast-fed baby. \u003cu\u003eFertility\u003c\/u\u003e No data are available on the effect of Enterogermina on human fertility.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eEnterogermina does not alter the ability to drive or use machines.\u003c\/p\u003e","brand":"Sanofi","offers":[{"title":"Default Title","offer_id":40207823798387,"sku":"013046089","price":25.02,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/sanofi-spa-enterogermina-4-miliardi-5-ml-20-flaconcini-farmacia-dottor-tili-1213792750.webp?v=1767125928"},{"product_id":"enterogermina-4-miliardi-5-ml-10-flaconcini","title":"Enterogermina 4 Billion\/5 Ml 10 Vials","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eTreatment and prophylaxis of intestinal dysmicrobism and consequent endogenous vitamin deficiency. Therapy assists the restoration of the intestinal microbial flora, altered during antibiotic or chemotherapy treatments. Acute and chronic gastrointestinal disorders in infants, attributable to intoxications or intestinal dysmicrobisms and vitamin deficiency.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eOne vial contains the active ingredient: polyantibiotic resistant Bacillus clausii spores (SIN, O\/C, T, N\/R strains) 4 billion. For the full list of excipients, see section 6.1\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eVials: Purified water.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to the active substance or to any of the excipients listed in paragraph 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDosage Adults: 1 vial per day. Infants and children: 1 vial per day. Method of administration Take the contents of the vial as is or diluted in water or other drinks (e.g. milk, tea, orange juice). This medicine is for oral use only. Do not inject or administer in any other way (see section 4.4).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eStore below 30°C.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eSpecial warnings\u003c\/i\u003e Bacteremia\/sepsis Post-marketing cases of bacteremia, septicemia and sepsis have been reported in immunocompromised or seriously ill patients and in preterm infants. In the case of some critically ill patients, the outcome was fatal. ENTEROGERMINA should be avoided in these patient groups (see section 4.8). This medicine is for oral use only. Do not inject or administer by other routes. Incorrect use of the medicine has caused serious anaphylactic reactions such as anaphylactic shock. \u003ci\u003ePrecautions for use\u003c\/i\u003e During antibiotic therapy it is recommended to administer the preparation in the interval between one antibiotic administration and the next. The possible presence of visible corpuscles in the vials of ENTEROGERMINA is due to aggregates of spores of \u003ci\u003eBacillus clausii\u003c\/i\u003e; it is therefore not an indication of an altered product. Shake the vial before use.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo interaction studies have been performed.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe following side effects have been observed during treatment with this medicine, classified according to the MedDRA classification by organ class and according to the following frequency classes: very common (≥1\/10); common (≥1\/100,\u003c1\/10); uncommon (≥1\/1,000, \u003c1\/100); rare (≥1\/10,000,\u003c1\/1,000); very rare \u003c1\/10,000); not known (frequency cannot be estimated from the available data).\u003c\/p\u003e\n\u003cp\u003eInfections and infestations - Not known: Bacteremia, septicemia and sepsis (in immunocompromised or seriously ill patients) (see section 4.4).\u003c\/p\u003e\n\u003cp\u003eSkin and subcutaneous tissue disorders - Not known: hypersensitivity reactions, including rash, urticaria and angioedema.\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eReporting of suspected adverse reactions. \u003c\/u\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at \u003cu\u003ehttps:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse\u003c\/u\u003e.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo cases of overdose have been reported.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003ePregnancy\u003c\/u\u003e There are no data available regarding the use of Enterogermina in pregnant women; therefore it is not possible to draw conclusions on the safety of the use of Enterogermina during pregnancy. Enterogermina should be used during pregnancy only if the potential benefits to the mother outweigh the potential risks, including those to the fetus. \u003cu\u003eBreastfeeding\u003c\/u\u003e There are no data available regarding the use of Enterogermina during breastfeeding regarding the composition of breast milk and the effects on the baby. It is not possible to draw any conclusions about the safety of using Enterogermina during breastfeeding. Enterogermina should be used during breastfeeding only if the potential benefits to the mother outweigh the potential risks, including those to the breast-fed baby. \u003cu\u003eFertility\u003c\/u\u003e No data are available on the effect of Enterogermina on human fertility.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eEnterogermina does not alter the ability to drive or use machines.\u003c\/p\u003e","brand":"Sanofi","offers":[{"title":"Default Title","offer_id":40207823831155,"sku":"013046077","price":9.99,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/sanofi-enterogermina-4-miliardi-5-ml-10-flaconcini-farmacia-dottor-tili-1258975964.jpg?v=1789562650"},{"product_id":"maalox-plus-30-compresse-masticabili","title":"Maalox plus 30 chewable tablets","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSymptomatic treatment of hyperacidity (including burning and pain) even in case of esophagitis, and hyperacidity when accompanied by dyspepsia. Symptomatic treatment of gastro-intestinal swelling when accompanied by hyperacidity.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003e100 ml of suspension contain\u003c\/u\u003e: \u003ci\u003eActive ingredients\u003c\/i\u003e: magnesium hydroxide 3.65 g, aluminum hydroxide 3.25 g, dimethicone 0.50 g. \u003ci\u003eExcipient(s) with known effects\u003c\/i\u003e: methyl parahydroxybenzoate, propyl parahydroxybenzoate, ethanol, invert sugar, sucrose, sulfur dioxide (E 220), sorbitol (E420) 4.48 g\/ 100ml (see section 4.4). For the full list of excipients, see section 6.1. \u003cu\u003eOne tablet contains\u003c\/u\u003e: \u003ci\u003eActive ingredients:\u003c\/i\u003e magnesium hydroxide 200 mg, aluminum oxide, hydrate 200 mg, dimethicone 25 mg. \u003ci\u003eExcipient(s) with known effects\u003c\/i\u003e: glucose, sucrose, sorbitol (E420) 45 mg per tablet (see section 4.4). For the full list of excipients, see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eMAALOX PLUS 3.65% + 3.25% + 0.5% oral suspension:\u003c\/i\u003e Methyl cellulose, methyl parahydroxybenzoate, propyl parahydroxybenzoate, carmellose, hydroxypropyl cellulose, citric acid, sodium saccharin, sorbitol (E420) non-crystallizable liquid, lemon flavor (containing ethanol), Swiss cream flavor (containing ethanol, invert sugar, sucrose, sulfur dioxide (E 220)), purified water. \u003ci\u003eMAALOX PLUS 200 mg + 200 mg + 25 mg chewable tablets:\u003c\/i\u003e Corn starch, citric acid, pregelatinized starch, glucose, mannitol, sucrose, sorbitol (E420), non-crystallizable liquid sorbitol, talc, magnesium stearate, sodium saccharin, lemon flavoring, Swiss cream flavoring, E 172.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e- Hypersensitivity to the active substances or to any of the excipients listed in paragraph 6.1; - Patients suffering from porphyria; - Severe forms of renal failure (creatinine clearance less than 30 mL\/min); - Generally contraindicated in pediatric age; - State of cachexia.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eMAALOX PLUS 3.65% + 3.25% + 0.5% oral suspension\u003c\/i\u003e \u003cu\u003eDosage \u003c\/u\u003e Do not exceed the maximum doses indicated unless prescribed by a doctor. Swallow 2-4 teaspoons (10-20 ml) 4 times a day, 20-60 minutes after meals and before bed. \u003cu\u003eMethod of administration \u003c\/u\u003e Shake well before use. It can be diluted in water or milk. \u003ci\u003eMAALOX PLUS 200 mg + 200 mg + 25 mg chewable tablets\u003c\/i\u003e\u003cu\u003eDosage \u003c\/u\u003e Do not exceed the maximum doses indicated unless prescribed by a doctor. 2-4 tablets 4 times a day, well chewed or sucked, 20-60 minutes after meals and before going to bed. \u003cu\u003eMethod of administration \u003c\/u\u003e The tablets should be well chewed or sucked. Their intake can be followed by ingestion of water or milk. \u003ci\u003ePediatric population\u003c\/i\u003e Administration of the medicine in pediatric age is not recommended.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eOral suspension\u003c\/i\u003e: Do not store below 4°C. Bottle: keep the bottle tightly closed. \u003ci\u003eChewable tablets\u003c\/i\u003e: Store below 25°C.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAluminum hydroxide can cause constipation and an overdose of magnesium salts can cause hypermotility of the intestine; high doses of this medicine may cause or aggravate intestinal and ileal obstruction in patients at higher risk, such as those with renal impairment, with underlying constipation, with alteration of intestinal motility, in children (0 to 24 months), or elderly. Aluminum hydroxide is not well absorbed from the gastrointestinal tract, and systemic effects are therefore rare in patients with normal renal function. However, excessive doses or long-term use, or even normal doses in patients on low-phosphorus diets or in children (0 to 24 months), can lead to phosphate elimination (due to an aluminium-phosphate bond) accompanied by increased bone resorption and hypercalciuria with risk of osteomalacia. It is advisable to consult your doctor in case of long-term use or in patients at risk of hypophosphatemia. In patients with renal impairment, plasma levels of aluminum and magnesium tend to increase, causing hyperaluminemia and hypermagnesemia, respectively. In these patients, long exposures to high doses of aluminum and magnesium salts can lead to encephalopathy, dementia, microcytic anemia or worsening of dialysis-induced osteomalacia. In the presence of mild and moderate forms of renal failure it is advisable to take the product under the supervision of a doctor. Prolonged use of antacids in patients with mild and moderate forms of renal insufficiency should be avoided. The administration of this medicine is contraindicated in subjects suffering from severe forms of renal failure (see section 4.3). Aluminum hydroxide may be unsafe in porphyria patients undergoing haemodialysis (see section 4.3). Maalox Plus, due to its composition, has no tendency to modify the behavior of the bird. However, in some particularly sensitive subjects and for high doses, an acceleration of intestinal transit may occur. \u003cu\u003eMAALOX PLUS 3.65% + 3.25% + 0.5% oral suspension contains\u003c\/u\u003e: - \u003cb\u003eparahydroxybenzoates\u003c\/b\u003e: may cause allergic reactions (even delayed); - 448 mg of \u003cstrong\u003esorbitol\u003c\/strong\u003e (E420) in 10 ml (2 teaspoons). Patients with hereditary fructose intolerance should not be given this medicine; - \u003cstrong\u003eethanol\u003c\/strong\u003e: This medicine contains 9.5 mg of ethanol in 10 ml (2 teaspoons). 10 ml of this medicine is equivalent to 0.2 ml of beer or 0.1 ml of wine. The small amount of alcohol in this medicine will not produce significant effects; - \u003cstrong\u003esucrose and invert sugar\u003c\/strong\u003e: patients suffering from rare hereditary problems of fructose intolerance, glucose-galactose malabsorption, or sucrase-isomaltase insufficiency should not take this medicine; - \u003cstrong\u003esulfur dioxide (E 220)\u003c\/strong\u003e: rarely can cause serious hypersensitivity reactions and bronchospasm; - less than 1 mmol (23 mg) of \u003cstrong\u003esodium\u003c\/strong\u003e per dose, i.e. it is essentially “sodium-free”. \u003cu\u003eMAALOX PLUS 200 mg + 200 mg + 25 mg chewable tablets contains\u003c\/u\u003e: - 45 mg of\u003cb\u003e sorbitol\u003c\/b\u003e, per tablet. The additive effect of co-administration of medicinal products containing sorbitol (or fructose) and daily dietary intake of sorbitol (or fructose) should be considered. The sorbitol content in oral medicinal products may modify the bioavailability of other co-administered oral medicinal products. Patients with hereditary fructose intolerance should not be given this medicine. - approximately 500 mg of \u003cb\u003eglucose\u003c\/b\u003e, per tablet: to be taken into consideration in people suffering from diabetes mellitus, if they take more than 10 tablets per day; Patients suffering from rare problems of glucose-galactose malabsorption should not take this medicine. - \u003cb\u003esucrose\u003c\/b\u003e; Patients suffering from rare hereditary problems of fructose intolerance, glucose-galactose malabsorption, or sucrase isomaltase insufficiency should not take this medicine. - less than 1 mmol (23 mg) of \u003cb\u003esodium\u003c\/b\u003e per tablet, i.e. it is essentially “sodium-free”. \u003cu\u003ePediatric population \u003c\/u\u003e In young children, the use of magnesium hydroxide can lead to hypermagnesemia, particularly if they have kidney damage or dehydration.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSince Al and Mg salts reduce the gastrointestinal absorption of tetracyclines, it is recommended to avoid taking Maalox Plus during oral tetracycline therapy. The use of aluminum-containing antacids may reduce the absorption of drugs in particular H2-antagonists, atenolol, bisphosphonates, cefdinir, cefpodoxime, chloroquine, tetracyclines, dasatinib monohydrate, diflunisal, digoxin, dexamethasone, eltrombopag olamine, elvitegravir, ethambutol, fluoroquinolones, glucocorticoids, indomethacin, iron salts, isoniazid, ketoconazole, levothyroxine, lincosamides, metoprolol, nilotinib, phenothiazine neuroleptics, penicillamines, propranolol, raltegravir potassium, rilpivirine, riociguat, rosuvastatin, sodium fluoride and antiviral treatments in combination with tenofovir alafenamide fumarate\/emtricitabine\/sodium bictegravir. • Polystyrene sulfonate (Kayexalate) Caution is advised when the medicinal product is taken together with polystyrene sulfonate (Kayexalate) due to the potential risk of reduced potassium-binding efficacy of the resin, metabolic alkalosis in patients with renal impairment (reported with aluminum hydroxide and magnesium hydroxide), and intestinal obstruction (reported with aluminum hydroxide). • Aluminum hydroxide and citrates can cause hyperaluminemia, especially in patients with renal impairment. The combination with the integrase inhibitors (dolutegravir, raltegravir, bictegravir) and MAALOX PLUS should be avoided (refer to the respective SmPCs for dose recommendations). Since the use of magnesium hydroxide causes alkalinization of the urine, increased excretion of salicylates has been observed when administered simultaneously. As a precaution, allow at least 2 hours (4 for fluoroquinolones) to pass between taking any oral medication and MAALOX PLUS. Concomitant use of quinidine may result in increased serum quinidine levels and lead to quinidine overdose. The simultaneous use of aluminum hydroxide and citrates can lead to an increase in aluminum levels, particularly in patients with renal failure. The alkalinization of the urine following the administration of magnesium hydroxide can modify the excretion of some drugs; therefore, increased excretion of salicylates was observed.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe frequency of the side effects reported below is defined using the following conventions: common (≥1\/100, \u003c1\/10); uncommon (≥1\/1,000, \u003c1\/100); rare (≥1\/10,000, \u003c1\/1,000); very rare (\u003c1\/10,000); not known (frequency cannot be estimated from the available data). \u003ci\u003e \u003cu\u003eImmune system disorders\u003c\/u\u003e \u003c\/i\u003e \u003ci\u003eFrequency not known (frequency cannot be estimated from the available data):\u003c\/i\u003e angioedema, anaphylactic reactions, hypersensitivity reactions, urticaria, pruritus. \u003ci\u003e \u003cu\u003eGastrointestinal disorders\u003c\/u\u003e \u003c\/i\u003e \u003ci\u003eUncommon\u003c\/i\u003e: diarrhea or constipation (see section 4.4); \u003ci\u003eFrequency not known\u003c\/i\u003e: abdominal pain. \u003ci\u003e \u003cu\u003eMetabolism and nutrition disorders\u003c\/u\u003e \u003c\/i\u003e \u003ci\u003eVery rare:\u003c\/i\u003e hypermagnesemia, including observations after prolonged administration to patients with renal impairment\u003ci\u003e;\u003c\/i\u003e \u003ci\u003eFrequency not known\u003c\/i\u003e: hyperaluminemia, hypophosphatemia, during prolonged use or at high doses or even at normal doses of the medicine in patients with low phosphorus diets or in children (0 to 24 months), which may cause increased bone resorption, hypercalciuria, osteomalacia (see section 4.4). \u003cb\u003eReporting of suspected adverse reactions\u003c\/b\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at: http:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eExperience with deliberate overdose is very limited. Cases of overdose with aluminum salts may occur more easily in patients with severe chronic renal impairment with the following symptoms: encephalopathy, convulsions and dementia, hypermagnesemia. The most frequently reported symptoms of acute overdose with aluminum hydroxide and in combination with magnesium salts include diarrhea, abdominal pain and vomiting. High doses of this medicinal product may cause or aggravate intestinal and ileal obstruction in patients at risk (see section 4.4). As in all cases of overdose, treatment must be symptomatic, adopting general supportive measures. Aluminum and magnesium are eliminated through urinary excretion; treatment of magnesium overdose involves rehydration and forced diuresis. In case of renal failure, hemodialysis or peritoneal dialysis is required.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThere are no data on the use of MAALOX PLUS in pregnant women. It is not possible to establish whether or not the use of MAALOX PLUS during pregnancy is safe. \u003cu\u003ePregnancy \u003c\/u\u003e The medicine must be used only if necessary, under the direct supervision of a doctor, after evaluating the expected benefit for the mother in relation to the possible risk for the fetus or infant. \u003cu\u003eBreastfeeding \u003c\/u\u003e Due to limited maternal absorption when taken according to the indicated dosing regimen (see section 4.2), aluminum hydroxide and its combinations with magnesium salts are considered compatible with breastfeeding.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eMAALOX PLUS does not alter the ability to drive and use machines.\u003c\/p\u003e","brand":"Sanofi","offers":[{"title":"Default Title","offer_id":40207823863923,"sku":"020702080","price":9.99,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/products\/sanofi-spa-maalox-plus-30-compresse-masticabili-farmacia-dottor-tili-1213792745.webp?v=1767125889"},{"product_id":"glicerolo-carlo-erba-18-supposte-2250-mg","title":"Glycerol Carlo Erba 18 Suppositories 2250 mg.","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eShort-term treatment of occasional constipation.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eGLYCEROL CARLO ERBA Early childhood 900 mg suppositories\u003c\/i\u003e An early childhood suppository contains: active ingredient: Glycerol 900 mg. \u003ci\u003eGLYCEROL CARLO ERBA Children 1375 mg\u003c\/i\u003e \u003ci\u003esuppositories\u003c\/i\u003e One children's suppository contains: active ingredient: Glycerol 1375 mg. \u003ci\u003eGLYCEROL CARLO ERBA Adults 2250 mg suppositories\u003c\/i\u003e An adult suppository contains: active ingredient: Glycerol 2250 mg. \u003ci\u003eGLYCEROL CARLO ERBA Children 2.25 g rectal solution\u003c\/i\u003e Each single-dose container contains: active ingredient: Glycerol 2.25 g. \u003ci\u003eGLYCEROL CARLO ERBA Adults 6.75 g rectal solution\u003c\/i\u003e Each single-dose container contains: active ingredient: Glycerol 6.75 g. For the full list of excipients, see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eSuppositories\u003c\/u\u003e: sodium stearate; sodium carbonate. \u003cu\u003eRectal solution\u003c\/u\u003e: chamomile fluid extract; mauve fluid extract; wheat starch; purified water.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e• hypersensitivity to the active ingredient or to any of the excipients; • acute abdominal pain or pain of unknown origin; • nausea or vomiting; • intestinal obstruction or stricture; • rectal bleeding of unknown origin; • acute hemorrhoidal crisis with pain and bleeding; • severe state of dehydration.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe correct dose is the minimum sufficient to produce an easy evacuation. It is advisable to initially use the minimum doses provided. \u003cu\u003eDosage\u003c\/u\u003e \u003cb\u003eSuppositories\u003c\/b\u003e: \u003cu\u003eAdults\u003c\/u\u003e: 1 adult suppository as needed, for a maximum of 1 or 2 administrations per day. \u003ci\u003ePediatric population\u003c\/i\u003e \u003cu\u003eAdolescents (12 – 18 years)\u003c\/u\u003e: 1 adult suppository as needed, for a maximum of 1 or 2 administrations per day. \u003cu\u003eChildren aged 2 – 11 years\u003c\/u\u003e: 1 suppository for children as needed, for a maximum of 1 or 2 administrations per day. \u003cu\u003eChildren aged between 1 month and 2 years\u003c\/u\u003e: 1 early childhood suppository as needed, for a maximum of 1 or 2 administrations per day. \u003cb\u003eRectal solution\u003c\/b\u003e: \u003cu\u003eAdults\u003c\/u\u003e: 1 single-dose container for adults as needed, for a maximum of 1 or 2 administrations per day. \u003ci\u003ePediatric population\u003c\/i\u003e \u003cu\u003eAdolescents (12 – 18 years)\u003c\/u\u003e: 1 single-dose container for adults as needed, for a maximum of 1 or 2 administrations per day. \u003cu\u003eChildren aged between 6 – 11 years\u003c\/u\u003e: 1 or 2 single-dose containers for children as needed, for a maximum of 1 or 2 administrations per day. \u003cu\u003eChildren aged between 2 – 6 years\u003c\/u\u003e: 1 single-dose container for children as needed for a maximum of 1 or 2 administrations per day. \u003cu\u003eMethod of administration\u003c\/u\u003e \u003cu\u003eSuppositories\u003c\/u\u003e: Remove the suppository from its container and then, if necessary, moisten it to facilitate rectal introduction. If the suppositories appear softened, immerse the containers in cold water before opening them. \u003cu\u003eRectal solution\u003c\/u\u003e: To remove the safety cannula cover from the single-dose container, place your index finger and thumb on the round ring placed above the bellows and, with the other hand, bend the cannula cover until it detaches from the body of the container. During the operation, never grasp the bellows, otherwise the medicine would leak before use. It may be useful to lubricate the cannula with a drop of the solution itself, before introducing it into the rectum and pressing the bellows. Extract the cannula while holding down the bellows. Each container must be used for a single administration only; any residual medicine must be discarded. In children under twelve years of age the medicine can only be used after consulting a doctor. Laxatives should be used as infrequently as possible and for no longer than seven days (see section 4.4). A diet rich in liquids favors the effect of the medicine.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eStore in the original packaging to protect the medicine from humidity and away from direct sources of heat.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eLaxatives should be used as infrequently as possible and for no longer than seven days. Use for longer periods of time requires a doctor's prescription after adequate evaluation of the individual case. The treatment of chronic or recurrent constipation always requires the intervention of a doctor for diagnosis, prescription of drugs and monitoring during the course of therapy. It is also advisable for elderly people or those in poor health to consult their doctor before using the medicine. Abuse of laxatives can cause persistent diarrhea with consequent loss of water, mineral salts (especially potassium) and other essential nutritional factors. In more serious cases of abuse, the onset of dehydration or hypokalemia is possible, which can cause cardiac or neuromuscular dysfunction, especially in case of simultaneous treatment with cardiac glycosides, diuretics or corticosteroids. The abuse of laxatives, especially contact laxatives (stimulant laxatives), can cause dependence (and, therefore, possible need to progressively increase the dosage), chronic constipation and loss of normal intestinal functions (intestinal atony). In episodes of constipation, it is recommended first of all to correct eating habits by integrating the daily diet with an adequate intake of fiber and water. When using laxatives it is advisable to drink at least 6-8 glasses of water or other liquids a day to help soften the stool.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo specific interaction studies have been performed.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eUndesirable effects observed during treatment in clinical studies and integrated with those collected during post-marketing experience are listed in the table below according to System Organ Class (using MedDRA terminology) and according to the following frequency: Very common ≥1\/10; Common ≥1\/100, \u003c1\/10; Uncommon ≥1\/1,000, \u003c1\/100; Rare ≥1\/10,000, \u003c1\/1,000; Very rare \u003c1\/10,000; Not known (frequency cannot be estimated from the available data). The available data are insufficient to establish the frequency of the individual effects listed.\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders.\u003c\/p\u003e\n\u003cp\u003eNot known: Cramp-like pain in the abdomen*; abdominal colic, diarrhea**, anal irritation.\u003c\/p\u003e\n\u003cp\u003e*usually isolated ** with loss of fluids and electrolytes Isolated cramping pain or abdominal colic and diarrhea are more frequent in cases of severe constipation. \u003cb\u003eReporting of suspected adverse reactions\u003c\/b\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at \"www.agenziafarmaco.gov.it\/it\/responsabili\".\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo cases of overdose have been reported. In any case, excessive doses (abuse of laxatives – frequent or prolonged use or with excessive doses) can cause abdominal pain and persistent diarrhea with consequent loss of water, mineral salts (especially potassium) and other essential nutritional factors. Fluid and electrolyte losses must be replaced. Electrolyte imbalances are characterized by the following symptoms: thirst, vomiting, weakness, edema, bone pain (osteomalacia) and hypoalbuminemia. In more serious cases, the onset of dehydration or hypokalaemia is possible which can cause cardiac or neuromuscular dysfunction, especially in the case of simultaneous treatment with cardiac glycosides, diuretics or corticosteroids. The abuse of laxatives, especially contact laxatives (stimulant laxatives), can cause dependence (and, therefore, possible need to progressively increase the dosage), chronic constipation and loss of normal intestinal functions (intestinal atony).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo adequate and well-controlled studies have been carried out on the use of the medicine during pregnancy or breastfeeding. Although there are no obvious contraindications to the use of the medicine during pregnancy and breastfeeding, it is recommended to take the medicine only if necessary and under medical supervision.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eGlycerol has no influence on the ability to drive vehicles and use machines. However, it is possible that side effects may occur during treatment, therefore it is good to know the reaction to the drug before driving vehicles or using machinery.\u003c\/p\u003e","brand":"Carlo Erba","offers":[{"title":"Default Title","offer_id":40207823896691,"sku":"029651039","price":6.5,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/products\/carlo-erba-otc-srl-glicerolo-carlo-erba-18-supposte-2250-mg-farmacia-dottor-tili-1213792744.jpg?v=1767125952"},{"product_id":"voltaren-emulgel-gel-60-gr-2","title":"Voltaren Emulgel Gel 60 Gr 2%","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eLocal treatment of painful and inflammatory conditions of a rheumatic or traumatic nature affecting the joints (such as osteoarthritis and arthritis), muscles (such as contractures or injuries), tendons, and ligaments (such as tendinitis).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e100 g of \u003ci\u003eVoltaren Emulgel\u003c\/i\u003e contain 2.32 g of diclofenac diethylammonium, equivalent to 2 g of diclofenac sodium. Excipients with known effects: propylene glycol (50 mg\/g of gel); butylated hydroxytoluene (0.2 mg\/g of gel); pungent eucalyptus fragrance. For the full list of excipients, see paragraph 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eButylated hydroxytoluene\u003c\/b\u003e, carbomers, cocoyl caprylocaprate, diethylamine, isopropyl alcohol, liquid paraffin, cetostearyl ether of macrogol, oleyl alcohol, \u003cb\u003epropylene glycol\u003c\/b\u003e, \u003cb\u003epungent eucalyptus fragrance\u003c\/b\u003e, purified water.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e• Hypersensitivity to the active substance or to any of the excipients listed in paragraph 6.1. • History of asthma, angioedema, urticaria, or acute rhinitis following the intake of acetylsalicylic acid or other non-steroidal anti-inflammatory drugs (NSAIDs). • During the third trimester of pregnancy. • Use in children and adolescents under 14 years of age is contraindicated.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cp\u003eFor cutaneous use.\u003c\/p\u003e \u003cb\u003eAdults over 18 years:\u003c\/b\u003e \u003ci\u003eVoltaren Emulgel 2% gel\u003c\/i\u003e provides pain relief for up to 12 hours: Apply \u003ci\u003eVoltaren Emulgel 2% gel\u003c\/i\u003e twice a day to the area to be treated (preferably in the morning and evening), rubbing in lightly. The amount to apply depends on the size of the affected area. For example, 2–4 g of Voltaren Emulgel 2% gel (an amount ranging in size from a cherry to a walnut) is sufficient to treat an area of 400–800 cm\u0026sup2;. After application, clean your hands with absorbent paper and then wash them, unless the hands are the site to be treated. The absorbent paper should be disposed of in household waste after use. Patients should wait for Voltaren Emulgel 2% to dry before taking a shower or bath. Warning: use only for short treatment periods. The duration of treatment depends on the indication for use and the clinical response. The gel should not be used for more than 14 days without a doctor's advice. Consult a doctor if symptoms persist or worsen after 7 days of treatment. \u003cb\u003eAdolescents from 14 to 18 years old:\u003c\/b\u003e Apply Voltaren Emulgel 2% gel twice a day to the area to be treated (preferably in the morning and evening), rubbing in gently. The amount to be applied depends on the size of the affected area. For example, 2-4 g of Voltaren Emulgel 2% gel (an amount ranging in size from a cherry to a walnut) is sufficient to treat an area of 400-800 cm\u0026sup2;. After application, clean hands with absorbent paper and then wash them, unless they are the site to be treated. The absorbent paper should be disposed of in household waste after use. Patients should wait for Voltaren Emulgel 2% to dry before showering or bathing. If this product is needed for more than 7 days to relieve pain or if symptoms worsen, consult a doctor. \u003cb\u003eChildren under 14 years:\u003c\/b\u003e There are insufficient data on the efficacy and safety in children and adolescents under 14 years (see paragraph 4.3 Contraindications). Therefore, the use of Voltaren Emulgel 2% gel is contraindicated in children under 14 years of age. \u003cb\u003eElderly (over 65 years)\u003c\/b\u003e The usual adult dosage can be used.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSTORAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThis medicinal product does not require any special storage conditions.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe possibility of systemic adverse events with the application of \u003ci\u003eVoltaren Emulgel 2%\u003c\/i\u003e cannot be excluded if the preparation is used on large areas of skin and for a prolonged period\u003ci\u003e.\u003c\/i\u003e \u003ci\u003eVoltaren Emulgel 2%\u003c\/i\u003e should be applied only on intact, healthy skin, and not on skin wounds or open lesions. It should not come into contact with the eyes or mucous membranes and should not be ingested. Discontinue treatment if a skin rash develops after application of the product. \u003ci\u003eVoltaren Emulgel 2%\u003c\/i\u003e can be used with non-occlusive dressings, but should not be used with an occlusive dressing that does not allow air to pass through. \u003cb\u003eImportant information about some excipients\u003c\/b\u003e \u003ci\u003eVoltaren Emulgel 2% gel\u003c\/i\u003e contains 200 mg of propylene glycol per dose (4 g), equivalent to 50 mg\/g, which may cause skin irritation. \u003ci\u003eVoltaren Emulgel 2% gel\u003c\/i\u003e contains butylated hydroxytoluene which may cause localized skin reactions (e.g., contact dermatitis) or irritation of the eyes and mucous membranes. \u003ci\u003eVoltaren Emulgel 2% gel\u003c\/i\u003e contains pungent eucalyptus fragrance, an aroma that in turn contains benzyl alcohol, citronellol, coumarin, d-limonene, eugenol, geraniol, linalool which may cause allergic reactions.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSince the systemic absorption of diclofenac following topical application is very low, interactions are very unlikely.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eADVERSE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAdverse effects include mild and transient skin reactions at the application site. In very rare cases, allergic reactions may occur. The adverse effects (Table 1) are listed below by organ, system, and MedDRA frequency. Frequencies are defined as: very common (≥ 1\/10); common (≥ 1\/100 to \u003c1\/10); uncommon (≥ 1\/1,000 to \u003c1\/100); rare (≥ 1\/10,000 to \u003c1\/1,000); very rare (\u003c 1\/10,000); unknown (frequency cannot be estimated from the available data). \u003cb\u003eTable 1\u003c\/b\u003e \u003ctable border=1 cellspacing=0 cellpadding=3\u003e \u003ctr\u003e \u003ctd colspan=2\u003e \u003cb\u003eInfections and infestations\u003c\/b\u003e \u003c\/td\u003e \u003c\/tr\u003e \u003ctr\u003e \u003ctd\u003e Very rare\u003c\/td\u003e \u003ctd\u003e Rash with pustules.\u003c\/td\u003e \u003c\/tr\u003e \u003ctr\u003e \u003ctd colspan=2\u003e \u003cb\u003eImmune system disorders\u003c\/b\u003e \u003c\/td\u003e \u003c\/tr\u003e \u003ctr\u003e \u003ctd\u003e Very rare\u003c\/td\u003e \u003ctd\u003e Hypersensitivity (including urticaria), angioedema.\u003c\/td\u003e \u003c\/tr\u003e \u003ctr\u003e \u003ctd colspan=2\u003e \u003cb\u003eRespiratory, thoracic, and mediastinal disorders\u003c\/b\u003e \u003c\/td\u003e \u003c\/tr\u003e \u003ctr\u003e \u003ctd\u003e Very rare\u003c\/td\u003e \u003ctd\u003e Asthma.\u003c\/td\u003e \u003c\/tr\u003e \u003ctr\u003e \u003ctd colspan=2\u003e \u003cb\u003eSkin and subcutaneous tissue disorders\u003c\/b\u003e \u003c\/td\u003e \u003c\/tr\u003e \u003ctr\u003e \u003ctd\u003e Common\u003c\/td\u003e \u003ctd\u003e Dermatitis (including contact dermatitis), rash, erythema, eczema, itching.\u003c\/td\u003e \u003c\/tr\u003e \u003ctr\u003e \u003ctd\u003e Rare\u003c\/td\u003e \u003ctd\u003e Bullous dermatitis.\u003c\/td\u003e \u003c\/tr\u003e \u003ctr\u003e \u003ctd\u003e Very rare\u003c\/td\u003e \u003ctd\u003e Photosensitivity reaction, allergic reactions.\u003c\/td\u003e \u003c\/tr\u003e \u003ctr\u003e \u003ctd\u003e Unknown\u003c\/td\u003e \u003ctd\u003e Burning sensation at the application site, dry skin.\u003c\/td\u003e \u003c\/tr\u003e \u003c\/table\u003e \u003cb\u003eReporting of suspected adverse reactions\u003c\/b\u003e The reporting of suspected adverse reactions that occur after the medicinal product has been authorized is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are requested to report any suspected adverse reaction via the national reporting system at the address: http:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe low systemic absorption of topical diclofenac makes an overdose very unlikely; however, adverse effects similar to those observed after an overdose of diclofenac tablets can be expected if Voltaren Emulgel 2% is ingested (1 tube of 60 g contains the equivalent of 1.2 g of diclofenac sodium). In case of ingestion leading to significant systemic adverse effects, general therapeutic measures normally adopted for treating poisoning with non-steroidal anti-inflammatory drugs should be undertaken. Further treatment procedures, within a short time after ingestion, should take into account clinical indications or recommendations from the poison center, where available.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003ePregnancy\u003c\/b\u003e The systemic concentration of diclofenac compared with oral formulations is lower after topical administration. Referring to the experience with NSAID treatment via systemic administration, the following is recommended: Inhibition of prostaglandin synthesis may negatively affect pregnancy and\/or embryonic\/fetal development. Results from epidemiological studies suggest an increased risk of miscarriage and of heart malformations and gastroschisis after the use of a prostaglandin synthesis inhibitor in the early stages of pregnancy. The absolute risk of heart malformations increases from less than 1% to about 1.5%. It is believed that the risk increases with the dose and the duration of therapy. In animals, administration of prostaglandin synthesis inhibitors has been shown to cause an increase in pre- and post-implantation loss and mortality. embryo-fetal; moreover, an increased incidence of various malformations, including cardiovascular ones, has been reported in animals that were administered prostaglandin synthesis inhibitors during the organogenetic period. During the first and second trimester of pregnancy, diclofenac should not be administered unless strictly necessary. If diclofenac is used by a woman planning to conceive, or during the first and second trimester of pregnancy, the dose should be kept as low as possible and the duration of treatment as short as possible. During the third trimester of pregnancy, all prostaglandin synthesis inhibitors may expose the fetus to: - cardiopulmonary toxicity (with premature closure of the ductus arteriosus and pulmonary hypertension); - renal dysfunction, which may progress to renal failure with oligohydramnios; the mother and the neonate, at the end of pregnancy, to: - possible prolongation of bleeding time, and anti-platelet effect that can occur even at very low doses; - inhibition of uterine contractions resulting in delay or prolongation of labor. Diclofenac is contraindicated during the third trimester of pregnancy. \u003cb\u003eBreastfeeding\u003c\/b\u003e Like other NSAIDs, diclofenac passes into breast milk in small amounts. However, at the therapeutic doses of \u003ci\u003eVoltaren Emulgel 2%\u003c\/i\u003e, no effects on the infant are expected. Due to the lack of controlled studies in breastfeeding women, the product should be used during breastfeeding only under the advice of a healthcare professional. In this case, \u003ci\u003eVoltaren Emulgel 2%\u003c\/i\u003e should not be applied to the breasts of nursing mothers, nor elsewhere on large areas of skin or for a prolonged period of time (see paragraph 4.4 Special warnings and precautions for use).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON ABILITY TO DRIVE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eVoltaren Emulgel 2%\u003c\/i\u003e does not impair the ability to drive vehicles or use machinery.\u003c\/p\u003e","brand":"Novartis","offers":[{"title":"Default Title","offer_id":40207823929459,"sku":"034548065","price":13.67,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/products\/novartis-farma-spa-voltaren-emulgel-gel-60-gr-2-farmacia-dottor-tili-1213792743.webp?v=1767125980"},{"product_id":"aspirina-c-20-compresse-effervescenti-400-240-mg","title":"Aspirin C 20 Effervescent Tablets 400+240 mg ","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSymptomatic therapy of feverish states and flu and cold syndromes. Symptomatic treatment of headaches and toothaches, neuralgia, menstrual pain, rheumatic and muscular pain.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eASPIRIN 400 mg effervescent tablets with vitamin C One tablet contains: \u003cu\u003eactive ingredients\u003c\/u\u003e: acetylsalicylic acid 400 mg ascorbic acid (Vitamin C) 240 mg For the complete list of excipients, see section 6.1\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eexcipients\u003c\/u\u003e: monosodium citrate sodium bicarbonate sodium carbonate citric acid\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eASPIRIN tablets \u003c\/b\u003eeffervescent with vitamin C is contraindicated in case of: - hypersensitivity to the active ingredients (acetylsalicylic acid and ascorbic acid), to other analgesics (painkillers) \/ antipyretics (antipyretics) \/ non-steroidal anti-inflammatory drugs (NSAIDs) or to any of the excipients; - gastroduodenal ulcer; - hemorrhagic diathesis; - severe renal, cardiac or hepatic failure; - glucose-6-phosphate dehydrogenase deficiency (G6PD\/favism); - concomitant treatment with methotrexate (at doses of 15 mg\/week or more) or with warfarin (see section 4.5); - history of asthma induced by the administration of salicylates or substances with similar activity, in particular non-steroidal anti-inflammatory drugs; - last trimester of pregnancy and breastfeeding (see section 4.6); - children and young people under 16 years of age. - Nephrolithiasis or previous history of nephrolithiasis - Hyperoxaluria - Hemochromatosis\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAdults 1-2 tablets as a single dose, repeating, if necessary, the dose at intervals of 4-8 hours up to 3-4 times a day. Aspirin C must always be dissolved before use (1 tablet in half a glass of water). The use of the product is reserved for adult patients only. Always use the minimum effective dosage and increase it only if it is not sufficient to relieve symptoms (pain and fever). Subjects most exposed to the risk of serious side effects, who can only use the drug if prescribed by their doctor, must follow the instructions scrupulously (see section 4.4). Use the medicine for the shortest period possible. Do not take the product for more than 3 - 5 days without medical advice. Consult your doctor if symptoms persist. Take the medicine preferably after main meals or, in any case, on a full stomach. \u003cb\u003eSpecial populations\u003c\/b\u003e \u003ci\u003e \u003cu\u003e Pediatric population\u003c\/u\u003e \u003c\/i\u003e Aspirin effervescent tablets with vitamin C are not indicated for use in the pediatric population (see section 4.4). \u003ci\u003eElderly\u003c\/i\u003e In elderly patients use the minimum effective dosage. \u003ci\u003e \u003cu\u003ePatients with impaired liver function \u003c\/u\u003e \u003c\/i\u003e Acetylsalicylic acid should be used with caution in patients with impaired hepatic function (see section 4.4). \u003ci\u003e \u003cu\u003ePatients with impaired renal function \u003c\/u\u003e \u003c\/i\u003e Acetylsalicylic acid should be used with caution in patients with impaired renal function (see section 4.4).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eStore at a temperature below 25° C.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eHypersensitivity reactions\u003c\/i\u003e Acetylsalicylic acid and other NSAIDs may cause hypersensitivity reactions (including asthma attacks, rhinitis, angioedema or urticaria). The risk is greater in subjects who have already presented a hypersensitivity reaction in the past after the use of this type of drug (see section 4.3) and in subjects who present allergic reactions to other substances (e.g. skin reactions, itching, urticaria). In subjects with asthma and\/or rhinitis (with or without nasal polyposis) and\/or urticaria the reactions may be more frequent and serious. In rare cases, reactions can be very serious and potentially fatal. In the following cases, administration of the drug requires a doctor's prescription after careful evaluation of the risk\/benefit ratio: - \u003ci\u003eSubjects at increased risk of hypersensitivity reactions (see above)\u003c\/i\u003e - \u003ci\u003eSubjects at increased risk of gastrointestinal lesions\u003c\/i\u003e Acetylsalicylic acid and other NSAIDs can cause serious side effects at the gastrointestinal level (bleeding, ulcer, perforation). For this reason these drugs should not be used by subjects suffering from gastrointestinal ulcers or gastrointestinal bleeding. It is prudent for those who have suffered from gastrointestinal ulcers or gastrointestinal bleeding in the past to avoid its use. The risk of gastrointestinal lesions is a dose-related effect, as gastrointestinal lesions are greater in subjects who use higher doses of acetylsalicylic acid. Even subjects with a habit of drinking large quantities of alcohol are more exposed to the risk of gastrointestinal lesions (bleeding in particular) (see paragraph 4.5). - \u003ci\u003eSubjects with coagulation defects or being treated with anticoagulants\u003c\/i\u003e In subjects suffering from coagulation defects or being treated with anticoagulants, acetylsalicylic acid and other NSAIDs can cause a serious reduction in haemostatic capacity, exposing them to the risk of haemorrhage. - \u003ci\u003eSubjects with impaired renal, cardiac or hepatic function\u003c\/i\u003e Acetylsalicylic acid and other NSAIDs can cause a critical reduction in renal function and water retention; the risk is greater in subjects treated with diuretics. This can be especially dangerous for the elderly and for those with impaired kidney, heart or liver function. - \u003ci\u003eSubjects suffering from asthma\u003c\/i\u003e Acetylsalicylic acid and other NSAIDs can cause an aggravation of asthma. - \u003ci\u003eGeriatric age (especially above 75 years)\u003c\/i\u003e The risk of serious side effects is greater in geriatric subjects. Individuals over the age of 70, especially in the presence of concomitant therapies, should use Aspirin only after consulting their doctor. Aspirin should not be used in the pediatric population (see section 4.3). Products containing acetylsalicylic acid should not be used in children and adolescents under 16 years of age with viral infections, regardless of the presence or absence of fever. In certain viral diseases, especially influenza A, influenza B and chickenpox, there is a risk of Reye's syndrome, a very rare but life-threatening disease that requires immediate medical intervention. The risk may be increased in case of simultaneous intake of acetylsalicylic acid, although a causal relationship has not been demonstrated. Persistent vomiting in patients with these diseases may be a sign of Reye's syndrome. - \u003ci\u003eSubjects with hyperuricemia\/gout\u003c\/i\u003e Acetylsalicylic acid can interfere with the elimination of uric acid: high doses have a uricosuric effect while (very) low doses can reduce its excretion. It should also be considered that acetylsalicylic acid and other NSAIDs can mask the symptoms of gout, delaying its diagnosis. An antagonistic effect with uricosuric drugs is also possible (see section 4.5).- \u003ci\u003eSubjects with a predisposition to calcium-oxal nephrolithiasis (kidney stones) or with recurrent nephrolithiasis\u003c\/i\u003e \u003ci\u003eAspirin effervescent tablets with vitamin C\u003c\/i\u003e: Vitamin C (ascorbic acid) should be used with caution by subjects with a predisposition to calcium-oxal nephrolithiasis (kidney stones) or with recurrent nephrolithiasis. - \u003ci\u003eCombination of drugs not recommended or requiring special precautions or dosage adjustment\u003c\/i\u003e. The use of acetylsalicylic acid in combination with some drugs may increase the risk of serious side effects (see section 4.5). Do not use acetylsalicylic acid together with another NSAID or, in any case, do not use more than one NSAID at a time. If you have to undergo surgery (even a small one, for example the extraction of a tooth) and in the previous days you have used acetylsalicylic acid or another NSAID, you must inform the surgeon due to the possible effects on coagulation. Since acetylsalicylic acid can cause gastrointestinal bleeding, this must be taken into account if it is necessary to carry out a search for occult blood. Before administering any medicine, all necessary precautions must be taken to prevent unwanted reactions; particularly important is the exclusion of previous hypersensitivity reactions to this or other medicines and the exclusion of other contraindications or conditions that may expose you to the risk of potentially serious side effects listed above. If in doubt, consult your doctor or pharmacist. Imperfect and prolonged storage of Aspirin C can cause variations in the color of the tablet which in themselves do not affect either the activity or tolerability of the active ingredient. In this case, it is still advisable to ask the pharmacy for the packaging to be replaced. The product must be taken on a full stomach. \u003cb\u003e \u003ci\u003eInformation on excipients\u003c\/i\u003e \u003c\/b\u003e This medicinal product contains 467 mg sodium per effervescent tablet equivalent to 23% of the WHO recommended maximum daily intake of 2 g sodium for an adult.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eContraindicated combinations (avoid concomitant use - see section 4.3):\u003c\/i\u003e - \u003cu\u003eMethotrexate (doses greater than or equal to 15 mg\/week)\u003c\/u\u003e: increased plasma levels and toxicity of methotrexate; the risk of toxic effects is greater if renal function is compromised. - \u003cu\u003eWarfarin:\u003c\/u\u003e serious increase in the risk of hemorrhage due to enhancement of the anticoagulant effect. \u003ci\u003eAssociations not recommended (the concomitant use of the two drugs requires a doctor's prescription after careful evaluation of the risk\/benefit ratio - see section 4.4):\u003c\/i\u003e \u003cu\u003eAntiplatelet agents:\u003c\/u\u003e increased risk of hemorrhage due to the sum of the anti-aggregating effect. \u003cu\u003eOral or parenteral thrombolytics or anticoagulants\u003c\/u\u003e: increased risk of bleeding due to enhancement of the pharmacological effect. \u003cu\u003eNSAIDs\u003c\/u\u003e (topical use excluded): increased risk of serious side effects. \u003cu\u003eMethotrexate (doses less than 15mg\/week)\u003c\/u\u003e: the increased risk of toxic effects (see above) must also be considered for treatment with methotrexate at low doses. \u003cu\u003eSelective serotonin re-uptake inhibitors (SSRIs):\u003c\/u\u003e increased risk of upper gastrointestinal bleeding due to a possible synergistic effect. \u003ci\u003eAssociations requiring particular precautions or dosage adjustment (concomitant use of the two drugs requires a doctor's prescription after careful evaluation of the risk\/benefit ratio - see section 4.4):\u003c\/i\u003e \u003cu\u003eACE inhibitors:\u003c\/u\u003e reduction of the hypotensive effect; increased risk of impaired renal function. \u003cu\u003eValproic Acid:\u003c\/u\u003e increased effect of valproic acid (risk of toxicity). \u003cu\u003eAntacids:\u003c\/u\u003e antacids taken at the same time as other drugs can reduce their absorption; the excretion of acetylsalicylic acid increases in alkalinized urine. \u003cu\u003eAntidiabetics (e.g. insulin and oral hypoglycemics)\u003c\/u\u003e: increased hypoglycemic effect; the use of acetylsalicylic acid in subjects being treated with antidiabetics must take into account the risk of inducing hypoglycemia. \u003cu\u003eDigoxin:\u003c\/u\u003e increased plasma concentration of digoxin due to decreased renal elimination. \u003cu\u003eDiuretics\u003c\/u\u003e: increased risk of nephrotoxicity of acetylsalicylic acid and other NSAIDs; reduction of the effect of diuretics. \u003cu\u003eAcetazolamide\u003c\/u\u003e: reduced elimination of acetazolamide (risk of toxicity). \u003cu\u003ePhenytoin: \u003c\/u\u003eincreased effect of phenytoin. \u003cu\u003eCorticosteroids \u003c\/u\u003e(excluding those for topical use and those used for the treatment of adrenocortical insufficiency): a) increased risk of gastrointestinal lesions; b) due to the increased elimination of salicylates induced by corticosteroids there is a reduction in plasma levels of salicylate. On the other hand, after discontinuation of corticosteroid treatment, overdose of salicylates may occur. \u003cu\u003eMetoclopramide\u003c\/u\u003e: increase in the effect of acetylsalicylic acid due to an increase in the speed of absorption. \u003cu\u003eUricosurics (e.g. probenecid, benzbromarone)\u003c\/u\u003e: decrease in the uricosuric effect. \u003cu\u003eZafirlukast\u003c\/u\u003e: increased plasma concentration of zafirlukast. Deferoxamine Aspirin effervescent tablets with vitamin C: the concomitant use of ascorbic acid can cause increased tissue toxicity of iron especially at the cardiac level and cause heart failure. Aspirin effervescent tablets with Vitamin C contain buffer systems that may reduce the effects of the thyroid hormone Levothyroxine. \u003ci\u003eAlcohol (see section 4.4)\u003c\/i\u003e The sum of the effects of alcohol and acetylsalicylic acid causes increased damage to the gastrointestinal mucosa and prolongation of bleeding time. However, it is advisable not to administer other drugs orally within 1 or 2 hours of using the product. \u003cb\u003e \u003cu\u003eInterference with clinical laboratory tests \u003c\/u\u003e \u003c\/b\u003e Vitamin C Because vitamin C is a reducing agent (i.e., an electron donor), it may cause chemical interference in laboratory tests involving oxidation-reduction reactions, such as analyzes of glucose, creatinine, carbamazepine, uric acid in urine, serum, and fecal occult blood. Vitamin C can interfere with tests that measure urine and blood glucose leading to a false reading of the results even if it has no effect on blood glucose levels.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe most frequently observed side effects affect the gastrointestinal system and can occur in approximately 4% of subjects taking acetylsalicylic acid as an analgesic-antipyretic. This percentage increases significantly in subjects at risk of gastrointestinal disorders. These disorders can be partially alleviated by taking the medicine on a full stomach. Most side effects are dependent on both the dose and duration of treatment. The side effects observed with acetylsalicylic acid are generally common to other NSAIDs. \u003cb\u003ePathologies of the blood and lymphatic system\u003c\/b\u003e Prolonged bleeding time, anemia due to gastrointestinal bleeding, reduction in platelets (thrombocytopenia) in extremely rare cases. Following hemorrhage, hemorrhagic\/iron-deficiency anemia may occur (due, for example, to occult microhemorrhages) with the related alterations in laboratory parameters and the related clinical signs and symptoms such as asthenia, pallor and hypoperfusion. \u003cb\u003eNervous system disorders\u003c\/b\u003e Headache, dizziness. Rarely: Reye's syndrome (*) Rarely to very rarely: cerebral hemorrhage, especially in patients with uncontrolled hypertension and\/or on anticoagulant therapy, which, in isolated cases, can be potentially lethal. \u003cb\u003eEar and labyrinth disorders\u003c\/b\u003e Tinnitus (buzzing\/rustling\/ringing\/ringing in the ears). \u003cb\u003eRespiratory, thoracic and mediastinal disorders\u003c\/b\u003e Respiratory disease exacerbated by acetylsalicylic acid, asthma syndrome, rhinitis (profuse rhinorrhoea), nasal congestion (associated with hypersensitivity reactions). Epistaxis. \u003cb\u003e \u003ci\u003eCardiac diseases\u003c\/i\u003e \u003c\/b\u003e Cardiorespiratory distress (associated with hypersensitivity reactions) \u003cb\u003e \u003ci\u003eEye pathologies\u003c\/i\u003e \u003c\/b\u003e Conjunctivitis (associated with hypersensitivity reactions) \u003cb\u003eGastrointestinal disorders\u003c\/b\u003e Gastrointestinal bleeding (occult), gastric disorders, heartburn, gastrointestinal pain, gingivorrhagia. Vomiting, diarrhoea, nausea, crampy abdominal pain (associated with hypersensitivity reactions). Rarely: gastrointestinal inflammation, gastrointestinal erosion, gastrointestinal ulceration, hematemesis (vomiting of blood or \"coffee-like\" material), melena (emission of black stools, esophagitis). Very rarely: hemorrhagic gastrointestinal ulcer and\/or gastrointestinal perforation with the related clinical signs and symptoms and alterations of laboratory parameters. Frequency not known (especially in long-term treatment): - Disease of the intestinal diaphragms. \u003cb\u003e \u003ci\u003eHepatobiliary disorders\u003c\/i\u003e \u003c\/b\u003e Rarely: hepatotoxicity (generally mild and asymptomatic hepatocellular injury) manifested by an increase in transaminases. \u003cb\u003e \u003ci\u003ePathologies of the skin and subcutaneous tissues\u003c\/i\u003e \u003c\/b\u003e Rash, edema, urticaria, pruritus, erythema, angioedema (associated with hypersensitivity reactions). \u003cb\u003e \u003ci\u003eRenal and urinary disorders\u003c\/i\u003e \u003c\/b\u003e Alteration of renal function (in the presence of conditions of altered renal hemodynamics) and acute renal injury, urogenital haemorrhages. \u003cb\u003e \u003ci\u003eSystemic pathologies and conditions relating to the administration site\u003c\/i\u003e \u003c\/b\u003e Procedural hemorrhages, hematomas. \u003cb\u003e \u003ci\u003eImmune system disorders\u003c\/i\u003e \u003c\/b\u003e Rarely: anaphylactic shock with related alterations in laboratory parameters and clinical manifestations. (*) Reye's syndrome (SdR) SdR initially manifests itself with vomiting (persistent or recurrent) and with other signs of encephalic distress of varying degrees: from listlessness, drowsiness or personality changes (irritability or aggressiveness) to disorientation, confusion or delirium up to convulsions or loss of consciousness. The variability of the clinical picture must be kept in mind: vomiting may also be absent or replaced by diarrhea. If these symptoms arise in the days immediately following a flu episode (or flu-like or chickenpox or another viral infection) during which acetylsalicylic acid or other medicines containing salicylates were administered, the doctor's attention must immediately be paid to the possibility of an SdR. \u003cu\u003e Reporting of suspected adverse reactions\u003c\/u\u003e Reporting suspected adverse reactions that occur after authorization of the medicinal product is important, as it allows continuous monitoring of the benefit\/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system of the Italian Medicines Agency. Website: https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eAcetylsalicylic acid\u003c\/u\u003e Toxicity from salicylates (a dosage exceeding 100 mg\/kg\/day for 2 consecutive days can induce toxicity) can be the consequence of chronic intake of excessive doses, or of acute overdose, potentially dangerous for life and which also includes accidental ingestion in children. Chronic salicylate intoxication Poisoning\u003cb\u003e chronic\u003c\/b\u003e from salicylates can be insidious since the signs and symptoms are nonspecific. Mild chronic salicylate intoxication, or salicylism, generally occurs only following repeated use of large doses. Symptoms include dizziness, vertigo, tinnitus, deafness, sweating, nausea and vomiting, headache and confusion. These symptoms can be controlled by reducing the dosage. Tinnitus can occur at plasma concentrations between 150 and 300 micrograms\/ml, while more serious adverse events occur at concentrations above 300 micrograms\/ml. Acute salicylate intoxication The main feature of intoxication\u003cb\u003e acute\u003c\/b\u003e it is a serious alteration of the acid-base balance, which can vary with age and the severity of the intoxication; the most common presentation in children is metabolic acidosis. It is not possible to estimate the severity of poisoning from plasma concentrations alone; the absorption of acetylsalicylic acid may be delayed due to reduced gastric emptying, the formation of concretions in the stomach, or as a consequence of the ingestion of gastro-resistant preparations. The management of acetylsalicylic acid poisoning is determined by the extent, stage and clinical symptoms of the latter, and must be implemented according to conventional poisoning management techniques. The main measures to be taken consist in accelerating drug excretion and restoring electrolyte and acid-base metabolism. Due to the complex pathophysiological effects connected with salicylate poisoning, the signs and symptoms\/results of biochemical and instrumental investigations may include:\u003c\/p\u003e\n\u003cp\u003eSigns and symptoms: MILD TO MODERATE INTOXICATION - Therapeutic measures: Gastric lavage, repeated administration of activated charcoal, forced alkaline diuresis.\u003c\/p\u003e\n\u003cp\u003eSigns and symptoms: Tachypnoea, hyperventilation, respiratory alkalosis - Results of biochemical and instrumental investigations: Alkalemia, alkaluria. Therapeutic measures: Fluid and electrolyte management.\u003c\/p\u003e\n\u003cp\u003eSigns and symptoms: Sweating.\u003c\/p\u003e\n\u003cp\u003eSigns and symptoms: Nausea, vomiting, headache, dizziness.\u003c\/p\u003e\n\u003cp\u003eSigns and symptoms: MODERATE TO SEVERE INTOXICATION - Therapeutic measures: Gastric lavage, repeated administration of activated charcoal, forced alkaline diuresis, hemodialysis in severe cases.\u003c\/p\u003e\n\u003cp\u003eSigns and symptoms: Respiratory alkalosis with compensatory metabolic acidosis, - Results of biochemical and instrumental investigations: Acidemia, aciduria. Therapeutic measures: Fluid and electrolyte management.\u003c\/p\u003e\n\u003cp\u003eSigns and symptoms: Hyperpyrexia - Therapeutic measures: Fluid and electrolyte management.\u003c\/p\u003e\n\u003cp\u003eSigns and symptoms: Respiratory: ranging from hyperventilation and non-cardiogenic pulmonary edema to respiratory arrest and asphyxia.\u003c\/p\u003e\n\u003cp\u003eSigns and symptoms: Cardiovascular: variable from arrhythmias and hypotension to cardiac arrest - Results of biochemical and instrumental investigations: E.g. alteration of blood pressure, alteration of ECG.\u003c\/p\u003e\n\u003cp\u003eSigns and symptoms: Loss of fluids and electrolytes: dehydration, from oliguria to renal failure - Results of biochemical and instrumental investigations: E.g. hypokalemia, hyperna–tremia, hyponatremia, impaired renal function. Therapeutic measures: Fluid and electrolyte management.\u003c\/p\u003e\n\u003cp\u003eSigns and symptoms: Alterations of glucose metabolism, ketosis - Results of biochemical and instrumental investigations: Hyperglycemia, hypoglycemia (especially in children) Increased levels of ketones.\u003c\/p\u003e\n\u003cp\u003eSigns and symptoms: Tinnitus, deafness\u003c\/p\u003e\n\u003cp\u003eSigns and symptoms: Gastrointestinal: gastrointestinal bleeding, gastric ulcer.\u003c\/p\u003e\n\u003cp\u003eSigns and symptoms: Haematological: coagulopathy, iron deficiency anemia - Results of biochemical and instrumental investigations: E.g. prolonged PT, hypoprothrombinemia.\u003c\/p\u003e\n\u003cp\u003eSigns and symptoms: Neurological: toxic encephalopathy and CNS depression with manifestations ranging from lethargy and confusion to coma and convulsions. Cerebral edema.\u003c\/p\u003e\n\u003cp\u003eSigns and symptoms: Liver: liver damage - Results of biochemical and instrumental investigations: Increased levels of liver enzymes.\u003c\/p\u003e\n\u003cp\u003eAt high doses the following may also appear: Taste alterations. Skin rashes (acneiform, erythematous, scarlatiniform, eczematoid, desquamative, bullous, purpuric), itching. Others: conjunctivitis, anorexia, reduced visual acuity, drowsiness. Rarely: aplastic anemia, agranulocytosis, disseminated intravascular coagulation, pancytopenia, leukopenia, thrombocytopenia, eosinopenia, purpura, eosinophilia associated with drug-induced hepatotoxicity, nephrotoxicity (allergic tubulointerstitial nephritis), hematuria (presence of blood in the urine). Acute allergic reactions following the intake of acetylsalicylic acid can be treated, if necessary, with the administration of adrenaline, corticosteroids and an antihistamine. In case of overdose, contact a poison control center or the nearest hospital immediately. Acetylsalicylic acid is dialysable. \u003cu\u003eAscorbic acid\u003c\/u\u003e Aspirin 400 mg effervescent tablets with vitamin C contains ascorbic acid: Single cases of acute and chronic overdose of \u003cb\u003eascorbic acid\u003c\/b\u003e. Overdose of ascorbic acid may cause oxidative haemolysis in patients with glucose-6-phosphate dehydrogenase deficiency, disseminated intravascular coagulation and significantly elevated serum and urinary oxalate levels. Increased levels of oxalates have been shown to result in the formation of calcium oxalate deposits in dialysis patients. High doses of vitamin C may cause calcium oxalate deposits, calcium oxalate crystalluria in patients with a predisposition to crystal formation, tubulointerstitial nephropathy, and acute renal failure resulting from calcium oxalate crystals.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eFertility\u003c\/u\u003e The use of acetylsalicylic acid as well as any drug that inhibits the synthesis of prostaglandins and cyclooxygenase could interfere with fertility; female subjects and in particular women who have fertility problems or who are undergoing fertility investigations must be informed of this. \u003cu\u003ePregnancy\u003c\/u\u003e Inhibition of prostaglandin synthesis can negatively affect pregnancy and\/or embryo\/foetal development. Results of epidemiological studies suggest an increased risk of miscarriage and cardiac malformation and gastroschisis after the use of a prostaglandin synthesis inhibitor in the early stages of pregnancy. The absolute risk of cardiac malformations was increased from less than 1% to approximately 1.5%. It has been estimated that the risk increases with the dose and duration of therapy. In animals, the administration of prostaglandin synthesis inhibitors has been shown to cause an increase in pre- and post-implantation loss and embryo-foetal mortality. Furthermore, an increased incidence of various malformations, including cardiovascular malformations, has been reported in animals to which prostaglandin synthesis inhibitors were administered during the organogenetic period. During the first and second trimester of pregnancy, acetylsalicylic acid should not be administered unless clearly necessary. If drugs containing acetylsalicylic acid are used by a woman trying to get pregnant, or during the first and second trimester of pregnancy, treatment should be as short as possible and the dose as low as possible. During the third trimester of pregnancy, all inhibitors of prostaglandin synthesis can expose: the fetus to: - cardiopulmonary toxicity (with premature closure of the ductus arteriosus and pulmonary hypertension); - renal dysfunction, which can progress to renal failure with oligo-hydramnios; the mother and the unborn child, at the end of pregnancy, to: - possible prolongation of bleeding time, an anti-aggregating effect which can occur even at very low doses; - inhibition of uterine contractions resulting in delayed or prolonged labor. Consequently, acetylsalicylic acid is contraindicated during the third trimester of pregnancy. \u003cu\u003e Breastfeeding\u003c\/u\u003e ASPIRIN 400 mg effervescent tablets with vitamin C is contraindicated during breastfeeding (see section 4.3).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDue to the possible onset of headache or dizziness, this medicine may impair the ability to drive and use machinery.\u003c\/p\u003e","brand":"Bayer","offers":[{"title":"Default Title","offer_id":40207823962227,"sku":"004763330","price":10.59,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/bayer-aspirina-c-20-compresse-effervescenti-400-240-mg-farmacia-dottor-tili-1254211172.jpg?v=1786732478"},{"product_id":"tachipirina-bambini-10-supposte-250-mg","title":"Tachipirina Children 10 Suppositories 250 mg","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAs an antipyretic: symptomatic treatment of febrile diseases such as influenza, exanthematous diseases, acute respiratory tract diseases, etc. As an analgesic: headaches, neuralgia, myalgia and other medium-level painful manifestations of various origins.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eTACHIPIRINA 500 mg tablets.\u003c\/i\u003e Each tablet contains: \u003cu\u003eactive ingredient: paracetamol 500 mg.\u003c\/u\u003e \u003ci\u003eTACHIPIRINA 500 mg effervescent granules.\u003c\/i\u003e Each sachet contains: \u003cu\u003eactive ingredient: paracetamol 500 mg.\u003c\/u\u003e \u003cu\u003eexcipients with known effects: aspartame, maltitol, 12.3 mmol sodium per sachet\u003c\/u\u003e \u003ci\u003eTACHIPIRINA 125 mg effervescent granules. \u003c\/i\u003e Each sachet contains: \u003cu\u003eactive ingredient: paracetamol 125 mg.\u003c\/u\u003e \u003cu\u003eexcipients with known effects: aspartame, maltitol, 3.07 mmol sodium per sachet\u003c\/u\u003e \u003ci\u003e \u003cu\u003eTACHIPIRINA Infants 62.5 mg suppositories.\u003c\/u\u003e \u003c\/i\u003e Each suppository contains. \u003cu\u003eactive ingredient: paracetamol 62.5 mg\u003c\/u\u003e \u003ci\u003e \u003cu\u003eTACHIPIRINA Early Childhood 125 mg suppositories.\u003c\/u\u003e \u003c\/i\u003e Each suppository contains: \u003cu\u003eactive ingredient: paracetamol 125 mg.\u003c\/u\u003e \u003ci\u003e \u003cu\u003eTACHIPIRINA Children 250 mg suppositories.\u003c\/u\u003e \u003c\/i\u003e Each suppository contains: \u003cu\u003eactive ingredient: paracetamol 250 mg.\u003c\/u\u003e \u003ci\u003e \u003cu\u003eTACHIPIRINA Children 500 mg suppositories.\u003c\/u\u003e \u003c\/i\u003e Each suppository contains: \u003cu\u003eactive ingredient: paracetamol 500 mg.\u003c\/u\u003e \u003ci\u003e \u003cu\u003eTACHIPIRINA Adults 1000 mg suppositories.\u003c\/u\u003e \u003c\/i\u003e Each suppository contains: \u003cu\u003eactive ingredient: paracetamol 1000 mg.\u003c\/u\u003e For the complete list of excipients, see par. 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e• \u003cu\u003eTablets:\u003c\/u\u003e microcrystalline cellulose, povidone, pregelatinized starch, stearic acid, croscarmellose sodium. • \u003cu\u003eEffervescent granules\u003c\/u\u003e: maltitol, mannitol, sodium bicarbonate, anhydrous citric acid, citrus flavouring, aspartame, sodium docusate. • \u003cu\u003eSuppositories\u003c\/u\u003e: solid semi-synthetic glycerides.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e• Hypersensitivity to paracetamol or to any of the excipients listed in paragraph 6.1. • Patients suffering from severe hemolytic anemia (this contraindication does not refer to the 500mg oral formulations). • Severe hepatocellular insufficiency (this contraindication does not refer to the 500mg oral formulations).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eFor children it is essential to respect the dosage defined according to their body weight, and therefore choose the suitable formulation. Approximate ages based on body weight are indicated for information. In adults, the maximum oral dosage is 3000 mg and rectally 4000 mg of paracetamol per day (see section 4.9). The doctor must evaluate the need for treatments for more than 3 consecutive days. The dosage schedule of Tachipirina in relation to body weight and route of administration is as follows: \u003cb\u003e500 mg tablets.\u003c\/b\u003e • \u003cu\u003eChildren weighing between 21 and 25 kg\u003c\/u\u003e (approximately between 6.5 and less than 8 years): ½ tablet at a time, to be repeated if necessary after 4 hours, without exceeding 6 administrations per day (3 tablets). • \u003cu\u003eChildren weighing between 26 and 40 kg\u003c\/u\u003e (approximately between 8 and 11 years): 1 tablet at a time, to be repeated if necessary after 6 hours, without exceeding 4 doses per day. • \u003cu\u003eChildren weighing between 41 and 50 kg\u003c\/u\u003e (approximately between 12 and 15 years): 1 tablet at a time, to be repeated if necessary after 4 hours, without exceeding 6 doses per day. • \u003cu\u003eChildren weighing more than 50 kg\u003c\/u\u003e (approximately over 15 years): 1 tablet at a time, to be repeated if necessary after 4 hours, without exceeding 6 administrations per day. • \u003cu\u003eAdults\u003c\/u\u003e: 1 tablet at a time, to be repeated if necessary after 4 hours, without exceeding 6 doses per day. In case of severe pain or high fever, 2 tablets of 500 mg to be repeated if necessary after no less than 4 hours. \u003cb\u003e500 mg effervescent granules in sachets.\u003c\/b\u003e Dissolve the effervescent granules in a glass of water. • \u003cu\u003eChildren weighing between 26 and 40 kg\u003c\/u\u003e (approximately between 8 and 11 years): 1 sachet at a time, to be repeated if necessary after 6 hours, without exceeding 4 doses per day. • \u003cu\u003eChildren weighing between 41 and 50 kg\u003c\/u\u003e (approximately between 12 and 15 years): 1 sachet at a time, to be repeated if necessary after 4 hours, without exceeding 6 doses per day. • \u003cu\u003eChildren weighing more than 50 kg\u003c\/u\u003e (approximately over 15 years): 1 sachet at a time, to be repeated if necessary after 4 hours, without exceeding 6 administrations per day. • \u003cu\u003eAdults\u003c\/u\u003e: 1 sachet at a time, to be repeated if necessary after 4 hours, without exceeding 6 administrations per day. In case of severe pain or high fever, 2 sachets of 500 mg to be repeated if necessary after no less than 4 hours. \u003cb\u003e125 mg effervescent granules in sachets.\u003c\/b\u003e Dissolve the effervescent granules in a glass of water. • \u003cu\u003eChildren weighing between 7 and 10 kg\u003c\/u\u003e (approximately between 6 and 19 months): 1 sachet at a time, to be repeated if necessary after 6 hours, without exceeding 4 doses per day. • \u003cu\u003eChildren weighing between 11 and 12 kg\u003c\/u\u003e (approximately between 20 and 29 months): 1 sachet at a time, to be repeated if necessary after 4 hours, without exceeding 6 administrations per day. • \u003cu\u003eChildren weighing between 13 and 20 kg\u003c\/u\u003e (approximately between 30 months and less than 6.5 years): 2 sachets at a time (corresponding to 250 mg of paracetamol), to be repeated if necessary after 6 hours, without exceeding 4 administrations per day. • \u003cu\u003eChildren weighing between 21 and 25 kg\u003c\/u\u003e (approximately between 6.5 and less than 8 years): 2 sachets at a time (corresponding to 250 mg of paracetamol), to be repeated if necessary after 4 hours, without exceeding 6 administrations per day. \u003cb\u003e62.5 mg suppositories for newborns.\u003c\/b\u003e • \u003cu\u003eChildren weighing between 3.2 and 5 kg \u003c\/u\u003e(approximately between birth and 2 months): 1 suppository at a time, to be repeated if necessary after 6 hours, without exceeding 4 administrations per day. \u003cb\u003eEarly Childhood Suppositories 125 mg. \u003c\/b\u003e • \u003cu\u003eChildren weighing between 6 and 7 kg \u003c\/u\u003e(approximately between 3 and 5 months): 1 suppository at a time, to be repeated if necessary after 6 hours, without exceeding 4 administrations per day. • \u003cu\u003eChildren weighing between 7 and 10 kg\u003c\/u\u003e (approximately between 6 and 19 months): 1 suppository at a time, to be repeated if necessary after 4 - 6 hours, without exceeding 5 administrations per day. • \u003cu\u003eChildren weighing between 11 and 12 kg\u003c\/u\u003e (approximately between 20 and 29 months): 1 suppository at a time, to be repeated if necessary after 4 hours, without exceeding 6 administrations per day. \u003cb\u003eSuppositories Children 250 mg.\u003c\/b\u003e • \u003cu\u003eChildren weighing between 11 and 12 kg\u003c\/u\u003e (approximately between 20 and 29 months): 1 suppository at a time, to be repeated if necessary after 8 hours, without exceeding 3 doses per day. • \u003cu\u003eChildren weighing between 13 and 20 kg\u003c\/u\u003e (approximately between 30 months and less than 6.5 years): 1 suppository at a time, to be repeated if necessary after 6 hours, without exceeding 4 administrations per day. \u003cb\u003eSuppositories Children 500 mg.\u003c\/b\u003e • \u003cu\u003eChildren weighing between 21 and 25 kg\u003c\/u\u003e (approximately between 6.5 and less than 8 years): 1 suppository at a time, to be repeated if necessary after 8 hours, without exceeding 3 doses per day. • \u003cu\u003eChildren weighing between 26 and 40 kg\u003c\/u\u003e (approximately between 8 and 11 years): 1 suppository at a time, to be repeated if necessary after 6 hours, without exceeding 4 administrations per day. \u003cb\u003eSuppositories Adults of 1000 mg.\u003c\/b\u003e • \u003cu\u003eChildren weighing between 41 and 50 kg\u003c\/u\u003e (approximately between 12 and 15 years): 1 suppository at a time, to be repeated if necessary after 8 hours, without exceeding 3 doses per day. • \u003cu\u003eChildren weighing more than 50 kg\u003c\/u\u003e (approximately over 15 years): 1 suppository at a time, to be repeated if necessary after 6 hours, without exceeding 4 administrations per day. • \u003cu\u003eAdults\u003c\/u\u003e: 1 suppository at a time, to be repeated if necessary after 6 hours, without exceeding 4 doses per day. \u003ci\u003e \u003cu\u003eRenal failure.\u003c\/u\u003e \u003c\/i\u003e In case of severe renal insufficiency (creatinine clearance less than 10 ml\/min), the interval between administrations must be at least 8 hours.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eEffervescent tablets and granules\u003c\/u\u003e: no special precautions for storage. \u003cu\u003eSuppositories:\u003c\/u\u003e Store at a temperature not exceeding 25°C.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIn rare cases of allergic reactions, administration must be suspended and appropriate treatment instituted. Use with caution in cases of chronic alcoholism, excessive alcohol intake (3 or more alcoholic drinks per day), anorexia, bulimia or cachexia, chronic malnutrition (low hepatic glutathione reserves), dehydration, hypovolemia. Paracetamol should be administered with caution to patients with mild to moderate hepatocellular insufficiency (including Gilbert's syndrome), severe hepatic insufficiency (Child-Pugh\u003e9), acute hepatitis, in concomitant treatment with drugs that alter liver function, glucose-6-phosphate dehydrogenase deficiency, hemolytic anemia. High or prolonged doses of the product can cause even serious alterations to the kidney and blood, therefore administration to subjects with renal insufficiency must be carried out only if actually necessary and under direct medical supervision. In case of prolonged use it is advisable to monitor liver and kidney function and blood count. During treatment with paracetamol, before taking any other medicine, check that it does not contain the same active ingredient, since if paracetamol is taken in high doses, serious adverse reactions may occur. Invite the patient to contact the doctor before combining any other drug. See also par. 4.5. \u003cb\u003e \u003cu\u003eImportant information about some excipients.\u003c\/u\u003e \u003c\/b\u003e \u003cu\u003eTachipirina 125 mg effervescent granules contains\u003c\/u\u003e \u003cu\u003e:\u003c\/u\u003e - \u003cb\u003easpartame\u003c\/b\u003e, is a source of phenylalanine. It can be harmful in case of phenylketonuria (deficiency of the enzyme phenylalanine hydroxylase) due to the risk linked to the accumulation of the amino acid phenylalanine. - \u003cb\u003emaltitol\u003c\/b\u003e: use with caution in patients suffering from rare hereditary problems of fructose intolerance. 70.6 mg of \u003cb\u003esodium\u003c\/b\u003e per sachet equivalent to 3.53% of the maximum daily intake recommended by WHO which corresponds to 2 g of sodium for an adult: to be taken into consideration in people with reduced kidney function or who follow a low-sodium diet. \u003cu\u003eTachipirina 500 mg effervescent granules contains:\u003c\/u\u003e - \u003cb\u003easpartame\u003c\/b\u003e, is a source of phenylalanine. It can be harmful in case of phenylketonuria (deficiency of the enzyme phenylalanine hydroxylase) due to the risk linked to the accumulation of the amino acid phenylalanine. - \u003cb\u003emaltitol\u003c\/b\u003e: use with caution in patients suffering from rare hereditary problems of fructose intolerance. - 283 mg of \u003cb\u003esodium\u003c\/b\u003e per sachet equivalent to 14.1% of the WHO recommended maximum daily intake which corresponds to 2 g of sodium for an adult. The maximum dose for this product is equivalent to 84.6% of the maximum daily sodium intake recommended by the WHO: to be taken into consideration in people with reduced kidney function or who follow a low-sodium diet.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eOral absorption of paracetamol depends on the speed of gastric emptying. Therefore, concomitant administration of drugs that slow (e.g. anticholinergics, opioids) or increase (e.g. prokinetics) the rate of gastric emptying may result in a decrease or increase in the bioavailability of the product, respectively. Concomitant administration of cholestyramine reduces the absorption of paracetamol. The simultaneous intake of paracetamol and chloramphenicol can induce an increase in the half-life of chloramphenicol, with the risk of increasing its toxicity. The concomitant use of paracetamol (4 g per day for at least 4 days) with oral anticoagulants can induce slight variations in INR values. In these cases, more frequent monitoring of INR values ​​should be conducted during concomitant use and after its discontinuation. Use with extreme caution and under strict control during chronic treatment with drugs that can cause the induction of hepatic monooxygenases or in case of exposure to substances that can have this effect (for example rifampicin, cimetidine, antiepileptics such as glutetimide, phenobarbital, carbamazepine). The same applies in cases of alcoholism and in patients treated with zidovudine. The administration of paracetamol can interfere with the determination of uric acid (using the phosphotungstic acid method) and with that of blood sugar (using the glucose-oxidase-peroxidase method).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eBelow are the side effects of paracetamol organized according to the MedDRA systemic and organic classification. There is insufficient data to establish the frequency of the individual effects listed.\u003c\/p\u003e\n\u003cp\u003eBlood and lymphatic system disorders: Thrombocytopenia, leukopenia, anemia, agranulocytosis.\u003c\/p\u003e\n\u003cp\u003eImmune system disorders: Hypersensitivity reactions (urticaria, laryngeal edema, angioedema, anaphylactic shock).\u003c\/p\u003e\n\u003cp\u003eNervous system disorders: Dizziness.\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders: Gastrointestinal reaction.\u003c\/p\u003e\n\u003cp\u003eHepatobiliary disorders: Abnormal liver function, hepatitis.\u003c\/p\u003e\n\u003cp\u003eSkin and subcutaneous tissue disorders: Erythema multiforme, Stevens Johnson Syndrome, Epidermal necrolysis, rash.\u003c\/p\u003e\n\u003cp\u003eRenal and urinary disorders: Acute renal failure, interstitial nephritis, hematuria, anuria.\u003c\/p\u003e\n\u003cp\u003eVery rare cases of serious skin reactions have been reported. Reporting of suspected adverse reactions. Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eThere is a risk of intoxication, especially in patients with liver disease, in cases of chronic alcoholism, in patients suffering from chronic malnutrition, and in patients receiving enzyme inducers. In these cases, overdose can be fatal.\u003c\/u\u003e \u003cu\u003eSymptoms\u003c\/u\u003e In case of accidental intake of very high doses of paracetamol, acute intoxication manifests itself with anorexia, nausea and vomiting followed by a profound deterioration of the general conditions; these symptoms typically appear within the first 24 hours. In case of overdose, paracetamol can cause hepatic cytolysis which can progress to massive and irreversible necrosis, resulting in hepatocellular failure, metabolic acidosis and encephalopathy, which can lead to coma and death. Simultaneously, an increase in the levels of hepatic transaminases, lactic dehydrogenase, and bilirubin are observed, and a reduction in prothrombin levels, which can occur in the 12-48 hours following ingestion. \u003cu\u003eTreatment\u003c\/u\u003e The measures to be adopted consist of early gastric emptying and hospitalization for the appropriate treatment, through administration, as early as possible, of N-acetylcysteine as an antidote: the dosage is 150 mg\/kg i.v. in glucose solution in 15 minutes, then 50 mg\/kg in the following 4 hours and 100 mg\/kg in the following 16 hours, for a total of 300 mg\/kg in 20 hours.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003ePregnancy: A large amount of data on pregnant women indicates neither malformation nor fetal\/neonatal toxicity. Epidemiological studies on neurodevelopment in children exposed to paracetamol in utero show inconclusive results. If clinically necessary, paracetamol can be used during pregnancy, however it should be used at the lowest effective dose for the shortest possible time and with the lowest possible frequency. Breastfeeding: It is recommended to administer the product only in cases of actual need and under the direct supervision of a doctor.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eTachipirina does not alter the ability to drive or use machines.\u003c\/p\u003e","brand":"Angelini","offers":[{"title":"Default Title","offer_id":40207823994995,"sku":"012745042","price":6.5,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/angelini-tachipirina-bambini-10-supposte-250-mg-farmacia-dottor-tili-1258975883.jpg?v=1789562619"},{"product_id":"gynocanesten-crema-vaginale-30-g-2","title":"Gynocanesten Vaginal Cream 30 g 2%","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eTreatment of localized symptoms such as itching, leucorrhea, redness and sensation of swelling of the vaginal mucosa and glans, burning when passing urine if these symptoms are the result of vulvovaginal infections and balanitis caused by candida previously diagnosed in adults and adolescents over 12 years of age.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eGYNO-CANESTEN 2% vaginal cream\u003c\/b\u003e 5 g of vaginal cream contains: \u003cb\u003eActive ingredient:\u003c\/b\u003e clotrimazole 100 mg \u003cb\u003eExcipient with known effects: \u003c\/b\u003ecetostearyl alcohol and benzyl alcohol \u003cb\u003eGYNO-CANESTEN 100 mg vaginal tablets\u003c\/b\u003e One vaginal tablet contains: \u003cb\u003eActive ingredient:\u003c\/b\u003e clotrimazole 100 mg For the full list of excipients, see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eGYNO-CANESTEN 2% vaginal cream\u003c\/b\u003e Sorbitan stearate, polysorbate 60, cetyl palmitate, \u003cb\u003ecetostearyl alcohol\u003c\/b\u003e, octyldodecanol\u003cb\u003e, benzyl alcohol\u003c\/b\u003e, purified water \u003cb\u003eGYNO-CANESTEN 100 mg vaginal tablets\u003c\/b\u003e Lactose monohydrate, corn starch, magnesium stearate, colloidal anhydrous silica, calcium lactate pentahydrate, crospovidone, lactic acid, hypromellose, microcrystalline cellulose\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to the active substance or to any of the excipients listed in paragraph 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eApply as deeply as possible into the vagina once a day, preferably in the evening, at bedtime. In case of Candida vulvitis or balanitis, apply a thin layer of Gyno-Canesten cream 2-3 times a day on the entire perineal area (urogenital and anal). In case of balanitis, apply the cream also on the foreskin. Facilitate the absorption of the cream applied locally with a light massage. \u003cb\u003eGYNO-CANESTEN 2% vaginal cream\u003c\/b\u003e Apply as deeply as possible into the vagina once a day, preferably in the evening, at bedtime, for 3 consecutive days. If necessary, the treatment can be continued for another 3 days. \u003ci\u003eApplication method:\u003c\/i\u003e The applicator should be used only once and then discarded in order to avoid possible reinfections. 1. Pull the piston out of the disposable applicator until it stops. 2. Open the tube. Insert the disposable applicator into the latter and hold it firmly. Fill the applicator by exerting careful pressure on the tube. 3. Once you have assumed the supine position with your legs slightly bent, remove the disposable applicator, introduce it as deeply as possible into the vagina and empty it by regular and continuous pressure on the piston. 4. Remove the applicator and throw it away.  \u003cb\u003eGYNO-CANESTEN 100 mg vaginal tablets\u003c\/b\u003e Apply one tablet as deeply as possible into the vagina once a day, preferably in the evening, at bedtime for six consecutive days or, alternatively, apply 2 for only 3 consecutive days. \u003ci\u003eApplication method:\u003c\/i\u003e After having washed your hands thoroughly, once you are in the supine position with your legs slightly bent, introduce the vaginal tablet directly with your finger as deeply as possible into the vagina. In chronic relapsing forms, the daily dosage can be increased to 2 vaginal tablets in the evening, for a period of 6-12 days. The vagina must have an adequate level of humidity to allow Gyno-Canesten vaginal tablets to dissolve completely. Failure to do so may result in undissolved fragments of the tablet coming out. To avoid this, it is important that the medicine is inserted as deeply as possible into the vagina at bedtime. If, despite this precaution, the tablet does not dissolve completely overnight, the use of vaginal cream should be considered. \u003ci\u003eDuration of treatment\u003c\/i\u003e The maximum duration of treatment is 7 days, if symptoms persist re-evaluate the clinical picture. In case of vulvitis or balanitis the treatment must be continued for 1-2 weeks.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eGYNO-CANESTEN 2% vaginal cream\u003c\/b\u003e This medicinal product does not require any special storage conditions. \u003cb\u003eGYNO-CANESTEN 100 mg vaginal tablets\u003c\/b\u003e Store at a temperature not exceeding 25°C\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIn case of fever, lower abdominal pain, back pain, foul-smelling vaginal discharge, nausea, vaginal bleeding and\/or shoulder pain, the clinical picture should be re-evaluated. Recurrent infections that recur within 2 months may be secondary to conditions such as diabetes or HIV infection that require in-depth clinical examinations. It is preferable to start and end treatment in the intermenstrual period. Tampons, vaginal douches, spermicides or other vaginal products should not be used during therapy with Gyno-Canesten. Recommend abstinence from vaginal intercourse because the infection could be transmitted to the partner. Furthermore, in order to avoid reinfection, particularly in the presence of Candida vulvitis or balanitis, recommend local treatment of the partner. During pregnancy, use vaginal tablets and insert them without the aid of the applicator. During treatment with Gyno-Canesten the effectiveness and safety of latex-based products such as condoms and diaphragms may be reduced. The use, especially if prolonged, of products for topical use can give rise to sensitization phenomena. In this case, it is necessary to stop treatment and adopt appropriate therapeutic measures. Avoid contact with eyes. Do not ingest. \u003cu\u003eImportant information about some excipients\u003c\/u\u003e: Gyno-Canesten cream contains cetostearyl alcohol: may cause local skin reactions (e.g. contact dermatitis). Gyno-Canesten cream contains 20mg\/g of benzyl alcohol - may cause allergic reactions; - may cause mild local irritation.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eConcomitant treatment with vaginal clotrimazole and oral tacrolimus (an immunosuppressant) may result in increased plasma levels of tacrolimus and similarly with sirolimus. Patients should therefore be carefully monitored for the onset of symptoms of tacrolimus or sirolimus overdose, if necessary by determining plasma drug levels.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe adverse reactions reported below are indicated according to the MedDRA System Organ Class. Since they derive from spontaneous post-marketing reports, their frequency is indicated as not known (the frequency cannot be defined on the basis of the available data). \u003cb\u003eImmune system disorders\u003c\/b\u003e: anaphylactic reaction, angioedema, hypersensitivity \u003cb\u003eVascular pathologies:\u003c\/b\u003e syncope, hypotension \u003cb\u003eRespiratory, thoracic and mediastinal disorders:\u003c\/b\u003e dyspnoea \u003cb\u003eGastrointestinal disorders\u003c\/b\u003e: abdominal pain, nausea \u003cb\u003eSkin and subcutaneous tissue disorders: \u003c\/b\u003eskin rash, urticaria \u003cb\u003eReproductive system and breast disorders: \u003c\/b\u003eexfoliation, vaginal discharge, vaginal bleeding, discomfort, erythema, burning, itching, pain. \u003cb\u003eSystemic disorders and conditions relating to the administration site: \u003c\/b\u003eirritation at the application site, edema, pain. Reporting of suspected adverse reactions. Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo risk of acute intoxication is expected since it is unlikely to occur after a single vaginal or topical application of an overdose (application over a large area in conditions favorable to absorption) or through involuntary oral intake. There is no specific antidote.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eFertility: No studies have been conducted in humans on the effects of clotrimazole on fertility, however animal studies have not shown reproductive toxicity effects (see section 5.3). Pregnancy Available clinical data regarding the risk in pregnancy are limited. Administration of Gyno-canesten during pregnancy should only be considered if the expected benefit to the mother outweighs the risk to the fetus or child. Breastfeeding No data are available on the excretion of clotrimazole in breast milk. However, systemic absorption is minimal following topical administration and is unlikely to lead to systemic effects. Clotrimazole can be used during breast-feeding.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe medicine has no or negligible influence on the ability to drive or use machinery.\u003c\/p\u003e","brand":"Bayer","offers":[{"title":"Default Title","offer_id":40207824060531,"sku":"025833068","price":16.25,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/bayer-spa-gynocanesten-crema-vaginale-30-g-2-farmacia-dottor-tili-1213792742.png?v=1767126671"},{"product_id":"froben-gola-spray-mucosa-orale-15-ml-flurbiprofene-0-25","title":"Froben Throat Oral Mucosa Spray 15 ml Flurbiprofen 0.25%","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eFroben Gola is indicated for the symptomatic treatment of irritative-inflammatory conditions also associated with pain in the oropharyngeal cavity (e.g. gingivitis, stomatitis, pharyngitis), also as a consequence of conservative or extractive dental therapy.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e• \u003cb\u003eFROBEN THROAT 250mg\/100ml Mouthwash\u003c\/b\u003e 100 ml of solution contains: \u003cu\u003eActive ingredient\u003c\/u\u003e: Flurbiprofen 0.25 g \u003cu\u003eExcipients with known effect\u003c\/u\u003e: Ethanol, patent blue V(E131). • \u003cb\u003eFROBEN THROAT 250mg\/100ml Spray for oral mucosa\u003c\/b\u003e 100 ml of solution contains: \u003cu\u003eActive ingredient\u003c\/u\u003e: Flurbiprofen 0.25 g \u003cu\u003eExcipients with known effect\u003c\/u\u003e: Ethanol, patent blue V(E131). For the full list of excipients, see section 6.1\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003ePurified water, alcohol, patent blue VE 131, glycerol, mint essence, 40-polyoxyethylene hydrogenated castor oil, potassium bicarbonate, sodium saccharinate, sorbitol.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to flurbiprofen or to any of the excipients listed in section 6.1. Froben Gola is also contraindicated in: • patients who have previously experienced hypersensitivity reactions (e.g. asthma, urticaria) after taking aspirin or other NSAIDs. • patients with a history of gastrointestinal bleeding or perforation related to previous treatment with NSAIDs. • patients with active or anamnestic ulcerative colitis, Crohn's disease, recurrent peptic ulcer or gastrointestinal bleeding (defined as two or more distinct episodes of demonstrated ulceration or bleeding). • patients with severe cardiac, renal or hepatic insufficiency (see section 4.4). Froben Gola is contraindicated during the third trimester of pregnancy.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eUndesirable effects can be minimized by using the lowest effective dose for the shortest possible duration of treatment needed to control symptoms (see section 4.4). It is recommended to use this medicine for a maximum of three days. \u003cb\u003eDosage:\u003c\/b\u003e • \u003cb\u003eMOUTHWASH\u003c\/b\u003e The recommended dose is two or three rinses or gargles per day with 10 ml of mouthwash. Can be diluted in water • \u003cb\u003eSPRAY FOR ORAL MUCOSA\u003c\/b\u003e The recommended dose is 2 sprays 3 times a day aimed directly at the affected part. \u003ci\u003ePediatric population\u003c\/i\u003e No adequate data are available on the pediatric population; therefore the use of the medicine is not recommended.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eMouthwash: this medicine must not be stored above 25 C. Oral mucosa spray: this medicine must not be stored above 25 C; Keep the bottle in the outer carton to protect the medicine from light.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eGeneral precautions \u003c\/b\u003e Undesirable effects can be minimized by using the lowest effective dose for the shortest possible duration of treatment needed to control symptoms (see section 4.2 and the sections below on gastrointestinal and cardiovascular risks). \u003cb\u003eUse in elderly patients \u003c\/b\u003e Elderly patients have an increased frequency of adverse reactions to NSAIDs, especially gastrointestinal bleeding and perforation, which may be fatal. \u003cb\u003e \u003ci\u003e \u003cu\u003eGastrointestinal effects \u003c\/u\u003e \u003c\/i\u003e \u003c\/b\u003e Flurbiprofen should be administered with caution to patients with a history of peptic ulcers and other gastrointestinal diseases as these conditions may be exacerbated. Gastrointestinal bleeding, ulcer or perforation have been reported with all NSAIDs at any time during treatment. These adverse events can be fatal and can occur with or without warning symptoms or in case of a previous history of serious gastrointestinal events. The risk of gastrointestinal haemorrhage, ulcer or perforation is higher with increasing dosage of flurbiprofen in patients with a history of ulcer, particularly if complicated by haemorrhage and perforation, and in the elderly. These patients should start treatment with the lowest available dose. Concomitant use of protective agents (misoprostol or proton pump inhibitors) should be considered for these patients and also for patients taking low doses of aspirin or other drugs that may increase the risk of gastrointestinal events (see section below and section 4.5). Patients with a history of gastrointestinal disease, especially if elderly, should report any unusual abdominal symptoms (especially gastrointestinal bleeding) in the initial stages of treatment. When gastrointestinal bleeding or ulceration occurs in patients taking Froben Gola, treatment should be suspended. \u003cb\u003e \u003ci\u003e \u003cu\u003eRespiratory Disorders\u003c\/u\u003e \u003c\/i\u003e \u003c\/b\u003e Cases of bronchospasm have been reported with flurbiprofen in patients with a history of bronchial asthma. \u003cb\u003e \u003ci\u003e \u003cu\u003eCardiac, renal and hepatic impairment \u003c\/u\u003e \u003c\/i\u003e \u003c\/b\u003e Particular caution must be taken when treating patients with severely compromised renal, cardiac or hepatic function, as the use of NSAIDs can lead to deterioration of renal function. In such patients the dosage should be kept as low as possible and renal function should be monitored. The administration of an NSAID can cause a dose-dependent reduction in the formation of prostaglandins, accelerating renal failure. Patients at highest risk of developing this reaction are those with impaired kidney function, heart failure and liver dysfunction, those taking diuretics and elderly people. Renal function should be monitored in these patients (see also section 4.3). Flurbiprofen should be administered with caution in patients with a history of heart failure or hypertension as cases of edema have been reported in association with the administration of flurbiprofen. \u003cb\u003e \u003ci\u003e \u003cu\u003eCardiovascular and cerebrovascular effects\u003c\/u\u003e \u003c\/i\u003e \u003c\/b\u003e Adequate monitoring and appropriate instructions are necessary in patients with a history of hypertension and\/or mild to moderate congestive heart failure since, in association with the administration of flurbiprofen and treatment with NSAIDs, fluid retention and edema have been found. In these patients Froben Gola should be taken with caution. Clinical studies and epidemiological data suggest that the use of some NSAIDs, especially at high doses and for long-term treatments, may be associated with a modest increase in the risk of arterial thrombotic events such as myocardial infarction or stroke. There are insufficient data to exclude a similar risk for flurbiprofen. Patients with uncontrolled hypertension, congestive heart failure, established ischemic heart disease, peripheral arterial disease and\/or cerebrovascular disease should be treated with flurbiprofen only after careful consideration. Similar considerations must be made before starting long-term treatment in patients with risk factors for cardiovascular disease (e.g. hypertension, hyperlipidemia, diabetes mellitus, smoking). \u003cb\u003e \u003cu\u003eSkin reactions\u003c\/u\u003e \u003c\/b\u003e Serious skin reactions, some of them fatal, including exfoliative dermatitis, Stevens-Johnson syndrome and toxic epidermal necrolysis, have been reported very rarely in association with the use of NSAIDs. In the early stages of therapy, patients appear to be at higher risk: the onset of the reaction occurs in most cases within the first month of treatment. Flurbiprofen should be discontinued at the first appearance of skin rash, mucosal lesions or any other sign of hypersensitivity. \u003cb\u003e \u003ci\u003e \u003cu\u003eRenal effects\u003c\/u\u003e \u003c\/i\u003e \u003c\/b\u003e Caution should be used when initiating treatment with NSAIDs such as flurbiprofen in patients with considerable dehydration. \u003cb\u003e \u003ci\u003e \u003cu\u003eHematological effects\u003c\/u\u003e \u003c\/i\u003e \u003c\/b\u003e Flurbiprofen, like other NSAIDs, can inhibit platelet aggregation and prolong bleeding time. \u003cb\u003e \u003ci\u003e \u003cu\u003eSystemic lupus erythematosus (SLE) and connective system diseases\u003c\/u\u003e \u003c\/i\u003e \u003c\/b\u003e An increased risk of aseptic meningitis may occur in patients with Systemic Lupus Erythematosus (SLE) and connective system disorders (see section 4.8). The effects reported above have been reported in particular after the administration of formulations based on Flurbiprofen for systemic use. At the recommended doses, swallowing FROBEN GOLA does not cause any harm to the patient as these doses are significantly lower than those of the single dosage of the product systemically. The use of FROBEN GOLA, especially if prolonged, can give rise to local sensitization or irritation phenomena; in such cases it is necessary to interrupt the treatment and consult the doctor to institute, if necessary, a suitable therapy. Flurbiprofen should not be used for prolonged treatments. It is necessary to inform patients to seek medical advice if after short periods of treatment without appreciable results. \u003cb\u003eImpairment of fertility\u003c\/b\u003e The use of flurbiprofen may impair female fertility and is not recommended in women trying to become pregnant. In women who have difficulty conceiving or who are undergoing infertility investigations, discontinuation of treatment with flurbiprofen should be considered. \u003cb\u003e \u003ci\u003e \u003cu\u003eImportant information about some excipients\u003c\/u\u003e \u003c\/i\u003e \u003c\/b\u003e \u003cu\u003eFROBEN THROAT 250mg\/100ml Mouthwash\u003c\/u\u003e contains: • \u003ci\u003eSorbitol (E420)\u003c\/i\u003e. Patients with hereditary fructose intolerance should not be given this medicine. • \u003ci\u003eEthanol\u003c\/i\u003e. This medicine contains 12 vol% ethanol (alcohol), e.g. up to 1 g per dose, equivalent to 24 ml of beer, 10 ml of wine per dose. It can be harmful to alcoholics. To be taken into consideration in pregnant or breastfeeding women, children and high-risk groups such as people with liver disease or epilepsy. For those who carry out sporting activities, the use of medicines containing ethyl alcohol can lead to positive anti-doping tests in relation to the blood alcohol concentration limits indicated by some sports federations. • \u003ci\u003ePatent blue dye V(E131)\u003c\/i\u003e which can cause allergic reactions. \u003cu\u003eFROBEN THROAT 250mg\/100ml Spray for oral mucosa\u003c\/u\u003e contains: • \u003ci\u003eSorbitol\u003c\/i\u003e. The additive effect of co-administration of medicinal products containing sorbitol (or fructose) and daily dietary intake of sorbitol (or fructose) should be considered. The sorbitol content in oral medicinal products may modify the bioavailability of other co-administered oral medicinal products. • \u003ci\u003eEthanol\u003c\/i\u003e. This medicine contains 12 vol% ethanol (alcohol), e.g. up to 40 mg per dose, equivalent to 1 ml of beer, 0.4 ml of wine per dose. For those who carry out sporting activities, the use of medicines containing ethyl alcohol can lead to positive anti-doping tests in relation to the blood alcohol concentration limits indicated by some sports federations. • \u003ci\u003ePatent blue dye V(E131)\u003c\/i\u003e which can cause allergic reactions.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eCaution should be exercised in patients treated with any of the medicines listed below, as interactions have been reported in some patients. \u003cb\u003eDiuretics, ACE inhibitors and angiotensin II antagonists\u003c\/b\u003e: NSAIDs can reduce the effect of diuretics and other antihypertensive drugs. Diuretics may also increase the risk of NSAID nephrotoxicity. In some patients with compromised renal function (e.g. dehydrated patients or elderly patients with compromised renal function) co-administration of an ACE inhibitor or an angiotensin II antagonist and agents that inhibit the cyclo-oxygenase system may lead to further deterioration of renal function, including possible acute renal failure, which is usually reversible. These interactions should be considered in patients taking Flurbiprofen concomitantly with ACE inhibitors or angiotensin II antagonists. Therefore, the combination should be administered with caution, especially in elderly patients. Patients should be adequately hydrated and consideration should be given to monitoring renal function after initiation of concomitant therapy and on a periodic basis thereafter. \u003cb\u003eLithium salts:\u003c\/b\u003e decrease in lithium elimination. \u003cb\u003eMethotrexate: \u003c\/b\u003ecaution is advised in case of concomitant administration of flurbiprofen and methotrexate as NSAIDs can increase the levels of methotrexate and therefore its toxic effects). \u003cb\u003eAnticoagulants, such as warfarin: \u003c\/b\u003eincreased anticoagulant effect. \u003cb\u003eAnti-aggregating agents:\u003c\/b\u003e increased risk of gastrointestinal bleeding \u003cb\u003eSelective serotonin reuptake inhibitors (SSRIs):\u003c\/b\u003e increased risk of gastrointestinal bleeding. \u003cb\u003eAspirin:\u003c\/b\u003e As with other NSAID-containing medicines, concomitant administration of flurbiprofen and aspirin is generally not recommended due to the potential for increased side effects. \u003cb\u003eCardiac glycosides\u003c\/b\u003e: NSAIDs can exacerbate heart failure, reduce glomerular filtration rate and increase plasma levels of cardiac glycosides. \u003cb\u003eCyclosporins:\u003c\/b\u003e increased risk of nephrotoxicity with NSAIDs. \u003cb\u003eCorticosteroids:\u003c\/b\u003e increased risk of gastrointestinal ulcer or bleeding with NSAIDs. \u003cb\u003eCox-2 inhibitors and other NSAIDs:\u003c\/b\u003e Concomitant use of other NSAIDs, including selective cyclooxygenase-2 inhibitors, should be avoided due to potential additive effects. \u003cb\u003eMifepristone\u003c\/b\u003e: NSAIDs should not be taken for 8-12 days after administration of mifepristone as NSAIDs may reduce the effects of mifepristone. \u003cb\u003eQuinolone Antibiotics: \u003c\/b\u003eResults from animal studies suggest that NSAIDs may increase the risk of seizures associated with the use of quinolone antibiotics. Patients taking NSAIDs and Quinolones may have an increased risk of developing seizures. \u003cb\u003eTacrolimus\u003c\/b\u003e: possible increased risk of nephrotoxicity in case of co-administration with NSAIDs. \u003cb\u003eZidovudine\u003c\/b\u003e: increased risk of blood toxicity in case of co-administration with NSAIDs. There is evidence of an increased risk of haemarthrosis and haematoma in haemophilia patients affected by HIV in simultaneous treatment with Zidovudine and other NSAIDs. The interactions reported above have been reported in particular after the administration of Flurbiprofen-based formulations for systemic use. At the recommended doses of FROBEN GOLA, no interactions with other medicinal products or of any other nature have been reported. However, inform your doctor if you are taking other medicines.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe following adverse reactions, reported in particular after the administration of formulations for systemic use, are reported according to the MedDRA classification. Frequency groupings are classified according to the following convention: very common (≥ 1\/10), Common (≥1\/100 to \u003c1\/10), Uncommon (≥1\/1000 to \u003c1\/100), Rare (≥ 1\/10,000 to \u003c1\/1000), Very rare (\u003c1\/10,000) and Not Known (frequency cannot be estimated).\u003c\/p\u003e\n\u003cp\u003eMedDRA system organ class: Frequency of Adverse Reactions.\u003c\/p\u003e\n\u003cp\u003eBlood and lymphatic system disorders: Uncommon Anemia.\u003c\/p\u003e\n\u003cp\u003eBlood and lymphatic system disorders: Very rare Leukopenia, agranulocytosis, aplastic anemia, neutropenia, thrombocytopenia, haemolytic anemia.\u003c\/p\u003e\n\u003cp\u003eImmune system disorders: Uncommon Hypersensitivity\u003c\/p\u003e\n\u003cp\u003eImmune system disorders: Rare Anaphylactic reaction.\u003c\/p\u003e\n\u003cp\u003ePsychiatric disorders: Rare Depression, Confusional state.\u003c\/p\u003e\n\u003cp\u003ePsychiatric disorders: Very rare Hallucination.\u003c\/p\u003e\n\u003cp\u003eNervous System Disorders: Common Migraine, dizziness.\u003c\/p\u003e\n\u003cp\u003eNervous System Disorders: Uncommon Paraesthesia.\u003c\/p\u003e\n\u003cp\u003eNervous System Disorders: Rare Drowsiness, Insomnia.\u003c\/p\u003e\n\u003cp\u003eNervous System Disorders: Not known Optic neuritis, cerebrovascular accident, headache.\u003c\/p\u003e\n\u003cp\u003eEye disorders: Uncommon Visual disturbances.\u003c\/p\u003e\n\u003cp\u003eEar and labyrinth disorders: Uncommon Tinnitus, vertigo.\u003c\/p\u003e\n\u003cp\u003eRespiratory, thoracic and mediastinal disorders: Uncommon Asthma, dyspnoea.\u003c\/p\u003e\n\u003cp\u003eRespiratory, thoracic and mediastinal disorders: Rare Bronchospasm.\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders: Common Dyspepsia, diarrhoea, nausea, vomiting, abdominal pain, flatulence, constipation, melena, haematemesis, gastrointestinal haemorrhage.\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders: Uncommon Gastritis, duodenal ulcer, gastric ulcer, mouth ulcer, gastrointestinal perforation.\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders: Very rare Pancreatitis.\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders: Not known Colitis and Crohn's disease.\u003c\/p\u003e\n\u003cp\u003eHepatobiliary disorders: Very rare Jaundice, cholestatic jaundice, abnormal liver function.\u003c\/p\u003e\n\u003cp\u003eHepatobiliary disorders: Not known Hepatitis.\u003c\/p\u003e\n\u003cp\u003eSkin and subcutaneous tissue disorders: Uncommon Rash, urticaria, pruritus, purpura, angioedema, photosensitivity reactions\u003c\/p\u003e\n\u003cp\u003eSkin and subcutaneous tissue disorders: Very rare Severe forms of bullous skin reactions (e.g. Erythema Multiforme, Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis).\u003c\/p\u003e\n\u003cp\u003eRenal and urinary disorders: Rare Nephrotoxicity in various forms i.e. interstitial nephritis, nephrotic syndrome, renal failure and acute renal failure. (see paragraph 4.4).\u003c\/p\u003e\n\u003cp\u003eRenal and urinary disorders: Not known Glomerulonephritis.\u003c\/p\u003e\n\u003cp\u003eGeneral disorders and administration site conditions: Common Fatigue, malaise, edema.\u003c\/p\u003e\n\u003cp\u003eCardiac disorders: Uncommon Heart failure.\u003c\/p\u003e\n\u003cp\u003eVascular disorders: Uncommon Hypertension.\u003c\/p\u003e\n\u003cp\u003eInvestigations: Common Liver function test abnormal, bleeding time prolonged.\u003c\/p\u003e\n\u003cp\u003eMetabolism and nutrition disorders: Common Fluid retention.\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eImmune system disorders\u003c\/b\u003e Hypersensitivity reactions have been reported following treatment with NSAIDs. These consist of: a) non-specific allergic reactions and anaphylaxis; b) reactions affecting the respiratory tract including asthma, even severe, bronchospasm or dyspnoea, or c) various skin disorders, such as various types of skin rashes, itching, urticaria, purpura, angioedema and, very rarely, exfoliative and bullous dermatitis (including Toxic Epidermal Necrolysis and erythema multiforme). \u003cb\u003eCardiac and vascular pathologies\u003c\/b\u003e Cases of edema, hypertension and heart failure have been reported in association with treatment with NSAIDs. Clinical studies and epidemiological data suggest that the intake of some NSAIDs (especially if at high doses and in case of long-term treatment) may be associated with an increased risk of arterial thrombotic events (for example myocardial infarction or stroke) (see section 4.4).\u003cb\u003eNervous System Pathologies \u003c\/b\u003e Aseptic meningitis (especially in patients with existing autoimmune disorders such as Systemic Lupus Erythematosus and connective tissue disorders) with symptoms such as stiff neck, headache, nausea, vomiting, fever or disorientation (see section 4.4). \u003cu\u003eReporting of suspected adverse reactions\u003c\/u\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at www.agenziafarmaco.gov.it\/content\/come-segnalare-una-sospetti-reazione-avversa.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eSymptoms\u003c\/b\u003e Symptoms of overdose may include nausea, vomiting, and gastrointestinal irritation. \u003cb\u003eTreatment\u003c\/b\u003e Treatment should include gastric lavage and, if necessary, correction of the serum electrolyte picture. There is no specific antidote for flurbiprofen.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eFertility\u003c\/i\u003e The use of FROBEN GOLA may negatively affect fertility and is not recommended in women who are trying to conceive. In women who have difficulty conceiving or who are undergoing fertility investigations, stopping taking FROBEN GOLA should be considered. \u003ci\u003ePregnancy \u003c\/i\u003e Inhibition of prostaglandin synthesis can negatively affect pregnancy and\/or embryo\/foetal development. Results of epidemiological studies suggest an increased risk of miscarriage and cardiac malformation and gastroschisis after the use of a prostaglandin synthesis inhibitor in the early stages of pregnancy. The absolute risk of cardiac malformations increased from less than 1% to approximately 1.5%. The risk was thought to increase with the dose and duration of therapy. In animals, the administration of prostaglandin synthesis inhibitors has been shown to cause an increase in pre- and post-implantation loss and embryo-foetal mortality. Furthermore, an increased incidence of various malformations, including cardiovascular malformations, has been reported in animals to which prostaglandin synthesis inhibitors were administered during the organogenetic period. During the first and second trimester of pregnancy, flurbiprofen should not be administered unless strictly necessary. If flurbiprofen is used by a woman attempting to conceive or during the first and second trimester of pregnancy, the dose and duration of treatment should be kept as low as possible. During the third trimester of pregnancy, all inhibitors of prostaglandin synthesis can expose the fetus to: • Cardiopulmonary toxicity (with premature closure of the ductus arteriosus and pulmonary hypertension); • Renal dysfunction, which may progress to renal failure with oligohydramnios. The mother and the newborn, at the end of pregnancy, to: • Possible prolongation of bleeding time, an anti-aggregating effect which can occur even at very low doses; • Inhibition of uterine contractions resulting in delayed or prolonged labor. \u003cb\u003eConsequently, flurbiprofen is contraindicated during the third trimester of pregnancy (see section 4.3). \u003c\/b\u003e \u003ci\u003eBreastfeeding\u003c\/i\u003e In the few studies available so far, NSAIDs can appear in breast milk in very low concentrations. If possible, NSAIDs should be avoided during breastfeeding. See paragraph \u003ci\u003e4.4 Special warnings and precautions for use\u003c\/i\u003e, regarding fertility in women.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSide effects such as dizziness, drowsiness, fatigue and visual disturbances are possible after taking NSAIDs. If these effects occur, patients should not drive or use machinery.\u003c\/p\u003e","brand":"Mylan","offers":[{"title":"Default Title","offer_id":40207824158835,"sku":"042822027","price":11.44,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/products\/mylan-italia-srl-froben-gola-spray-mucosa-orale-15-ml-flurbiprofene-0-25-farmacia-dottor-tili-1213792740.jpg?v=1767126746"},{"product_id":"rinazina-spray-nasale-decongestionante-15ml-0-1","title":"Rinazina Decongestant Nasal Spray 15ml 0.1%","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNasal decongestant during acute catarrhal rhinitis and pharyngitis, allergic rhinitis, acute sinusitis.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e1 ml of solution contains: Active ingredient: naphazoline nitrate 1 mg \u003cu\u003eExcipients with known effects\u003c\/u\u003e: benzalkonium chloride For the full list of excipients, see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eRINAZINA 1 mg\/ml nasal drops, solution: sodium chloride, disodium edetate, monobasic sodium phosphate dihydrate, concentrated phosphoric acid, \u003cb\u003ebenzalkonium chloride\u003c\/b\u003e, purified water. RINAZINA 1 mg\/ml nasal spray, solution: sodium chloride, disodium edetate, monobasic sodium phosphate dihydrate, concentrated phosphoric acid, \u003cb\u003ebenzalkonium chloride\u003c\/b\u003e, balsamic aroma, purified water.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to the active substance or to any of the excipients listed in paragraph 6.1. Severe heart disease and arterial hypertension. Glaucoma. Hyperthyroidism. \u003cb\u003e \u003cu\u003eThe medicine is contraindicated in children under 12 years of age.\u003c\/u\u003e \u003c\/b\u003e Do not administer during and in the two weeks following therapy with antidepressant drugs.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eNasal drops:\u003c\/b\u003e Adults: 2-3 drops in each nostril, 2-3 times a day \u003cb\u003eNasal spray:\u003c\/b\u003e Adults: 1-2 sprays in each nostril, 2-3 times a day. \u003ci\u003ePediatric population\u003c\/i\u003e: The medicine is contraindicated in children under 12 years of age (see section 4.3). Carefully follow the recommended doses. A higher dosage of the product, even if taken topically and for a short period of time, can give rise to serious systemic effects. In the absence of a complete therapeutic response within a few days, consult your doctor; in any case, the treatment must not be continued for more than a week.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eRINAZINA 1 mg\/ml nasal spray, solution:\u003c\/i\u003e This medicinal product does not require any special storage conditions. \u003ci\u003eRINAZINA 1 mg\/ml nasal drops, solution\u003c\/i\u003e: Store below 25°C. Store upright.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eUse with caution in the elderly and in those with prostatic hypertrophy due to the risk of urinary retention. In patients with cardiovascular diseases, especially in hypertensive patients, the use of nasal decongestants must in any case be subject to the doctor's judgment from time to time. The prolonged use of vasoconstrictors can alter the normal function of the mucosa of the nose and paranasal sinuses, also inducing addiction to the drug. Repeating applications over a long period of time can be harmful. RINAZINA nasal drops and nasal spray contain 0.1 mg\/ml of benzalkonium chloride. Benzalkonium chloride (BAC) contained as a preservative in RINAZINA nasal drops and nasal spray can cause irritation and swelling of the nasal mucosa, especially if used for long periods. If such a reaction (persistent nasal congestion) is suspected, a medicinal product for nasal use without BAC should be used, if possible. If such medicinal products for nasal use without BAC are not available, another pharmaceutical form should be considered. May cause bronchospasm. The use, especially if prolonged, of topical products can give rise to sensitization phenomena; in this case it is necessary to interrupt the treatment and, if necessary, institute suitable therapy. Rare cases of posterior reversible encephalopathy\/reversible cerebral vasoconstriction syndrome have been reported with the use of sympathomimetic drugs, to which naphazoline also belongs. Reported symptoms include sudden onset of severe headache, nausea, vomiting and vision disturbances. Most cases improve or resolve within a few days following appropriate treatment. The use of naphazoline should be discontinued immediately and a doctor should be consulted if signs and\/or symptoms of posterior reversible encephalopathy\/reversible cerebral vasoconstriction syndrome occur.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe drug may interact with antidepressant drugs.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe product can locally cause rebound phenomena of sensitization and congestion of the mucous membranes. Due to rapid absorption of naphazoline through inflamed mucous membranes, systemic effects consisting of arterial hypertension, reflex bradycardia, headache, urination disorders may occur. \u003cu\u003eReporting of suspected adverse reactions\u003c\/u\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe product, if accidentally ingested or if used for a long period in excessive doses, can cause toxic phenomena. It should be kept out of the reach of children as accidental ingestion can cause severe sedation. In case of overdose, arterial hypertension, tachycardia, photophobia, intense headache, chest tightness and, in children, hypothermia and severe depression of the Central Nervous System with marked sedation may appear, which require the adoption of adequate emergency measures.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDuring pregnancy and breastfeeding, RINAZINA must be used only after consulting your doctor and evaluating with him the risk\/benefit ratio in your case.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThere are no known side effects on the ability to drive or use machines.\u003c\/p\u003e","brand":"Gsk","offers":[{"title":"Default Title","offer_id":40207824191603,"sku":"000590051","price":11.59,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/products\/glaxosmithkline-c-health-spa-rinazina-spray-nasale-decongestionante-15ml-0-1-farmacia-dottor-tili-1213792738.webp?v=1767126771"},{"product_id":"proctolyn-crema-rettale-30-g","title":"Proctolyn Rectal Cream 30 g","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eInternal and external hemorrhoids; anal and perianal eczema and erythema; anal fissures; anal and perianal itching and burning; pre- and post-operative treatment in anorectal surgery.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003e \u003ci\u003eRectal cream\u003c\/i\u003e \u003c\/b\u003e One gram of rectal cream contains 0.1 mg of fluocinolone acetonide and 10 mg of ketocaine hydrochloride (equal to 8.9 mg of ketocaine). Excipients with known effects: One gram of rectal cream contains 1.5 mg of methyl parahydroxybenzoate, 0.5 mg of propyl parahydroxybenzoate, 70 mg of propylene glycol, 50 mg of stearyl alcohol, 50 mg of cetyl alcohol. \u003cb\u003e \u003ci\u003eSuppositories\u003c\/i\u003e \u003c\/b\u003e Each suppository contains 0.1 mg of fluocinolone acetonide and 10 mg of ketocaine hydrochloride (equal to 8.9 mg of ketocaine). Excipient with known effects: Each suppository contains 40 mg of propylene glycol. For the full list of excipients, see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003e \u003ci\u003eRectal cream\u003c\/i\u003e \u003c\/b\u003e citric acid menthol methyl parahydroxybenzoate propyl parahydroxybenzoate propylene glycol stearyl alcohol cetyl alcohol Vaseline oil sorbitan monostearate polysorbate 60 purified water \u003cb\u003e \u003ci\u003eSuppositories\u003c\/i\u003e \u003c\/b\u003e citric acid menthol propylene glycol polysorbate 60 sorbitan monostearate colloidal silica semi-synthetic glycerides\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to the active substances or to any of the excipients listed in paragraph 6.1. TB, mycosis, Herpes Symplex, viral diseases with skin localization.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003e \u003ci\u003eRectal cream\u003c\/i\u003e \u003c\/b\u003e Just enough to cover the affected part, massaging lightly and repeating the application 2-3 times a day. For internal application use the appropriate cannula inserted on the tube. \u003cb\u003e \u003ci\u003eSuppositories\u003c\/i\u003e \u003c\/b\u003e 1 suppository in the morning and 1 in the evening. \u003ci\u003eRectal cream and suppositories can be used for combined treatments\u003c\/i\u003e. \u003ci\u003ePediatric population\u003c\/i\u003e The use of Proctolyn is not recommended in children under 12 years of age, due to a lack of data on safety and efficacy.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThis medicinal product does not require any special storage conditions.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe topical application of cortisone in excessive doses and for prolonged periods can lead to systemic absorption. The use, especially if prolonged, of products for topical use can give rise to sensitization phenomena. In the presence of a skin infection, appropriate coverage therapy should be instituted. \u003cu\u003eVisual disturbances\u003c\/u\u003e Visual disturbances may be reported with the use of systemic and topical corticosteroids. If a patient presents with symptoms such as blurred vision or other visual disturbances, referral to an ophthalmologist should be considered for evaluation of possible causes which may include cataracts, glaucoma, or rare diseases such as central serous chorioretinopathy (CSCR), which have been reported after the use of systemic and topical corticosteroids. \u003cu\u003eImportant information about some excipients\u003c\/u\u003e: Proctolyn rectal cream contains • methyl parahydroxybenzoate and propyl parahydroxybenzoate which may cause allergic reactions (even delayed ones); • stearyl alcohol and cetyl alcohol which can cause localized skin reactions (e.g. contact dermatitis).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eConcomitant treatment with CYP3A inhibitors, including cobicistat-containing medicinal products, is thought to increase the risk of systemic side effects. The combination should be avoided unless the benefit outweighs the increased risk of systemic side effects due to corticosteroids; in this case it is necessary to monitor patients to verify the absence of systemic side effects due to corticosteroids.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDuring topical cortisone therapy, especially for intense and prolonged treatments, the following side effects may occur: burning sensation, itching, irritation. Blurred vision may occur (see also section 4.4), with an unknown frequency. \u003cu\u003eReporting of suspected adverse reactions\u003c\/u\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at \u003cu\u003ehttp:\/\/www.agenziafarmaco.gov.it\/content\/come-segnalare-una-sospetta-reazione-avversa\u003c\/u\u003e.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo cases of overdose have been reported.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003ePregnancy\u003c\/u\u003e Topical administration of corticosteroids during pregnancy in laboratory animals may cause abnormalities in fetal development. There are no adequate data from the use of fluocinolone acetonide in pregnant women. Therefore the medicine must be used only if necessary, after evaluating the expected benefit for the mother in relation to the possible risk for the fetus. \u003cu\u003eBreastfeeding\u003c\/u\u003e When administered systemically, corticosteroids are excreted through breast milk. It is not known whether they are also effective when administered topically. Therefore, topical corticosteroids should be used with caution during breastfeeding.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eProctolyn does not affect the ability to drive or use machines.\u003c\/p\u003e","brand":"Recordati","offers":[{"title":"Default Title","offer_id":40207824289907,"sku":"021925060","price":12.74,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/recordati-proctolyn-crema-rettale-30-g-farmacia-dottor-tili-1254215807.jpg?v=1786737489"},{"product_id":"vicks-sinex-aloe-spray-nasale-15-ml","title":"Vicks Sinex Aloe Nasal Spray 15ml","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDecongestant of the nasal mucosa, especially in case of colds.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e- Active ingredient: oxymetazoline hydrochloride 0.0500% w\/v. 1 ml of product contains 0.5 mg of oxymetazoline hydrochloride. 1 spray (50 microlitres) contains approximately 25 micrograms of oxymetazoline hydrochloride. - Excipients with known effects: benzalkonium chloride, benzyl alcohol For the complete list of excipients, see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eLevomenthol, sodium citrate, anhydrous citric acid, benzalkonium chloride solution, disodium edetate, eucalyptol (cineole), non-crystallizable liquid sorbitol, aloe vera, acesulfame potassium, Lcarvone, polysorbate 80, benzyl alcohol and purified water.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to the active substance or to any of the excipients listed in paragraph 6.1, prostatic hypertrophy, severe heart disease and arterial hypertension. Glaucoma, hyperthyroidism. Do not administer during and in the two weeks following therapy with antidepressant drugs (MAOI). Inflammation or lesions of the oral mucosa or the skin around the nostrils. The drug is contraindicated in children under 12 years of age.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAdults and children over 12 years: 1-2 sprays per nostril every 8 - 12 hours, unless otherwise indicated by the doctor. Hold the bottle in a vertical position, insert its end into the nostril and press the nebulizer quickly and firmly. After application, inhale deeply with your mouth closed.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThis medicinal product does not require any special storage conditions.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eUse with caution in the first months of pregnancy and, due to the risk of urinary retention, in the elderly. Also use with caution in patients with angina and diabetes. If symptoms persist, a clinical reassessment must be considered; in any case, treatment must not be continued for more than 4 consecutive days to avoid a rebound effect and rhinitis phenomena induced by the drug. Carefully follow the recommended doses. Accidental ingestion may cause severe sedation. It should not be used orally. Avoid contact of the liquid with the eyes. Prolonged use of vasoconstrictors can alter the normal function of the mucosa of the nose and paranasal sinuses, also inducing addiction to the drug. Repeating applications for long periods can be harmful. The use, especially if prolonged, of topical products can give rise to sensitization phenomena; in this case it is necessary to interrupt the treatment and institute suitable therapy. \u003ci\u003eImportant information about some excipients\u003c\/i\u003e Vicks Sinex Aloe 0.05% nebulizer solution contains benzalkonium chloride may cause bronchospasm. This medicine contains 0.01 mg of benzalkonium chloride per dose (1 spray) which is equivalent to 0.2 mg\/ml. Benzalkonium chloride can cause irritation and swelling inside the nose, especially if used for long periods. Vicks Sinex Aloe 0.05% spray solution contains benzyl alcohol. This medicine contains 0.1 mg of benzyl alcohol per dose (1 spray), equivalent to 2 mg\/ml. Benzyl alcohol can cause allergic reactions. Benzyl alcohol may cause mild local irritation\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThere is the possibility of interaction between sympathomimetic amines such as oxymetazoline with anti-MAO drugs, therefore use is not recommended during or in the two weeks following treatment with anti-MAO drugs (see section 4.3). Oxymetazoline could reduce the effectiveness of beta-blocking drugs, methyl dopa or other antihypertensive drugs. Hypertension and arrhythmias may occur when tricyclic antidepressants are administered with sympathomimetic drugs such as oxymetazoline. Increased cardiovascular toxicity may occur when sympathomimetic drugs are administered concomitantly with antiparchinsonian drugs such as bromocriptines.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIf accidentally ingested or if used for a long period in excessive doses, the product can cause toxic phenomena. The product can locally cause sensitization phenomena and rebound congestion of the mucous membranes. In general, no serious side effects were observed. Due to rapid absorption of oxymetazoline through inflamed mucous membranes, side effects may occur divided into the following frequencies: very common (≥1\/10); common (≥1\/100, \u003c1\/10); uncommon (≥1\/1000, \u003c1\/100); rare (≥1\/10000, \u003c1\/1000); very rare (\u003e1\/10000); not known (frequency cannot be estimated from the available data). \u003cb\u003e \u003cu\u003eRare:\u003c\/u\u003e \u003c\/b\u003e \u003ci\u003eEye pathologies\u003c\/i\u003e: eye irritation, discomfort or redness. \u003ci\u003eRespiratory, thoracic and mediastinal disorders\u003c\/i\u003e: discomfort or irritation of the nose, mouth or throat, sneezing. \u003cb\u003e \u003cu\u003eVery rare:\u003c\/u\u003e \u003c\/b\u003e \u003ci\u003eCardiac diseases\u003c\/i\u003e: tachycardia, palpitations, increased blood pressure, reflex bradycardia. \u003ci\u003eCentral nervous system disorders\u003c\/i\u003e: insomnia, nervousness, tremor, anxiety, agitation, irritability and headache. \u003ci\u003eGastrointestinal disorders\u003c\/i\u003e: nausea. \u003ci\u003eRenal and urinary disorders\u003c\/i\u003e: urination disorders. \u003cb\u003eReporting of suspected adverse reactions\u003c\/b\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eSymptoms\u003c\/b\u003e Symptoms due to moderate or acute overdose may include mydriasis, nausea, cyanosis, fever, tachycardia, cardiac arrhythmias, hypertension, dyspnea, cardiac arrest, photophobia, headache, intense chest tightness and, in children, severe Central Nervous System depression with symptoms such as decreased body temperature, bradycardia, hypotension, apnea and loss of consciousness requiring the adoption of appropriate emergency measures. \u003cb\u003eTreatment\u003c\/b\u003e Treatment should be symptomatic. In more serious cases, intubation and artificial respiration are required.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThere are no studies on the use of the product during pregnancy and breastfeeding. Use with caution in the first months of pregnancy. Administration should only be considered if the expected benefit to the mother outweighs the risk to the baby.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo effects on the ability to drive and use machines have been observed.\u003c\/p\u003e","brand":"Procter \u0026 Gamble","offers":[{"title":"Default Title","offer_id":40207824322675,"sku":"023198029","price":11.88,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/products\/procter-gamble-srl-vicks-sinex-aloe-spray-nasale-15-ml-farmacia-dottor-tili-1213792733.webp?v=1767126758"},{"product_id":"imodium-12-capsule-2-mg","title":"Imodium 12 Capsules 2mg","description":"\u003cp dir=\"ltr\"\u003e\u003cspan\u003eImodium 12 Capsules 2 mg is an antidiarrheal drug indicated for the treatment of \u003c\/span\u003e\u003cspan\u003eacute and chronic diarrhea\u003c\/span\u003e\u003cspan\u003e. Each capsule contains 2 mg of loperamide hydrochloride, the active ingredient that works by slowing down intestinal movements, thus promoting a \u003c\/span\u003e\u003cspan\u003egreater absorption of liquids and reducing the frequency of discharges\u003c\/span\u003e\u003cspan\u003e. Imodium is indicated for adults and children aged 12 and over, and is effective in \u003c\/span\u003e\u003cspan\u003erapidly reduce the symptoms of diarrhea\u003c\/span\u003e\u003cspan\u003e, improving stool consistency and reducing fluid loss.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eImodium is indicated for:\u003c\/span\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli dir=\"ltr\" aria-level=\"1\"\u003e\n\u003cp dir=\"ltr\" role=\"presentation\"\u003e\u003cspan\u003eSymptomatic treatment of acute diarrhea in adults and children over 12 years.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli dir=\"ltr\" aria-level=\"1\"\u003e\n\u003cp dir=\"ltr\" role=\"presentation\"\u003e\u003cspan\u003eTreatment of chronic diarrhea linked to specific pathological conditions.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli dir=\"ltr\" aria-level=\"1\"\u003e\n\u003cp dir=\"ltr\" role=\"presentation\"\u003e\u003cspan\u003eRegulation of stool consistency in patients with ileostomy.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eINDICATIONS\u003c\/h2\u003e\n\u003ch3\u003eWhy is Imodium 12 Capsules 2 mg used? What is it for?\u003c\/h3\u003e\u003cp dir=\"ltr\"\u003e\u003cspan\u003eImodium is indicated for the symptomatic treatment of acute diarrhea.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2\u003eACTIVE INGREDIENTS AND EXCIPIENTS\u003c\/h2\u003e\n\u003ch3\u003eWhat is the composition of Imodium 12 Capsules 2 mg?\u003c\/h3\u003e\u003cp dir=\"ltr\"\u003e\u003cspan\u003eOne hard capsule contains the active ingredient: loperamide hydrochloride 2 mg. One buccal tablet contains the active ingredient: loperamide hydrochloride 2 mg. One soft capsule contains the active ingredient: loperamide hydrochloride 2 mg. Excipients with known effects. Imodium 2 mg hard capsules: lactose 127 mg. Imodium 2 mg buccal tablets: each tablet contains 750 micrograms of aspartame; the mint flavor contains traces of sulphites. Imodium 2 mg soft capsules: Each soft capsule contains 115.31 mg of propylene glycol. For the full list of excipients, see section 6.1.\u003c\/span\u003e\u003c\/p\u003e\u003cbr\u003e\u003cbr\u003e\u003cp dir=\"ltr\"\u003e\u003cspan\u003eImodium mg hard capsules: lactose, corn starch, talc, magnesium stearate. A green-grey hard capsule consists of: erythrosine (E 127); indigo carmine (E 132); yellow iron oxide (E 172); black iron oxide (E 172); titanium dioxide and gelatin. Imodium 2 mg buccal tablets: gelatin, mannitol, aspartame, mint flavouring, sodium bicarbonate. Imodium 2 mg soft capsules: propylene glycol mono caprylate, propylene glycol, distilled water. One capsule consists of: gelatin, glycerol 99%, propylene glycol, FD\u0026C blue n.1. \u003c\/span\u003e\u003c\/p\u003e\n\u003ch2\u003eDOSAGE\u003c\/h2\u003e\n\u003ch3\u003eHow to take Imodium 12 Capsules 2 mg?\u003c\/h3\u003e\u003cp dir=\"ltr\"\u003e\u003cspan\u003eDosage. Adults: the initial dose is 2 hard capsules or 2 soft capsules or 2 buccal tablets (4 mg). Continue treatment with 1 capsule or 1 tablet (2 mg), after each subsequent evacuation of unformed (soft) stools. The maximum daily dose is 8 capsules or tablets per day (16 mg). Special populations. Children aged between 6 and 17 years (see section 4.3): the initial dose is 1 hard capsule or 1 soft capsule or 1 buccal tablet (2 mg). Continue treatment with 1 capsule or 1 tablet (2 mg), after each subsequent evacuation of unformed (soft) stools. The maximum daily dose in children must be established on the basis of body weight (3 capsules or tablets\/20 kg), but must not exceed a maximum of 8 capsules or tablets per day (16 mg). There is limited data available regarding the use of loperamide HCl in children under 12 years of age (see section 4.8 \"\"Undesirable effects\"\"). Elderly: No dose adjustment is necessary in the elderly. Impaired renal function: No dose adjustment is necessary in patients with impaired renal function. Hepatic impairment: Although no data are available in patients with hepatic impairment, loperamide HCl should be used with caution in these patients due to reduced first pass metabolism (see section 4.4 \"Special warnings and precautions for use\"). Method of administration. Imodium 2 mg hard capsules\/2 mg soft capsules: take by mouth with a little water. Imodium 2 mg buccal tablets: leave the tablet to dissolve on the tongue for a few seconds; the tablet will be dissolved quickly by saliva. It does not require the use of water. Warning: do not use for more than 2 days. In any case, stop treatment when the stool returns to normal, or if you have not had any bowel movements for 12 hours, or if constipation appears. In episodes of acute diarrhea, loperamide HCl is generally able to stop symptoms within 48 hours. After this period without appreciable results, stop treatment and consult your doctor.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/h2\u003e\n\u003ch3\u003eWhen should Imodium 12 Capsules 2 mg not be used and what side effects can it cause?\u003c\/h3\u003e\u003cp dir=\"ltr\"\u003e\u003cspan\u003eHypersensitivity to the active substance or to any of the excipients listed in paragraph 6.1; children under 6 years old; Pregnancy and breastfeeding (see section 4.6 \"\"Pregnancy and breastfeeding\"\"). Imodium must not be used as primary therapy: in acute dysentery characterized by the presence of blood in the stool and high fever; in patients with acute ulcerative colitis or pseudomembranous colitis due to the use of broad-spectrum antibiotics; in patients with bacterial enterocolitis caused by invasive organisms including Salmonella, Shigella and Campylobacter. In general, the use of loperamide HCl is contraindicated in all cases where peristalsis inhibition must be initiated due to the possible risk of significant consequences such as ileus, megacolon and toxic megacolon.\u003c\/span\u003e\u003c\/p\u003e\u003cbr\u003e\u003cbr\u003e\u003cp dir=\"ltr\"\u003e\u003cspan\u003eAdults and children aged \u003e=12 years Adverse reactions reported in clinical trials with loperamide HCl The safety of Loperamide HCl was evaluated in 3076 adult subjects and children aged \u003e=12 years who took part in 31 controlled and uncontrolled clinical trials with loperamide HCl used for the treatment of diarrhoea. Of these, 26 studies involved acute diarrhea (N=2755) and 5 chronic diarrhea (N=321). The most commonly reported adverse drug reactions (ADRs) (i.e., incidence \u003e=1%) in clinical trials with Loperamide HCl for the treatment of acute diarrhea were as follows: constipation (2.7%), flatulence (1.7%), headache (1.2%), and nausea (1.1%). In clinical trials for the treatment of chronic diarrhea, the most commonly reported ADRs (i.e., \u003e=1% incidence) were as follows: flatulence (2.8%), constipation (2.2%), nausea (1.2%), and dizziness (1.2%). The following list shows ADRs that have been reported with the use of loperamide HCl in clinical trials (in cases of acute or chronic diarrhea) in adults and in children aged \u003e= 12 years. The frequency of adverse reactions presented below is defined using the following convention: very common (\u003e=1\/10); common (\u003e=1\/100 to \u003c1\/10); uncommon (\u003e=1\/1,000 to \u003c1\/100); rare (\u003e=1\/10,000 to \u003c1\/1,000); very rare (\u003c1\/10,000); not known (frequency cannot be estimated from the available data). Adverse reactions reported with the use of loperamide HCl in clinical trials in adults and children aged \u003e= 12 years. Nervous system disorders. Headache. Acute diarrhea: common; chronic diarrhea: uncommon. Dizziness. Acute diarrhea: uncommon; Chronic diarrhea: common. Gastrointestinal disorders. Constipation, nausea, flatulence. Acute diarrhea: common; Chronic diarrhea: common. Abdominal pain, abdominal discomfort, dry mouth. Acute diarrhea: uncommon; chronic diarrhea: uncommon. Pain in the upper abdomen, vomiting. Acute diarrhea: uncommon. Dyspepsia. Chronic diarrhea: uncommon. Abdominal distension. Acute diarrhea: rare. Pathology of the skin and subcutaneous tissue. Rash. Acute diarrhea: uncommon. Adverse reactions reported in post-marketing experience with loperamide HCl: Determination of adverse reactions through post-marketing experience for loperamide HCl does not distinguish acute and chronic diarrhea indications or adult and pediatric populations; the data collected therefore represents the combination of the indications (acute and chronic diarrhea) and the populations in question (adults and children). Adverse reactions observed during post-marketing experience for loperamide HCl are listed below by System Organ Class, using MedDRA terminology. Adverse reactions reported with the use of loperamide HCl in post-marketing experience in adults and children. Immune system disorders: hypersensitivity reaction, anaphylactic reaction (including anaphylactic shock), anaphylactic reaction. Nervous system disorders: drowsiness, loss of consciousness, stupor, reduced level of consciousness, hypertonia, coordination disorders. Eye pathologies: myosis. Gastrointestinal disorders: ileus (including paralytic ileus), megacolon (including toxic megacolon), glossodynia, acute pancreatitis (frequency not known). Skin and subcutaneous tissue disorders: bullous rash (including Stevens-Johnson syndrome, toxic epidermal necrolysis and erythema multiforme), angioedema, urticaria, pruritus. Renal and urinary disorders: urinary retention. General disorders and conditions relating to the administration site: fatigue. Pediatric population: The safety of loperamide HCl was evaluated in 607 patients aged 10 days to 13 years, who took part in 13 controlled and uncontrolled clinical trials with loperamide HCl used for the treatment of acute diarrhea. Generally speaking, the profile of ADR in this patient population it was similar to that observed in clinical studies with loperamide HCl used in adults and children aged 12 years and older. Reporting of suspected adverse reactions. Reporting suspected adverse reactions that occur after authorization of the medicinal product is important, as it allows continuous monitoring of the benefit\/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reaction via the national reporting system at http:\/\/www.agenziafarmaco.gov.it\/content\/come-segnalare-unasospe tta-reazione-avversa.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2\u003eINTERACTIONS\u003c\/h2\u003e\n\u003ch3\u003eWhich medicines or foods can change the effect of Imodium 12 Capsules 2 mg?\u003c\/h3\u003e\u003cp dir=\"ltr\"\u003e\u003cspan\u003eNon-clinical data have demonstrated that loperamide is a substrate of P-glycoprotein. Concomitant administration of loperamide (in a single dose of 16 mg) with quinidine or ritonavir (both inhibitors of P-glycoprotein) has shown increases in plasma levels of loperamide by 2 to 3 times. The clinical relevance of this pharmacokinetic interaction with P-glycoprotein inhibitors when loperamide is administered at recommended doses (2 to a maximum of 16 mg per day) is unknown. Concomitant administration of loperamide (4 mg single dose) and itraconazole, an inhibitor of CYP3A4 and P-glycoprotein, showed a 34-fold increase in plasma levels of loperamide. In the same study, gemfibrozil, a CYP2C8 inhibitor, showed a 2-fold increase in plasma levels of loperamide. The combination of itraconazole and gemfibrozil showed a 4-fold increase in peak plasma loperamide level and a 13-fold increase in total plasma exposure. These increases were not associated with central nervous system (CNS) effects as detected by psychomotor tests (e.g., subjective dizziness and the Digit Symbol Substitution Test). Concomitant administration of loperamide (single dose of 16 mg) and ketoconazole, an inhibitor of CYP3A4 and P-glycoprotein, showed a 5-fold increase in plasma levels of loperamide. This increase was not associated with an increase in pharmacodynamic effects as detected by pupillometry. Concomitant treatment with oral desmopressin resulted in a 3-fold increase in plasma desmopressin concentrations, presumably due to slowed gastrointestinal motility. Concomitant use of cytochrome CYP450 inhibitors is not recommended. Substances that accelerate gastrointestinal transit may decrease Imodium. Drugs with pharmacological properties similar to those of loperamide or drugs that can slow intestinal peristalsis (e.g. anticholinergics), may increase Imodium.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2\u003ePREGNANCY AND BREASTFEEDING\u003c\/h2\u003e\n\u003ch3\u003eCan Imodium 12 Capsules 2 mg be used during pregnancy and breastfeeding?\u003c\/h3\u003e\u003cp dir=\"ltr\"\u003e\u003cspan\u003eThe administration of Imodium is contraindicated during pregnancy and breastfeeding. Pregnant or breastfeeding women should therefore be advised of the need to consult their doctor for the most appropriate treatment.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2\u003eWARNINGS\u003c\/h2\u003e\n\u003ch3\u003eWhat are the warnings of Imodium 12 Capsules 2 mg?\u003c\/h3\u003e\u003cp dir=\"ltr\"\u003e\u003cspan\u003eTreatment of diarrhea with loperamide HCl is symptomatic only. Therefore, where possible, it is also advisable to intervene on the causes of the disorder. In episodes of acute diarrhea, loperamide HCl is generally able to stop the symptoms within 48 hours; after this period without appreciable results, the treatment must be interrupted and the patient must be advised of the need to go to the doctor for a consultation. In patients with diarrhea, especially in children, a significant loss of fluids and electrolytes may occur. In such cases it can be very important to appropriately replenish fluids and electrolytes. Although no pharmacokinetic data are available in patients with hepatic dysfunction, loperamide HCl should be used with caution in these patients due to extensive first-pass metabolism. The drug should be used with caution in patients with hepatic impairment as it can lead to relative overdose with CNS toxicity. AIDS patients treated with loperamide HCl for diarrhea should discontinue therapy at the first signs of abdominal distension. In these patients with infectious colitis of bacterial or viral origin, treated with loperamide HCl, isolated cases of intestinal obstruction with an increased risk of toxic megacolon have been found. If constipation or abdominal or ileal distension occurs, stop treatment immediately. Cases of abuse and misuse of loperamide, used as a substitute for opioids, have been reported in individuals with opioid dependence (see section 4.9). Cardiac events including QT and QRS complex prolongation and torsades de pointes have been reported in association with overdose. Some cases have been fatal (see section 4.9). Overdose can manifest the presence of Brugada syndrome. Patients should not exceed the recommended dose and\/or prolong the duration of therapy. Pediatric population: In children between 6 and 12 years of age, Imodium should only be used under medical supervision. There is limited data available regarding the use of loperamide HCl in children under 12 years of age (see section 4.8 \"\"Undesirable effects\"\"). Important information about some excipients: Imodium 2 mg hard capsules contains lactose. Patients suffering from rare hereditary problems of galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption should not take this medicine. Imodium 2 mg buccal tablets contains: traces of sulphites. Sulfites rarely can cause severe hypersensitivity reactions and bronchospasm; 0.750 mg of aspartame per single dose which is equivalent to 0.011 mg\/kg for a 70 kg adult and 0.038 mg\/kg for a 20 kg child. Aspartame is hydrolyzed in the gastrointestinal tract when taken orally. One of the major products of its hydrolysis is phenylalanine. No clinical or nonclinical data are available to evaluate the use of aspartame in infants younger than 12 weeks; less than 1 mmol (23 mg) sodium per single dose. It can therefore be considered essentially sodium-free; 0.00066 mg of benzyl alcohol per single tablet. Benzyl alcohol can cause allergic reactions. It is possible that the accumulation of large quantities of benzyl alcohol could cause metabolic acidosis; use with caution and only if necessary, especially in patients with hepatic or renal insufficiency; 0.00003 mg of alcohol (ethanol) in each tablet. The Amount in Ethanol of this medicine is equivalent to less than 0.00000075 ml of beer or 0.0000003 of wine. This medicine contains a quantity of ethanol that does not produce significant effects. Imodium 2 mg soft capsules contains: 115.31 mg of propylene glycol. 115.31 mg of propylene glycol for a single dose, equivalent to 1.65 mg\/kg for a 70 kg adult and 5.77 mg\/kg for a 20 kg child; less than 1 mmol (23 mg) sodium per single dose. It can therefore be considered essentially sodium-free.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2\u003eCONSERVATION\u003c\/h2\u003e\n\u003ch3\u003eHow is Imodium 12 Capsules 2 mg stored?\u003c\/h3\u003e\u003cp dir=\"ltr\"\u003e\u003cspan\u003eStore the medicine at a temperature not exceeding 25 degrees C.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2\u003eFORMAT\u003c\/h2\u003e\n\u003ch3\u003eWhat is the format of Imodium 12 Capsules 2 mg?\u003c\/h3\u003e\u003cp\u003e12 Capsules\u003c\/p\u003e\n\u003ch2\u003eDRUG LEGAL TEXT\u003c\/h2\u003e\n\u003cp\u003eContent responsibility\u003c\/p\u003e\u003cp\u003eThis sheet contains information that is not intended to replace a doctor's diagnosis or advice, as only the doctor can draw up any prescription and give therapeutic indications. All contents must be understood and are of an exclusively informative nature and aimed exclusively at bringing to the attention of customers or potential customers in the pre-purchase phase of the products sold through this site. In case of pathologies, disorders or allergies it is always best to consult your doctor first.\u003c\/p\u003e\u003cp\u003ePlease note\u003c\/p\u003e\u003cp\u003eThe product names, ingredients and percentages indicated in the descriptions are purely indicative and may be subject to changes or updates by the manufacturing companies. Due to the impossibility of adapting to these updates in real time, the photos and technical information of the products included on Dottortili.com may differ from those shown on the label or otherwise disseminated by the manufacturing companies. The only identification element appears to be the ministerial code MINSAN. The online pharmacy Dottortili.com does not guarantee the truthfulness and timeliness of the information published and declines any responsibility for any errors, omissions or failure to update the same. Dottortili.com assumes no responsibility for damages of any nature that may arise from access to the information published.\u003c\/p\u003e\u003cp\u003eData source: Farmadati Italia\u003c\/p\u003e\u003cp\u003eWebsite: www.farmadati.it\u003c\/p\u003e\u003cp\u003eThe Farmadati Italia database is used by almost all pharmacies, parapharmacies, herbalist shops, health shops, large-scale retail trade, computerized doctors, etc. thanks to the guarantee of historical reliability, seriousness and professionalism of the company on the national territory.\u003c\/p\u003e\u003cp\u003eThe Farmadati Italia S.r.l management system complies with the requirements of the UNI EN ISO 9001:2015 standards for quality management systems and UNI CEI ISO\/IEC 27001:2017 for information security management systems.\u003c\/p\u003e","brand":"Johnson \u0026 Johnson","offers":[{"title":"Default Title","offer_id":40207824355443,"sku":"023673128","price":12.92,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/johnson-johnson-spa-imodium-12-capsule-2-mg-farmacia-dottor-tili-1213792735.jpg?v=1767126790"},{"product_id":"fluibron-aerosol-20-fiale-15-mg-2-ml","title":"Fluibron Aerosol 20 vials 15mg\/2ml","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eTreatment of secretion disorders in acute and chronic bronchopulmonary diseases.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e100 ml of sterile solution contains: Active ingredient: Ambroxol hydrochloride 750 mg. A single-dose container contains 15 mg of ambroxol hydrochloride. For the full list of excipients, see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSodium chloride, water for injections.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to the active substance or to any of the excipients listed in paragraph 6.1. Severe hepatic and\/or renal alterations. First three months of pregnancy (see par. 4.6) \u003ci\u003ePediatric population\u003c\/i\u003e The medicine is contraindicated in children under 2 years of age.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eDosage\u003c\/u\u003e \u003ci\u003e Pediatric population\u003c\/i\u003e FLUIBRON must not be used in children under 2 years of age due to safety concerns (paragraph 4.8). Adults and children over 5 years of age: one single-dose container, 2 times a day. Children aged 2 to 5 years: half a container or a single-dose container, 1-2 times a day. Do not exceed the recommended doses. Do not use for prolonged treatments. After a short period of treatment without appreciable results, consult your doctor. \u003cu\u003eMethod of administration\u003c\/u\u003e The solution can be administered using normal aerosol therapy devices. It can also be diluted in distilled water in the ratio 1:1. To use, carry out the following operations: 1) Flex the single-dose container in both directions. 2) Detach the single-dose container from the strip first at the top and then in the center. 3) Open the single-dose container by rotating the flap in the direction indicated by the arrow. 4) By exerting moderate pressure on the walls of the single-dose container, release the medicine in the prescribed quantity and introduce it into the nebulizer ampoule. 5) If half the dose is used, the container can be closed as indicated in the information leaflet. The closed container must be stored at a temperature between 2°C and 8°C (in the refrigerator) and the remaining quantity must be used within 12 hours of first opening.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSingle-dose containers must be stored inside the protective bag, protected from light. If half the dose is used, the closed container should be stored at a temperature between 2°C and 8°C (in the refrigerator) and used within 12 hours.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003e \u003cu\u003ePediatric population\u003c\/u\u003e \u003c\/i\u003e Mucolytics can induce bronchial obstruction in children under 2 years of age. In fact, the drainage capacity of bronchial mucus is limited in this age group, due to the physiological characteristics of the respiratory tract. They should therefore not be used in children under 2 years of age (see section 4.3). Since inhaling aerosols too deeply can cause an irritating cough, you should try to inhale and exhale normally during inhalation. In particularly sensitive patients, pre-warming the inhaled product to body temperature may be recommended. For patients suffering from bronchial asthma it is advisable to use a bronchial spasmolytic before inhalation. Fluibron should be administered with caution in patients with peptic ulcers. Cases of serious skin reactions such as erythema multiforme, Stevens-Johnson syndrome (SJS)\/toxic epidermal necrolysis (TEN), and acute generalized exanthematous pustulosis (AGEP) have been reported associated with the administration of ambroxol. If symptoms or signs of progressive skin rash are present (sometimes associated with blisters or mucosal lesions), treatment with ambroxol should be stopped immediately and a doctor should be consulted. The majority of these cases can be explained by the severity of the patient's underlying disease and\/or concomitant therapy. Additionally, during the early phase of Stevens-Johnson syndrome or TEN, patients may experience nonspecific flu-like prodromes such as fever, muscle aches, rhinitis, cough, and sore throat. Because of these misleading, nonspecific flu-like prodromes, symptomatic treatment with cough-and-cold medications may be instituted. Therefore, if new lesions of the skin or mucous membranes appear, it is necessary to immediately consult your doctor and discontinue treatment with ambroxol hydrochloride as a precaution. In the presence of mild or moderate renal insufficiency, Fluibron should be used only after consulting your doctor. As with any medicinal product with hepatic metabolism followed by renal elimination, accumulation of ambroxol metabolites generated in the liver may occur in severe renal insufficiency.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eFollowing the administration of ambroxol, the concentrations of antibiotics (amoxicillin, cefuroxime, erythromycin) in bronchopulmonary secretions and saliva are increased. No interactions with other medicinal products have been observed.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAt the recommended doses the medicine is normally well tolerated. The following side effects were observed during therapy with ambroxol hydrochloride, with the frequencies: Very common ≥1\/10 Common ≥1\/100 and \u003c1\/10 Uncommon ≥1\/1,000 and \u003c1\/100 Rare ≥1\/10,000 and \u003c1\/1,000 Very rare \u003c1\/10,000 Not known not known (the frequency cannot be estimated based on available data)\u003c\/p\u003e\n\u003cp\u003eImmune System Disorders - Adverse reaction: Hypersensitivity reactions. Frequency: Rare.\u003c\/p\u003e\n\u003cp\u003eImmune System Disorders - Adverse Reaction: Anaphylactic reactions, including anaphylactic shock, angioedema and pruritus. Frequency: Not known.\u003c\/p\u003e\n\u003cp\u003eNervous system disorders - Adverse reaction: Dysgeusia (e.g. alteration of the sense of taste). Frequency: Common.\u003c\/p\u003e\n\u003cp\u003eNervous system disorders - Adverse reaction: Headache. Frequency: Rare.\u003c\/p\u003e\n\u003cp\u003eRespiratory, thoracic and mediastinal disorders - Adverse reaction: Hypoesthesia of the oral cavity and pharynx. Frequency: Common.\u003c\/p\u003e\n\u003cp\u003eRespiratory, thoracic and mediastinal disorders - Adverse reaction: Bronchial obstruction. Frequency: Not known.\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders - Adverse reaction: Nausea. Frequency: Common.\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders - Adverse reaction: Vomiting, diarrhea, dyspepsia and abdominal pain, dry mouth. Frequency: Uncommon.\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders - Adverse reaction: Dry throat. Frequency: Not known.\u003c\/p\u003e\n\u003cp\u003eSkin and subcutaneous tissue disorders - Adverse reaction: Rash, urticaria. Frequency: Rare.\u003c\/p\u003e\n\u003cp\u003eSkin and subcutaneous tissue disorders - Adverse reaction: Serious cutaneous adverse reactions (including erythema multiforme, Stevens-Johnson syndrome\/toxic epidermal necrolysis and acute generalized exanthematous pustulosis). Frequency: Not known.\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eReporting of suspected adverse reactions\u003c\/u\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at \u003cu\u003ehttp:\/\/www.agenziafarmaco.gov.it\/content\/come-segnalare-una-sospetta-reazione-avversa\u003c\/u\u003e\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThere are no known cases of overdose with Fluibron for inhalation use. The symptoms observed in cases of accidental overdose and\/or in cases of errors in administration of the medicinal product are consistent with the expected side effects of ambroxol hydrochloride at recommended doses and may require symptomatic treatment.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAmbroxol hydrochloride crosses the placental barrier. Animal studies have not shown any direct or indirect harmful effects on pregnancy, embryonic\/foetal development, parturition or postnatal development. Clinical studies and extensive clinical experience after the 28th week of pregnancy have shown no evidence of harmful effects on the fetus. However, it is recommended that you observe the usual precautions regarding the use of medicines during pregnancy. Particularly during the first trimester, the use of Fluibron is not recommended. Ambroxol hydrochloride is secreted into breast milk. Although no side effects on infants are expected, the use of Fluibron is not recommended in breastfeeding mothers.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThere is no evidence of effects on the ability to drive or use machines.\u003c\/p\u003e","brand":"Chiesi","offers":[{"title":"Default Title","offer_id":40207824420979,"sku":"024596153","price":16.15,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/products\/chiesi-farmaceutici-spa-fluibron-aerosol-20-fiale-15-mg-2-ml-farmacia-dottor-tili-1213792734.webp?v=1767126819"},{"product_id":"verolax-ad-rettale-6-clismi-6-75g","title":"Verolax AD Rectal 6 Enemas 6.75g","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eConstipation.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eVerolax “6.75 g Adults Rectal Solution” 6 Single-dose Containers 9 G\u003c\/i\u003e: Each 9G single-dose container contains: \u003ci\u003eActive ingredient\u003c\/i\u003e: glycerin 6.75 g \u003ci\u003eVerolax “2.25 g Children Rectal Solution” 6 Single-dose Containers 3 G\u003c\/i\u003e: Each 3G single-dose container contains: \u003ci\u003eActive ingredient\u003c\/i\u003e: glycerin 2.25 g \u003ci\u003eVerolax “2.25 g Adult Suppositories” 18 Suppositories\u003c\/i\u003e:Each adult suppository contains: \u003ci\u003eActive ingredient\u003c\/i\u003e: glycerin 2.25 g \u003ci\u003eVerolax “1,375 g Children Suppositories” 18 Suppositories\u003c\/i\u003e: Each children's suppository contains: \u003ci\u003eActive ingredient\u003c\/i\u003e: glycerin 1.375 g \u003ci\u003eVerolax “0.675 g Infant Suppositories” 12 Suppositories\u003c\/i\u003e: Each infant suppository contains: \u003ci\u003eActive ingredient\u003c\/i\u003e: glycerin 0.675 g\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eRectal solution for adults and children:\u003c\/i\u003e Mallow fluid extract; Chamomile fluid extract; Wheat starch; Purified water. \u003ci\u003eSuppositories Adults, Children, Infants:\u003c\/i\u003e Sodium stearate, Sodium carbonate.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIndividual hypersensitivity confirmed towards the product. Anorectal diseases, hemorrhagic rectocolitis and inflammation of hemorrhoids. \u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eRectal solution:\u003c\/i\u003e 1 or 2 single-dose containers in 24 hours. In case of stubborn constipation, no more than 2 doses can be introduced into the rectum at the same time. \u003ci\u003eSuppositories:\u003c\/i\u003e 1 suppository as needed. Do not exceed the recommended doses.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo special precautions for storage.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe continuous use of laxatives can cause addiction or damage of various types. Do not use laxatives if abdominal pain, nausea and vomiting are present. If constipation is stubborn, consult your doctor.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo interactions with other drugs have been found. \u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe only effects that may be encountered are irritative, at the level of the rectal area. These are usually mild forms, which do not require medical intervention.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThere are no known symptoms of overdose.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eBased on its chemical-physical properties, rectal glycerin can be usefully used during pregnancy or the puerperium.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eTaking the drug does not alter the ability to drive or use machines.\u003c\/p\u003e","brand":"Angelini","offers":[{"title":"Default Title","offer_id":40207824453747,"sku":"026525055","price":5.21,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/angelini-verolax-ad-rettale-6-clismi-6-75g-farmacia-dottor-tili-1254215759.jpg?v=1786737460"},{"product_id":"benactiv-gola-arancia-16-pastiglie","title":"Benactiv Throat Orange 16 Lozenges","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eBENACTIV THROAT Mouthwash\u003c\/b\u003e \u003cb\u003eBENACTIV THROAT Spray for oral mucosa\u003c\/b\u003e Symptomatic treatment of irritative-inflammatory states also associated with pain in the oropharyngeal cavity (e.g. gingivitis, stomatitis, pharyngitis), also as a consequence of conservative or extractive dental therapy. \u003cb\u003eBENACTIV THROAT Lemon and Honey flavored lozenges\u003c\/b\u003e \u003cb\u003eBENACTIV GOLA Orange flavored sugar-free lozenges\u003c\/b\u003e Symptomatic treatment of irritative-inflammatory conditions also associated with oropharyngeal pain (e.g. gingivitis, stomatitis, pharyngitis).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eBENACTIV THROAT Mouthwash\u003c\/b\u003e 100 ml of mouthwash contains: \u003cb\u003eactive ingredient:\u003c\/b\u003e flurbiprofen 250 mg Excipients with known effects: hydrogenated castor oil-40-polyoxyethylene, methyl parahydroxybenzoate, propyl parahydroxybenzoate, mint essence (containing d-limonene). \u003cb\u003eBENACTIV THROAT Spray for oral mucosa\u003c\/b\u003e 100 ml of solution contains: \u003cb\u003eactive ingredient:\u003c\/b\u003e flurbiprofen 250 mg Excipients with known effects: hydrogenated castor oil-40-polyoxyethylene, methyl parahydroxybenzoate, propyl parahydroxybenzoate, mint essence (containing d-limonene). \u003cb\u003eBENACTIV THROAT Lemon and Honey flavored lozenges\u003c\/b\u003e One tablet contains: \u003cb\u003eactive ingredient:\u003c\/b\u003e flurbiprofen 8.75 mg Excipients with known effects: liquid glucose (containing sulphites and wheat starch), liquid sucrose, honey, lemon flavoring and levomenthol (containing butylated hydroxyanisole, citral, citronellol, d-limonene, farfalle, geraniol, linalool). \u003cb\u003eBENACTIV GOLA Orange flavored sugar-free lozenges\u003c\/b\u003e One tablet contains: \u003cb\u003eactive ingredient:\u003c\/b\u003e flurbiprofen 8.75 mg Excipients with known effects: liquid maltitol (E965), isomalt (E953), orange flavoring and levomenthol (containing citral, citronellol, d-limonene, geraniol, linalool). For the full list of excipients, see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eBENACTIV THROAT Mouthwash\u003c\/b\u003e Glycerol, ethanol (96 percent), sorbitol 70, hydrogenated castor oil-40-polyoxyethylene, sodium hydroxide, sodium saccharin, methyl parahydroxybenzoate, propyl parahydroxybenzoate, mint essence (containing d-limonene), patent blue V (E131), purified water. \u003cb\u003eBENACTIV THROAT Spray for oral mucosa\u003c\/b\u003e Glycerol, ethanol (96 percent), sorbitol 70, hydrogenated castor oil-40-polyoxyethylene, sodium hydroxide, sodium saccharin, methyl parahydroxybenzoate, propyl parahydroxybenzoate, mint essence (containing d-limonene), patent blue V (E131), purified water. \u003cb\u003eBENACTIV THROAT Lemon and Honey flavored lozenges\u003c\/b\u003e Liquid sucrose, liquid glucose (containing sulphites and wheat starch), macrogol 300, potassium hydroxide, lemon flavoring and levomenthol (containing butylated hydroxyanisole, citral, citronellol, d-limonene, farfalle, geraniol, linalool), honey. \u003cb\u003eBENACTIV GOLA Orange flavored sugar-free lozenges\u003c\/b\u003e Macrogol 300, potassium hydroxide, orange flavor and levomenthol (containing citral, citronellol, dlimonene, geraniol, linalool), acesulfame potassium (E950), liquid maltitol (E965), isomalt (E953).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDo not use the medicine in children under 12 years of age. Flurbiprofen is contraindicated in patients with known hypersensitivity to flurbiprofen or to any of the excipients listed in section 6.1. Patients who have previously shown hypersensitivity reactions (e.g. asthma, urticaria, allergy, rhinitis, angioedema, bronchospasm) towards ibuprofen, acetylsalicylic acid (aspirin) or other non-steroidal anti-inflammatory drugs (NSAIDs). Flurbiprofen is also contraindicated in patients with a history of gastrointestinal bleeding or perforation related to previous NSAID treatment. Flurbiprofen should not be taken by patients with active or anamnestic ulcerative colitis, Crohn's disease, recurrent peptic ulcer or gastrointestinal haemorrhage (defined as two or more distinct episodes of demonstrated ulceration or bleeding). Flurbiprofen is contraindicated in patients with severe heart failure, severe hepatic failure and renal failure (see section 4.4). Third trimester of pregnancy.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eUndesirable effects can be minimized by using the lowest effective dose for the shortest possible duration of treatment needed to control symptoms (see section 4.4). \u003cb\u003eBENACTIV THROAT Mouthwash\u003c\/b\u003e \u003cu\u003eDosage\u003c\/u\u003e \u003ci\u003eAdults\u003c\/i\u003e: 2-3 rinses or gargles per day with 10 ml (1 scoop) of mouthwash. \u003ci\u003ePediatric population\u003c\/i\u003e Children over 12 years old: same as adults. Children under 12 years of age: Do not administer to children under 12 years of age (see section 4.3). \u003ci\u003eSpecial populations\u003c\/i\u003e \u003ci\u003eElderly\u003c\/i\u003e: The clinical data currently available are limited, therefore no recommendation regarding posology can be made. Elderly people are at greater risk of serious consequences in case of adverse reactions (see section 4.4). \u003ci\u003ePatients with liver failure\u003c\/i\u003e: A dosage reduction is not necessary in patients with mild to moderate hepatic impairment. Flurbiprofen is contraindicated in patients with severe hepatic impairment (see section 4.3). \u003ci\u003ePatients with renal failure\u003c\/i\u003e: A dosage reduction is not necessary in patients with mild to moderate renal impairment. Flurbiprofen is contraindicated in patients with severe hepatic impairment (see section 4.3).\u003cu\u003eMethod of administration\u003c\/u\u003e For oropharyngeal use. Rinse or keep in mouth while gargling for up to 1 minute. Do not ingest. The mouthwash can be used pure or diluted in half a glass of water. \u003cb\u003eBENACTIV THROAT Spray for oral mucosa\u003c\/b\u003e \u003cu\u003eDosage\u003c\/u\u003e \u003ci\u003eAdults\u003c\/i\u003e: apply one dose (2 sprays) 3 times a day, directed directly onto the affected part. Each spray delivers 0.2 ml of solution, equivalent to 0.5 mg of active ingredient. \u003ci\u003ePediatric population\u003c\/i\u003e Children over 12 years old: same as adults. Children under 12 years of age: Do not administer to children under 12 years of age (see section 4.3). \u003ci\u003eSpecial populations\u003c\/i\u003e \u003ci\u003eElderly\u003c\/i\u003e: The clinical data currently available are limited, therefore no recommendation regarding posology can be made. Elderly people are at greater risk of serious consequences in case of adverse reactions (see section 4.4). \u003ci\u003ePatients with liver failure\u003c\/i\u003e: A dosage reduction is not necessary in patients with mild to moderate hepatic impairment. Flurbiprofen is contraindicated in patients with severe hepatic impairment (see section 4.3). \u003ci\u003ePatients with renal failure\u003c\/i\u003e: A dosage reduction is not necessary in patients with mild to moderate renal impairment. Flurbiprofen is contraindicated in patients with severe hepatic impairment (see section 4.3).\u003cu\u003eMethod of administration\u003c\/u\u003e For oropharyngeal use. Direct the nozzle towards the back of the throat and spray on the affected part. \u003cb\u003eBENACTIV THROAT Lemon and Honey flavored lozenges\u003c\/b\u003e \u003cb\u003eBENACTIV GOLA Orange flavored sugar-free lozenges\u003c\/b\u003e \u003cu\u003eDosage\u003c\/u\u003e \u003ci\u003eAdults\u003c\/i\u003e: 1 tablet every 3-6 hours, as needed. Do not exceed the dose of 8 tablets in 24 hours. \u003ci\u003ePediatric population\u003c\/i\u003e Children over 12 years old: same as adults. Children under 12 years of age: Do not administer to children under 12 years of age (see section 4.3). \u003ci\u003eSpecial populations\u003c\/i\u003e \u003ci\u003eElderly\u003c\/i\u003e: The clinical data currently available are limited, therefore no recommendation regarding posology can be made. Elderly people are at greater risk of serious consequences in case of adverse reactions (see section 4.4). \u003ci\u003ePatients with liver failure\u003c\/i\u003e: A dosage reduction is not necessary in patients with mild to moderate hepatic impairment. Flurbiprofen is contraindicated in patients with severe hepatic impairment (see section 4.3). \u003ci\u003ePatients with renal failure\u003c\/i\u003e: A dosage reduction is not necessary in patients with mild to moderate renal impairment. Flurbiprofen is contraindicated in patients with severe hepatic impairment (see section 4.3).\u003cu\u003eMethod of administration\u003c\/u\u003e For oropharyngeal use. Dissolve slowly in your mouth. As with all lozenges, in order to avoid local irritation, flurbiprofen lozenges should also be moved inside the mouth during administration. If mouth irritation occurs, treatment should be discontinued.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eBenactiv Gola Orange flavored sugar-free lozenges and Benactiv Gola Lemon and Honey flavored lozenges: store at temperatures below 25°C.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAt the recommended doses, when using the medicine in its various pharmaceutical forms, any swallowing does not cause any harm to the patient, as the dose of flurbiprofen is significantly lower than that commonly used in systemic treatments. Elderly: Elderly patients have an increased frequency of adverse reactions to NSAIDs, especially gastrointestinal haemorrhage and perforation, which may be fatal. \u003ci\u003eRespiratory disorders \u003c\/i\u003e Cases of bronchospasm have been reported with flurbiprofen in patients with a history of bronchial asthma or allergies. Flurbiprofen should be used with caution in these patients. \u003ci\u003eOther NSAIDs \u003c\/i\u003e It is advisable not to combine the medicine with other NSAIDs (see section 4.5). \u003ci\u003eSystemic lupus erythematosus (SLE) and mixed connective tissue disease \u003c\/i\u003e Patients with systemic lupus erythematosus and mixed connective tissue disease may have an increased risk of aseptic meningitis (see section 4.8), however this effect is not usually seen with products intended for limited and short-term use such as flurbiprofen. \u003ci\u003eCardiac, hepatic and renal impairment \u003c\/i\u003e The medicine should be used with caution in patients with cardiac, renal or hepatic insufficiency. NSAIDs have been reported to cause various forms of nephrotoxicity, including interstitial nephritis, nephrotic syndrome, and renal failure. The administration of an NSAID can cause a dose-dependent reduction in the formation of prostaglandins and precipitate renal failure. Patients at highest risk of developing this reaction are those with impaired renal function, cardiac impairment, liver dysfunction, those on diuretic therapy and the elderly; however, this effect is not usually observed with products intended for limited and short-term use such as flurbiprofen. \u003ci\u003eCardiovascular and cerebrovascular effects \u003c\/i\u003e Before starting treatment in patients with a positive history of hypertension and\/or heart failure, caution is required (discuss with your doctor or pharmacist), since fluid retention, hypertension and edema have been reported in association with treatment with NSAIDs. Clinical studies and epidemiological data suggest that the use of some NSAIDs, especially at high doses and for long-term treatments, may be associated with a modest increase in the risk of arterial thrombotic events such as myocardial infarction or stroke. There are insufficient data to exclude a similar risk for flurbiprofen. Patients with uncontrolled hypertension, congestive heart failure, established ischemic heart disease, peripheral arterial disease and\/or cerebrovascular disease should be treated with flurbiprofen only after careful consideration. Similar considerations must be made before starting long-term treatment in patients with risk factors for cardiovascular disease (e.g. hypertension, hyperlipidemia, diabetes mellitus, smoking). \u003ci\u003eEffects on the central nervous system \u003c\/i\u003e Analgesic-induced headache. In case of prolonged or irregular use of analgesics, headache may occur, which must not be treated by increasing the dose of the medicine. \u003ci\u003eGastrointestinal effects\u003c\/i\u003e Flurbiprofen should be administered with caution to patients with a history of peptic ulcers and other gastrointestinal diseases as these conditions may be exacerbated. The risk of gastrointestinal haemorrhage, ulcer or perforation is higher with increasing dosage of flurbiprofen in patients with a history of ulcer, particularly if complicated by haemorrhage and perforation, and in the elderly. These patients should start treatment with the lowest available dose. Gastrointestinal bleeding, ulcer or perforation have been reported with all NSAIDs at any time during treatment. These adverse reactions can be fatal and can occur with or without warning symptoms or in case of a previous history of serious gastrointestinal reactions. Patients with a history of gastrointestinal disease, especially if elderly, should report any unusual abdominal symptoms (especially gastrointestinal bleeding) in the initial stages of treatment. Undesirable effects can be minimized by using the lowest effective dose for the shortest possible duration of treatment needed to control symptoms (see section 4.2). Caution should be advised in patients receiving concomitant medicinal products that may increase the risk of ulceration or bleeding, such as oral corticosteroids, anticoagulants such as warfarin, selective serotonin reuptake inhibitors or antiplatelet agents such as acetylsalicylic acid (see section 4.5). When gastrointestinal bleeding or ulceration occurs in patients taking flurbiprofen, treatment should be discontinued. \u003ci\u003eDermatological effects\u003c\/i\u003e The use of the medicine, especially if prolonged, can give rise to sensitization or local irritation phenomena. In such cases it is necessary to interrupt the treatment and consult a doctor to institute, if necessary, suitable therapy. Serious skin reactions, some of them fatal, including exfoliative dermatitis, Stevens-Johnson syndrome and toxic epidermal necrolysis, have been reported very rarely in association with the use of NSAIDs (see section 4.8). Flurbiprofen should be discontinued at the first appearance of skin rash, mucosal lesions or any other sign of hypersensitivity. \u003ci\u003eInfections\u003c\/i\u003e Since isolated cases of exacerbation of inflammation related to infections (e.g. development of necrotizing fasciitis) have been described in temporal association with the systemic use of drugs belonging to the NSAID class, patients are recommended to immediately consult a doctor in case of appearance or worsening of signs of a bacterial infection during flurbiprofen-based therapy. A possible indication for starting antibiotic therapy must be taken into consideration. If mouth irritation develops, treatment should be discontinued. BENACTIV GOLA Mouthwash and BENACTIV GOLA Spray contain para-hydroxybenzoates which can cause allergic reactions (even delayed). BENACTIV GOLA Mouthwash and BENACTIV GOLA Spray contain hydrogenated 40-polyoxyethylene castor oil which may cause localized skin reactions. BENACTIV GOLA Mouthwash and BENACTIV GOLA Spray contain an aroma which in turn contains d-limonene. D-limonene can cause allergic reactions. BENACTIV GOLA Mouthwash and BENACTIV GOLA Spray contain less than 1 mmol (23mg) sodium per 10 ml dose, i.e. essentially \"sodium-free\". BENACTIV GOLA Lemon and Honey flavored lozenges contain liquid glucose, liquid sucrose and honey (invert sugar). Patients suffering from rare problems of fructose intolerance, glucose-galactose malabsorption or sucrase isomaltase insufficiency should not take this medicine. To be taken into consideration in people with diabetes mellitus: this medicine contains 1.07 g of glucose and 1.41 g of sucrose per tablet. BENACTIV GOLA Lemon and Honey flavored lozenges contain sulphites. Rarely it can cause serious hypersensitivity reactions and bronchospasm. BENACTIV GOLA Lemon and Honey flavored lozenges contain only a very small amount of gluten (from wheat starch). This medicine is considered “gluten-free” and is very unlikely to cause problems for a celiac patient. One tablet contains no more than 21.38 micrograms of gluten. If a patient is allergic to wheat (condition other than celiac disease) he or she should not take this medicine. BENACTIV THROAT Lemon and Honey flavored lozenges contain an aroma which in turn contains citral, citronellol, d-limonene, farfalle, geraniol and linalool. Citral, citronellol, d-limonene, farfalle, geraniol and linalool can cause allergic reactions. BENACTIV THROAT Lemon and Honey flavored lozenges contain an aroma which in turn contains butylated hydroxyanisole which can cause localized skin reactions (e.g. contact dermatitis) or irritation to the eyes and mucous membranes. BENACTIV GOLA Sugar-Free Lozenges Orange flavor is instead indicated for those patients who need to control their intake of sugars and calories. BENACTIV GOLA Orange flavored sugar-free lozenges contain an aroma which in turn contains citral, citronellol, d-limonene, geraniol and linalool. Citral, citronellol, d-limonene, geraniol and linalool can cause allergic reactions. BENACTIV GOLA Orange flavored sugar-free lozenges contain liquid maltitol and isomalt. Patients with rare hereditary problems of fructose intolerance should not take this medicine. May have a mild laxative effect. The caloric value of maltitol and isomalt is 2.3 kcal\/g. Do not use for prolonged treatments beyond 7 days. If you do not notice appreciable results after 3 days of treatment, the cause could be a different pathological condition. In these cases it is advisable to consult your doctor.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eCaution should be exercised in patients treated with any of the medicines listed below, as interactions have been reported in some patients. However, inform your doctor if you are taking other medicines. Flurbiprofen should be avoided in association with: - Aspirin: unless the intake of low-dose aspirin (not exceeding 100 mg\/day or local prophylactic doses for cardiovascular protection) has been recommended by the doctor; As with other NSAID-containing medicinal products, concomitant administration of flurbiprofen and aspirin is generally not recommended due to the potential for increased side effects (see section 4.4). - Cox-2 inhibitors and other NSAIDs: concomitant use of other NSAIDs, including selective cyclooxygenase-2 inhibitors, should be avoided due to potential additive effects and an increased risk of adverse reactions (see section 4.4). Flurbiprofen should be used with caution in association with: - Anticoagulants: NSAIDs can potentiate the effects of anticoagulants such as warfarin (see section 4.4) - Antiaggregating agents: increased risk of gastrointestinal bleeding - Selective serotonin reuptake inhibitors (SSRIs): increased risk of gastrointestinal bleeding - Antihypertensives (diuretics, ACE inhibitors and angiotensin II antagonists): i NSAIDs can reduce the effect of diuretics. Other antihypertensive drugs may potentiate nephrotoxicity caused by inhibition of cyclooxygenase, especially in patients with impaired renal function (these patients must be adequately hydrated) - Alcohol: may increase the risk of adverse reactions, especially bleeding in the gastrointestinal tract - Cardiac glycosides: NSAIDs may exacerbate heart failure, reduce GFR (glomerular filtration rate) and increase plasma levels of glycosides - Cyclosporine: increased risk of nephrotoxicity - Corticosteroids: increased risk of gastrointestinal ulcer or haemorrhage with NSAIDs (see section 4.4) - Lithium: there is evidence for a possible increase in plasma lithium levels - Methotrexate: there may be an increase in plasma levels of methotrexate - Mifepristone: NSAIDs should not be used for 8-12 days after administration of mifepristone, as NSAIDs may reduce the effect of mifepristone - Quinolone antibiotics: data obtained in animals indicate that NSAIDs may increase the risk of convulsions associated with quinolone antibiotics. Patients taking NSAIDs and quinolones may have an increased risk of developing seizures - Tacrolimus: possible increased risk of nephrotoxicity when NSAIDs are administered together with tacrolimus - Zidovudine: increased risk of haematological toxicity when NSAIDs are administered with zidovudine.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity reactions to NSAIDs have been reported and these may consist of: (a) non-specific allergic reactions and anaphylaxis (b) respiratory tract reactivity, e.g. asthma, aggravated asthma, bronchospasm, dyspnoea (c) various skin disorders, including for example skin rashes of different types, pruritus, urticaria, purpura, angioedema and, more rarely, exfoliative and bullous dermatosis (including necrolysis epidermal and erythema multiforme). The most commonly observed adverse reactions are gastrointestinal in nature. Local use of the medicine, especially if prolonged, can give rise to local sensitization or irritation phenomena. The dissolution of the medicine in tablet form in the oral cavity may be accompanied by sensations of heat or tingling in the oropharynx. In such cases it is necessary to interrupt treatment and institute, if necessary, suitable therapy. The following side effects have been reported, particularly after the administration of formulations for systemic use. They refer to those detected with the use of flurbiprofen used short term and at doses compatible with the classification of self-medication medicines. When treating chronic conditions and for long periods of time, additional side effects may occur. The side effects associated with the use of flurbiprofen are divided below based on system organ classification and frequency. Frequency is defined as: very common (≥ 1\/10), common (≥1\/100, \u003c1\/10), uncommon (≥1\/1,000, \u003c1\/100), rare (≥1\/10,000, \u003c1\/1,000), very rare (\u003c1\/10,000) and not known (cannot be estimated from the available data). Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.\u003c\/p\u003e\n\u003cp\u003eDisorders of the blood and lymphatic system - Frequency: Not known. Adverse reactions: Anemia, thrombocytopenia, aplastic anemia and agranulocytosis.\u003c\/p\u003e\n\u003cp\u003eNervous system disorders - Frequency: Common. Adverse reactions: Dizziness, headache, paraesthesia.\u003c\/p\u003e\n\u003cp\u003eNervous system disorders - Frequency: Uncommon. Adverse reactions: Drowsiness.\u003c\/p\u003e\n\u003cp\u003eNervous system disorders - Frequency: Not known. Adverse reactions: Cerebrovascular accident, optic neuritis, migraine, confusional states, dizziness.\u003c\/p\u003e\n\u003cp\u003eImmune system disorders - Frequency: Rare. Adverse reactions: Anaphylactic reaction.\u003c\/p\u003e\n\u003cp\u003eImmune system disorders - Frequency: Not known. Adverse reactions: Angioedema, hypersensitivity\u003c\/p\u003e\n\u003cp\u003eEye disorders - Frequency: Not known. Adverse reactions: Vision impairment.\u003c\/p\u003e\n\u003cp\u003eEar and labyrinth disorders - Frequency: Not known. Adverse reactions: Tinnitus.\u003c\/p\u003e\n\u003cp\u003eCardiac disorders - Frequency: Not known. Adverse reactions: Heart failure, edema.\u003c\/p\u003e\n\u003cp\u003eVascular disorders - Frequency: Not known. Adverse reactions: Hypertension.\u003c\/p\u003e\n\u003cp\u003eRespiratory, thoracic and mediastinal disorders - Frequency: Common. Adverse reactions: Throat irritation.\u003c\/p\u003e\n\u003cp\u003eRespiratory, thoracic and mediastinal disorders - Frequency: Uncommon. Adverse reactions: Asthma, bronchospasm and dyspnea, oropharyngeal vesicular rash, oropharyngeal hypoesthesia.\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders - Frequency: Common. Adverse reactions: Diarrhoea, mouth ulceration, nausea, oral pain, oral paraesthesia, oropharyngeal pain, oral discomfort (hot or burning sensation, tingling in the mouth).\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders - Frequency: Uncommon. Adverse reactions: Abdominal distension, abdominal pain, constipation, dry mouth, dyspepsia, flatulence, glossodynia, dysgeusia, oral dysesthesia, vomiting.\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders - Frequency: Not known. Adverse reactions: Melena, haematemesis, gastrointestinal haemorrhage, colitis, exacerbation of Crohn's disease, gastritis, peptic ulcer, gastric perforation, ulcer haemorrhage.\u003c\/p\u003e\n\u003cp\u003eSkin and subcutaneous tissue disorders - Frequency: Uncommon. Adverse reactions: Skin rash, itching.\u003c\/p\u003e\n\u003cp\u003eSkin and subcutaneous tissue disorders - Frequency: Not known. Adverse reactions: Urticaria, purpura, bullous dermatitis (including Stevens-Johnson syndrome, toxic epidermal necrolysis and erythema multiforme).\u003c\/p\u003e\n\u003cp\u003eRenal and urinary disorders - Frequency: Not known. Adverse reactions: Toxic nephropathy, tubulointerstitial nephritis and nephrotic syndrome, renal failure (as with other NSAIDs).\u003c\/p\u003e\n\u003cp\u003eGeneral disorders and administration site conditions - Frequency: Uncommon. Adverse reactions: Pyrexia, pain.\u003c\/p\u003e\n\u003cp\u003eGeneral disorders and conditions relating to the administration site - Frequency: Not known. Adverse reactions: Discomfort, tiredness.\u003c\/p\u003e\n\u003cp\u003eHepatobiliary disorders - Frequency: Not known. Adverse reactions: Hepatitis.\u003c\/p\u003e\n\u003cp\u003ePsychiatric disorders - Frequency: Uncommon. Adverse reactions: Insomnia.\u003c\/p\u003e\n\u003cp\u003ePsychiatric disorders - Frequency: Not known. Adverse reactions: Depression, hallucination.\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eReporting of suspected adverse reactions\u003c\/u\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eGiven the reduced content of the active ingredient and its local use, it is unlikely that overdose situations may occur. \u003cb\u003eSymptoms\u003c\/b\u003e The majority of patients who ingest clinically large quantities of NSAIDs develop nausea, vomiting, gastrointestinal irritation, epigastric pain, or more rarely diarrhea. Tinnitus, headache and gastrointestinal bleeding are also possible. In more severe cases of NSAID intoxication, central nervous system toxicity is observed, manifested by drowsiness, occasionally excitability, blurred vision and disorientation or coma. Occasionally patients develop seizures. In case of severe NSAID intoxication, metabolic acidosis may occur and the prothrombin time\/INR may be prolonged, probably due to interference with the action of coagulation factors present in circulation. Acute renal failure and liver damage may occur. An exacerbation of asthma is possible in asthmatic subjects. \u003cb\u003eTreatment\u003c\/b\u003e Treatment should be symptomatic and supportive and should include maintaining a patent airway and monitoring cardiac function and vital signs until stabilization. Oral administration of activated charcoal and, if necessary, correction of serum electrolytes should be considered if the patient presents within one hour of ingesting a potentially toxic amount. Seizures should be treated with intravenous diazepam or lorazepam if they are frequent or prolonged. Administer bronchodilators for asthma. There is no specific antidote for flurbiprofen.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003ePregnancy\u003c\/u\u003e Flurbiprofen should not be administered during the first and second trimester of pregnancy unless strictly necessary. The use of flurbiprofen during the third trimester of pregnancy is contraindicated. \u003cu\u003eBreastfeeding\u003c\/u\u003e In a limited number of studies, flurbiprofen appears in breast milk in very low concentrations and is unlikely to have negative effects on the breastfed infant. However, administration of flurbiprofen is not recommended in breastfeeding mothers. \u003cu\u003eFertility\u003c\/u\u003e There is evidence to suggest that cyclooxygenase\/prostaglandin synthesis inhibitors may cause impairment of female fertility through an effect on ovulation. This is reversible upon discontinuation of treatment.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIt does not interfere with the ability to drive and use machinery.\u003c\/p\u003e","brand":"Reckitt Benckiser","offers":[{"title":"Default Title","offer_id":40207824552051,"sku":"033262078","price":12.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/products\/reckitt-benckiser-h-it-spa-benactiv-gola-arancia-16-pastiglie-farmacia-dottor-tili-1213792732.webp?v=1767126886"},{"product_id":"fexallegra-10-compresse-rivestite-120-mg","title":"Fexallegra 10 Coated Tablets 120 mg","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eFexallegra is indicated in adults and children from 12 years of age for the symptomatic treatment of allergic rhinitis.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eOne tablet contains\u003c\/u\u003e: \u003ci\u003eActive ingredient:\u003c\/i\u003e 120 mg of fexofenadine hydrochloride, equal to 112 mg of fexofenadine. For the full list of excipients, see section 6.1\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eTablet core \u003c\/i\u003e microcrystalline cellulose; pregelatinized corn starch; croscarmellose sodium; magnesium stearate \u003ci\u003eFilm coating\u003c\/i\u003e hypromellose; povidone K30; titanium dioxide (E171); anhydrous colloidal silica; macrogol 400; red iron oxide (E172), yellow iron oxide (E172).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe medicine is contraindicated in patients with hypersensitivity to the active substance or to any of the excipients listed in paragraph 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eDosage \u003c\/u\u003e \u003ci\u003eAdults \u003c\/i\u003e The recommended dose of fexofenadine hydrochloride for adults is 120 mg once daily, before meals. Fexofenadine is a pharmacologically active metabolite of terfenadine. \u003ci\u003ePediatric population Children 12 years of age and older \u003c\/i\u003e The recommended dose of fexofenadine hydrochloride for children aged 12 years and older is 120 mg once a day, before meals. \u003ci\u003eChildren under 12 years of age \u003c\/i\u003e The efficacy and safety of fexofenadine hydrochloride 120 mg have not been studied in children under 12 years of age. In children 6 to 11 years of age: fexofenadine hydrochloride 30 mg tablets is the appropriate formulation for administration and dosing in this population. \u003ci\u003eParticular populations \u003c\/i\u003e Studies carried out in risk groups of patients (elderly, patients with renal or hepatic insufficiency) indicate that it is not necessary to adapt the dose of fexofenadine hydrochloride in these patients.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThis medicinal product does not require any special precautions for storage.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eData in elderly subjects and patients with impaired renal or hepatic function are limited. Fexofenadine hydrochloride should be administered with caution to these groups of subjects (see section 4.2). Patients with previous or current cardiovascular disease should be informed that antihistamines, as a class of medicinal products, have been associated with adverse reactions such as tachycardia and palpitations (see section 4.8). \u003cu\u003eFexallegra contains sodium \u003c\/u\u003e This medicinal product contains less than 1 mmol (23 mg) sodium per tablet, i.e. essentially 'sodium-free'.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eFexofenadine does not undergo hepatic biotransformation and therefore will not interact with other medicinal products at the level of hepatic mechanisms. Coadministration of fexofenadine hydrochloride and erythromycin or ketoconazole has been found to increase plasma levels of fexofenadine 2-3-fold. These alterations were not accompanied by any effect on the QT interval and were not associated with any increase in adverse reactions compared to that observed with the same medicinal products administered individually. Animal studies have shown that the increase in plasma levels of fexofenadine observed after concomitant treatment with erythromycin or ketoconazole appears to be caused by an increase in gastrointestinal absorption and a decrease in both biliary excretion and gastrointestinal secretion, respectively. No interaction was observed between fexofenadine and omeprazole. However, administration of an antacid containing aluminum and magnesium hydroxide 15 minutes before administration of fexofenadine hydrochloride resulted in a reduction in bioavailability, most likely due to binding in the gastrointestinal tract. An interval of 2 hours is advisable between the administration of fexofenadine hydrochloride and antacids containing aluminum and magnesium hydroxide.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe following frequency class has been used when applicable: very common (≥ 1\/10); common (≥ 1\/100 and \u003c 1\/10); uncommon (≥ 1\/1000 and \u003c 1\/100); rare (≥ 1\/10,000 and \u003c 1\/1,000); very rare (\u003c 1\/10,000) and not known (frequency cannot be estimated from the available data). Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness. In adults, the following side effects were reported in clinical trials, with an incidence similar to that observed with placebo: \u003ci\u003e \u003cu\u003eNervous system disorders.\u003c\/u\u003e \u003c\/i\u003e Common: headache, drowsiness, dizziness. \u003ci\u003e \u003cu\u003eGastrointestinal disorders.\u003c\/u\u003e \u003c\/i\u003e Common: nausea. \u003ci\u003e \u003cu\u003eSystemic pathologies and conditions relating to the administration site.\u003c\/u\u003e \u003c\/i\u003e Uncommon: fatigue. In adults, the following side effects have been reported during post-marketing surveillance. The frequency with which they occur is not known (an estimate cannot be made based on the available data): \u003ci\u003e \u003cu\u003eImmune system disorders:\u003c\/u\u003e \u003c\/i\u003e Hypersensitivity reactions with manifestations such as angioedema, chest tightness, dyspnoea, hot flushes and systemic anaphylaxis. \u003ci\u003e \u003cu\u003ePsychiatric disorders:\u003c\/u\u003e \u003c\/i\u003e Insomnia, nervousness, sleep disturbances or nightmares\/excessive dreaming (paronyria). \u003ci\u003e \u003cu\u003eCardiac disorders:\u003c\/u\u003e \u003c\/i\u003e Tachycardia, palpitations. \u003ci\u003e \u003cu\u003eGastrointestinal disorders:\u003c\/u\u003e \u003c\/i\u003e Diarrhoea. \u003ci\u003e \u003cu\u003eSkin and subcutaneous tissue disorders:\u003c\/u\u003e \u003c\/i\u003eRash, urticaria and itching. \u003cb\u003eReporting of suspected adverse reactions\u003c\/b\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDizziness, drowsiness, fatigue and dry mouth have been reported following overdose of fexofenadine hydrochloride. Single doses of up to 800 mg and doses of up to 690 mg twice daily for one month or 240 mg once daily for one year have been administered to healthy volunteers without resulting in clinically significant adverse reactions when compared to placebo. The maximum tolerated dose of fexofenadine hydrochloride has not been established. Standard measures to remove unabsorbed drug should be considered. Symptomatic and supportive treatment is recommended. Hemodialysis does not effectively remove fexofenadine hydrochloride from the blood.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003ePregnancy \u003c\/u\u003e There are no adequate data on the use of fexofenadine hydrochloride in pregnant women. Limited animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryonic\/foetal development, parturition or postnatal development (see section 5.3). Fexofenadine hydrochloride should not be used during pregnancy unless absolutely necessary.\u003cu\u003eBreastfeeding \u003c\/u\u003e There are no data on the concentration in breast milk after administration of fexofenadine hydrochloride. However, when terfenadine was administered to breastfeeding mothers, fexofenadine was found to pass into breast milk. Therefore the use of fexofenadine hydrochloride is not recommended during breastfeeding. \u003cu\u003eFertility \u003c\/u\u003e No data are available on the effect of fexofenadine hydrochloride on human fertility. In mice, treatment with fexofenadine hydrochloride showed no effect on fertility (see section 5.3).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eBased on the pharmacodynamic profile and adverse reactions reported, fexofenadine hydrochloride tablets are unlikely to produce any effects on the ability to drive and use machinery. In objective tests, FEXALLEGRA was not shown to have significant effects on the function of the central nervous system. This means patients can drive or perform tasks that require concentration. However, in order to identify sensitive people who may have an unusual reaction to medicines, it is advisable to test the individual response before driving or performing complex tasks.\u003c\/p\u003e","brand":"Sanofi","offers":[{"title":"Default Title","offer_id":40207824584819,"sku":"042554042","price":12.93,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/sanofi-fexallegra-10-compresse-rivestite-120-mg-farmacia-dottor-tili-1258975929.jpg?v=1789562590"},{"product_id":"tachifludec-limone-polvere-10-bustine","title":"Tachifludec Lemon Powder 10 Sachets","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eShort-term treatment of cold and flu symptoms, including mild\/moderate pain and fever, when associated with nasal congestion.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eEach sachet contains: \u003cu\u003eactive ingredients:\u003c\/u\u003e paracetamol 600 mg, ascorbic acid 40 mg and phenylephrine hydrochloride 10 mg (equal to phenylephrine 8.2 mg). \u003cu\u003eExcipients with known effects:\u003c\/u\u003e \u003cu\u003eTACHIFLUDEC lemon flavor contains:\u003c\/u\u003e 1,817 g of \u003cb\u003esucrose\u003c\/b\u003e, 112.86 mg of \u003cb\u003esodium\u003c\/b\u003e, 6.65 mg of \u003cb\u003eglucose\u003c\/b\u003e. \u003cu\u003eTACHIFLUDEC lemon and honey flavor contains:\u003c\/u\u003e 1,892g of \u003cb\u003esucrose\u003c\/b\u003e, 135.79 mg of \u003cb\u003esodium\u003c\/b\u003e. For the full list of excipients, see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e- TACHIFLUDEC powder for oral solution lemon flavour: \u003cb\u003esucrose\u003c\/b\u003e, anhydrous citric acid, \u003cb\u003esodium\u003c\/b\u003e citrate, corn starch, \u003cb\u003esodium\u003c\/b\u003e cyclamate, saccharin \u003cb\u003esodium\u003c\/b\u003e, anhydrous colloidal silica, lemon flavouring, curcumin (E100), syrup \u003cb\u003eglucose\u003c\/b\u003e dried. - TACHIFLUDEC powder for oral solution lemon and honey flavour: \u003cb\u003esucrose\u003c\/b\u003e, anhydrous citric acid, \u003cb\u003esodium\u003c\/b\u003e citrate, corn starch, \u003cb\u003esodium\u003c\/b\u003e cyclamate, saccharin \u003cb\u003esodium\u003c\/b\u003e, lemon flavouring, honey flavouring, caramel (E150), colloidal anhydrous silica.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e- Children under the age of 12. - Hypersensitivity to the active substances or to any of the excipients (listed in paragraph 6.1). - Patients taking beta-blockers. - Patients taking tricyclic antidepressants and those taking or have taken in the last 2 weeks monoamine oxidase inhibitors. - Patients with bronchial asthma, pheochromocytoma, narrow-angle glaucoma, or who simultaneously take other sympathetic mimetic medicinal products (such as decongestants, appetite suppressants and amphetamine-like psychostimulants). - Patients suffering from liver or kidney failure, diabetes, hyperthyroidism, hypertension and cardiovascular diseases. - Paracetamol-based products are contraindicated in patients with manifest glucose-6-phosphate dehydrogenase insufficiency and in those suffering from severe hemolytic anemia. - Severe hepatocellular insufficiency.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eDosage\u003c\/u\u003e \u003cu\u003eAdults and children over 12 years old\u003c\/u\u003e: 1 sachet every 4-6 hours and up to a maximum of 3 sachets in 24 hours. The medicine should not be used for more than 3 consecutive days without consulting your doctor. \u003ci\u003ePediatric population\u003c\/i\u003e \u003cu\u003eChildren under 12 years:\u003c\/u\u003e TACHIFLUDEC lemon, lemon and honey flavor is contraindicated in children under 12 years of age (see section 4.3). \u003cu\u003eMethod of administration\u003c\/u\u003e Dissolve the contents of 1 sachet in half a glass of very hot water and, to taste, dilute with cold water to cool and sweeten as desired.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eStore below 25°C. Store in the original container to protect the medicine from moisture and light.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003ePatients should be advised not to take other medicines containing paracetamol while taking TACHIFLUDEC as high doses of paracetamol may cause serious adverse reactions. Avoid alcohol consumption during treatment with TACHIFLUDEC. The danger of overdose is in fact greater in patients with liver problems. Invite the patient to contact the doctor before combining warfarin or any other drug (see also section 4.5). The use of the product is not recommended if the patient is being treated with anti-inflammatories. Caution is advised if acetaminophen is administered concurrently with flucloxacillin due to the increased risk of high anion gap metabolic acidosis (HAGMA), particularly in patients with severe renal impairment, sepsis, malnutrition, and other sources of glutathione deficiency (e.g., chronic alcoholism), as well as in those using maximum daily doses of acetaminophen. Close monitoring, including measurement of urinary 5-oxoproline, is recommended. Consult your doctor before using the product in patients with enlarged prostate gland or occlusive vascular disease (e.g. Raynaud's syndrome). Do not exceed the recommended dose and do not administer for more than 3 consecutive days. TACHIFLUDEC lemon flavor contains: - \u003cb\u003esodium\u003c\/b\u003e: This medicinal product contains 112.86 mg sodium per sachet equivalent to 5.64% of the maximum daily intake recommended by WHO which corresponds to 2 g sodium for an adult, to be taken into consideration in patients with reduced renal function or following a low-sodium diet. - \u003cb\u003esucrose:\u003c\/b\u003e Patients suffering from rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase isomaltase insufficiency should not take this medicine. Patients with diabetes must take into consideration the sucrose content within TACHIFLUDEC when taking more than 2 sachets per day (sucrose \u003e 5g). - \u003cb\u003eglucose:\u003c\/b\u003e Patients suffering from rare problems of glucose-galactose malabsorption should not take this medicine. TACHIFLUDEC lemon and honey flavor contains: - \u003cb\u003esodium:\u003c\/b\u003e 135.79 mg of sodium per sachet equivalent to 6.79% of the maximum daily intake recommended by WHO which corresponds to 2 g of sodium for an adult, to be taken into consideration in patients with reduced renal function or who follow a low-sodium diet. - \u003cb\u003esucrose:\u003c\/b\u003e Patients suffering from rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase isomaltase insufficiency should not take this medicine. The sucrose content within TACHIFLUDEC is to be taken into consideration in people suffering from diabetes mellitus if they take more than 2 sachets per day (sucrose \u003e 5g).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003e \u003cu\u003eParacetamol\u003c\/u\u003e \u003c\/i\u003e The hepatotoxic effect of paracetamol can be potentiated by the intake of other drugs active on the liver such as zidovudine and isoniazid which can produce an inhibition of the metabolism of paracetamol. The administration of probenecid before paracetamol decreases the clearance of paracetamol and the urinary elimination of paracetamol sulphate and paracetamol-glucuronide, and increases the half-life of paracetamol itself. Use with extreme caution and under strict control during chronic treatment with drugs that can cause the induction of hepatic monooxygenases or in case of exposure to substances that can have this effect (for example rifampicin, cimetidine, antiepileptics such as glutetimide, phenobarbital, carbamazepine). Paracetamol increases the half-life of chloramphenicol. The product taken in high doses can enhance the effect of coumarin anticoagulants (warfarin). Metoclopramide and domperidone can increase the absorption of paracetamol, while it is reduced or delayed by cholestyramine and anticholinergics, respectively. Caution should be exercised when paracetamol is used concomitantly with flucloxacillin as concomitant use has been associated with high anion gap metabolic acidosis, especially in patients with risk factors (see section 4.4). \u003ci\u003e \u003cu\u003ePhenylephrine\u003c\/u\u003e \u003c\/i\u003e Phenylephrine can antagonize the effect of beta-blocking and antihypertensive drugs (including debrisoquine, guanethidine, reserpine and methyldopa) and can potentiate the action of monoamine oxidase inhibitors (see section 4.3). The simultaneous use of phenylephrine with tricyclic antidepressants or sympathetic mimetic amines may increase the risk of cardiovascular effects. Phenylephrine can interact with digoxin and cardiac glycosides, increasing the risk of arrhythmia or heart attack, and with alkaloids (ergotamine and methylsergide), increasing the risk of ergotism. \u003ci\u003e \u003cu\u003eAscorbic acid\u003c\/u\u003e \u003c\/i\u003e Ascorbic acid can increase the absorption of iron and estrogen. Ascorbic acid is metabolised to oxalate, and can potentially cause hyperoxaluria and kidney stones in patients through the crystallisation of calcium oxalate in patients who are prone to forming calcium stones. \u003ci\u003e \u003cu\u003eInterference with some laboratory tests\u003c\/u\u003e \u003c\/i\u003e The administration of paracetamol can interfere with the determination of uric acid (using the phosphotungstic acid method) and with that of blood sugar (using the glucose-oxidase-peroxidase method). Ascorbic acid can interfere in the measurement of blood and urinary parameters (e.g. urate, glucose, bilirubin, hemoglobin).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eBelow are the side effects organized according to the MedDRA System Organ classification. The frequency is defined as follows: very common (≥1\/10), common (≥1\/100 to \u003c1\/10), uncommon (≥1\/1000 to \u003c1\/100), rare (≥1\/10,000 to \u003c1\/1000), very rare (\u003c1\/10,000), not known (cannot be estimated from the available data).\u003c\/p\u003e\n\u003cp\u003ePathologies of the blood and lymphatic system.\u003c\/p\u003e\n\u003cp\u003eRare - Side effect: Agranulocytosis¹, leukopenia¹, thrombocytopenia¹\u003c\/p\u003e\n\u003cp\u003eNot known - Side effect: Anemia¹\u003c\/p\u003e\n\u003cp\u003eImmune system disorders.\u003c\/p\u003e\n\u003cp\u003eRare - Side effect: Allergic reactions1,2, hypersensitivity reactions1,2, anaphylaxis1,2.\u003c\/p\u003e\n\u003cp\u003eNot known - Side effect: Anaphylactic shock1,2.\u003c\/p\u003e\n\u003cp\u003eMetabolism and nutrition disorders.\u003c\/p\u003e\n\u003cp\u003eCommon - Side effect: Anorexia²\u003c\/p\u003e\n\u003cp\u003ePsychiatric disorders.\u003c\/p\u003e\n\u003cp\u003eVery rare - Side effect: Insomnia², nervousness², anxiety², restlessness², confusion², irritability²\u003c\/p\u003e\n\u003cp\u003eNervous system disorders.\u003c\/p\u003e\n\u003cp\u003eVery rare - Side effect: Tremor², dizziness², headache²\u003c\/p\u003e\n\u003cp\u003eEye pathologies.\u003c\/p\u003e\n\u003cp\u003eNot known - Side effect: Mydriasis², acute angle-closure glaucoma²\u003c\/p\u003e\n\u003cp\u003eCardiac diseases.\u003c\/p\u003e\n\u003cp\u003eRare - Side effect: Tachycardia², palpitations²\u003c\/p\u003e\n\u003cp\u003eVascular pathologies.\u003c\/p\u003e\n\u003cp\u003eNot known - Side effect: Hypertension²\u003c\/p\u003e\n\u003cp\u003eRespiratory, thoracic and mediastinal disorders.\u003c\/p\u003e\n\u003cp\u003eRare - Side effect: Bronchospasm1,2.\u003c\/p\u003e\n\u003cp\u003eNot known - Side effect: Edema of the larynx¹\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders.\u003c\/p\u003e\n\u003cp\u003eCommon - Side effect: Nausea², vomiting²\u003c\/p\u003e\n\u003cp\u003eNot known - Side effect: Diarrhoea¹, gastrointestinal pathology¹\u003c\/p\u003e\n\u003cp\u003eHepatobiliary disorders.\u003c\/p\u003e\n\u003cp\u003eRare - Side effect: Abnormal liver function¹\u003c\/p\u003e\n\u003cp\u003eNot known - Side effect: Liver disease¹, hepatitis¹\u003c\/p\u003e\n\u003cp\u003ePathologies of the skin and subcutaneous tissue.\u003c\/p\u003e\n\u003cp\u003eRare - Side effect: Skin rash1,2, angioedema²\u003c\/p\u003e\n\u003cp\u003eNot known - Side effect: Toxic epidermal necrolysis¹, Steven Johnson Syndrome¹, erythema multiforme or polymorph¹\u003c\/p\u003e\n\u003cp\u003eKidney and urinary disorders.\u003c\/p\u003e\n\u003cp\u003eVery rare - Side effect: Tubulointerstitial nephritis (after prolonged use of paracetamol at high doses)¹\u003c\/p\u003e\n\u003cp\u003eNot known - Side effect: Aggravated renal failure¹, haematuria¹, anuria¹ urine retention²\u003c\/p\u003e\n\u003cp\u003eVery rare cases of serious skin reactions have been reported. ¹ Side effects associated with paracetamol ² Side effects associated with phenylephrine \u003cu\u003eReporting of suspected adverse reactions\u003c\/u\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system to the site \u003cb\u003ehttps:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse\u003c\/b\u003e.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eParacetamol\u003c\/i\u003e At the recommended doses, or even if you were to take the entire pack, no symptoms of paracetamol overdose should appear. However, in case of ingestion of very high doses of paracetamol (greater than 10 g), the most commonly encountered complication is liver damage, which typically occurs 12-48 hours after ingestion. \u003cu\u003eRisk factors\u003c\/u\u003e a. Long-term treatment with carbamazepine, phenobarbital, phenytoin, primidone, rifampicin, St. John's wort or other liver enzyme-inducing drugs; b. regular consumption of ethanol in quantities higher than recommended; c. glutathione depletion (e.g. eating disorders, cystic fibrosis, HIV infection, starvation, cachexia). \u003cu\u003eSymptoms\u003c\/u\u003e Early symptoms of paracetamol overdose in the first 24 hours are paleness, nausea, vomiting, anorexia and abdominal pain. Abnormalities of glucose metabolism and metabolic acidosis may occur. In severe poisoning, liver failure may progress to encephalopathy, hemorrhage, hypoglycemia, brain edema, and death. Even in the absence of severe liver damage, acute renal failure with acute tubular necrosis, strongly suggested by flank pain, hematuria, and proteinuria can develop, even in the absence of severe liver damage. Cardiac arrhythmias and pancreatitis have been reported. \u003cu\u003eTreatment\u003c\/u\u003e In the management of paracetamol overdose, immediate treatment is essential. Despite a lack of significant initial symptoms, patients should be referred to hospital urgently for immediate medical attention. Symptoms may be limited to nausea or vomiting and may not reflect the severity of the overdose or the risk of organ damage. Management must be in accordance with treatment guidelines. If overdose has occurred within 1 hour, treatment with activated charcoal should be considered. Paracetamol plasma concentration should be measured 4 or more hours after ingestion (initial concentrations are not reliable). Treatment with N-acetylcysteine ​​can be used up to 24 hours after ingestion of paracetamol, however, the maximum protective effect is achieved up to 8 hours after ingestion. The effectiveness of the antidote declines sharply after this period. If necessary, the patient should be administered N-acetylcysteine ​​intravenously, in line with the established dosing regimen. If vomiting is not a problem, oral methionine may be a suitable alternative in more remote areas, outside of hospital. Management of patients who present with severe hepatic dysfunction more than 24 hours after ingestion should be discussed with the National Poison Control Center or liver unit. \u003ci\u003ePhenylephrine\u003c\/i\u003e \u003cu\u003eSymptoms\u003c\/u\u003e Symptoms of overdose caused by phenylephrine are irritability, headache and increased blood pressure. In more serious cases, confusion, hallucinations, convulsions and arrhythmias may occur. However, the amount needed to produce severe phenylephrine toxicity would be greater than that related to acetaminophen. \u003cu\u003eTreatment\u003c\/u\u003e Treatment must be clinically appropriate. Severe hypertension should be treated with alpha blocker drugs such as phentolamine. \u003ci\u003eAscorbic acid\u003c\/i\u003e \u003cu\u003eSymptoms\u003c\/u\u003e High doses of ascorbic acid (\u003e3000mg) may cause transient osmotic diarrhea and gastrointestinal effects such as nausea and abdominal discomfort. The effects of ascorbic acid overdose may be hidden by the severe liver toxicity caused by acetaminophen overdose. \u003cu\u003eTreatment\u003c\/u\u003e Treatment must be clinically appropriate.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003ePREGNANCY \u003ci\u003e \u003cu\u003eParacetamol\u003c\/u\u003e \u003c\/i\u003e A large amount of data on pregnant women indicates neither malformation nor fetal\/neonatal toxicity. Epidemiological studies on neurodevelopment in children exposed to paracetamol in utero show inconclusive results. If clinically necessary, paracetamol can be used during pregnancy, however it should be used at the lowest effective dose for the shortest possible time and with the lowest possible frequency. Epidemiological studies in pregnant women have shown that there are no contraindications in the use of paracetamol when used in the recommended doses, but the administration of the preparation during pregnancy and breastfeeding must take place under the direct supervision of a doctor. \u003ci\u003e \u003cu\u003ePhenylephrine\u003c\/u\u003e \u003c\/i\u003e Data regarding the use of phenylephrine in pregnancy are limited. Vasoconstriction of the uterine vessels and reduction of blood flow to the uterus associated with the use of phenylephrine may result in fetal hypoxia. The use of phenylephrine during pregnancy should be avoided as further information is needed. \u003ci\u003e \u003cu\u003eAscorbic acid\u003c\/u\u003e \u003c\/i\u003e There are no controlled data relating to use during pregnancy. The use of ascorbic acid during pregnancy is recommended only when the benefit outweighs the risk. BREASTFEEDING \u003ci\u003e \u003cu\u003eParacetamol \u003c\/u\u003e \u003c\/i\u003e Paracetamol is excreted in breast milk but in clinically insignificant quantities. The available published data do not contraindicate its use during breastfeeding. \u003ci\u003e \u003cu\u003ePhenylephrine\u003c\/u\u003e \u003c\/i\u003e No data are available regarding the excretion of phenylephrine in breast milk, nor is there information regarding the effects of phenylephrine on breast-fed infants. In the absence of available data, the use of phenylephrine should be avoided during breastfeeding. \u003ci\u003e \u003cu\u003eAscorbic acid\u003c\/u\u003e \u003c\/i\u003e Ascorbic acid is excreted in breast milk. The effects on breast-fed infants are not known. In summary, the use of TACHIFLUDEC is not recommended during pregnancy and breastfeeding. FERTILITY There is no evidence in non-clinical studies to indicate effects of paracetamol on male and female fertility at commonly used clinical doses. The effect of phenylephrine on male and female fertility has not been studied. There is sufficient evidence indicating the importance of ascorbic acid at different levels in the reproductive process. However, no definitive human data on the clinical potential of vitamin C are available.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eTACHIFLUDEC does not affect the ability to drive or use machines. However, patients should be advised not to drive or operate machines if they feel dizzy.\u003c\/p\u003e","brand":"Angelini","offers":[{"title":"Default Title","offer_id":40207824814195,"sku":"034358010","price":9.21,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/products\/angelini-spa-tachifludec-limone-polvere-10-bustine-farmacia-dottor-tili-1213792728.webp?v=1767127487"},{"product_id":"tachifludec-limone-e-miele-polvere-10-bustine","title":"Tachifludec Lemon and Honey Powder 10 Sachets","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eShort-term treatment of cold and flu symptoms, including mild\/moderate pain and fever, when associated with nasal congestion.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eEach sachet contains: \u003cu\u003eactive ingredients:\u003c\/u\u003e paracetamol 600 mg, ascorbic acid 40 mg and phenylephrine hydrochloride 10 mg (equal to phenylephrine 8.2 mg). \u003cu\u003eExcipients with known effects:\u003c\/u\u003e \u003cu\u003eTACHIFLUDEC lemon flavor contains:\u003c\/u\u003e 1,817 g of \u003cb\u003esucrose\u003c\/b\u003e, 112.86 mg of \u003cb\u003esodium\u003c\/b\u003e, 6.65 mg of \u003cb\u003eglucose\u003c\/b\u003e. \u003cu\u003eTACHIFLUDEC lemon and honey flavor contains:\u003c\/u\u003e 1,892g of \u003cb\u003esucrose\u003c\/b\u003e, 135.79 mg of \u003cb\u003esodium\u003c\/b\u003e. For the full list of excipients, see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e- TACHIFLUDEC powder for oral solution lemon flavour: \u003cb\u003esucrose\u003c\/b\u003e, anhydrous citric acid, \u003cb\u003esodium\u003c\/b\u003e citrate, corn starch, \u003cb\u003esodium\u003c\/b\u003e cyclamate, saccharin \u003cb\u003esodium\u003c\/b\u003e, anhydrous colloidal silica, lemon flavouring, curcumin (E100), syrup \u003cb\u003eglucose\u003c\/b\u003e dried. - TACHIFLUDEC powder for oral solution lemon and honey flavour: \u003cb\u003esucrose\u003c\/b\u003e, anhydrous citric acid, \u003cb\u003esodium\u003c\/b\u003e citrate, corn starch, \u003cb\u003esodium\u003c\/b\u003e cyclamate, saccharin \u003cb\u003esodium\u003c\/b\u003e, lemon flavouring, honey flavouring, caramel (E150), colloidal anhydrous silica.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e- Children under the age of 12. - Hypersensitivity to the active substances or to any of the excipients (listed in paragraph 6.1). - Patients taking beta-blockers. - Patients taking tricyclic antidepressants and those taking or have taken in the last 2 weeks monoamine oxidase inhibitors. - Patients with bronchial asthma, pheochromocytoma, narrow-angle glaucoma, or who simultaneously take other sympathetic mimetic medicinal products (such as decongestants, appetite suppressants and amphetamine-like psychostimulants). - Patients suffering from liver or kidney failure, diabetes, hyperthyroidism, hypertension and cardiovascular diseases. - Paracetamol-based products are contraindicated in patients with manifest glucose-6-phosphate dehydrogenase insufficiency and in those suffering from severe hemolytic anemia. - Severe hepatocellular insufficiency.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eDosage\u003c\/u\u003e \u003cu\u003eAdults and children over 12 years old\u003c\/u\u003e: 1 sachet every 4-6 hours and up to a maximum of 3 sachets in 24 hours. The medicine should not be used for more than 3 consecutive days without consulting your doctor. \u003ci\u003ePediatric population\u003c\/i\u003e \u003cu\u003eChildren under 12 years:\u003c\/u\u003e TACHIFLUDEC lemon, lemon and honey flavor is contraindicated in children under 12 years of age (see section 4.3). \u003cu\u003eMethod of administration\u003c\/u\u003e Dissolve the contents of 1 sachet in half a glass of very hot water and, to taste, dilute with cold water to cool and sweeten as desired.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eStore below 25°C. Store in the original container to protect the medicine from moisture and light.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003ePatients should be advised not to take other medicines containing paracetamol while taking TACHIFLUDEC as high doses of paracetamol may cause serious adverse reactions. Avoid alcohol consumption during treatment with TACHIFLUDEC. The danger of overdose is in fact greater in patients with liver problems. Invite the patient to contact the doctor before combining warfarin or any other drug (see also section 4.5). The use of the product is not recommended if the patient is being treated with anti-inflammatories. Caution is advised if acetaminophen is administered concurrently with flucloxacillin due to the increased risk of high anion gap metabolic acidosis (HAGMA), particularly in patients with severe renal impairment, sepsis, malnutrition, and other sources of glutathione deficiency (e.g., chronic alcoholism), as well as in those using maximum daily doses of acetaminophen. Close monitoring, including measurement of urinary 5-oxoproline, is recommended. Consult your doctor before using the product in patients with enlarged prostate gland or occlusive vascular disease (e.g. Raynaud's syndrome). Do not exceed the recommended dose and do not administer for more than 3 consecutive days. TACHIFLUDEC lemon flavor contains: - \u003cb\u003esodium\u003c\/b\u003e: This medicinal product contains 112.86 mg sodium per sachet equivalent to 5.64% of the maximum daily intake recommended by WHO which corresponds to 2 g sodium for an adult, to be taken into consideration in patients with reduced renal function or following a low-sodium diet. - \u003cb\u003esucrose:\u003c\/b\u003e Patients suffering from rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase isomaltase insufficiency should not take this medicine. Patients with diabetes must take into consideration the sucrose content within TACHIFLUDEC when taking more than 2 sachets per day (sucrose \u003e 5g). - \u003cb\u003eglucose:\u003c\/b\u003e Patients suffering from rare problems of glucose-galactose malabsorption should not take this medicine. TACHIFLUDEC lemon and honey flavor contains: - \u003cb\u003esodium:\u003c\/b\u003e 135.79 mg of sodium per sachet equivalent to 6.79% of the maximum daily intake recommended by WHO which corresponds to 2 g of sodium for an adult, to be taken into consideration in patients with reduced renal function or who follow a low-sodium diet. - \u003cb\u003esucrose:\u003c\/b\u003e Patients suffering from rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase isomaltase insufficiency should not take this medicine. The sucrose content within TACHIFLUDEC is to be taken into consideration in people suffering from diabetes mellitus if they take more than 2 sachets per day (sucrose \u003e 5g).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003e \u003cu\u003eParacetamol\u003c\/u\u003e \u003c\/i\u003e The hepatotoxic effect of paracetamol can be potentiated by the intake of other drugs active on the liver such as zidovudine and isoniazid which can produce an inhibition of the metabolism of paracetamol. The administration of probenecid before paracetamol decreases the clearance of paracetamol and the urinary elimination of paracetamol sulphate and paracetamol-glucuronide, and increases the half-life of paracetamol itself. Use with extreme caution and under strict control during chronic treatment with drugs that can cause the induction of hepatic monooxygenases or in case of exposure to substances that can have this effect (for example rifampicin, cimetidine, antiepileptics such as glutetimide, phenobarbital, carbamazepine). Paracetamol increases the half-life of chloramphenicol. The product taken in high doses can enhance the effect of coumarin anticoagulants (warfarin). Metoclopramide and domperidone can increase the absorption of paracetamol, while it is reduced or delayed by cholestyramine and anticholinergics, respectively. Caution should be exercised when paracetamol is used concomitantly with flucloxacillin as concomitant use has been associated with high anion gap metabolic acidosis, especially in patients with risk factors (see section 4.4). \u003ci\u003e \u003cu\u003ePhenylephrine\u003c\/u\u003e \u003c\/i\u003e Phenylephrine can antagonize the effect of beta-blocking and antihypertensive drugs (including debrisoquine, guanethidine, reserpine and methyldopa) and can potentiate the action of monoamine oxidase inhibitors (see section 4.3). The simultaneous use of phenylephrine with tricyclic antidepressants or sympathetic mimetic amines may increase the risk of cardiovascular effects. Phenylephrine can interact with digoxin and cardiac glycosides, increasing the risk of arrhythmia or heart attack, and with alkaloids (ergotamine and methylsergide), increasing the risk of ergotism. \u003ci\u003e \u003cu\u003eAscorbic acid\u003c\/u\u003e \u003c\/i\u003e Ascorbic acid can increase the absorption of iron and estrogen. Ascorbic acid is metabolised to oxalate, and can potentially cause hyperoxaluria and kidney stones in patients through the crystallisation of calcium oxalate in patients who are prone to forming calcium stones. \u003ci\u003e \u003cu\u003eInterference with some laboratory tests\u003c\/u\u003e \u003c\/i\u003e The administration of paracetamol can interfere with the determination of uric acid (using the phosphotungstic acid method) and with that of blood sugar (using the glucose-oxidase-peroxidase method). Ascorbic acid can interfere in the measurement of blood and urinary parameters (e.g. urate, glucose, bilirubin, hemoglobin).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eBelow are the side effects organized according to the MedDRA System Organ classification. The frequency is defined as follows: very common (≥1\/10), common (≥1\/100 to \u003c1\/10), uncommon (≥1\/1000 to \u003c1\/100), rare (≥1\/10,000 to \u003c1\/1000), very rare (\u003c1\/10,000), not known (cannot be estimated from the available data).\u003c\/p\u003e\n\u003cp\u003ePathologies of the blood and lymphatic system.\u003c\/p\u003e\n\u003cp\u003eRare - Side effect: Agranulocytosis¹, leukopenia¹, thrombocytopenia¹\u003c\/p\u003e\n\u003cp\u003eNot known - Side effect: Anemia¹\u003c\/p\u003e\n\u003cp\u003eImmune system disorders.\u003c\/p\u003e\n\u003cp\u003eRare - Side effect: Allergic reactions1,2, hypersensitivity reactions1,2, anaphylaxis1,2.\u003c\/p\u003e\n\u003cp\u003eNot known - Side effect: Anaphylactic shock1,2.\u003c\/p\u003e\n\u003cp\u003eMetabolism and nutrition disorders.\u003c\/p\u003e\n\u003cp\u003eCommon - Side effect: Anorexia²\u003c\/p\u003e\n\u003cp\u003ePsychiatric disorders.\u003c\/p\u003e\n\u003cp\u003eVery rare - Side effect: Insomnia², nervousness², anxiety², restlessness², confusion², irritability²\u003c\/p\u003e\n\u003cp\u003eNervous system disorders.\u003c\/p\u003e\n\u003cp\u003eVery rare - Side effect: Tremor², dizziness², headache²\u003c\/p\u003e\n\u003cp\u003eEye pathologies.\u003c\/p\u003e\n\u003cp\u003eNot known - Side effect: Mydriasis², acute angle-closure glaucoma²\u003c\/p\u003e\n\u003cp\u003eCardiac diseases.\u003c\/p\u003e\n\u003cp\u003eRare - Side effect: Tachycardia², palpitations²\u003c\/p\u003e\n\u003cp\u003eVascular pathologies.\u003c\/p\u003e\n\u003cp\u003eNot known - Side effect: Hypertension²\u003c\/p\u003e\n\u003cp\u003eRespiratory, thoracic and mediastinal disorders.\u003c\/p\u003e\n\u003cp\u003eRare - Side effect: Bronchospasm1,2.\u003c\/p\u003e\n\u003cp\u003eNot known - Side effect: Edema of the larynx¹\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders.\u003c\/p\u003e\n\u003cp\u003eCommon - Side effect: Nausea², vomiting²\u003c\/p\u003e\n\u003cp\u003eNot known - Side effect: Diarrhoea¹, gastrointestinal pathology¹\u003c\/p\u003e\n\u003cp\u003eHepatobiliary disorders.\u003c\/p\u003e\n\u003cp\u003eRare - Side effect: Abnormal liver function¹\u003c\/p\u003e\n\u003cp\u003eNot known - Side effect: Liver disease¹, hepatitis¹\u003c\/p\u003e\n\u003cp\u003ePathologies of the skin and subcutaneous tissue.\u003c\/p\u003e\n\u003cp\u003eRare - Side effect: Skin rash1,2, angioedema²\u003c\/p\u003e\n\u003cp\u003eNot known - Side effect: Toxic epidermal necrolysis¹, Steven Johnson Syndrome¹, erythema multiforme or polymorph¹\u003c\/p\u003e\n\u003cp\u003eKidney and urinary disorders.\u003c\/p\u003e\n\u003cp\u003eVery rare - Side effect: Tubulointerstitial nephritis (after prolonged use of paracetamol at high doses)¹\u003c\/p\u003e\n\u003cp\u003eNot known - Side effect: Aggravated renal failure¹, haematuria¹, anuria¹ urine retention²\u003c\/p\u003e\n\u003cp\u003eVery rare cases of serious skin reactions have been reported. ¹ Side effects associated with paracetamol ² Side effects associated with phenylephrine \u003cu\u003eReporting of suspected adverse reactions\u003c\/u\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system to the site \u003cb\u003ehttps:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse\u003c\/b\u003e.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eParacetamol\u003c\/i\u003e At the recommended doses, or even if you were to take the entire pack, no symptoms of paracetamol overdose should appear. However, in case of ingestion of very high doses of paracetamol (greater than 10 g), the most commonly encountered complication is liver damage, which typically occurs 12-48 hours after ingestion. \u003cu\u003eRisk factors\u003c\/u\u003e a. Long-term treatment with carbamazepine, phenobarbital, phenytoin, primidone, rifampicin, St. John's wort or other liver enzyme-inducing drugs; b. regular consumption of ethanol in quantities higher than recommended; c. glutathione depletion (e.g. eating disorders, cystic fibrosis, HIV infection, starvation, cachexia). \u003cu\u003eSymptoms\u003c\/u\u003e Early symptoms of paracetamol overdose in the first 24 hours are paleness, nausea, vomiting, anorexia and abdominal pain. Abnormalities of glucose metabolism and metabolic acidosis may occur. In severe poisoning, liver failure may progress to encephalopathy, hemorrhage, hypoglycemia, brain edema, and death. Even in the absence of severe liver damage, acute renal failure with acute tubular necrosis, strongly suggested by flank pain, hematuria, and proteinuria can develop, even in the absence of severe liver damage. Cardiac arrhythmias and pancreatitis have been reported. \u003cu\u003eTreatment\u003c\/u\u003e In the management of paracetamol overdose, immediate treatment is essential. Despite a lack of significant initial symptoms, patients should be referred to hospital urgently for immediate medical attention. Symptoms may be limited to nausea or vomiting and may not reflect the severity of the overdose or the risk of organ damage. Management must be in accordance with treatment guidelines. If overdose has occurred within 1 hour, treatment with activated charcoal should be considered. Paracetamol plasma concentration should be measured 4 or more hours after ingestion (initial concentrations are not reliable). Treatment with N-acetylcysteine ​​can be used up to 24 hours after ingestion of paracetamol, however, the maximum protective effect is achieved up to 8 hours after ingestion. The effectiveness of the antidote declines sharply after this period. If necessary, the patient should be administered N-acetylcysteine ​​intravenously, in line with the established dosing regimen. If vomiting is not a problem, oral methionine may be a suitable alternative in more remote areas, outside of hospital. Management of patients who present with severe hepatic dysfunction more than 24 hours after ingestion should be discussed with the National Poison Control Center or liver unit. \u003ci\u003ePhenylephrine\u003c\/i\u003e \u003cu\u003eSymptoms\u003c\/u\u003e Symptoms of overdose caused by phenylephrine are irritability, headache and increased blood pressure. In more serious cases, confusion, hallucinations, convulsions and arrhythmias may occur. However, the amount needed to produce severe phenylephrine toxicity would be greater than that related to acetaminophen. \u003cu\u003eTreatment\u003c\/u\u003e Treatment must be clinically appropriate. Severe hypertension should be treated with alpha blocker drugs such as phentolamine. \u003ci\u003eAscorbic acid\u003c\/i\u003e \u003cu\u003eSymptoms\u003c\/u\u003e High doses of ascorbic acid (\u003e3000mg) may cause transient osmotic diarrhea and gastrointestinal effects such as nausea and abdominal discomfort. The effects of ascorbic acid overdose may be hidden by the severe liver toxicity caused by acetaminophen overdose. \u003cu\u003eTreatment\u003c\/u\u003e Treatment must be clinically appropriate.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003ePREGNANCY \u003ci\u003e \u003cu\u003eParacetamol\u003c\/u\u003e \u003c\/i\u003e A large amount of data on pregnant women indicates neither malformation nor fetal\/neonatal toxicity. Epidemiological studies on neurodevelopment in children exposed to paracetamol in utero show inconclusive results. If clinically necessary, paracetamol can be used during pregnancy, however it should be used at the lowest effective dose for the shortest possible time and with the lowest possible frequency. Epidemiological studies in pregnant women have shown that there are no contraindications in the use of paracetamol when used in the recommended doses, but the administration of the preparation during pregnancy and breastfeeding must take place under the direct supervision of a doctor. \u003ci\u003e \u003cu\u003ePhenylephrine\u003c\/u\u003e \u003c\/i\u003e Data regarding the use of phenylephrine in pregnancy are limited. Vasoconstriction of the uterine vessels and reduction of blood flow to the uterus associated with the use of phenylephrine may result in fetal hypoxia. The use of phenylephrine during pregnancy should be avoided as further information is needed. \u003ci\u003e \u003cu\u003eAscorbic acid\u003c\/u\u003e \u003c\/i\u003e There are no controlled data relating to use during pregnancy. The use of ascorbic acid during pregnancy is recommended only when the benefit outweighs the risk. BREASTFEEDING \u003ci\u003e \u003cu\u003eParacetamol \u003c\/u\u003e \u003c\/i\u003e Paracetamol is excreted in breast milk but in clinically insignificant quantities. The available published data do not contraindicate its use during breastfeeding. \u003ci\u003e \u003cu\u003ePhenylephrine\u003c\/u\u003e \u003c\/i\u003e No data are available regarding the excretion of phenylephrine in breast milk, nor is there information regarding the effects of phenylephrine on breast-fed infants. In the absence of available data, the use of phenylephrine should be avoided during breastfeeding. \u003ci\u003e \u003cu\u003eAscorbic acid\u003c\/u\u003e \u003c\/i\u003e Ascorbic acid is excreted in breast milk. The effects on breast-fed infants are not known. In summary, the use of TACHIFLUDEC is not recommended during pregnancy and breastfeeding. FERTILITY There is no evidence in non-clinical studies to indicate effects of paracetamol on male and female fertility at commonly used clinical doses. The effect of phenylephrine on male and female fertility has not been studied. There is sufficient evidence indicating the importance of ascorbic acid at different levels in the reproductive process. However, no definitive human data on the clinical potential of vitamin C are available.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eTACHIFLUDEC does not affect the ability to drive or use machines. However, patients should be advised not to drive or operate machines if they feel dizzy.\u003c\/p\u003e","brand":"Angelini","offers":[{"title":"Default Title","offer_id":40207824879731,"sku":"034358022","price":9.21,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/products\/angelini-spa-tachifludec-limone-e-miele-polvere-10-bustine-farmacia-dottor-tili-1213792714.jpg?v=1767127548"},{"product_id":"tachifludec-arancia-polvere-10-bustine","title":"Tachifludec Orange Powder 10 Sachets","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eShort-term treatment of cold and flu symptoms, including mild\/moderate pain and fever, when associated with nasal congestion.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eEach sachet contains: \u003cu\u003eactive ingredients:\u003c\/u\u003e paracetamol 600 mg, ascorbic acid 40 mg and phenylephrine hydrochloride 10 mg (equal to phenylephrine 8.2 mg). \u003cu\u003eExcipients with known effects\u003c\/u\u003e: 2 g of \u003cb\u003esucrose\u003c\/b\u003e; 135.82 mg of \u003cb\u003esodium\u003c\/b\u003e; 33.25 mg of \u003cb\u003eglucose\u003c\/b\u003e. For the complete list of excipients see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eSucrose\u003c\/b\u003e, anhydrous citric acid, \u003cb\u003esodium\u003c\/b\u003e citrate, corn starch, \u003cb\u003esodium\u003c\/b\u003e cyclamate, saccharin \u003cb\u003esodium\u003c\/b\u003e, colloidal anhydrous silica, blood orange flavour, curcumin (E100), syrup \u003cb\u003eglucose\u003c\/b\u003e dried.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e- Children under the age of 12. - Hypersensitivity to the active substances or to any of the excipients (listed in paragraph 6.1). - Patients taking beta-blockers. - Patients taking tricyclic antidepressants and those taking or have taken in the last 2 weeks monoamine oxidase inhibitors. - Patients with bronchial asthma, pheochromocytoma, narrow-angle glaucoma, or who simultaneously take other sympathetic mimetic medicinal products (such as decongestants, appetite suppressants and amphetamine-like psychostimulants). - Patients suffering from liver or kidney failure, diabetes, hyperthyroidism, hypertension and cardiovascular diseases. - Paracetamol-based products are contraindicated in patients with manifest glucose-6-phosphate dehydrogenase insufficiency and in those suffering from severe hemolytic anemia. - Severe hepatocellular insufficiency.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eDosage\u003c\/u\u003e \u003cu\u003eAdults and children over 12 years:\u003c\/u\u003e 1 sachet every 4-6 hours and up to a maximum of 3 sachets in 24 hours. The medicine should not be used for more than 3 consecutive days without consulting your doctor. \u003ci\u003ePediatric population\u003c\/i\u003e Children under 12 years: TACHIFLUDEC orange flavor is contraindicated in children under 12 years of age (see section 4.3). \u003cu\u003eMethod of administration\u003c\/u\u003e Dissolve the contents of a sachet in a glass of hot or cold water and sweeten to taste. Once dissolved, the medicine gives rise to a yellow opalescent solution, free of foreign particles and with an orange flavour.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eStore below 25°C. Store in the original container to protect the medicine from moisture and light.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003ePatients should be advised not to take other medicines containing paracetamol while taking TACHIFLUDEC as high doses of paracetamol may cause serious adverse reactions. Avoid alcohol consumption during treatment with TACHIFLUDEC. The danger of overdose is in fact greater in patients with liver problems. Invite the patient to contact the doctor before combining warfarin or any other drug (see also section 4.5). The use of the product is not recommended if the patient is being treated with anti-inflammatories. Caution is advised if acetaminophen is administered concurrently with flucloxacillin due to the increased risk of high anion gap metabolic acidosis (HAGMA), particularly in patients with severe renal impairment, sepsis, malnutrition, and other sources of glutathione deficiency (e.g., chronic alcoholism), as well as in those using maximum daily doses of acetaminophen. Close monitoring, including measurement of urinary 5-oxoproline, is recommended. Consult your doctor before using the product in patients with enlarged prostate gland or occlusive vascular disease (e.g. Raynaud's syndrome). Do not exceed the recommended dose and do not administer for more than 3 consecutive days. TACHIFLUDEC orange flavor contains: - \u003cb\u003esodium:\u003c\/b\u003e This medicine contains 135.82 mg sodium per sachet, equivalent to 6.79% of the maximum daily intake recommended by WHO which corresponds to 2 g sodium for an adult, to be taken into consideration in patients with reduced renal function or following a low-sodium diet. - \u003cb\u003esucrose:\u003c\/b\u003e Patients suffering from rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase isomaltase insufficiency should not take this medicine. Patients with diabetes must take into consideration the sucrose content within TACHIFLUDEC when taking more than 2 sachets per day (sucrose \u003e 5g). - \u003cb\u003eglucose:\u003c\/b\u003e Patients suffering from rare problems of glucose-galactose malabsorption should not take this medicine.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003e \u003cu\u003eParacetamol\u003c\/u\u003e \u003c\/i\u003e The hepatotoxic effect of paracetamol can be potentiated by the intake of other drugs active on the liver, such as zidovudine and isoniazid which can produce an inhibition of the metabolism of paracetamol. The administration of probenecid before paracetamol decreases the clearance of paracetamol and the urinary elimination of paracetamol sulphate and paracetamol-glucuronide, and increases the half-life of paracetamol itself. Use with extreme caution and under strict control during chronic treatment with drugs that can cause the induction of hepatic monooxygenases or in case of exposure to substances that can have this effect (for example rifampicin, cimetidine, antiepileptics such as glutetimide, phenobarbital, carbamazepine). Paracetamol increases the half-life of chloramphenicol. The product taken in high doses can enhance the effect of coumarin anticoagulants (warfarin). Metoclopramide and domperidone can increase the absorption of paracetamol, while it is reduced or delayed by cholestyramine and anticholinergics, respectively. Caution should be exercised when paracetamol is used concomitantly with flucloxacillin as concomitant use has been associated with high anion gap metabolic acidosis, especially in patients with risk factors (see section 4.4). \u003ci\u003e \u003cu\u003ePhenylephrine\u003c\/u\u003e \u003c\/i\u003e Phenylephrine can antagonize the effect of beta-blocking and antihypertensive drugs (including debrisoquine, guanethidine, reserpine and methyldopa) and can potentiate the action of monoamine oxidase inhibitors (see section 4.3). The simultaneous use of phenylephrine with tricyclic antidepressants or sympathetic mimetic amines may increase the risk of cardiovascular effects. Phenylephrine can interact with digoxin and cardiac glycosides, increasing the risk of arrhythmia or heart attack, and with alkaloids (ergotamine and methylsergide), increasing the risk of ergotism. \u003ci\u003e \u003cu\u003eAscorbic acid\u003c\/u\u003e \u003c\/i\u003e Ascorbic acid can increase the absorption of iron and estrogen. Ascorbic acid is metabolised to oxalate, and can potentially cause hyperoxaluria and kidney stones in patients through the crystallisation of calcium oxalate in patients who are prone to forming calcium stones. \u003ci\u003e \u003cu\u003eInterference with some laboratory tests\u003c\/u\u003e \u003c\/i\u003e The administration of paracetamol can interfere with the determination of uric acid (using the phosphotungstic acid method) and with that of blood sugar (using the glucose-oxidase-peroxidase method). Ascorbic acid can interfere in the measurement of blood and urinary parameters (e.g. urate, glucose, bilirubin, hemoglobin).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe following are the side effects organized according to the MedDRA System Organ classification. The frequency is defined as follows: very common (≥1\/10), common (≥1\/100 to \u003c1\/10), uncommon (≥1\/1000 to \u003c1\/100), rare (≥1\/10,000 to \u003c1\/1000), very rare (\u003c1\/10,000), not known (cannot be estimated from the available data).\u003c\/p\u003e\n\u003cp\u003ePathologies of the blood and lymphatic system.\u003c\/p\u003e\n\u003cp\u003eRare - Side effect: Agranulocytosis¹, leukopenia¹, thrombocytopenia¹\u003c\/p\u003e\n\u003cp\u003eNot known - Side effect: Anemia¹\u003c\/p\u003e\n\u003cp\u003eImmune system disorders.\u003c\/p\u003e\n\u003cp\u003eRare - Side effect: Allergic reactions1,2, hypersensitivity reactions1,2, anaphylaxis1,2.\u003c\/p\u003e\n\u003cp\u003eNot known - Side effect: Anaphylactic shock1, 2.\u003c\/p\u003e\n\u003cp\u003eMetabolism and nutrition disorders.\u003c\/p\u003e\n\u003cp\u003eCommon - Side effect: Anorexia²\u003c\/p\u003e\n\u003cp\u003ePsychiatric disorders.\u003c\/p\u003e\n\u003cp\u003eVery rare - Side effect: Insomnia², nervousness², anxiety², restlessness², confusion², irritability²\u003c\/p\u003e\n\u003cp\u003eNervous system disorders.\u003c\/p\u003e\n\u003cp\u003eVery rare - Side effect: Tremor², dizziness², headache²\u003c\/p\u003e\n\u003cp\u003eEye pathologies.\u003c\/p\u003e\n\u003cp\u003eNot known - Side effect: Mydriasis², acute angle-closure glaucoma²\u003c\/p\u003e\n\u003cp\u003eCardiac diseases.\u003c\/p\u003e\n\u003cp\u003eRare - Side effect: Tachycardia², palpitations²\u003c\/p\u003e\n\u003cp\u003eVascular pathologies.\u003c\/p\u003e\n\u003cp\u003eNot known - Side effect: Hypertension²\u003c\/p\u003e\n\u003cp\u003eRespiratory, thoracic and mediastinal disorders.\u003c\/p\u003e\n\u003cp\u003eRare - Side effect: Bronchospasm1,2.\u003c\/p\u003e\n\u003cp\u003eNot known - Side effect: Edema of the larynx¹\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders.\u003c\/p\u003e\n\u003cp\u003eCommon - Side effect: Nausea², vomiting²\u003c\/p\u003e\n\u003cp\u003eNot known - Side effect: Diarrhoea¹, gastrointestinal pathology¹\u003c\/p\u003e\n\u003cp\u003eHepatobiliary disorders.\u003c\/p\u003e\n\u003cp\u003eRare - Side effect: Abnormal liver function¹\u003c\/p\u003e\n\u003cp\u003eNot known - Side effect: Liver disease¹, hepatitis¹\u003c\/p\u003e\n\u003cp\u003ePathologies of the skin and subcutaneous tissue.\u003c\/p\u003e\n\u003cp\u003eRare - Side effect: Skin rash1,2, angioedema²\u003c\/p\u003e\n\u003cp\u003eNot known - Side effect: Toxic epidermal necrolysis¹, Steven Johnson Syndrome¹, erythema multiforme or polymorph¹\u003c\/p\u003e\n\u003cp\u003eKidney and urinary disorders.\u003c\/p\u003e\n\u003cp\u003eVery rare - Side effect: Tubulointerstitial nephritis (after prolonged use of paracetamol at high doses)¹\u003c\/p\u003e\n\u003cp\u003eNot known - Side effect: Aggravated renal failure¹, haematuria¹, anuria¹ urine retention²\u003c\/p\u003e\n\u003cp\u003eVery rare cases of serious skin reactions have been reported. ¹ Side effects associated with paracetamol ² Side effects associated with phenylephrine \u003cu\u003eReporting of suspected adverse reactions\u003c\/u\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system to the site \u003cb\u003ehttps:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse\u003c\/b\u003e.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eParacetamol\u003c\/i\u003e At the recommended doses, or even if you were to take the entire pack, no symptoms of paracetamol overdose should appear. However, in case of ingestion of very high doses of paracetamol (greater than 10 g), the most commonly encountered complication is liver damage, which typically occurs 12-48 hours after ingestion. \u003cu\u003eRisk factors\u003c\/u\u003e a. Long-term treatment with carbamazepine, phenobarbital, phenytoin, primidone, rifampicin, St. John's wort or other liver enzyme-inducing drugs; b. regular consumption of ethanol in quantities higher than recommended; c. glutathione depletion (e.g. eating disorders, cystic fibrosis, HIV infection, starvation, cachexia). \u003cu\u003eSymptoms\u003c\/u\u003e Early symptoms of paracetamol overdose in the first 24 hours are paleness, nausea, vomiting, anorexia and abdominal pain. Abnormalities of glucose metabolism and metabolic acidosis may occur. In severe poisoning, liver failure may progress to encephalopathy, hemorrhage, hypoglycemia, brain edema, and death. Even in the absence of severe liver damage, acute renal failure with acute tubular necrosis, strongly suggested by flank pain, hematuria, and proteinuria can develop, even in the absence of severe liver damage. Cardiac arrhythmias and pancreatitis have been reported. \u003cu\u003eTreatment\u003c\/u\u003e In the management of paracetamol overdose, immediate treatment is essential. Despite a lack of significant initial symptoms, patients should be referred to hospital urgently for immediate medical attention. Symptoms may be limited to nausea or vomiting and may not reflect the severity of the overdose or the risk of organ damage. Management must be in accordance with treatment guidelines. If overdose has occurred within 1 hour, treatment with activated charcoal should be considered. Paracetamol plasma concentration should be measured 4 or more hours after ingestion (initial concentrations are not reliable). Treatment with N-acetylcysteine ​​can be used up to 24 hours after ingestion of paracetamol, however, the maximum protective effect is achieved up to 8 hours after ingestion. The effectiveness of the antidote declines sharply after this period. If necessary, the patient should be administered N-acetylcysteine ​​intravenously, in line with the established dosing regimen. If vomiting is not a problem, oral methionine may be a suitable alternative in more remote areas, outside of hospital. Management of patients who present with severe hepatic dysfunction more than 24 hours after ingestion should be discussed with the National Poison Control Center or liver unit. \u003ci\u003ePhenylephrine\u003c\/i\u003e \u003cu\u003eSymptoms\u003c\/u\u003e Symptoms of overdose caused by phenylephrine are irritability, headache and increased blood pressure. In more serious cases, confusion, hallucinations, convulsions and arrhythmias may occur. However, the amount needed to produce severe phenylephrine toxicity would be greater than that related to acetaminophen. \u003cu\u003eTreatment\u003c\/u\u003e Treatment must be clinically appropriate. Severe hypertension should be treated with alpha blocker drugs such as phentolamine. \u003ci\u003eAscorbic acid\u003c\/i\u003e \u003cu\u003eSymptoms\u003c\/u\u003e High doses of ascorbic acid (\u003e3000mg) may cause transient osmotic diarrhea and gastrointestinal effects such as nausea and abdominal discomfort. The effects of ascorbic acid overdose may be hidden by the severe liver toxicity caused by acetaminophen overdose. \u003cu\u003eTreatment\u003c\/u\u003e Treatment must be clinically appropriate.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003ePREGNANCY \u003ci\u003e \u003cu\u003eParacetamol\u003c\/u\u003e \u003c\/i\u003e A large amount of data on pregnant women indicates neither malformation nor fetal\/neonatal toxicity. Epidemiological studies on neurodevelopment in children exposed to paracetamol in utero show inconclusive results. If clinically necessary, paracetamol can be used during pregnancy, however it should be used at the lowest effective dose for the shortest possible time and with the lowest possible frequency. Epidemiological studies in pregnant women have shown that there are no contraindications in the use of paracetamol when used in the recommended doses, but the administration of the preparation during pregnancy and breastfeeding must take place under the direct supervision of a doctor. \u003ci\u003e \u003cu\u003ePhenylephrine\u003c\/u\u003e \u003c\/i\u003e Data regarding the use of phenylephrine in pregnancy are limited. Vasoconstriction of the uterine vessels and reduction of blood flow to the uterus associated with the use of phenylephrine may result in fetal hypoxia. The use of phenylephrine during pregnancy should be avoided as further information is needed. \u003ci\u003e \u003cu\u003eAscorbic acid\u003c\/u\u003e \u003c\/i\u003e There are no controlled data relating to use during pregnancy. The use of ascorbic acid during pregnancy is recommended only when the benefit outweighs the risk. BREASTFEEDING \u003ci\u003e \u003cu\u003eParacetamol \u003c\/u\u003e \u003c\/i\u003e Paracetamol is excreted in breast milk but in clinically insignificant quantities. The available published data do not contraindicate its use during breastfeeding. \u003ci\u003e \u003cu\u003ePhenylephrine\u003c\/u\u003e \u003c\/i\u003e No data are available regarding the excretion of phenylephrine in breast milk, nor is there information regarding the effects of phenylephrine on breast-fed infants. In the absence of available data, the use of phenylephrine should be avoided during breastfeeding. \u003ci\u003e \u003cu\u003eAscorbic acid\u003c\/u\u003e \u003c\/i\u003e Ascorbic acid is excreted in breast milk. The effects on breast-fed infants are not known. In summary, the use of TACHIFLUDEC is not recommended during pregnancy and breastfeeding. FERTILITY There is no evidence in non-clinical studies to indicate effects of paracetamol on male and female fertility at commonly used clinical doses. The effect of phenylephrine on male and female fertility has not been studied. There is sufficient evidence indicating the importance of ascorbic acid at different levels in the reproductive process. However, no definitive human data on the clinical potential of vitamin C are available.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eTACHIFLUDEC does not affect the ability to drive or use machines. However, patients should be advised not to drive or operate machines if they feel dizzy.\u003c\/p\u003e","brand":"Angelini","offers":[{"title":"Default Title","offer_id":40207824912499,"sku":"034358034","price":9.21,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/products\/angelini-spa-tachifludec-arancia-polvere-10-bustine-farmacia-dottor-tili-1213792726.jpg?v=1767127528"},{"product_id":"tachipirina-orosolubile-12-bustine-500-mg","title":"Tachipirina Orosolubile 12 Sachets 500 mg","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eOROSOLUBLE TACHIPIRINA is indicated for the symptomatic treatment of mild to moderate pain and fever.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eOne sachet contains 500 mg of paracetamol. Excipients with known effects: One sachet contains: sorbitol (E420) 801.30 mg, sucrose 0.14 mg, propylene glycol 1.315 mg and sodium. For the full list of excipients, see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSorbitol Talc Butyl methacrylate basic copolymer Magnesium oxide light Hypromellose Carmellose sodium Stearic acid Sodium lauryl sulphate Magnesium stearate (Ph.Eur.) Titanium dioxide (E 171) Sucralose Simethicone N,2,3-trimethyl-2-(propan-2-yl) butanamide Strawberry flavor (contains maltodextrin, gum arabic (E414), natural and\/or natural-identical flavoring substances, propylene glycol (E1520), triacetin (E1518), maltol (E636)) Vanilla flavor (contains maltodextrin, natural and\/or natural-identical flavoring substances, propylene glycol (E1520), sucrose)\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to the active substance or to any of the excipients listed in paragraph 6.1. • severe kidney failure • alcohol abuse\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDoses depend on body weight and age. A single dose ranges from 10 to 15 mg\/kg of body weight up to a maximum of 60 to 75 mg\/kg for the total daily dose. The time interval between individual doses depends on the symptoms and the maximum daily dose. In any case, it must not be less than 4 hours. OROSOLUBLE TACHIPIRINA must not be used for more than three days without consulting your doctor. 500 mg sachets\u003c\/p\u003e\n\u003cp\u003eBody weight (age): Single dose [sachet] Maximum daily dose [sachets].\u003c\/p\u003e\n\u003cp\u003e26 - 40 kg (8 - 12 years): 500 mg paracetamol (1 sachet) 1500 mg paracetamol (3 sachets).\u003c\/p\u003e\n\u003cp\u003e\u003e 40 kg (children over 12 years and adults): 500 - 1000 mg paracetamol (1 - 2 sachets) 3000 mg paracetamol (6 sachets of 500 mg).\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eMethod of administration:\u003c\/u\u003e For oral use only. The granules should be taken by placing them directly on the tongue and should be swallowed without water. TACHIPIRINA OROSOLUBILE should not be taken on a full stomach. Special populations. Hepatic or renal insufficiency: In patients with hepatic or renal insufficiency or Gilbert's syndrome, the dose should be reduced or the time interval between administrations should be prolonged. Patients with renal insufficiency: In patients with severe renal insufficiency (creatinine clearance \u003c 10 ml\/min.), a time interval of at least 8 hours between administrations should be respected. Chronic alcoholism: Chronic alcohol consumption can lower the toxicity threshold of paracetamol. In these patients, the time interval between two doses should be at least 8 hours. The dose of 2 g of paracetamol per day must not be exceeded. Elderly patients: Dose adjustment is not required in the elderly. Children and adolescents with low weight. Paracetamol 500 mg sachets: Paracetamol 500 mg sachets are not suitable for children under 8 years of age and with a body weight of less than 26 kg. For this group of patients, other formulations and dosages are available. For all indications: Adults, elderly and children over 12 years of age: the usual dose is 500 - 1000 mg every 4 - 6 hours up to a maximum of 3 g per day. The dose should not be repeated before four hours. Renal insufficiency: The dose must be reduced in case of renal insufficiency.\u003c\/p\u003e\n\u003cp\u003eGlomerular filtration: Dose.\u003c\/p\u003e\n\u003cp\u003e10 - 50 ml\/min.: 500 mg every 6 hours.\u003c\/p\u003e\n\u003cp\u003e\u003c 10 ml\/min.: 500 mg every 8 hours.\u003c\/p\u003e\n\u003cp\u003eThe effective daily dose should be considered, without exceeding 60 mg\/kg\/day (without exceeding 3 g\/day), in the following situations: Adults weighing less than 50 kg; Hepatocellular insufficiency (mild to moderate); Chronic alcoholism; Dehydration; Chronic malnutrition; Liver or kidney failure. In patients with hepatic or renal insufficiency or Gilbert's syndrome, the dose should be reduced or the dosing interval should be prolonged. The sachet formulation is not recommended for children under 4 years of age. To older children (4 - 12 years) 250 - 500 mg can be administered every 4 - 6 hours up to a maximum of 4 doses within 24 hours.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDo not store above 30°C. Store in the original package to protect the medicine from light and moisture.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eTo avoid the risk of overdose, it is necessary to check that any other drugs taken concurrently do not contain paracetamol. Paracetamol should be administered with caution to patients with mild to moderate hepatocellular insufficiency (including Gilbert's syndrome), severe hepatic insufficiency (Child-Pugh \u003e9), acute hepatitis, in concomitant treatment with drugs that impair liver function, glucose-6-phosphate dehydrogenase deficiency, haemolytic anemia, chronic alcohol abuse, severe renal insufficiency (creatinine clearance \u003c 10 ml\/min. [see section 4.2]). If there is a high fever or signs of secondary infection, or if symptoms persist for more than 3 days, you should consult your doctor. In general, medicines containing paracetamol can only be taken for a few days and in low doses without consulting your doctor or dentist. In case of prolonged incorrect use of analgesics at high doses, headache episodes may occur which should not be treated with higher doses of the drug. In general, the habitual intake of analgesics, especially a combination of different analgesic substances, can cause permanent kidney damage with the risk of renal failure (analgesic nephropathy). Prolonged or frequent use is not recommended. Patients should be advised not to take other products containing paracetamol at the same time. Taking multiple daily doses in a single administration can seriously damage the liver. In this case, the patient does not lose consciousness, but a doctor should be consulted immediately. Prolonged use without medical supervision may be harmful. In children treated with 60 mg\/kg per day of paracetamol, the association with another antipyretic is not justified except in cases of ineffectiveness. Suddenly stopping taking analgesics after a prolonged period of incorrect use, at high doses, can cause headache, fatigue, muscle pain, nervousness and autonomic symptoms. These withdrawal symptoms resolve within a few days. Until that time, further intake of painkillers should be avoided and should not be resumed without consulting your doctor. Caution should be exercised if paracetamol is taken in association with CYP3A4 inducers or the use of substances that induce hepatic enzymes such as rifampicin, cimetidine and antiepileptics such as glutethimide, phenobarbital and carbamazepine. Caution should be exercised when administering paracetamol to patients with renal insufficiency (creatinine clearance ≤ 30 ml\/min., see section 4.2). Consumption of alcohol should be avoided during treatment with paracetamol. The risks of overdose are greater in patients with non-cirrhotic alcoholic liver disease. Caution should be exercised in case of chronic alcoholism. In patients with alcohol abuse the dose should be reduced (see section 4.2). In this case, the daily dose should not exceed 2 grams. OROSOLUBLE TACHIPIRINA contains: - \u003cb\u003esorbitol\u003c\/b\u003e: This medicine contains 801.30 mg of sorbitol per sachet. Patients with hereditary fructose intolerance should not be given this medicine; The additive effect of co-administration of medicinal products containing sorbitol (or fructose) and daily dietary intake of sorbitol (or fructose) should be considered. The sorbitol content in oral medicinal products may modify the bioavailability of other co-administered oral medicinal products. - \u003cb\u003esucrose\u003c\/b\u003e patients suffering from rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase isomaltase insufficiency should not take this medicine; - \u003cb\u003epropylene glycol:\u003c\/b\u003e This medicine contains 1.315 mg of propylene glycol per sachet. Coadministration with any alcohol dehydrogenase substrate such as ethanol may induce serious adverse effects in neonates; - \u003cb\u003esodium\u003c\/b\u003e: This medicine contains less than 1 mmol (23 mg) sodium per sachet, i.e. “essentially sodium-free”. In the presence of high fever or signs of secondary infection or persistence of symptoms beyond 3 days, a re-evaluation of the treatment should be carried out. Doses higher than recommended imply the risk of very serious liver injury. Treatment with the antidote should be administered as soon as possible (see section 4.9). Paracetamol should be used with caution in cases of dehydration and chronic malnutrition.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe intake of probenecid inhibits the binding of paracetamol to glucuronic acid, resulting in a reduction in the clearance of paracetamol approximately twofold. In patients taking probenecid concomitantly, the dose of paracetamol should be reduced. The metabolism of paracetamol is increased in patients taking enzyme-inducing medicines, such as rifampin and some antiepileptics (carbamazepine, phenytoin, phenobarbital, primidone). Some isolated reports describe unexpected hepatotoxicity in patients taking enzyme-inducing drugs. Concomitant administration of paracetamol and AZT (zidovudine) increases the tendency to neutropenia. Therefore, co-administration of this drug together with AZT should only take place on the advice of your doctor. Concomitant intake of drugs that accelerate gastric emptying, such as metoclopramide, accelerates the absorption and onset of action of paracetamol. The concomitant use of drugs that slow gastric emptying can delay the absorption and onset of action of paracetamol. Cholestyramine reduces the absorption of paracetamol and, therefore, cannot be administered until one hour has passed after administration of paracetamol. Repeated intake of paracetamol for periods longer than one week increases the effect of anticoagulants, particularly warfarin. Therefore, long-term administration of paracetamol in patients treated with anticoagulants should only take place under medical supervision. Occasional intake of paracetamol has no significant effect on bleeding tendency. Effects on laboratory tests Paracetamol can interfere with uric acid determinations that use phosphotungstic acid and with blood glucose determinations that use the glucose-oxidase-peroxidase reaction. Probenecid causes an almost two-fold reduction in the clearance of paracetamol by inhibiting its conjugation with glucuronic acid. A reduction in paracetamol should be considered in case of concomitant treatment with probenecid. Paracetamol increases plasma levels of acetylsalicylic acid and chloramphenicol.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe MedDRA system organ classification is used with the following frequencies: very common (≥ 1\/10), common (≥ 1\/100, \u003c 1\/10), uncommon (≥ 1\/1,000, \u003c 1\/100), rare (≥ 1\/10,000, \u003c 1\/1,000), very rare (\u003c1\/10,000).\u003c\/p\u003e\n\u003cp\u003ePathologies of the blood and lymphatic system.\u003c\/p\u003e\n\u003cp\u003eSOC\/FREQUENCY: Rare - Adverse reactions: anemia, non-hemolytic anemias and bone marrow depression; thrombocytopenia.\u003c\/p\u003e\n\u003cp\u003eVascular pathologies:\u003c\/p\u003e\n\u003cp\u003eSOC\/FREQUENCY: Rare - Adverse reactions: edema.\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders.\u003c\/p\u003e\n\u003cp\u003eSOC\/FREQUENCY: Rare - Adverse reactions: exocrine pancreatic conditions, acute and chronic pancreatitis, gastrointestinal bleeding, abdominal pain, diarrhea, nausea, vomiting.\u003c\/p\u003e\n\u003cp\u003eHepatobiliary disorders.\u003c\/p\u003e\n\u003cp\u003eSOC\/FREQUENCY: Rare - Adverse reactions: hepatic failure, hepatic necrosis, jaundice.\u003c\/p\u003e\n\u003cp\u003eImmune system disorders.\u003c\/p\u003e\n\u003cp\u003eSOC\/FREQUENCY: Rare - Adverse reactions: allergic conditions, anaphylactic reaction, allergies to foods, food additives, drugs and other chemicals.\u003c\/p\u003e\n\u003cp\u003ePathologies of the skin and subcutaneous tissue.\u003c\/p\u003e\n\u003cp\u003eSOC\/FREQUENCY: Rare - Adverse reactions: urticaria, pruritus, rash, sweating, purpura, angioedema.\u003c\/p\u003e\n\u003cp\u003eSOC\/FREQUENCY: Very rare - Adverse reactions: Very rare cases of serious skin reactions have been reported.\u003c\/p\u003e\n\u003cp\u003eRenal and urinary disorders.\u003c\/p\u003e\n\u003cp\u003eSOC\/FREQUENCY: Rare - Adverse reactions: nephropathy, nephropathy and tubular disorders.\u003c\/p\u003e\n\u003cp\u003eVery rare cases of serious skin reactions have been reported. Nephrotoxic effects are infrequent and have not been reported in association with therapeutic doses, except after prolonged administration. Reporting of suspected adverse reactions. Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThere is a risk of poisoning, especially in elderly subjects, young children, patients with liver disease, chronic alcoholism and patients with chronic malnutrition. Overdose can be fatal in these cases. Symptoms generally appear within the first 24 hours and include: nausea, vomiting, anorexia, paleness and abdominal pain. Overdose, i.e. the administration of 10 g of paracetamol or more in a single dose in adults or the administration of 150 mg\/kg of body weight in a single dose in children, causes necrosis of liver cells which may induce complete and irreversible necrosis, resulting in hepatocellular failure, metabolic acidosis and encephalopathy which may lead to coma and death. At the same time, increased levels of hepatic transaminases (AST, ALT), lactate dehydrogenase and bilirubin are observed, together with increased levels of prothrombin which may appear 12 - 48 hours after administration. Emergency procedure: Immediate hospitalization Taking blood samples to determine the initial plasma concentration of paracetamol Gastric lavage IV administration (or oral if possible) of the antidote N-acetylcysteine ​​as soon as possible and before 10 hours have passed from the overdose Implement symptomatic treatment.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003ePregnancy:\u003c\/u\u003e A large amount of data on pregnant women indicates neither malformation nor fetal\/neonatal toxicity. Epidemiological studies on neurodevelopment in children exposed to paracetamol in utero show inconclusive results. If clinically necessary, paracetamol can be used during pregnancy, however it should be used at the lowest effective dose for the shortest possible time and with the lowest possible frequency. \u003cu\u003eBreastfeeding:\u003c\/u\u003e After oral intake, paracetamol is excreted in breast milk in small quantities. No side effects have been reported in breastfed infants. Therapeutic doses of this medicine can be used during breastfeeding.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eOROSOLUBLE TACHIPIRINA does not alter the ability to drive or use machinery. No studies on the effects on the ability to drive and use machines have been performed.\u003c\/p\u003e","brand":"Angelini","offers":[{"title":"Default Title","offer_id":40207824945267,"sku":"040313049","price":8.5,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/angelini-tachipirina-orosolubile-12-bustine-500-mg-farmacia-dottor-tili-1258975928.jpg?v=1789562561"},{"product_id":"imidazyl-collirio-flacone-10-ml-0-1","title":"Imidazyl Eye Drops Bottle 10 ml 0.1%","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIn allergic and inflammatory states of the conjunctiva characterized by a burning sensation, even from external agents, associated with excessive tearing, photophobia, hyperemia.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e1 ml of solution contains 1 mg of naphazoline nitrate (equal to 770 mcg of naphazoline). Excipient with known effects: 10 ml bottle: 1 ml of solution contains 0.10 mg of benzalkonium chloride. For the full list of excipients, see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eImidazyl 10 ml bottle\u003c\/u\u003e Benzalkonium chloride Sodium chloride Disodium edetate Sodium dihydrogen phosphate dihydrate Disodium phosphate dihydrate Purified water. \u003cu\u003eImidazyl single-dose container\u003c\/u\u003e Monobasic sodium phosphate Sodium chloride Water for injections.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to the active ingredient or to any of the excipients listed in paragraph 6.1 or to other closely related substances from a chemical point of view; in particular towards xylometazoline, oxymetazoline, tetrizoline. Narrow-angle glaucoma or other serious eye diseases. Children under 12 years old. Simultaneous treatment with monoamine oxidase inhibitor drugs (see section 4.5).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eInstill 1-2 drops into the affected eye, 1-2 times a day. Do not exceed the recommended doses. If symptoms persist or worsen after a short period of treatment, consult your doctor. In any case, the product must not be used for more than 4 consecutive days unless otherwise prescribed by a doctor given the possibility that otherwise unwanted effects may occur. Carefully follow the recommended doses. A higher dosage of the product, even if taken topically and for a short period of time, can give rise to serious systemic effects.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eStore in the original packaging.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe product, although presenting very little systemic absorption, must be used with caution in subjects suffering from hypertension, hyperthyroidism, cardiac disorders, bronchial asthma and hyperglycemia (diabetes). The product should be kept out of the reach of children as accidental ingestion can cause CNS depression. (marked sedation and hypotonia), coma. In these cases, immediate medical assistance is always necessary. The product is not suitable for the treatment of infections, mechanical (trauma), chemical or heat damage or for eliminating foreign bodies in the eye. These situations require medical attention. Imidazyl 10 ml bottle contains benzalkonium chloride. May cause eye irritation during treatment, soft contact lenses should not be worn. Since benzalkonium chloride is not present in the single-dose package, this can be used by contact lens wearers, or by those who show hypersensitivity to benzalkonium chloride.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eImidazyl must not be used if you are taking monoamine oxidase inhibitor drugs or if less than two weeks have passed since the last administration of these medicines as serious hypertensive crises may occur.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe use of the product can sometimes cause pupillary dilation, systemic effects from absorption (hypertension, cardiac disorders, hyperglycemia), increased intraocular pressure, nausea, headache. Rarely, hypersensitivity phenomena may occur. In this case it is necessary to interrupt the treatment and institute suitable therapy. \u003cu\u003eReporting of suspected adverse reactions\u003c\/u\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at \u003cu\u003ewww.agenziafarmaco.gov.it\/it\/responsabili.\u003c\/u\u003e\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eCarefully follow the recommended doses. The product, if accidentally ingested or if used for a long period in excessive doses, can cause toxic phenomena. Accidental ingestion of the drug, especially in children, can cause central nervous system depression: marked sedation (severe drowsiness), hypotonia and coma. If this occurs: gastric lavage, sedation with diazepam and general supportive measures.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThere are no known teratogenic and embryotoxic effects of the specialty component in topical use. However, in pregnant and breastfeeding women, the product should only be used in case of actual need and under the direct supervision of a doctor.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eImidazyl does not affect the ability to drive or use machines.\u003c\/p\u003e","brand":"Recordati","offers":[{"title":"Default Title","offer_id":40207825240179,"sku":"003410026","price":8.93,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/recordati-imidazyl-collirio-flacone-10-ml-0-1-farmacia-dottor-tili-1254215804.jpg?v=1786737399"},{"product_id":"imidazyl-collirio-10-flaconcini-monodose-1-mg-ml","title":"Imidazyl Eye Drops 10 Single Dose Vials 1 mg\/ml","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIn allergic and inflammatory states of the conjunctiva characterized by a burning sensation, even from external agents, associated with excessive tearing, photophobia, hyperemia.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e1 ml of solution contains 1 mg of naphazoline nitrate (equal to 770 mcg of naphazoline). Excipient with known effects: 10 ml bottle: 1 ml of solution contains 0.10 mg of benzalkonium chloride. For the full list of excipients, see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eImidazyl 10 ml bottle\u003c\/u\u003e Benzalkonium chloride Sodium chloride Disodium edetate Sodium dihydrogen phosphate dihydrate Disodium phosphate dihydrate Purified water. \u003cu\u003eImidazyl single-dose container\u003c\/u\u003e Monobasic sodium phosphate Sodium chloride Water for injections.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to the active ingredient or to any of the excipients listed in paragraph 6.1 or to other closely related substances from a chemical point of view; in particular towards xylometazoline, oxymetazoline, tetrizoline. Narrow-angle glaucoma or other serious eye diseases. Children under 12 years old. Simultaneous treatment with monoamine oxidase inhibitor drugs (see section 4.5).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eInstill 1-2 drops into the affected eye, 1-2 times a day. Do not exceed the recommended doses. If symptoms persist or worsen after a short period of treatment, consult your doctor. In any case, the product must not be used for more than 4 consecutive days unless otherwise prescribed by a doctor given the possibility that otherwise unwanted effects may occur. Carefully follow the recommended doses. A higher dosage of the product, even if taken topically and for a short period of time, can give rise to serious systemic effects.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eStore in the original packaging.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe product, although presenting very little systemic absorption, must be used with caution in subjects suffering from hypertension, hyperthyroidism, cardiac disorders, bronchial asthma and hyperglycemia (diabetes). The product should be kept out of the reach of children as accidental ingestion can cause CNS depression. (marked sedation and hypotonia), coma. In these cases, immediate medical assistance is always necessary. The product is not suitable for the treatment of infections, mechanical (trauma), chemical or heat damage or for eliminating foreign bodies in the eye. These situations require medical attention. Imidazyl 10 ml bottle contains benzalkonium chloride. May cause eye irritation during treatment, soft contact lenses should not be worn. Since benzalkonium chloride is not present in the single-dose package, this can be used by contact lens wearers, or by those who show hypersensitivity to benzalkonium chloride.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eImidazyl must not be used if you are taking monoamine oxidase inhibitor drugs or if less than two weeks have passed since the last administration of these medicines as serious hypertensive crises may occur.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe use of the product can sometimes cause pupillary dilation, systemic effects from absorption (hypertension, cardiac disorders, hyperglycemia), increased intraocular pressure, nausea, headache. Rarely, hypersensitivity phenomena may occur. In this case it is necessary to interrupt the treatment and institute suitable therapy. \u003cu\u003eReporting of suspected adverse reactions\u003c\/u\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at \u003cu\u003ewww.agenziafarmaco.gov.it\/it\/responsabili.\u003c\/u\u003e\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eCarefully follow the recommended doses. The product, if accidentally ingested or if used for a long period in excessive doses, can cause toxic phenomena. Accidental ingestion of the drug, especially in children, can cause central nervous system depression: marked sedation (severe drowsiness), hypotonia and coma. If this occurs: gastric lavage, sedation with diazepam and general supportive measures.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThere are no known teratogenic and embryotoxic effects of the specialty component in topical use. However, in pregnant and breastfeeding women, the product should only be used in case of actual need and under the direct supervision of a doctor.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eImidazyl does not affect the ability to drive or use machines.\u003c\/p\u003e","brand":"Recordati","offers":[{"title":"Default Title","offer_id":40207825272947,"sku":"003410065","price":9.49,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/recordati-imidazyl-collirio-10-flaconcini-monodose-1-mg-ml-farmacia-dottor-tili-1254215801.jpg?v=1786737388"},{"product_id":"levoreact-ofta-collirio-4-ml-0-5-mg-ml","title":"Levoreact Ofta Eye Drops 4 ml 0.5 mg\/ml","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAllergic conjunctivitis.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eOne ml of eye drops, suspension contains: levocabastine hydrochloride 0.54 mg (equal to 0.5 mg of levocabastine). Excipients with known effects: propylene glycol, benzalkonium chloride. For the full list of excipients, see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003ePropylene glycol, sodium dihydrogen phosphate monohydrate, disodium hydrogen phosphate anhydrous, hydroxypropyl methylcellulose 2910, polysorbate 80, benzalkonium chloride, disodium edetate, water for injections.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to the active substance or to any of the excipients listed in paragraph 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDosage \u003cb\u003eAdults and children\u003c\/b\u003e: the usual dose is 1 drop of \u003cu\u003eOPHTHALMIC LEVOREACT \u003c\/u\u003e per eye, 2 times a day. The dose can be increased to 1 drop up to 3 or 4 times a day. Treatment must be continued for the period necessary for the symptoms to disappear. Method of administration Ophthalmic use. For instructions on the use and handling of the medicinal product before administration, see section 6.6.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDo not store above 25°C.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAs with all ophthalmic preparations containing benzalkonium chloride, propylene glycol and esters, patients should be advised not to use soft (hydrophilic) contact lenses during treatment with \u003cu\u003eLEVOREACT OFTHALMIC eye drops suspension\u003c\/u\u003e because they can cause eye irritation. Remove contact lenses before applying the medicine and wait at least 15 minutes before putting them back. The medicine discolors soft contact lenses.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo interaction studies have been carried out.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAdverse drug reactions identified during clinical and epidemiological studies and with postmarketing experience following the use of \u003cu\u003eOPHTHALMIC LEVOREACT \u003c\/u\u003e are reported in \u003cb\u003eTable 1\u003c\/b\u003e; frequencies are reported according to the following conventional classification: Very common ≥1\/10 Common ≥1\/100 and \u003c1\/10 Uncommon ≥1\/1000 and \u003c1\/100 Rare ≥1\/10,000 and \u003c1\/1000 Very rare \u003c1\/10,000 Not known The frequency cannot be estimated from the available data \u003cb\u003eTable 1: Adverse drug reactions identified during clinical trials and postmarketing experience with LEVOREACT OFTHALMIC.\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003eCardiac diseases.\u003c\/p\u003e\n\u003cp\u003eNot known: Palpitations.\u003c\/p\u003e\n\u003cp\u003eEye pathologies.\u003c\/p\u003e\n\u003cp\u003eCommon: Eye pain, blurred vision;\u003c\/p\u003e\n\u003cp\u003eUncommon: Edema of the eyelids;\u003c\/p\u003e\n\u003cp\u003eNot known: Conjunctivitis, eye swelling, blepharitis, ocular hyperaemia.\u003c\/p\u003e\n\u003cp\u003eSystemic pathologies and conditions relating to the administration site.\u003c\/p\u003e\n\u003cp\u003eCommon: Application site reaction, including burning\/eye irritation, eye irritation.\u003c\/p\u003e\n\u003cp\u003eVery rare: Application site reaction, such as redness of the eyes, ocular itching.\u003c\/p\u003e\n\u003cp\u003eNot known: Application site reaction, such as tearing.\u003c\/p\u003e\n\u003cp\u003eImmune system disorders.\u003c\/p\u003e\n\u003cp\u003eNot known: Angioedema, hypersensitivity, anaphylactic reaction.\u003c\/p\u003e\n\u003cp\u003ePathologies of the skin and subcutaneous tissue.\u003c\/p\u003e\n\u003cp\u003eNot known: Contact dermatitis, urticaria.\u003c\/p\u003e\n\u003cp\u003eNervous system disorders.\u003c\/p\u003e\n\u003cp\u003eCommon: Headache.\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eReporting of suspected adverse reactions\u003c\/b\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at www.agenziafarmaco.gov.it\/it\/responsabili.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eSymptoms\u003c\/b\u003e No cases of overdose have been reported with LEVOREACT OFTHALMIC. However, the occurrence of sedation after accidental ingestion of the contents of the bottle cannot be excluded. \u003cb\u003eTreatment\u003c\/b\u003e In case of accidental ingestion, advise the patient to drink plenty of non-alcoholic liquids in order to accelerate the renal elimination of levocabastine.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003ePregnancy Studies conducted in animals have not shown embryotoxic or teratogenic effects (see section 5.3). Postmarketing data regarding the use of levocabastine eye drops, suspension in pregnant women are limited; the risk for humans is not known, therefore LEVOREACT OPHTHALMIC should not be used during pregnancy, unless the potential benefit for the woman justifies the potential fetal risk. Breastfeeding Based on determinations of the concentration of levocabastine in saliva and breast milk of a breastfeeding woman who has been administered a single 0.5 mg oral dose of levocabastine, approximately 0.3% of the total dose of levocabastine administered ophthalmologically is expected to be transmitted to the nursing infant. However, due to the limited availability of clinical and experimental data, caution is recommended when administering LEVOREACT OPHTHALMIC to breastfeeding women. Fertility Animal data showed no effects on male or female fertility (see section 5.3).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eLEVOREACT OPHTHALMIC does not induce sedation or interfere with psychomotor activity. Adverse reactions such as irritation, pain, swelling, itching, redness of the eyes, burning sensation in the eyes, tearing and blurred vision have been reported. Therefore, caution is advised when driving vehicles and using machinery after the application of \u003cu\u003eOPHTHALMIC LEVOREACT\u003c\/u\u003e.\u003c\/p\u003e","brand":"Johnson \u0026 Johnson","offers":[{"title":"Default Title","offer_id":40207825338483,"sku":"027699026","price":12.87,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/johnson-johnson-levoreact-ofta-collirio-4-ml-0-5-mg-ml-farmacia-dottor-tili-1254211168.jpg?v=1786732359"},{"product_id":"somatoline-emulsione-30-bustine-0-1-0-3","title":"Somatoline Emulsion 30 Sachets 0.1% + 0.3%","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eStates of localized adiposity accompanied by cellulite. SOMATOLINE is indicated in adults.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e100 g of emulsion contains: active ingredients: levothyroxine 100 mg escin 300 mg Excipients with known effects: methyl p-hydroxybenzoate, propyl p-hydroxybenzoate. For the full list of excipients, see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eGlyceryl monostearate A.E., xanthan gum, liquid paraffin, decyloleate, 70% non-crystallizable sorbitol, polyacrylamide isoparaffin laureth–7, imidazolidinylurea, \u003cb\u003emethyl para-hydroxybenzoate, propyl para-hydroxybenzoate\u003c\/b\u003e, citric acid monohydrate, rose scent, purified water.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to the active substances or to any of the excipients listed in paragraph 6.1. Iodine intolerance. Generally contraindicated during pregnancy and breastfeeding (see par. 4.6).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eDosage and method of administration\u003c\/u\u003e \u003ci\u003e \u003cu\u003eSachets\u003c\/u\u003e \u003c\/i\u003e: apply locally 20 g of product per day (equal to 2 sachets) for the first two consecutive days, then 10 g of product (equal to 1 sachet) per day or every other day. If the product is to be used on the thighs, apply 1 sachet (10 g) to each thigh for the first two days. The following days half a sachet (5 g) per thigh. \u003ci\u003e \u003cu\u003eMulti-dose bottle with dispenser\u003c\/u\u003e \u003c\/i\u003e: (4 pumps correspond to 10 g of product). Apply locally 20 g of product per day (equal to 8 sprays) for the first two days, then 10 g of product (equal to 4 sprays) per day or every other day. If the product must be used on the thighs, apply a dose corresponding to 4 pumps (10 g) for each thigh for the first two days. The following days 2 sprays (5 g) per thigh. To obtain 1 delivery, press the dispenser all the way down. Each treatment cycle can range from a minimum of 15 – 20 days to a maximum of 2 – 3 months and can be repeated at various time intervals. Massage the product into the area to be treated (the surface of which should not, as a rule, exceed 15 cm on each side), until completely absorbed. Follow with a second, deeper massage, lasting a few minutes (5'–10'). If the skin is oily or thickened, it is advisable to first wash the area to be treated, dry well and then practice a simple massage until a slight redness is produced; then proceed with the application of the treatment as illustrated above; clinical results generally begin to become evident towards the end of the second week of treatment. \u003cb\u003e \u003ci\u003ePediatric population\u003c\/i\u003e \u003c\/b\u003e Safety and effectiveness in children and adolescents have not yet been demonstrated. There is no data available.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThis medicinal product does not require any special storage conditions.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe use, especially if repeated or prolonged, of products for topical use can give rise to sensitization phenomena. If this occurs, discontinue treatment and evaluate the need to institute suitable therapy. Do not use near mucous membranes. SOMATOLINE contains para-hydroxybenzoates which can cause allergic reactions (even delayed).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThere are no phenomena of intolerance or incompatibility with other drugs.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eVery rarely, cases with symptoms attributable to impaired thyroid function have been reported. \u003cb\u003e \u003ci\u003eReporting of suspected adverse reactions\u003c\/i\u003e \u003c\/b\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reaction via the website: http:\/\/agenziafarmaco.gov.it\/it\/responsabili\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo phenomena of overdose have been highlighted.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThere are no experimental or clinical data that argue against the use of the product during pregnancy. However, prudence advises against applying the product during pregnancy or breastfeeding.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSomatoline does not affect the ability to drive or use machines.\u003c\/p\u003e","brand":"Manetti \u0026 Roberts","offers":[{"title":"Default Title","offer_id":40207831203955,"sku":"022816021","price":59.99,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/manetti-roberts-somatoline-emulsione-30-bustine-0-1-0-3-farmacia-dottor-tili-1254211161.jpg?v=1786732152"},{"product_id":"somatoline-cutanea-emulsione-25-applicazioni","title":"Somatoline Cutaneous Emulsion 25 Applications","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eStates of localized adiposity accompanied by cellulite. SOMATOLINE is indicated in adults.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e100 g of emulsion contains: active ingredients: levothyroxine 100 mg escin 300 mg Excipients with known effects: methyl p-hydroxybenzoate, propyl p-hydroxybenzoate. For the full list of excipients, see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eGlyceryl monostearate A.E., xanthan gum, liquid paraffin, decyloleate, 70% non-crystallizable sorbitol, polyacrylamide isoparaffin laureth–7, imidazolidinylurea, \u003cb\u003emethyl para-hydroxybenzoate, propyl para-hydroxybenzoate\u003c\/b\u003e, citric acid monohydrate, rose scent, purified water.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to the active substances or to any of the excipients listed in paragraph 6.1. Iodine intolerance. Generally contraindicated during pregnancy and breastfeeding (see par. 4.6).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eDosage and method of administration\u003c\/u\u003e \u003ci\u003e \u003cu\u003eSachets\u003c\/u\u003e \u003c\/i\u003e: apply locally 20 g of product per day (equal to 2 sachets) for the first two consecutive days, then 10 g of product (equal to 1 sachet) per day or every other day. If the product is to be used on the thighs, apply 1 sachet (10 g) to each thigh for the first two days. The following days half a sachet (5 g) per thigh. \u003ci\u003e \u003cu\u003eMulti-dose bottle with dispenser\u003c\/u\u003e \u003c\/i\u003e: (4 pumps correspond to 10 g of product). Apply locally 20 g of product per day (equal to 8 sprays) for the first two days, then 10 g of product (equal to 4 sprays) per day or every other day. If the product must be used on the thighs, apply a dose corresponding to 4 pumps (10 g) for each thigh for the first two days. The following days 2 sprays (5 g) per thigh. To obtain 1 delivery, press the dispenser all the way down. Each treatment cycle can range from a minimum of 15 – 20 days to a maximum of 2 – 3 months and can be repeated at various time intervals. Massage the product into the area to be treated (the surface of which should not, as a rule, exceed 15 cm on each side), until completely absorbed. Follow with a second, deeper massage, lasting a few minutes (5'–10'). If the skin is oily or thickened, it is advisable to first wash the area to be treated, dry well and then practice a simple massage until a slight redness is produced; then proceed with the application of the treatment as illustrated above; clinical results generally begin to become evident towards the end of the second week of treatment. \u003cb\u003e \u003ci\u003ePediatric population\u003c\/i\u003e \u003c\/b\u003e Safety and effectiveness in children and adolescents have not yet been demonstrated. There is no data available.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThis medicinal product does not require any special storage conditions.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe use, especially if repeated or prolonged, of products for topical use can give rise to sensitization phenomena. If this occurs, discontinue treatment and evaluate the need to institute suitable therapy. Do not use near mucous membranes. SOMATOLINE contains para-hydroxybenzoates which can cause allergic reactions (even delayed).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThere are no phenomena of intolerance or incompatibility with other drugs.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eVery rarely, cases with symptoms attributable to impaired thyroid function have been reported. \u003cb\u003e \u003ci\u003eReporting of suspected adverse reactions\u003c\/i\u003e \u003c\/b\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reaction via the website: http:\/\/agenziafarmaco.gov.it\/it\/responsabili\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo phenomena of overdose have been highlighted.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThere are no experimental or clinical data that argue against the use of the product during pregnancy. However, prudence advises against applying the product during pregnancy or breastfeeding.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSomatoline does not affect the ability to drive or use machines.\u003c\/p\u003e","brand":"Manetti \u0026 Roberts","offers":[{"title":"Default Title","offer_id":40207831236723,"sku":"022816060","price":59.99,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/manetti-roberts-somatoline-cutanea-emulsione-25-applicazioni-farmacia-dottor-tili-1254211160.jpg?v=1786732119"},{"product_id":"vicks-inalante-rinforzato-flacone-1-g","title":"Vicks Inhalant Reinforced Bottle 1 g","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIn colds and congestion of the nasal mucosa, it frees the stuffy nose and promotes breathing.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eEach stick contains: 1.00 ml of medicinal liquor, absorbed onto a piece of cellulose. ACTIVE INGREDIENTS: menthol 415.4 mg, camphor 415.4 mg. For the complete list of excipients see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSiberian pine essential oil, methyl salicylate.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to the active substances or to any of the excipients listed in paragraph 6.1. Children up to 30 months of age. Children with a history of epilepsy or febrile seizures.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eVicks Inhalant is contraindicated in children up to 30 months of age (see paragraph 4.3) and its use is not recommended in children under 6 years of age. Unscrew the cap and insert the tip of the nasal stick into one nostril, closing the other with a finger and inhale deeply. Repeat in each nostril several times a day. Do not exceed the recommended doses. \u003ci\u003eThe duration of treatment should not exceed 3 days.\u003c\/i\u003e\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNone.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThis product contains terpene derivatives which, in excessive doses, can cause neurological disorders such as seizures in infants and children. Vicks Inhalant is contraindicated in children up to 30 months of age and its use is not recommended in children under 6 years of age. The treatment must not be prolonged for more than 3 days due to the risks associated with the accumulation of terpene derivatives, such as \u003ci\u003ecamphor, cineol, niaouli, wild thyme, terpineol, terpine, citral, menthol and essential oils of pine needle, eucalyptus and turpentine\u003c\/i\u003e (due to their lipophilic properties the rate of metabolism and disposal is not known) in tissues and the brain, in particular neuropsychological disorders. A higher dose than the recommended one should not be used to avoid a greater risk of adverse reactions to the medicinal product and disorders associated with overdose (see section 4.9). The product is flammable, it must not be brought close to flames. Prolonged use may cause sensitization. In this case or in the absence of therapeutic effect, discontinue use and consult your doctor. Use the product according to the instructions. External use.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eVicks Inhalant must not be used concomitantly with other products (medicines or cosmetics) containing terpene derivatives, regardless of the route of administration (oral, rectal, cutaneous, nasal or inhalation).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIn general, no serious or serious side effects are expected with this product. Cases of nasal pain have been reported very rarely. Due to the presence of camphor and menthol and in case of non-compliance with the recommended doses there may be a risk of convulsions in children and infants. The use, especially if prolonged, of products for topical use can cause sensitization phenomena. In this case it is necessary to interrupt the treatment and institute suitable therapy. \u003cu\u003eReporting of suspected adverse reactions\u003c\/u\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reaction via the national reporting system reported on the website: www.agenziafarmaco.gov.it\/it\/responsabili dell'Agenzia Italiana del Farmaco.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo clinically significant cases of overdose have been reported. \u003ci\u003eIn case of accidental oral intake or incorrect administration in newborns and children there may be a risk of neurological disorders.\u003c\/i\u003e \u003ci\u003eIf necessary, administer appropriate symptomatic treatment in specialized treatment centers.\u003c\/i\u003e\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003ePregnancy\u003c\/u\u003e There are no or limited data available on the use of camphor and menthol in pregnant women. Vicks Inhalant is not recommended during pregnancy and in women of childbearing potential who are not using contraceptive measures. \u003cu\u003eBreastfeeding\u003c\/u\u003e There is insufficient information on the excretion of camphor and menthol in breast milk. Vicks Inhalant should not be used during breastfeeding.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNot applicable.\u003c\/p\u003e","brand":"Procter \u0026 Gamble","offers":[{"title":"Default Title","offer_id":40207831597171,"sku":"003136025","price":7.42,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/procter-gamble-srl-vicks-inalante-rinforzato-flacone-1-g-farmacia-dottor-tili-1213793061.jpg?v=1767128289"},{"product_id":"vicks-vaporub-unguento-inalante-50-g","title":"Vicks Vaporub Inhalant Ointment 50 g","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eBalsamic treatment for diseases of the upper respiratory tract.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e100 g of ointment contains: \u003ci\u003eactive ingredients\u003c\/i\u003e: camphor 5 g; turpentine essential oil 5 g; menthol 2.75 g; eucalyptus essential oil 1.5 g. For the complete list of excipients see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThymol, cedarwood essential oil, white petrolatum.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to the active substances or to any of the excipients listed in paragraph 6.1. Children up to 30 months of age. Administration through steam inhalation is contraindicated in children under 12 years of age. Children with a history of epilepsy or febrile convulsions. Generally contraindicated during pregnancy and breastfeeding (see section 4.6).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eVicks Vaporub is contraindicated in children up to 30 months of age and vapor inhalation is contraindicated in children under 12 years (see section 4.3). Children must always be supervised. Vicks Vaporub ointment can be used in two ways: \u003cb\u003e1) Topical use (\u003cu\u003eadults and children over 30 months of age\u003c\/u\u003e)\u003c\/b\u003e Apply externally by first rubbing the chest, throat and back for 3 - 5 minutes and then spreading a thick layer on the chest. Repeat the treatment 2 times a day, one in the evening before going to sleep. Do not rub more than twice a day on the front of the chest, neck and back. Wear loose clothing to facilitate inhalation of vapours. \u003cb\u003e2) Inhalations (\u003cu\u003eadults and children over 12 years of age\u003c\/u\u003e)\u003c\/b\u003e Dissolve 2 teaspoons (2x5 ml) in half a liter of hot (not boiling) water and aspirate the released steam for a time not exceeding 10 minutes. To avoid the risk of serious burns, do not heat the mixture a second time or heat the mixture during inhalation (see section 4.4). Do not heat in the microwave. Do not exceed the recommended doses. The duration of treatment should not exceed 3 days. \u003ci\u003eTHE PRODUCT MUST NOT BE INGESTED\u003c\/i\u003e\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThis medicinal product does not require any special storage conditions.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eUse the product according to the instructions. For external use only. Do not apply on wounds, abrasions and mucous membranes. Do not ingest or apply directly into the nostrils, eyes, mouth or face. Do not make a tight bandage. Do not use with hot compress or any type of heat. This product contains terpene derivatives which, in excessive doses, can cause neurological disorders such as seizures in infants and children. If symptoms persist, consult your doctor. The product should be used with caution or under medical suggestion by patients who present: • hypersensitivity reactions to perfumes or solvents; • convulsions or epilepsy (it is contraindicated in children with a history of epilepsy or febrile convulsions, see section 4.3); • Marked hypersensitivity of the respiratory tract including those conditions such as asthma and chronic obstructive pulmonary disease (COPD) as it can cause bronchospasm in these patients Inhalations: In order to avoid the risk of serious burns, do not use boiling water to prepare inhalations. Do not heat the mixture in the microwave and do not heat it again during and after use (see also section 6.6). The treatment must not be prolonged for more than 3 days due to the risks associated with the accumulation of terpene derivatives, such as \u003ci\u003ecamphor, cineol, niaouli, wild thyme, terpineol, terpine, citral, menthol and essential oils of pine needle, eucalyptus and turpentine\u003c\/i\u003e (due to their lipophilic properties the rate of metabolism and disposal is not known) in tissues and the brain, in particular neuropsychological disorders. A higher than recommended dose should not be used to avoid an increased risk of adverse drug reactions and disorders associated with overdose (see section 4.9). The product is flammable, it must not be brought near flames.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eVicks Vaporub must not be used concomitantly with other products (medicines or cosmetics) containing terpene derivatives, regardless of the route of administration (oral, rectal, cutaneous, nasal or inhalation).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSide effects may occur with the use of the medicine. Such effects may occur with the following frequency categories: Very common (≥1\/10) Common (≥1\/100; \u003c1\/10) Uncommon (≥1\/1,000; \u003c1\/100) Rare (≥1\/10,000; \u003c1\/1,000) Very rare (\u003c1\/10,000) Not known (frequency cannot be predicted from the available data). \u003cb\u003ePathologies of the skin and subcutaneous tissue\u003c\/b\u003e Not known: erythema or heat erythema (redness and sensation of heat in the skin caused by camphor and menthol, which have rubefacient effects), skin irritation, allergic dermatitis, itching. \u003cb\u003eImmune system disorders\u003c\/b\u003e Not known: hypersensitivity, symptom of respiratory allergy (dyspnea and cough). If such events occur, treatment should be suspended and the necessary clinical measures adopted. \u003cb\u003eEye pathologies\u003c\/b\u003e Not known: eye irritation (following topical use or inhalation). \u003ci\u003eSystemic pathologies and conditions relating to the administration site\u003c\/i\u003e: Due to the recommended route of administration, systemic exposure is very low and no undesirable effects due to systemic exposure have been observed. Not known: burns at the application site. Other adverse events may be linked to improper use of the product (ingestion), in this regard see paragraph 4.9. \u003cb\u003e \u003cu\u003ePediatric population\u003c\/u\u003e \u003c\/b\u003e Due to the presence of camphor, turpentine essential oil, menthol and eucalyptus essential oil and in case of non-compliance with the recommended doses there may be a risk of convulsions in children and infants. \u003cb\u003eReporting of suspected adverse reactions\u003c\/b\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at: http:\/\/www.agenziafarmaco.gov.it\/content\/comesegnalare-una-sospetti-reazione-avversa.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIn case of accidental oral intake or incorrect administration in newborns and children there may be a risk of neurological disorders. If necessary, administer appropriate symptomatic treatment in specialized treatment centers. Overdose can cause skin irritation. \u003cu\u003eImproper use\u003c\/u\u003e: Ingestion of the ointment may cause gastrointestinal symptoms such as vomiting and diarrhea. Treatment is symptomatic. Acute poisoning has been observed following significant accidental intake with nausea, vomiting, abdominal pain, headache, dizziness, feeling hot\/hot flashes, convulsions, respiratory depression and coma. Patients with severe gastrointestinal or neurologic symptoms of poisoning should be observed and treated symptomatically. Do not induce vomiting. A) Topical administration: in the event of application of an excessive dose topically, skin irritation reactions may rarely occur. In this case, remove the excess product with a paper towel and administer, if necessary, an adequate therapy for such reactions. B) Inhalation: the symptoms and treatment are the same as in case of accidental ingestion. C) Accidental ingestion: the symptoms are mainly due to the presence of camphor. These include gastrointestinal problems such as nausea, vomiting and diarrhea. In the event of significant overdose, effects on the central nervous system are possible, such as ataxia, convulsions and respiratory depression. Treatment must be symptomatic and gastric lavage can be performed if necessary. In the presence of serious symptoms of poisoning at a gastrointestinal or neurological level, the patient must immediately consult his doctor for appropriate therapeutic measures.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003e \u003cu\u003ePregnancy\u003c\/u\u003e \u003c\/b\u003e There are no or limited data available on the use of camphor, turpentine essential oil, menthol, eucalyptus essential oil in pregnant women. There are no clinical data relating to the use of the components of Vicks Vaporub during pregnancy. Camphor is able to cross the placenta but there is no data on the other components. Animal studies do not indicate harmful effects, direct or indirect, on pregnancy, embryonic\/foetal development, parturition or postnatal development (see section 5.3). However, Vicks Vaporub is not recommended during pregnancy and in women of childbearing potential who are not using contraceptive measures. The use of the drug during pregnancy should only take place after consulting your doctor. \u003cb\u003e \u003cu\u003eBreastfeeding\u003c\/u\u003e \u003c\/b\u003e There is insufficient information on the excretion of camphor, turpentine essential oil, menthol, eucalyptus essential oil in breast milk. There are no clinical data relating to the use of the components of Vicks Vaporub during breastfeeding. Vicks Vaporub should not be used during breastfeeding. The product, applied to the mother's chest during breastfeeding, poses a potential risk of apneic reflex in the breast-fed infant.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eVicks Vaporub does not affect the ability to drive or use machines.\u003c\/p\u003e","brand":"Procter \u0026 Gamble","offers":[{"title":"Default Title","offer_id":40207831629939,"sku":"021625064","price":11.02,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/procter-gamble-vicks-vaporub-unguento-inalante-50-g-farmacia-dottor-tili-1254211152.jpg?v=1786731971"},{"product_id":"momentact-400-mg-analgesico-20-compresse","title":"Momentact 400 mg Analgesic 20 Tablets","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eMomentact is indicated in adults and adolescents over 12 years of age. Pain of various origins and nature (headache, toothache, neuralgia, osteo-articular and muscular pain, menstrual pain). Adjuvant in the symptomatic treatment of fever and flu.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eEach film-coated tablet contains: \u003cu\u003eActive ingredient\u003c\/u\u003e: ibuprofen 400 mg. \u003cu\u003eExcipients with known effects\u003c\/u\u003e: lactose, sodium. For the complete list of excipients see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003ePregelatinized starch, carboxymethyl starch \u003cb\u003esodium\u003c\/b\u003e, carmellosa \u003cb\u003esodium\u003c\/b\u003e, povidone, microcrystalline cellulose, precipitated silica, talc, \u003cb\u003esodium\u003c\/b\u003e lauryl sulfate,\u003cb\u003e lactose\u003c\/b\u003e monohydrate, hypromellose, titanium dioxide, Macrogol 4000.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e• Hypersensitivity to the active ingredient, to other antirheumatic drugs (acetylsalicylic acid, etc.) or to any of the excipients listed in paragraph 6.1. • Do not administer to children under 12 years of age. • Ibuprofen is contraindicated during the third trimester of pregnancy and during breastfeeding (see section 4.6). • Active or severe gastroduodenal ulcer or other gastropathies. • History of gastrointestinal hemorrhage or perforation related to previous active treatment or history of recurrent peptic hemorrhage\/ulcer (two or more distinct episodes of demonstrated ulceration or bleeding). • Severe hepatic or renal insufficiency. • Severe heart failure (NYHA class IV). • Severe dehydration (caused by vomiting, diarrhea or insufficient fluid intake).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003e \u003cu\u003eDosage\u003c\/u\u003e \u003c\/b\u003e \u003cb\u003eAdults and adolescents over 12 years old\u003c\/b\u003e: 1 tablet 2-3 times a day. Do not exceed the dose of 3 tablets per day. Undesirable effects can be minimized by using the lowest effective dose for the shortest possible treatment duration needed to control symptoms (see section 4.4). If the use of the medicine is necessary for more than 3 days in adolescents, or in the case of worsening of symptoms, the doctor should be consulted. Do not exceed the recommended doses: elderly patients in particular must stick to the minimum dosages indicated above. \u003ci\u003eElderly\u003c\/i\u003e: NSAIDs should be used with particular caution in elderly patients who are more prone to adverse events and are at increased risk of potentially fatal gastrointestinal bleeding, ulceration or perforation (see section 4.4). If treatment is considered necessary, the lowest dose for the shortest duration necessary to control symptoms should be used (see section 4.4). \u003ci\u003eRenal failure\u003c\/i\u003e: In patients with mild or moderate reduction in renal function, the dosage should be kept as low as possible for the shortest duration necessary to control symptoms and renal function should be monitored. \u003ci\u003eLiver failure\u003c\/i\u003e: In patients with mild or moderate reduction in liver function, the dosage should be kept as low as possible for the shortest duration necessary to control symptoms and liver function should be monitored. Momentact is contraindicated in patients with severe hepatic impairment (see section 4.3). \u003ci\u003ePediatric population\u003c\/i\u003e Momentact is contraindicated in children under 12 years of age (see section 4.3). \u003cb\u003e \u003cu\u003eMethod of administration\u003c\/u\u003e \u003c\/b\u003e You can take Momentact on an empty stomach. In subjects with gastric tolerability problems, it is preferable to take the medicine on a full stomach.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThis medicine does not require any particular storage temperature.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e• The use of Momentact, like any drug that inhibits the synthesis of prostaglandins and cyclooxygenase, is not recommended in women who intend to become pregnant. • The administration of Momentact should be suspended in women who have fertility problems or who are undergoing fertility investigations. • Side effects can be minimized by using the lowest effective dose for the shortest possible duration of treatment needed to control symptoms (see paragraphs below on gastrointestinal and cardiovascular risks). • Elderly: Elderly patients have an increased frequency of adverse reactions to NSAIDs, especially gastrointestinal bleeding and perforation, which may be fatal (see section 4.2). • \u003ci\u003e \u003cu\u003eCardiovascular and cerebrovascular effects\u003c\/u\u003e \u003c\/i\u003e Caution is required before starting treatment in patients with a history of hypertension and\/or heart failure since fluid retention, hypertension and edema have been reported in association with treatment with NSAIDs. NSAIDs can reduce the effect of diuretics and other antihypertensive drugs (see section 4.5). Clinical studies suggest that the use of ibuprofen, especially at high doses (2400 mg\/day), may be associated with a modest increase in the risk of arterial thrombotic events (e.g. myocardial infarction or stroke). In general, epidemiological studies do not suggest that low doses of ibuprofen (e.g. ≤ 1200 mg\/day) are associated with an increased risk of arterial thrombotic events. Patients with uncontrolled hypertension, congestive heart failure (NYHA class II-III), established ischemic heart disease, peripheral arterial disease and\/or cerebrovascular disease should be treated with ibuprofen only after careful consideration and high doses (2400 mg\/day) should be avoided. Careful consideration must also be exercised before starting patients with risk factors for cardiovascular events (e.g. hypertension, hyperlipidemia, diabetes mellitus, cigarette smoking habit) on long-term treatment, especially if high doses (2400 mg\/day) of ibuprofen are necessary. Patients with uncontrolled hypertension, congestive heart failure, established ischemic heart disease, peripheral arterial disease, and\/or cerebrovascular disease should be treated with ibuprofen only after careful consideration. Similar considerations must be made before starting long-term treatment in patients with risk factors for cardiovascular events (e.g. hypertension, hyperlipidemia, diabetes mellitus, smoking). • \u003ci\u003e \u003cu\u003eGastrointestinal bleeding, ulceration and perforation\u003c\/u\u003e \u003c\/i\u003e The use of Momentact should be avoided concomitantly with NSAIDs, including selective cyclooxygenase-2 (COX-2) inhibitors due to an increased risk of ulceration or bleeding (see section 4.5). In particular, gastrointestinal bleeding, ulceration and perforation, which may be fatal, have been reported during treatment with all NSAIDs at any time, with or without warning symptoms or previous history of serious gastrointestinal events. In the elderly and in patients with a history of ulcer, especially if complicated by haemorrhage or perforation (see section 4.3), the risk of gastrointestinal haemorrhage, ulceration or perforation is higher with increased doses of NSAIDs. These patients should start treatment with the lowest available dose. The concomitant use of protective agents (misoprostol or proton pump inhibitors) should be considered for these patients and also for patients taking low doses of acetylsalicylic acid or other drugs that may increase the risk of gastrointestinal events (see below and section 4.5). Patients with a history of gastrointestinal toxicity, particularly the elderly, should report any unusual gastrointestinal symptoms (especially gastrointestinal haemorrhage) particularly in the initial stages of treatment. Carefully monitor patients taking concomitant medications that may increase the risk of ulceration or bleeding, such as oral corticosteroids, anticoagulants such as warfarin, selective serotonin reuptake inhibitors or antiplatelet agents such as acetylsalicylic acid (see section 4.5). When gastrointestinal bleeding or ulceration occurs in patients taking Momentact, treatment should be discontinued. NSAIDs should be administered with caution to patients with a history of gastrointestinal disease (ulcerative colitis, Crohn's disease) as these conditions may be exacerbated (see section 4.8). • \u003ci\u003e \u003cu\u003eSevere skin reactions\u003c\/u\u003e \u003c\/i\u003e Serious skin reactions, some of them fatal, including exfoliative dermatitis, Stevens-Johnson syndrome and toxic epidermal necrolysis, have been reported rarely in association with the use of NSAIDs (see section 4.8). Patients appear to be at higher risk in the early stages of therapy: the onset of the reaction occurs in most cases within the first month of treatment. Acute generalized exanthematous pustulosis (PEAG) has been reported in connection with ibuprofen-containing medicinal products. Ibuprofen should be discontinued at the first appearance of signs and symptoms of severe skin reactions, such as rash, mucosal lesions or any other sign of hypersensitivity as well as if visual disturbances or persistent signs of liver dysfunction occur. • \u003ci\u003e \u003cu\u003eRenal effects\u003c\/u\u003e \u003c\/i\u003e When initiating treatment with ibuprofen, caution should be exercised in patients with considerable dehydration. Ibuprofen may cause water and sodium, potassium retention in patients who have never suffered from kidney disease due to its effects on renal perfusion. This may cause edema or heart failure or hypertension in predisposed patients. Long-term use of ibuprofen, as with other NSAIDs, has led to renal papillary necrosis and other renal pathological changes. In general, the habitual use of analgesics, especially combinations of different analgesic active ingredients, can lead to permanent kidney damage, with the risk of onset of renal failure (analgesic nephropathy). Renal toxicity has been reported in patients in whom renal prostaglandins have a compensatory role in maintaining renal perfusion. The administration of NSAIDs in these patients can lead to a dose-dependent reduction in the formation of prostaglandins and, as a secondary effect, in renal blood flow which can quickly lead to renal decompensation. The patients most at risk of these reactions are those with reduced renal function, heart failure, liver dysfunction, the elderly and all those patients taking diuretics and ACE inhibitors. Discontinuation of NSAID therapy is usually followed by recovery to the pretreatment state. In dehydrated adolescents there is a risk of impaired renal function. In case of prolonged use, monitor renal function, particularly in cases of diffuse lupus erythematosus. • \u003ci\u003e \u003cu\u003eRespiratory disorders\u003c\/u\u003e \u003c\/i\u003e Momentact should be prescribed with caution in patients with bronchial asthma, chronic rhinitis, nasal polyps, sinusitis or current or previous allergic diseases because bronchospasm, urticaria and angioedema may occur. The same applies to those subjects who have experienced bronchospasm after the use of acetylsalicylic acid or other NSAIDs. • \u003ci\u003e \u003cu\u003eHypersensitivity reactions\u003c\/u\u003e \u003c\/i\u003e Analgesics, antipyretics, NSAIDs can cause potentially serious hypersensitivity reactions (anaphylactoid reactions), even in subjects not previously exposed to this type of drugs. The risk of hypersensitivity reactions after taking ibuprofen is greater in subjects who have experienced such reactions after the use of other analgesics, antipyretics, NSAIDs and in subjects with bronchial hyperreactivity (asthma), hay fever, nasal polyposis or chronic obstructive respiratory diseases or previous episodes of angioedema (see sections 4.3 and 4.8). Hypersensitivity reactions may present in the form of asthma attacks (so-called analgesic asthma), Quincke's edema or urticaria. Severe hypersensitivity reactions (e.g. anaphylactic shock) have been observed rarely. At the first signs of hypersensitivity reaction after administration of ibuprofen, treatment should be discontinued. Medically assisted measures must be initiated by specialized medical personnel, in line with the symptoms. • \u003ci\u003e \u003cu\u003eReduced cardiac, renal and hepatic function\u003c\/u\u003e \u003c\/i\u003e Particular caution must be taken when treating patients with reduced cardiac, hepatic or renal function since the use of NSAIDs may cause a deterioration of renal function. The usual concomitant use of different painkillers can further increase this risk. In patients with reduced cardiac, hepatic or renal function it is advisable to use the lowest effective dose for the shortest period of treatment and periodic monitoring of clinical and laboratory parameters, especially in case of prolonged treatment. • \u003ci\u003e \u003cu\u003eHematological effects\u003c\/u\u003e \u003c\/i\u003e Ibuprofen, like other NSAIDs, can inhibit platelet aggregation and has shown evidence of prolonging bleeding time in healthy subjects. Therefore, patients with coagulation defects or on anticoagulant therapy should be carefully observed. • \u003ci\u003e \u003cu\u003eAseptic meningitis\u003c\/u\u003e \u003c\/i\u003e On rare occasions, symptoms of aseptic meningitis have been observed in patients treated with ibuprofen. Although this is more likely to occur in patients with systemic lupus erythematosus and related connective tissue disorders, it has also been observed in patients without concomitant chronic diseases (see section 4.8). • Since ocular alterations have been detected during animal studies with NSAIDs, it is recommended, in case of prolonged treatments, to carry out periodic ophthalmological checks. • Alcohol consumption should be avoided as it can intensify the side effects of NSAIDs, especially those affecting the gastrointestinal tract or central nervous system. • Masking of symptoms of underlying infections • Momentact may mask symptoms of infection, which may delay the initiation of appropriate treatment and therefore worsen the outcome of the infection. This has been observed in community-acquired bacterial pneumonia and bacterial complications of chickenpox. When Momentact is administered for the relief of fever or pain related to infection, monitoring of the infection is recommended. In non-hospital settings, the patient should seek medical attention if symptoms persist or worsen. \u003ci\u003e \u003cu\u003eImportant information about some excipients\u003c\/u\u003e \u003c\/i\u003e Momentact contains:- \u003cb\u003eLactose\u003c\/b\u003e: Patients suffering from rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicine. - \u003cb\u003eSodium\u003c\/b\u003e: This medicinal product contains less than 1 mmol (23 mg) sodium per dose, i.e. essentially 'sodium-free'.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIt is advisable to seek medical advice in case of any concomitant therapy before administering the product. Ibuprofen (like other NSAIDs) should be taken with caution in combination with the substances listed below. • Corticosteroids: increased risk of gastrointestinal ulceration or haemorrhage (see section 4.4). • Anticoagulants: NSAIDs may increase the effects of anticoagulants, such as warfarin or heparin (see section 4.4). In case of concomitant treatment, monitoring of coagulation status is recommended. • Cyclooxygenase-2 (COX-2) inhibitors and other NSAIDs: these substances may increase the risk of adverse reactions affecting the gastrointestinal tract (see section 4.4). It is advisable not to combine ibuprofen with other NSAIDs, including selective COX-2 inhibitors, due to potential additive effects (see section 4.4). • Acetylsalicylic acid: Concomitant administration of ibuprofen and acetylsalicylic acid is generally not recommended due to the potential for increased side effects. Experimental data suggest that ibuprofen can competitively inhibit the effect of low-dose acetylsalicylic acid on platelet aggregation when the two drugs are administered simultaneously. Although there are uncertainties regarding the extrapolation of these data to the clinical situation, the possibility cannot be excluded that regular, long-term use of ibuprofen may reduce the cardioprotective effect of acetylsalicylic acid at low doses. No relevant clinical effects are considered likely following occasional use of ibuprofen (see section 5.1). • Anti-platelet agents and selective serotonin reuptake inhibitors (SSRIs): increased risk of gastrointestinal haemorrhage (see section 4.4). • Diuretics, ACE inhibitors (such as captopril), beta blockers and angiotensin II antagonists: NSAIDs can reduce the effect of diuretics and other antihypertensive drugs. Diuretics may also increase the risk of NSAID-associated nephrotoxicity. In some patients with compromised renal function (e.g. dehydrated patients or elderly patients with compromised renal function) co-administration of an ACE inhibitor or an angiotensin II antagonist and agents that inhibit the cyclo-oxygenase system may lead to further deterioration of renal function, including possible acute renal failure, which is usually reversible. These interactions should be considered in patients taking Momentact concomitantly with ACE inhibitors or angiotensin II antagonists. Therefore, the combination should be administered with caution, especially in elderly patients. Patients should be adequately hydrated and monitoring of renal function should be considered after initiation of concomitant therapy and thereafter. • Phenytoin and lithium: concomitant administration of ibuprofen and phenytoin or lithium preparations may result in reduced elimination of these medicines with consequent increase in their plasma levels with the possibility of reaching the toxic threshold. If this association is deemed necessary, monitoring of plasma levels of phenytoin and lithium is recommended in order to adapt the appropriate dosage during simultaneous treatment with ibuprofen. • Methotrexate: NSAIDs may inhibit the tubular secretion of methotrexate and some metabolic interactions may occur resulting in reduced clearance of methotrexate and resulting in an increased risk of toxicity. • Moclobemide: increases the effect of ibuprofen. • Aminoglycosides: NSAIDs can decrease the excretion of aminoglycosides, increasing their toxicity. • Cardiac glycosides: NSAIDs can exacerbate heart failure, reduce the glomerular filtration rate and increase plasma levels of cardiac glycosides. Monitoring of serum glycoside levels is recommended. • Cholestyramine: the concomitant administration of ibuprofen and cholestyramine can reduce the absorption of ibuprofen from the gastrointestinal tract. However, the clinical relevance of this interaction is not known.• Cyclosporins: concomitant administration of ciclosporin and some NSAIDs causes an increased risk of renal damage. This effect cannot be excluded for the combination of ciclosporin and ibuprofen. • Plant extracts: Ginkgo Biloba may increase the risk of bleeding in association with NSAIDs. • Mifepristone: due to the anti-prostaglandin properties of NSAIDs, their use after the administration of mifepristone may lead to a reduction in the effect of mifepristone. Limited evidence suggests that co-administration of NSAIDs and prostaglandins on the same day does not adversely influence the effects of mifepristone or prostaglandin on cervical ripening or uterine contractility and does not reduce the clinical efficacy of the medicinal product on pregnancy termination. • Quinolone antibiotics: Patients taking NSAIDs and quinolones may have an increased risk of developing seizures. • Sulfonylureas: NSAIDs can increase the hypoglycemic effect of sulfonylureas. In the case of simultaneous treatment, monitoring of blood glucose levels is recommended. • Tacrolimus: co-administration of NSAIDs and tacrolimus may lead to an increased risk of nephrotoxicity. • Zidovudine: there is evidence of an increased risk of haemarthrosis and hematoma in HIV-positive haemophiliac patients in simultaneous treatment with Zidovudine and other NSAIDs. A haematological examination is recommended 1-2 weeks after starting treatment. • Ritonavir: may cause an increase in plasma concentrations of NSAIDs. • Probenecid: slows the excretion of ibuprofen, with possible increase in their plasma concentrations. • CYP2C9 inhibitors: Concomitant administration of ibuprofen and CYP2C9 inhibitors may slow the elimination of ibuprofen (CYP2C9 substrate) resulting in increased ibuprofen exposure. In a study with voriconazole and fluconazole (CYP2C9 inhibitors), increased exposure to S(+)-ibuprofen by approximately 80% to 100% was observed. Reduction of the ibuprofen dose should be considered in cases of co-administration with strong CYP2C9 inhibitors, particularly when high doses of ibuprofen are administered with voriconazole or fluconazole. • Alcohol, bisphosphonates and oxypentifylline (pentoxifylline): can potentiate gastrointestinal side effects and the risk of bleeding and ulcers. • Baclofen: high toxicity of baclofen.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe side effects observed with ibuprofen are generally common to other analgesics, antipyretics, non-steroidal anti-inflammatory drugs and are reported below using the following convention: Very common (≥1\/10); Common (≥1\/100, \u003c1\/10); Uncommon (≥ 1\/1,000, \u003c 1\/100); Rare (≥1\/10,000, \u003c1\/1,000); Very rare (\u003c1\/10,000); Not known (frequency cannot be estimated from the available data). The most commonly observed adverse events are gastrointestinal in nature. Clinical studies and epidemiological data suggest that the use of ibuprofen (especially at high doses 2400 mg\/day) and for long-term treatments may be associated with a modest increase in the risk of arterial thrombotic events (e.g. myocardial infarction or stroke) (see section 4.4). \u003cu\u003eGastrointestinal disorders:\u003c\/u\u003e Peptic ulcers, perforation or gastrointestinal haemorrhage, sometimes fatal, may occur, particularly in the elderly (see section 4.4). Gastrointestinal perforation with ibuprofen use has been observed rarely. After administration of ibuprofen the following have been reported: feeling of heaviness in the stomach, nausea, vomiting, diarrhoea, flatulence, constipation, dyspepsia, abdominal pain, melena, haematemesis, ulcerative stomatitis, exacerbation of colitis and Crohn's disease (see section 4.4). Uncommon: gastritis; Very rare: pancreatitis. \u003cu\u003eImmune system disorders\u003c\/u\u003e. The following side effects have been reported following treatment with NSAIDs: non-specific allergic reaction and anaphylaxis; uncommon: hypersensitivity reactions such as skin rash of various types, urticaria, pruritus, purpura, angioedema, exanthema, respiratory tract reactions including asthma, even severe, bronchospasm or dyspnea asthmatic attack (sometimes with hypotension); rare: lupus erythematosus syndrome; very rare: serious hypersensitivity reactions. Symptoms may include: facial edema, tongue edema, laryngeal edema, airway edema with constriction, dyspnoea, tachycardia, anaphylaxis, exfoliative and bullous dermatitis (including Stevens-Johnson syndrome, toxic epidermal necrolysis and erythema multiforme). \u003cu\u003eCardiac and vascular pathologies\u003c\/u\u003e: Edema, fatigue, hypertension and heart failure have been reported in association with treatment with NSAIDs. Clinical studies suggest that the use of ibuprofen, especially at high doses (2400 mg\/day) may be associated with a modest increase in the risk of arterial thrombotic events (e.g. myocardial infarction or stroke) (see section 4.4). Very rare: palpitations, heart failure, myocardial infarction, acute pulmonary edema, edema, hypertension. These phenomena generally tend to regress upon suspension of treatment. Other adverse events reported less frequently and for which causality has not necessarily been established include: \u003cu\u003ePathologies of the blood and lymphatic system\u003c\/u\u003e. Rare: leukopenia, thrombocytopenia, neutropenia, agranulocytosis, aplastic anemia and haemolytic anemia. \u003cu\u003ePsychiatric disorders\u003c\/u\u003e. Uncommon: insomnia, anxiety; Rare: depression, confusional state, hallucinations. \u003cu\u003eNervous system disorders\u003c\/u\u003e. Common: dizziness; Uncommon: paraesthesia, drowsiness; Rare: optic neuritis. \u003cu\u003eInfections and infestations\u003c\/u\u003e. Uncommon: rhinitis; Rare: aseptic meningitis. Aseptic rhinitis and meningitis (especially in patients with pre-existing autoimmune disorders, such as systemic lupus erythematosus and mixed connective tissue disease) with symptoms of neck stiffness, headache, nausea, vomiting, fever or disorientation (see section 4.4). Exacerbation of infection-related inflammation has been described (e.g. development of necrotizing fasciitis). \u003cu\u003eThoracic and mediastinal respiratory disorders\u003c\/u\u003e. Uncommon: bronchospasm, dyspnea, apnea. \u003cu\u003eEye pathologies\u003c\/u\u003e. Uncommon: visual disturbances; Rare: ocular alteration resulting in visual disturbances, toxic optic neuropathy. \u003cu\u003eEar and labyrinth disorders\u003c\/u\u003e. Uncommon: impaired hearing, tinnitus, vertigo. \u003cu\u003eHepatobiliary disorders\u003c\/u\u003e. Uncommon: abnormal liver function, hepatitis and jaundice; Very rare: liver failure. \u003cu\u003ePathologies of the skin and subcutaneous tissue\u003c\/u\u003e. Sometimes allergic skin rashes may occur (erythema, itching, urticaria). Uncommon: photosensitivity reactions; Very rare: bullous reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis. In exceptional cases, serious skin infections and soft tissue disorders may occur during chickenpox infection (see “infections and infestations”). Not known: drug reaction with eosinophilia and systemic symptoms (DRESS syndrome), acute generalized exanthematous pustulosis (PEAG). \u003cu\u003eRenal and urinary disorders\u003c\/u\u003e. Uncommon: impairment of renal function and toxic nephropathy in various forms, including interstitial nephritis, nephrotic syndrome and renal failure. \u003cu\u003eSystemic pathologies and conditions relating to the administration site\u003c\/u\u003e. Common: malaise, fatigue; Rare: edema. \u003ci\u003e \u003cu\u003eReporting of suspected adverse reactions\u003c\/u\u003e \u003c\/i\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003e \u003cu\u003eToxicity\u003c\/u\u003e \u003c\/i\u003e Signs and symptoms of toxicity were generally not observed at doses below 100 mg\/kg in children or adults. However, in some cases supportive treatment may be necessary. Children have been observed to exhibit signs and symptoms of toxicity after ingesting ibuprofen at doses of 400 mg\/kg or greater. \u003ci\u003e \u003cu\u003eSymptoms\u003c\/u\u003e \u003c\/i\u003e Most patients who have ingested significant amounts of ibuprofen will experience symptoms within 4 to 6 hours. The most commonly reported overdose symptoms include: nausea, vomiting, abdominal pain, lethargy, and drowsiness. Central nervous system (CNS) effects include headache, tinnitus, dizziness, seizures, and loss of consciousness. Nystagmus, metabolic acidosis, hypothermia, renal effects, gastrointestinal bleeding, coma, apnea, diarrhea and CNS and respiratory depression have also been reported rarely. Disorientation, arousal, fainting and cardiovascular toxicity including hypotension, bradycardia and tachycardia have been reported. In cases of significant overdose, renal failure and liver damage are possible. In cases of severe poisoning, metabolic acidosis may occur. \u003ci\u003e \u003cu\u003eTreatment\u003c\/u\u003e \u003c\/i\u003e There is no specific antidote for ibuprofen overdose. In case of overdose, symptomatic and supportive treatment is therefore indicated. Particular attention is due to the control of blood pressure, acid-base balance and any gastrointestinal bleeding. Administration of activated charcoal should be considered within one hour of ingesting a potentially toxic quantity. Alternatively, in adults, gastric lavage should be considered within one hour of ingesting a potentially life-threatening overdose. Adequate diuresis must be ensured and renal and hepatic functions must be closely monitored. The patient must remain under observation for at least four hours following ingestion of a potentially toxic amount of drug. Any occurrence of frequent or prolonged convulsions should be treated with intravenous diazepam. Depending on the patient's clinical condition, other support measures may be necessary. For more information, contact your local poison control center.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003e \u003cu\u003ePregnancy\u003c\/u\u003e \u003c\/i\u003e Inhibition of prostaglandin synthesis can negatively affect pregnancy and\/or embryo\/foetal development. Results of epidemiological studies suggest an increased risk of miscarriage and cardiac malformation and gastroschisis after the use of a prostaglandin synthesis inhibitor in the early stages of pregnancy. The absolute risk of cardiac malformations increased from less than 1% to approximately 1.5%. The risk has been thought to increase with dose and duration of therapy. In animals, the administration of prostaglandin synthesis inhibitors has been shown to cause an increase in pre- and post-implantation loss and embryo-foetal mortality. Furthermore, an increased incidence of various malformations, including cardiovascular malformations, has been reported in animals to which prostaglandin synthesis inhibitors were administered during the organogenetic period. From the twentieth week of pregnancy onwards, the use of Momentact may cause oligohydramnios resulting from fetal renal dysfunction. This may occur shortly after starting treatment and is usually reversible upon discontinuation. Additionally, cases of ductus arteriosus constriction have been reported following treatment in the second trimester, most of which resolved after treatment discontinuation. Therefore, during the first and second trimester of pregnancy, Momentact should not be administered unless strictly necessary. If Momentact is used by a woman trying to conceive or during the first and second trimester of pregnancy, the dose and duration of treatment should be kept as low as possible. Following exposure to MOMENTACT for several days from gestational week 20 onwards, prenatal monitoring for oligohydramnios and ductus arteriosus constriction should be considered. MOMENTACT should be discontinued if oligohydramnios or constriction of the ductus arteriosus occurs. \u003cu\u003eDuring the third trimester of pregnancy, all inhibitors of prostaglandin synthesis can expose the fetus to\u003c\/u\u003e: - cardiopulmonary toxicity (premature constriction\/closure of the ductus arteriosus and pulmonary hypertension); - renal dysfunction (see above); \u003cu\u003eAt the end of pregnancy, all inhibitors of prostaglandin synthesis can expose the mother and newborn, to\u003c\/u\u003e:- possible prolongation of bleeding time, and anti-aggregating effect which can occur even at very low doses; - inhibition of uterine contractions resulting in delayed or prolonged labor. Consequently, Momentact is contraindicated during the third trimester of pregnancy (see sections 4.3 and 5.3). \u003cu\u003eBreastfeeding\u003c\/u\u003e Ibuprofen is excreted in breast milk, but at therapeutic doses during short-term treatment, the risk of influencing the newborn appears unlikely. If, however, the treatment is longer term, early weaning should be considered. NSAIDs should be avoided during breastfeeding. \u003cu\u003eFertility\u003c\/u\u003e The use of Ibuprofen may compromise female fertility and is not recommended in women attempting to conceive. This effect is reversible upon discontinuation of treatment. In women who have difficulty conceiving or who are under investigation for infertility, discontinuation of ibuprofen treatment should be considered.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAs a rule, the use of ibuprofen does not alter the ability to drive or use machinery. However, patients whose activity requires vigilance should use caution if they notice drowsiness, dizziness or depression during ibuprofen therapy.\u003c\/p\u003e","brand":"Angelini","offers":[{"title":"Default Title","offer_id":40207837298803,"sku":"035618053","price":13.49,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/products\/angelini-spa-momentact-400-mg-analgesico-20-compresse-farmacia-dottor-tili-1213793024.webp?v=1767129047"},{"product_id":"lattulosio-sand-sciroppo-180-ml","title":"Lactulose Sand Syrup 180 ml","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eShort-term treatment of occasional constipation. \u003cu\u003eAdults:\u003c\/u\u003e occasional constipation; adjuvant in intestinal bacterial diseases caused by coliform germs (Salmonella, Shigella, etc.) \u003cu\u003eChildren and infants:\u003c\/u\u003e constipation; treatment of putrefactive syndromes due to eating disorders; as a corrective to the infant's diet, especially in the transition from maternal to artificial breastfeeding.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003e66.7% syrup, 180 ml bottle\u003c\/u\u003e 100 ml of syrup contains 66.7 g of lactulose Excipients with known effect: 100 ml of syrup contains 0.118 g of sodium benzoate. For the complete list of excipients see section 6.1\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003esodium benzoate; purified water.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to the active substance or to any of the excipients listed in paragraph 6.1. Laxatives are contraindicated in subjects with acute abdominal pain or pain of unknown origin, nausea or vomiting, intestinal obstruction or stenosis, rectal bleeding of unknown origin, severe dehydration. Contraindicated in subjects suffering from galactosemia. Generally contraindicated in pediatric age (see section 4.4).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDosage \u003cu\u003eAdults: \u003c\/u\u003ethe average daily dosage is 10-15 g in two administrations. This dosage can be doubled or halved depending on the individual response or clinical picture. Pediatric population \u003cu\u003eChildren:\u003c\/u\u003e from 2.5 to 10 g\/day, even in a single administration, depending on the age and severity of the case. \u003cu\u003eInfants:\u003c\/u\u003e on average 2.5 g per day. The correct dose is the minimum sufficient to produce an easy evacuation of loose stools. It is advisable to initially use the minimum doses provided. When necessary, the dose can then be increased, but without ever exceeding the maximum indicated. Take preferably in the evening. Laxatives should be used as infrequently as possible and for no longer than seven days. Use for longer periods of time requires a doctor's prescription after adequate evaluation of the individual case. Swallow together with an adequate quantity of water (a large glass). A diet rich in liquids favors the effect of the medicine.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThis medicinal product does not require any special storage conditions.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eSpecial warnings\u003c\/u\u003e Lactulose is absorbed to a very small extent and has no caloric value. However, in addition to lactulose, Lactulose Sandoz also contains galactose, lactose and small quantities of other sugars. This must be taken into account in the treatment of diabetic patients and in patients following low-calorie diets. Abuse of laxatives (frequent or prolonged use or with excessive doses) can cause persistent diarrhea with consequent loss of water, mineral salts (especially potassium) and other essential nutritional factors. In more severe cases, the onset of dehydration or hypokalemia is possible which can cause cardiac or neuromuscular dysfunction, especially in the case of simultaneous treatment with cardiac glycosides, diuretics or corticosteroids. The abuse of laxatives, especially contact laxatives (stimulant laxatives), can cause dependence (and, therefore, possible need to progressively increase the dosage), chronic constipation and loss of normal intestinal functions (intestinal atony). \u003cu\u003ePrecautions for use\u003c\/u\u003e Do not use the medicine if abdominal pain, nausea and vomiting are present. If constipation is stubborn, consult a doctor. In patients who present disorders caused by excessive intestinal meteorism it is advisable to start treatment with the minimum doses indicated; these doses can be gradually increased in relation to the patient's response. In children under 12 years of age the medicine can only be used after consulting a doctor. The treatment of chronic or recurrent constipation always requires the intervention of a doctor for diagnosis, prescription of medicines and monitoring during the course of therapy. Consult your doctor when the need for the laxative derives from a sudden change in previous intestinal habits (frequency and characteristics of evacuations) that lasts for more than two weeks or when the use of the laxative fails to produce effects. It is also advisable for elderly people or those in poor health to consult their doctor before using the medicine. \u003cb\u003e \u003cu\u003eImportant information about some excipients\u003c\/u\u003e \u003c\/b\u003e Lactulose Sandoz contains 26.4 mg of sodium benzoate per average daily dose equivalent to 0.14 mg\/ml. Sodium benzoate may increase jaundice (yellowing of the skin and eyes) in newborns up to 4 weeks of age. The increase in bilirubin following its detachment from albumin can increase neonatal jaundice which can progress to kernicterus (deposits of unconjugated bilirubin in the brain tissue). Lactulose Sandoz contains less than 1 mmol (23 mg) sodium per dose, i.e. essentially 'sodium-free'.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eBroad-spectrum antibacterial agents, administered orally at the same time as lactulose, can reduce degradation, limiting the possibility of acidification of the intestinal contents and consequently the therapeutic efficacy. Laxatives can reduce the residence time in the intestine, and therefore the absorption, of other medicines administered simultaneously orally. Therefore, avoid ingesting laxatives and other medicines at the same time: after taking a medicine, leave an interval of at least 2 hours before taking the laxative.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders: Occasionally: isolated cramping pain or abdominal colic, more frequent in cases of severe constipation. Frequency not known: flatulence. Immune system disorders: Frequency not known: hypersensitivity reactions. Skin and subcutaneous tissue disorders: Frequency not known: rash, itching, urticaria. Reporting of suspected adverse reactions. Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eExcessive doses can cause abdominal pain and diarrhea; the resulting losses of fluids and electrolytes must be replaced. Also see what is reported in the paragraph “Special warnings and precautions for use” regarding the abuse of laxatives.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThere are no adequate and well-controlled studies on the use of the medicine during pregnancy or breastfeeding. Therefore the medicine must be used only if necessary, under the direct supervision of the doctor, after having evaluated the expected benefit for the mother in relation to the possible risk for the fetus or infant.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eLactulose sandoz does not alter the ability to drive and use machines.\u003c\/p\u003e","brand":"Sandoz","offers":[{"title":"Default Title","offer_id":40207839035507,"sku":"027668019","price":7.49,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/sandoz-lattulosio-sand-sciroppo-180-ml-farmacia-dottor-tili-1254215794.jpg?v=1786737131"},{"product_id":"daflon-30-compresse-rivestite-500mg","title":"Daflon 30 Coated Tablets 500mg","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSymptoms attributable to venous insufficiency; states of capillary fragility. Symptomatic treatment of acute hemorrhoidal crisis.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eEach film-coated tablet contains 500 mg of micronized purified flavonoid fraction consisting of 450 mg of diosmin and 50 mg of flavonoids expressed as hesperidin. For the full list of excipients, see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSodium starch starch, microcrystalline cellulose, gelatin, glycerin, hypromellose, sodium lauryl sulphate, yellow iron oxide E172, red iron oxide E 172, titanium dioxide, macrogol 6000, magnesium stearate, talc.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to the active substance or to any of the excipients listed in paragraph 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDosage \u003ci\u003eVenous insufficiency (also of the haemorrhoidal plexus) and capillary fragility \u003c\/i\u003e The recommended dose is 2 tablets to be taken in two doses per day. Do not exceed the maximum daily dose. \u003ci\u003eAcute hemorrhoidal crisis\u003c\/i\u003e The recommended dose is 3 tablets twice a day during the first 4 days of treatment; in the following 3 days the daily dose is 4 tablets in two administrations. Do not exceed the maximum daily dose. Method of administration Take the tablets with the two main meals. Duration of treatment Treatment must not be continued beyond 7 days. In the absence of a therapeutic response, reassess the situation.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThis medicinal product does not require any special storage conditions.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eImportant information about some excipients Daflon contains less than 1 mmol (23 mg) sodium per tablet, i.e. it is essentially 'sodium-free'.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo interaction studies have been performed. To date, no clinically relevant drug interactions have been reported from post-marketing experience on the product.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe following adverse effects or reactions have been reported and are classified according to the following frequency: very common (≥1\/10); common (≥1\/100, \u003c1\/10); uncommon (≥1\/1,000, \u003c1\/100); rare (≥1\/10,000, \u003c1\/1,000); very rare (\u003c1\/10,000), not known (frequency cannot be estimated from the available data). \u003ci\u003eNervous system disorders\u003c\/i\u003e Rare: dizziness, headache, malaise \u003ci\u003eGastrointestinal disorders\u003c\/i\u003e Common: diarrhoea, dyspepsia, nausea, vomiting Uncommon: colitis Not known: abdominal pain \u003ci\u003ePathologies of the skin and subcutaneous tissue\u003c\/i\u003e Rare: rash, pruritus, urticaria Not known: edema of the face, lips, eyelid; Quincke's edema \u003ci\u003ePathologies of the blood and lymphatic system\u003c\/i\u003e Not known: thrombocytopenia \u003cu\u003eReporting of suspected adverse reactions\u003c\/u\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the risk\/benefit ratio of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eSymptoms\u003c\/u\u003e There is limited experience with Daflon overdose. The most frequently reported adverse events in cases of overdose were gastrointestinal events (such as diarrhea, nausea, abdominal pain) and skin events (such as pruritus, rash). \u003cu\u003eManagement\u003c\/u\u003e Management of overdose should consist of treatment of clinical symptoms.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003ePregnancy\u003c\/u\u003e Data relating to the use of purified micronized flavonoid fraction in pregnant women do not exist or are limited in number. Animal studies do not indicate reproductive toxicity (see section 5.3). As a precaution, it is preferable to avoid the use of Daflon during pregnancy. \u003cu\u003eBreastfeeding\u003c\/u\u003e It is not known whether the active substance\/metabolites are excreted in breast milk. A risk to the newborn\/infants cannot be excluded. A decision must be made whether to discontinue breast-feeding or to discontinue\/abstain from Daflon therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman. \u003cu\u003eFertility\u003c\/u\u003e Reproductive toxicity studies have shown no effects on fertility in either male or female rats (see section 5.3).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo studies have been conducted to evaluate the effect of the flavonoid fraction on the ability to drive or use machinery.\u003c\/p\u003e","brand":"Servier","offers":[{"title":"Default Title","offer_id":40207839920243,"sku":"023356025","price":16.55,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/products\/servier-italia-spa-daflon-30-compresse-rivestite-500mg-farmacia-dottor-tili-1213792983.webp?v=1767129769"},{"product_id":"ruscoroid-1-1-crema-40gr","title":"Ruscoroid 1% + 1% Cream 40gr","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eTreatment of symptoms associated with hemorrhoids, anal fissures and proctitis, such as: itching, pain and feeling of weight.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e100 g of cream contains: Ruscogenin 1 g Tetracaine hydrochloride 1 g Excipients with known effects: cetyl alcohol, methyl parahydroxybenzoate, ethyl parahydroxybenzoate, propyl parahydroxybenzoate, Rosemary 7144 perfume. For the complete list of excipients, see paragraph 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eCetyl alcohol, polysorbate 80, macrogol 400, macrogol 4000, methyl parahydroxybenzoate, ethyl parahydroxybenzoate, propyl parahydroxybenzoate, Rosemary 7144* perfume, purified water. *Rosemary 7144 perfume contains the following allergens: amyl cinnamale, amylcinnamal alcohol, benzyl benzoate, citral, citronellol, coumarin, eugenol, geraniol, hexylcinnamale, hydroxycitronellal, d-limonene, linalool (see section 4.4).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to the active ingredient or to any of the excipients listed in paragraph 6.1 or to other closely related substances from a chemical point of view.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDosage 1 - 2 applications per day Do not exceed the recommended doses. Method of administration Apply directly or using the appropriate applicator.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eStore below 25°C.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDo not use for prolonged treatments. After a short period of treatment without appreciable results and in case of prolonged use, consult your doctor. The use, especially if prolonged, of products for topical use can give rise to sensitization phenomena; if this happens, treatment should be stopped and the doctor should be consulted to adopt suitable therapeutic measures. Clinical use has not highlighted the need for particular precautions for the use of Ruscoroid. Use under 12 years of age is not recommended, unless under direct medical supervision. \u003cb\u003eRuscoroid 10 mg\/g + 10 mg\/g cream contains cetyl alcohol\u003c\/b\u003e May cause localized skin reactions (e.g. contact dermatitis). \u003cb\u003eRuscoroid 10 mg\/g + 10 mg\/g cream contains methyl parahydroxybenzoate, ethyl parahydroxybenzoate, propyl parahydroxybenzoate\u003c\/b\u003e They can cause allergic reactions (even delayed). \u003cb\u003eRuscoroid 10 mg\/g + 10 mg\/g cream contains Rosemary 7144 perfume\u003c\/b\u003e This medicine contains a flavoring (Rosemary 7144 perfume) which itself contains allergens which may cause allergic reactions. For the complete composition of allergens see paragraph 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003ePhenomena referable to interaction with other substances have never been reported.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eRare cases of sensitization, such as local and generalized erythema associated with itching. \u003cu\u003eReporting of suspected adverse reactions\u003c\/u\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThere are no known cases of overdose.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe product should be used in cases of actual necessity under direct medical supervision.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eRuscoroid does not alter the ability to drive and use machines.\u003c\/p\u003e","brand":"Vemedia","offers":[{"title":"Default Title","offer_id":40207840936051,"sku":"025825023","price":12.09,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/vemedia-ruscoroid-1-1-crema-40gr-farmacia-dottor-tili-1254215793.jpg?v=1786737070"},{"product_id":"biochetasi-os-granulato-effervescente-18-bustine","title":"Biochetasi Os Effervescent Granules 18 Sachets","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e- Hyperacidity - Digestive difficulties - Liver insufficiency - Ketonemic states - Pregnant nausea.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eEffervescent granules.\u003c\/b\u003e One sachet contains: \u003cu\u003eActive ingredients\u003c\/u\u003e: sodium citrate mg 425 potassium citrate mg 50 thiamine diphosphate free ester mg 50 riboflavin monosodium 5-monophosphate mg 25 (equal to 23.8 mg of free acid) vitamin B\u003csub\u003e6\u003c\/sub\u003e hydrochloride 12.5 mg citric acid 100 mg Excipients with known effects: sorbitol (E420), sucrose, fructose, glucose, sodium. One sachet contains: sorbitol (E420): 125 mg sucrose: 1.7 g fructose: 650 mg glucose: 1.4 g sodium: 142 mg \u003cb\u003eEffervescent tablets\u003c\/b\u003e. One effervescent tablet contains: \u003cu\u003eActive ingredients\u003c\/u\u003e: sodium citrate mg 425 potassium citrate mg 50 free thiamine diphosphate ester mg 50 riboflavin monosodium 5-monophosphate mg 25 vitamin B6 hydrochloride mg 12.5 citric acid mg 70 Excipients with known effects: aspartame (E951), sucrose, sodium. One effervescent tablet contains: aspartame (E951): 20 mg sucrose: 737.5 mg sodium 238 mg\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eEffervescent granules\u003c\/b\u003e malic acid; sorbitol; tartaric acid; sodium bicarbonate; polyvinylpyrrolidone; orange aroma; saccharin; sodium edetate; propyl gallate; sucrose; fructose; glucose. \u003cb\u003eEffervescent tablets\u003c\/b\u003e tartaric acid; aspartame; orange aroma; sucrose; insoluble polyvinylpyrrolidone; polyvinylpyrrolidone; talc; precipitated silica; sodium bicarbonate.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to the active substances or to any of the excipients listed in paragraph 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAdults and children over 12 years of age: 2 sachets or 2 effervescent tablets 3 times a day, dissolved in half a glass of water. Children under 12 years of age: half dose. \u003ci\u003eSpecial populations\u003c\/i\u003e. Patients with hepatic impairment: No studies have been conducted with Biochetase in patients with hepatic impairment. Patients with renal insufficiency: No studies have been conducted with Biochetase in patients with renal insufficiency.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThis medicinal product does not require any special storage conditions.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIf symptoms persist, clinical reassessment should be considered. Medicines containing vitamin B1 or its derivatives can, especially if administered parenterally, induce the onset of atopic manifestations in patients with hypersensitivity. Important information about some excipients BIOCHETASI effervescent granules contains sorbitol and fructose. Patients with hereditary fructose intolerance should not be given this medicine. The additive effect of co-administration of medicinal products containing sorbitol or fructose and daily dietary intake of sorbitol or fructose should be considered. The sorbitol content in oral medicinal products may modify the bioavailability of other co-administered oral medicinal products. BIOCHETASI effervescent granules contain glucose. Patients suffering from rare problems of glucose-galactose malabsorption should not take this medicine. BIOCHETASI effervescent granules contains sucrose. Patients suffering from rare hereditary problems of fructose intolerance, glucose-galactose malabsorption, or sucrase isomaltase insufficiency should not take this medicine. BIOCHETASI effervescent granules contains approximately 1.7 g of sucrose and 1.4 g of glucose per dose (sachet). This should be taken into account in diabetic patients and in patients following low-calorie diets. BIOCHETASI effervescent granules contains 142 mg of sodium per sachet equivalent to 7.1% of the maximum daily intake recommended by WHO which corresponds to 2 g of sodium for an adult. The maximum daily dose of this product is equivalent to 42.6% of the WHO recommended maximum daily sodium intake. BIOCHETASI effervescent granules are considered to be high in sodium. To be taken into consideration especially in people following a low sodium diet. BIOCHETASI effervescent tablets contain aspartame, a source of phenylalanine, which can be harmful to patients suffering from phenylketonuria. There are no non-clinical or clinical studies available on the use of aspartame in children under 12 weeks of age. BIOCHETASI effervescent tablets contain sucrose. Patients suffering from rare hereditary problems of fructose intolerance, glucose-galactose malabsorption, or sucrase isomaltase insufficiency should not take this medicine. BIOCHETASI effervescent tablets contain 238 mg of sodium per dose equivalent to 11.9% of the maximum daily intake recommended by WHO which corresponds to 2 g of sodium for an adult. The maximum daily dose of this product is equivalent to 71.4% of the WHO recommended maximum daily sodium intake. BIOCHETASI effervescent granules are considered to be high in sodium. To be taken into consideration especially in people following a low sodium diet.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eRiboflavin absorption is affected by propantheline bromide. Particular caution is required in Parkinson's patients treated with levodopa because vitamin B6 (pyridoxine) can antagonize the therapeutic effects. The use of citrate preparations may increase the gastrointestinal absorption of aluminum (e.g. aluminum-containing antacids).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe following are the side effects organized according to the MedDRA System Organ classification. The adverse reactions derive from literature data and post-marketing reports. Since it was not possible to calculate their frequency they are indicated as not known (the frequency cannot be defined on the basis of the available data). \u003ci\u003eImmune system disorders\u003c\/i\u003e: Urticaria. Anaphylactic shock has been reported in patients treated with parenteral thiamine. \u003ci\u003eGastrointestinal disorders:\u003c\/i\u003e Nausea. \u003ci\u003ePathologies of the skin and subcutaneous tissue\u003c\/i\u003e: Skin rash, Lip edema. \u003ci\u003eRenal and urinary disorders:\u003c\/i\u003e Chromaturia. \u003cu\u003eReporting of suspected adverse reactions.\u003c\/u\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at http:\/\/www.agenziafarmaco.gov.it\/content\/come-segnalare-una-sospetti-reazione-avversa\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eProlonged use of pyridoxine at high doses can cause neuropathy. High doses of potassium-containing products may cause hyperkalemia and alkalosis, particularly in patients with renal insufficiency. High doses of citrate preparations may have a saline-type laxative effect when administered orally.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eBIOCHETASI can be administered both in case of pregnancy and during breastfeeding.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eBIOCHETASI does not alter the ability to drive or use machines.\u003c\/p\u003e","brand":"Alfasigma","offers":[{"title":"Default Title","offer_id":40207843688563,"sku":"015784097","price":13.59,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/products\/alfasigma-spa-biochetasi-os-granulato-effervescente-18-bustine-farmacia-dottor-tili-1213792664.jpg?v=1767119087"},{"product_id":"okitask-10-bustine-granulato-40-mg","title":"Okitask 10 granulated sachets 40 mg.","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003ePain of different origins and nature, and in particular: headache, toothache, neuralgia, menstrual pain, muscular and osteoarticular pain.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eEach sachet contains: Active ingredient: ketoprofen lysine salt 40 mg (corresponding to 25 mg of ketoprofen). Excipients with known effect: aspartame, sodium dodecyl sulphate. For the full list of excipients, see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003ePovidone, colloidal silica, hydroxypropyl methylcellulose, eudragit EPO, sodium dodecyl sulphate, stearic acid, magnesium stearate, aspartame, mannitol, xylitol, talc, lime flavour, lemon flavour, frescofort flavour.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eOkitask 40 mg granules must not be administered in the following cases: • hypersensitivity to the active substance, to other non-steroidal anti-inflammatory drugs (NSAIDs) or to any of the excipients, listed in paragraph 6.1; • asthma, bronchospasm, acute rhinitis, urticaria, skin rashes, nasal polyps, angioneurotic edema or other allergic reactions caused by ketoprofen, or by medicines with a similar mechanism of action (for example acetylsalicylic acid, other NSAIDs and selective cyclo-oxygenase 2 inhibitors), see section 4.8; • previous bronchial asthma; • severe heart failure; • gastritis; • active peptic ulcer\/haemorrhage or history of recurrent peptic ulcer\/haemorrhage (two or more distinct episodes of demonstrated ulceration or haemorrhage); • previous history of gastrointestinal bleeding, ulceration or perforation, or chronic dyspepsia; • history of gastrointestinal bleeding or perforation following previous therapy with NSAIDs; • Crohn's disease or ulcerative colitis; • severe liver failure (liver cirrhosis, severe hepatitis); • severe renal failure; • leukopenia and thrombocytopenia; • haemorrhagic diathesis and other coagulation disorders, haemostatic disorders; • use of a high dosage of diuretics; • third trimester of pregnancy; • children under 15 years old.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eDosage.\u003c\/u\u003e Adults and over 15 years: the recommended dose is 40 mg (corresponding to 1 sachet), in a single dose, or repeated 2-3 times a day, in the most intense forms of pain. Do not exceed the recommended doses. \u003cb\u003eParticular populations. \u003c\/b\u003e \u003ci\u003eElderly:\u003c\/i\u003e The dosage must be carefully established taking into consideration a possible reduction in the above dosages. \u003ci\u003ePatients with hepatic or renal insufficiency: \u003c\/i\u003e Therapy at the minimum daily dosage and careful monitoring are recommended (see section 4.4). In case of renal insufficiency it is recommended to monitor the volume of urine output and renal function (see section 4.4). Okitask 40 mg granules must not be used in patients with severe hepatic or renal dysfunction (see section 4.3). \u003ci\u003ePediatric population:\u003c\/i\u003e The safety and effectiveness of Okitask 40 mg granules in children have not yet been established. \u003cu\u003eMethod of administration:\u003c\/u\u003e The contents of the sachet can be placed directly on the tongue. It dissolves with saliva: this allows it to be used without water. It is preferable to take the product on a full stomach. \u003cu\u003eTreatment duration:\u003c\/u\u003e The duration of therapy must be limited to overcoming the painful episode. The lowest effective dose should be used for the shortest period necessary to relieve symptoms (see section 4.4).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThis medicinal product does not require any special storage conditions.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eWarnings: Undesirable effects can be minimized by using the lowest effective dose for the shortest possible duration of treatment needed to control symptoms (see section 4.2 and the sections below on gastrointestinal and cardiovascular risks). The concomitant use of Okitask 40 mg granules with other NSAIDs, including selective cyclooxygenase-2 inhibitors, should be avoided. \u003cu\u003eGastrointestinal reactions:\u003c\/u\u003e Gastrointestinal haemorrhage, ulceration and perforation: Gastrointestinal haemorrhage, ulceration and perforation, which may be fatal, have been reported at any time during treatment with all NSAIDs, with or without warning symptoms or previous history of serious gastrointestinal events. In patients with a history of ulcer, especially if complicated by haemorrhage or perforation (see section 4.3), the risk of gastrointestinal haemorrhage, ulceration or perforation is higher with increased doses of NSAIDs. These patients should start treatment at the lowest possible dose. The concomitant use of protective agents (misoprostol or proton pump inhibitors) should be considered for these patients and also for patients concomitantly taking low doses of acetylsalicylic acid or other drugs that may increase the risk of gastrointestinal events (see below and section 4.5). Patients with a history of gastrointestinal toxicity, especially the elderly, should report any abdominal symptoms and\/or signs (including gastrointestinal bleeding) even at the start of treatment. Caution should be exercised in patients taking concomitant medications that may increase the risk of ulceration or haemorrhage, such as oral corticosteroids, anticoagulants such as warfarin, selective serotonin reuptake inhibitors or antiplatelet agents such as acetylsalicylic acid (see section 4.5). \u003cu\u003eElderly:\u003c\/u\u003e Elderly people have an increased frequency of adverse reactions to NSAIDs, especially gastrointestinal bleeding and perforation, which can be fatal (see section 4.2). Patients with current or previous gastrointestinal disease should be carefully monitored for the appearance of digestive disorders, especially gastrointestinal bleeding. When gastrointestinal bleeding or ulceration occurs in patients taking Okitask 40 mg granules, treatment should be suspended. \u003cu\u003ePatients with active or previous peptic ulcer:\u003c\/u\u003e Some epidemiological evidence suggests that ketoprofen may be associated with a high risk of serious gastrointestinal toxicity compared to other NSAIDs, especially at high doses (see sections 4.2 and 4.3). \u003cu\u003eSkin reactions:\u003c\/u\u003e Serious skin reactions, some of them fatal, including exfoliative dermatitis, Stevens-Johnson syndrome and toxic epidermal necrolysis, have been reported very rarely in association with the use of NSAIDs (see section 4.8). At the beginning of treatment patients appear to be at higher risk. Okitask 40 mg granules should be discontinued at the first appearance of skin rash, mucosal lesions or any other sign of hypersensitivity. Precautions. \u003cu\u003eCardiovascular, renal and hepatic dysfunction:\u003c\/u\u003e In patients with impaired renal function, the administration of ketoprofen must be carried out with particular caution given the essentially renal elimination of the drug. Renal function should be carefully monitored in patients with heart failure, cirrhosis and nephrosis, in patients receiving diuretic therapy, in patients with chronic renal impairment, particularly if patients are elderly. In these patients, administration of ketoprofen may cause a decrease in renal blood flow caused by inhibition of prostaglandins and lead to renal decompensation (see section 4.3). Caution is also required in patients subject to diuretic therapy or likely to be hypovolemic because the risk of nephrotoxicity is increased. As with all NSAIDs, Okitask 40 mg granules can increase plasma urea nitrogen and creatinine. As with other prostaglandin synthesis inhibitors, Okitas 40 mg granules may be associated with adverse effects on the renal system which may lead to glomerular nephritis, renal papillary necrosis, nephrotic syndrome and acute renal failure (see section 4.8). In patients with abnormal liver function values ​​or a history of liver disease, transaminase levels should be evaluated periodically. As with other NSAIDs, Okitask 40 mg granules can cause increases in some hepatic parameters and also significant increases in SGOT and SGPT (see section 4.8). In case of significant increase in these parameters, therapy must be interrupted. Cases of jaundice and hepatitis have been reported with the use of ketoprofen (see section 4.8). Elderly patients are more predisposed to reduced renal, cardiovascular or hepatic function. \u003cu\u003eCardiovascular and cerebrovascular effects:\u003c\/u\u003e As with other NSAIDs, patients with uncontrolled hypertension, congestive heart failure, established ischemic heart disease, peripheral arterial disease and\/or cerebrovascular disease should be treated with ketoprofen only after careful consideration. Similar considerations must be made before starting treatment in patients with risk factors for cardiovascular disease (e.g. hypertension, hyperlipidemia, diabetes mellitus, smoking). Caution is required before starting treatment in patients with a history of hypertension and\/or mild to moderate congestive heart failure as fluid retention and edema have been reported related to treatment with NSAIDs. Clinical studies and epidemiological data suggest that the use of some NSAIDs may be associated with an increased risk of arterial thrombotic events (e.g. myocardial infarction or stroke). There are insufficient data to exclude a similar risk for Okitask 40 mg granules. An increased risk of atrial fibrillation associated with the use of NSAIDs has been reported. Hyperkalaemia may occur, especially in patients with underlying diabetes, renal insufficiency, and\/or concomitant treatment with agents promoting hyperkalaemia (see section 4.5). In these circumstances potassium levels should be assessed periodically. \u003cu\u003eInfections.\u003c\/u\u003e Masking of symptoms of underlying infections: Okitask 40 mg granules may mask the symptoms of infection, which may delay the initiation of appropriate treatment and therefore worsen the outcome of the infection. This has been observed in community-acquired bacterial pneumonia and bacterial complications of chickenpox. When Okitask 40 mg granules are administered for the relief of fever or pain related to infection, monitoring of the infection is recommended. In non-hospital settings, the patient should seek medical attention if symptoms persist or worsen. \u003cu\u003eRespiratory disorders:\u003c\/u\u003e Like all non-steroidal drugs, the use of ketoprofen in patients with bronchial asthma or allergic diathesis can cause an asthma attack. Patients with asthma associated with chronic rhinitis, chronic sinusitis and\/or nasal polyposis are more exposed to the risk of allergy to acetylsalicylic acid and\/or NSAIDs than the rest of the population. The administration of this drug can cause asthmatic attacks or bronchospasm, shock and other allergic phenomena, especially in subjects allergic to acetylsalicylic acid or NSAIDs (see section 4.3). Due to the action on the metabolism of arachidonic acid, bronchospasm attacks and possibly shock and other allergic phenomena may arise in asthmatics and predisposed subjects. Administer with caution in patients with allergic manifestations or previous allergy. \u003cu\u003eVisual disturbances:\u003c\/u\u003e In case of visual disturbances, such as blurred vision, treatment should be stopped. Okitask 40 mg granules should be administered with caution in patients suffering from haematopoietic alterations, systemic lupus erythematosus or mixed connective tissue diseases. When Okitask 40 mg granules are administered to patients with hepatic porphyria, caution is required as it may trigger an attack. Important information about some excipients: Okitask 40 mg granules contains less than 1mmol (23 mg) sodium per sachet, i.e. essentially 'sodium-free'. Okitask 40 mg granules contains lemon flavoring and lime flavouring. The lemon flavor contains sucrose. Patients suffering from rare hereditary problems of fructose intolerance, glucose-galactose malabsorption, or sucrase isomaltase insufficiency should not take this medicine. The lime flavor contains glucose. Patients suffering from rare problems of glucose-galactose malabsorption should not take this medicine.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eAssociations not recommended.\u003c\/b\u003e - Other NSAIDs (including selective cyclooxygenase 2 inhibitors) and high doses of salicylates (\u003e 3 g\/day): the simultaneous administration of several NSAIDs may increase the risk of gastrointestinal ulcers and bleeding, due to a synergistic effect. - Anticoagulants (heparin and warfarin): NSAIDs can amplify the effects of anticoagulants. If coadministration cannot be avoided, the patient should be closely monitored. - Platelet aggregation inhibitors (ticlopidine and clopidogrel): concomitant administration of an NSAID may increase the risk of bleeding due to inhibition of platelet function and damage to the gastrointestinal mucosa (see section 4.4). If coadministration cannot be avoided, the patient should be closely monitored. - Lithium: the simultaneous administration of several NSAIDs can increase plasma levels of lithium, which can reach toxic values, due to reduced renal excretion. Plasma lithium levels should be carefully monitored and the lithium dosage should be adjusted during and after discontinuation of treatment with ketoprofen and other NSAIDs. - Methotrexate, at doses higher than 15 mg\/week: the simultaneous administration of an NSAID may increase the risk of blood toxicity of methotrexate, especially if administered at high doses, probably due to a displacement of plasma protein binding and a decrease in renal clearance. The intake of the two medicines must be spaced at least 12 hours apart. - Hydantoins and sulphonamides: the toxic effects of these substances may be increased; since the protein binding of ketoprofen is high, it may be necessary to reduce the dosage of diphenylhydantoin or sulphonamides, in case of concomitant administration. \u003cb\u003eAssociations requiring precaution.\u003c\/b\u003e - Drugs or therapeutic categories that can promote hyperkalemia: potassium salts, potassium-sparing diuretics, inhibitors of enzyme converters (ACE inhibitors), angiotensin II receptor blockers, NSAIDs, heparins (low molecular weight or unfractionated), ciclosporin, tacrolimus and trimethoprim. The occurrence of hyperkalemia may depend on the presence of cofactors. The risk is increased in case of simultaneous administration of the above-mentioned drugs. - Tenofovir: concomitant administration of tenofovir disoproxil fumarate and NSAIDs may increase the risk of renal failure. - Diuretics: subjects treated with diuretics, especially in case of dehydration, are at greater risk of developing renal failure secondary to the reduction in renal blood flow caused by the inhibition of prostaglandins. Hydration before starting concomitant therapy and close monitoring of renal function after initiation of treatment are recommended (see section 4.4). NSAIDs can reduce the effect of diuretics. - ACE inhibitors and angiotensin II antagonists: coadministration with cyclo-oxygenase inhibitors may lead to a further deterioration of renal function and possible acute renal failure, especially in dehydrated and elderly subjects. Caution, hydration and monitoring of renal function are recommended in case of combined therapy. -Methotrexate at doses lower than 15 mg\/week: anti-inflammatories cause a decrease in the renal clearance of methotrexate with a consequent increase in blood toxicity. In case of impaired renal function or advanced age, monitoring must be more frequent. - Corticosteroids: concomitant administration of NSAIDs may increase the risk of gastrointestinal ulceration or bleeding (see section 4.4). - Pentoxifylline: co-administration may cause an increased risk of bleeding: monitoring of bleeding time is recommended. - Zidovudine: the combination with NSAIDs increases the risk of toxicity on reticulocytes, with severe anemia occurring one week after starting treatment with NSAIDs. Complete blood cell count and reticulocyte count should be checked one week after starting treatment with the NSAID. - Sulfonylureas: NSAIDs can increase the hypoglycemic effect of sulfonylureas by displacing them from the binding sites with plasma proteins. Possible interactions with other oral hypoglycemics should also be kept in mind. - Cardiac glycosides: NSAIDs can exacerbate heart failure, reduce the glomerular filtration rate and increase levels of cardiac glycosides; however, the pharmacokinetic interaction between ketoprofen and active glycosides has not been demonstrated. \u003cb\u003eAssociations that need to be taken into consideration.\u003c\/b\u003e - Antihypertensive agents (Beta-blockers, ACE inhibitors diuretics): treatment with an NSAID can reduce the effect of antihypertensive drugs by inhibiting the synthesis of vasodilatory prostaglandins. - Mifepristone: the effectiveness of the contraceptive method may, theoretically, be reduced due to the antiprostaglandin properties of NSAIDs including acetylsalicylic acid. There is some evidence to suggest that co-administration of NSAIDs on the day of administration of the prostaglandin dose does not unfavorably influence the effects of mifepristone or prostaglandin on cervical maturation or uterine contractility and does not reduce the clinical efficacy of medical termination of pregnancy. - Intrauterine contraceptive devices (IUDs): the effectiveness of the device may be reduced resulting in pregnancy. - Ciclosporin and tacrolimus: simultaneous treatment with NSAIDs may lead to a greater risk of nephrotoxicity, especially in elderly subjects. - Thrombolytics: concomitant administration with NSAIDs may increase the risk of bleeding. - Anti-aggregating agents (ticlopidine and clopidogrel) and selective serotonin reuptake inhibitors (SSRIs): NSAIDs may increase the risk of gastrointestinal bleeding (see section 4.4). - Probenecid: the concomitant administration of probenecid can markedly reduce the plasma clearance of ketoprofen due to inhibition of tubular secretion and glucuronide conjugation, therefore an adaptation of the dose of ketoprofen is necessary. - Quinolone antibiotics: animal data indicate that NSAIDs may increase the risk of convulsions related to quinolone use. Patients being treated with NSAIDs and quinolones may have an increased risk of developing seizures. - Diphenylhydantoin and sulphonamides: since the protein binding of ketoprofen is high, it may be necessary to reduce the dosage of diphenylhydantoin or sulphonamides in case of co-administration. - Gemeprost: combined use with an NSAID may reduce its effectiveness. Alcohol intake during treatment should be avoided.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe most commonly observed adverse events are gastrointestinal in nature. Classification of expected frequencies: very common (1\/10), common (1\/100 to ≤1\/10), uncommon (1\/1000 to ≤1\/100), rare (1\/10000 to ≤1\/1000), very rare (≤1\/10000), not known (cannot be estimated from the available data). The following adverse reactions have been observed with the use of ketoprofen in adults:\u003c\/p\u003e\n\u003cp\u003eBlood and lymphatic system disorders - Rare (≥1\/10,000, \u003c1\/1,000): haemorrhagic anemia. Frequency not known: thrombocytopenia, agranulocytosis, bone marrow failure, haemolytic anemia, leucopenia, neutropenia, aplastic anemia, leukocytosis, thrombocytopenic purpura.\u003c\/p\u003e\n\u003cp\u003eImmune system disorders - Frequency not known: anaphylactic reaction (including shock), hypersensitivity\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders - Common (≥1\/100, \u003c1\/10): dyspepsia, nausea, abdominal pain, vomiting. Uncommon (≥1\/1,000, \u003c1\/100): constipation, diarrhoea, flatulence, gastritis. Rare (≥1\/10,000, \u003c1\/1,000): stomatitis, peptic ulcer. Frequency not known: exacerbation of colitis and Crohn's disease, gastrointestinal haemorrhage, gastrointestinal perforation (sometimes fatal, particularly in the elderly - see section 4.4), gastric ulcer, mouth ulceration, duodenal ulcer, duodenal perforation, melena, haematemesis, abdominal discomfort, colitis, heartburn, mouth edema, pancreatitis, hyperchlorhydria, gastric pain, erosive gastritis, mouth edema language.\u003c\/p\u003e\n\u003cp\u003eSkin and subcutaneous tissue disorders - Uncommon (≥1\/1,000, \u003c1\/100): rash, pruritus. Very rare (\u003c1\/10,000): erythema. Frequency not known: photosensitivity reaction, alopecia, urticaria, angioedema, bullous dermatitis including Stevens-Johnson syndrome and toxic epidermal necrolysis, edema, exanthema, Lyell's syndrome, maculopapular exanthema, purpura, acute generalized exanthematous pustulosis, dermatitis.\u003c\/p\u003e\n\u003cp\u003eGeneral disorders and administration site conditions - Uncommon (≥1\/1,000, \u003c1\/100): fatigue,. Very rare (\u003c1\/10,000): facial edema. Frequency not known: peripheral edema, chills, asthenia.\u003c\/p\u003e\n\u003cp\u003eNervous system disorders - Uncommon (≥1\/1,000, \u003c1\/100): headache, dizziness, drowsiness. Rare (≥1\/10,000, \u003c1\/1,000): paraesthesia. Frequency not known: seizure, dysgeusia, dizziness, dyskinesia, syncope, tremor, hyperkinesia.\u003c\/p\u003e\n\u003cp\u003eEye disorders - Rare (≥1\/10,000, \u003c1\/1,000): blurred vision (see section 4.4). Frequency not known: periorbital edema.\u003c\/p\u003e\n\u003cp\u003eEar and labyrinth disorders - Rare (≥1\/10,000, \u003c1\/1,000): tinnitus.\u003c\/p\u003e\n\u003cp\u003eHepatobiliary disorders - Rare (≥1\/10,000, \u003c1\/1,000): hepatitis, increased transaminases, increased blood bilirubin. Frequency not known: jaundice.\u003c\/p\u003e\n\u003cp\u003eRespiratory, thoracic and mediastinal disorders - Rare (≥1\/10,000, \u003c1\/1,000): asthma. Frequency not known: bronchospasm (especially in patients with known hypersensitivity to acetylsalicylic acid and other NSAIDs), rhinitis, dyspnoea, laryngeal edema, laryngospasm, acute respiratory failure (one case with fatal outcome has been reported in an asthmatic patient sensitive to acetylsalicylic acid).\u003c\/p\u003e\n\u003cp\u003eRenal and urinary disorders: - Frequency not known: acute renal failure, tubulointerstitial nephritis, nephritic syndrome, abnormal renal function test, haematuria, nephritis, nephrotic syndrome, glomerulonephritis, sodium\/water retention with possible edema, acute tubular necrosis, renal papillary necrosis, oliguria.\u003c\/p\u003e\n\u003cp\u003ePsychiatric disorders - Frequency not known: altered mood, depression, hallucination, confusional state, agitation, insomnia.\u003c\/p\u003e\n\u003cp\u003eCardiac disorders - Frequency not known: heart failure, atrial fibrillation, palpitations, tachycardia.\u003c\/p\u003e\n\u003cp\u003eVascular disorders - Frequency not known: hypertension, vasodilation, hypotension, vasculitis (including leukocytoclastic vasculitis).\u003c\/p\u003e\n\u003cp\u003eMetabolism and nutrition disorders - Frequency not known: hyperkalemia, hyponatremia.\u003c\/p\u003e\n\u003cp\u003eInfections and infestations - Frequency not known: aseptic meningitis, lymphangitis.\u003c\/p\u003e\n\u003cp\u003eInvestigations - Rare (≥1\/10,000, \u003c1\/1,000): Increased weight.\u003c\/p\u003e\n\u003cp\u003eClinical studies and epidemiological data suggest that the use of some NSAIDs (especially at high doses and for long-term treatments) may be associated with an increased risk of arterial thrombotic events (e.g. myocardial infarction or stroke) (see section 4.4). \u003cu\u003eReporting of suspected adverse reactions.\u003c\/u\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eCases of overdose have been reported with doses of up to 2.5 g of ketoprofen. In most cases, observed symptoms were limited to lethargy, confusion, loss of consciousness, drowsiness, headache, vertigo, dizziness, nausea, vomiting, epigastric pain, abdominal pain and diarrhea. In case of severe overdose, gastrointestinal bleeding, hypotension, respiratory depression and cyanosis may also occur, in which case the patient should be immediately transferred to a specialized hospital center to begin symptomatic treatment. There are no specific antidotes in case of ketoprofen overdose. In case of suspected massive overdose, gastric lavage is recommended and symptomatic and supportive treatment is advised to compensate for dehydration, monitor urinary excretion and correct acidosis, if present. In cases of renal failure, hemodialysis may be useful to remove the drug from the circulation.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003ePregnancy:\u003c\/u\u003e The use of ketoprofen during the first and second trimester of pregnancy should be avoided, the administration of ketoprofen should only be considered if the expected benefit for the mother exceeds the risk for the embryo or fetus. Inhibition of prostaglandin synthesis can negatively affect pregnancy and\/or embryo\/foetal development. Results of epidemiological studies suggest an increased risk of miscarriage and cardiac malformation and gastroschisis after the use of a prostaglandin synthesis inhibitor in early pregnancy. The absolute risk of cardiac malformations increased from less than 1% to approximately 1.5%. The risk was thought to increase with the dose and duration of therapy. In animals, the administration of prostaglandin synthesis inhibitors has been shown to cause an increase in pre- and post-implantation loss and embryo-foetal mortality. Furthermore, an increased incidence of various malformations, including cardiovascular malformations, has been reported in animals to which prostaglandin synthesis inhibitors were administered during the organogenetic period. Therefore ketoprofen should not be administered during the first and second trimester of pregnancy unless strictly necessary. If ketoprofen is used by a woman desiring to become pregnant, or during the first and second trimester of pregnancy, the dosage should be kept as low as possible for the shortest possible duration of treatment. During the third trimester of pregnancy, all inhibitors of prostaglandin synthesis can expose the fetus to: - cardiopulmonary toxicity (with premature closure of the ductus arteriosus and pulmonary hypertension); - renal dysfunction, which can progress to renal failure with oligo-hydramnios; the mother and the newborn, at the end of pregnancy, to: - possible prolongation of bleeding time and anti-aggregating effect which can occur even at very low doses; - inhibition of uterine contractions resulting in delayed or prolonged labor. The use of the medicine close to childbirth can cause alterations in the hemodynamics of the small circulation of the unborn child with serious consequences for breathing. Consequently, ketoprofen is contraindicated during the third trimester of pregnancy. \u003cu\u003eBreastfeeding:\u003c\/u\u003e There is no information available on the excretion of ketoprofen in breast milk. Ketoprofen is not recommended during breast-feeding. \u003cu\u003eFertility:\u003c\/u\u003e The use of NSAIDs can reduce female fertility and is therefore not recommended in women intending to become pregnant. The administration of NSAIDs, as well as Okitask 40 mg granules, must be suspended in women who have fertility problems or who are undergoing fertility investigations.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eFollowing the administration of ketoprofen, drowsiness, dizziness or convulsions and visual disturbances may occur. It is recommended to avoid driving, using machinery or carrying out activities requiring particular vigilance.\u003c\/p\u003e","brand":"Dompé","offers":[{"title":"Default Title","offer_id":40207845523571,"sku":"042028011","price":3.49,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/products\/dompe-farmaceutici-spa-okitask-10-bustine-granulato-40-mg-farmacia-dottor-tili-1213792643.jpg?v=1767119471"},{"product_id":"benactiv-gola-miele-limone-16-pastiglie","title":"Benactiv Throat Honey Lemon 16 Lozenges","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eBENACTIV THROAT Mouthwash\u003c\/b\u003e \u003cb\u003eBENACTIV THROAT Spray for oral mucosa\u003c\/b\u003e Symptomatic treatment of irritative-inflammatory states also associated with pain in the oropharyngeal cavity (e.g. gingivitis, stomatitis, pharyngitis), also as a consequence of conservative or extractive dental therapy. \u003cb\u003eBENACTIV THROAT Lemon and Honey flavored lozenges\u003c\/b\u003e \u003cb\u003eBENACTIV GOLA Orange flavored sugar-free lozenges\u003c\/b\u003e Symptomatic treatment of irritative-inflammatory conditions also associated with oropharyngeal pain (e.g. gingivitis, stomatitis, pharyngitis).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eBENACTIV THROAT Mouthwash\u003c\/b\u003e 100 ml of mouthwash contains: \u003cb\u003eactive ingredient:\u003c\/b\u003e flurbiprofen 250 mg Excipients with known effects: hydrogenated castor oil-40-polyoxyethylene, methyl parahydroxybenzoate, propyl parahydroxybenzoate, mint essence (containing d-limonene). \u003cb\u003eBENACTIV THROAT Spray for oral mucosa\u003c\/b\u003e 100 ml of solution contains: \u003cb\u003eactive ingredient:\u003c\/b\u003e flurbiprofen 250 mg Excipients with known effects: hydrogenated castor oil-40-polyoxyethylene, methyl parahydroxybenzoate, propyl parahydroxybenzoate, mint essence (containing d-limonene). \u003cb\u003eBENACTIV THROAT Lemon and Honey flavored lozenges\u003c\/b\u003e One tablet contains: \u003cb\u003eactive ingredient:\u003c\/b\u003e flurbiprofen 8.75 mg Excipients with known effects: liquid glucose (containing sulphites and wheat starch), liquid sucrose, honey, lemon flavoring and levomenthol (containing butylated hydroxyanisole, citral, citronellol, d-limonene, farfalle, geraniol, linalool). \u003cb\u003eBENACTIV GOLA Orange flavored sugar-free lozenges\u003c\/b\u003e One tablet contains: \u003cb\u003eactive ingredient:\u003c\/b\u003e flurbiprofen 8.75 mg Excipients with known effects: liquid maltitol (E965), isomalt (E953), orange flavoring and levomenthol (containing citral, citronellol, d-limonene, geraniol, linalool). For the full list of excipients, see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eBENACTIV THROAT Mouthwash\u003c\/b\u003e Glycerol, ethanol (96 percent), sorbitol 70, hydrogenated castor oil-40-polyoxyethylene, sodium hydroxide, sodium saccharin, methyl parahydroxybenzoate, propyl parahydroxybenzoate, mint essence (containing d-limonene), patent blue V (E131), purified water. \u003cb\u003eBENACTIV THROAT Spray for oral mucosa\u003c\/b\u003e Glycerol, ethanol (96 percent), sorbitol 70, hydrogenated castor oil-40-polyoxyethylene, sodium hydroxide, sodium saccharin, methyl parahydroxybenzoate, propyl parahydroxybenzoate, mint essence (containing d-limonene), patent blue V (E131), purified water. \u003cb\u003eBENACTIV THROAT Lemon and Honey flavored lozenges\u003c\/b\u003e Liquid sucrose, liquid glucose (containing sulphites and wheat starch), macrogol 300, potassium hydroxide, lemon flavoring and levomenthol (containing butylated hydroxyanisole, citral, citronellol, d-limonene, farfalle, geraniol, linalool), honey. \u003cb\u003eBENACTIV GOLA Orange flavored sugar-free lozenges\u003c\/b\u003e Macrogol 300, potassium hydroxide, orange flavor and levomenthol (containing citral, citronellol, dlimonene, geraniol, linalool), acesulfame potassium (E950), liquid maltitol (E965), isomalt (E953).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDo not use the medicine in children under 12 years of age. Flurbiprofen is contraindicated in patients with known hypersensitivity to flurbiprofen or to any of the excipients listed in section 6.1. Patients who have previously shown hypersensitivity reactions (e.g. asthma, urticaria, allergy, rhinitis, angioedema, bronchospasm) towards ibuprofen, acetylsalicylic acid (aspirin) or other non-steroidal anti-inflammatory drugs (NSAIDs). Flurbiprofen is also contraindicated in patients with a history of gastrointestinal bleeding or perforation related to previous NSAID treatment. Flurbiprofen should not be taken by patients with active or anamnestic ulcerative colitis, Crohn's disease, recurrent peptic ulcer or gastrointestinal haemorrhage (defined as two or more distinct episodes of demonstrated ulceration or bleeding). Flurbiprofen is contraindicated in patients with severe heart failure, severe hepatic failure and renal failure (see section 4.4). Third trimester of pregnancy.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eUndesirable effects can be minimized by using the lowest effective dose for the shortest possible duration of treatment needed to control symptoms (see section 4.4). \u003cb\u003eBENACTIV THROAT Mouthwash\u003c\/b\u003e \u003cu\u003eDosage\u003c\/u\u003e \u003ci\u003eAdults\u003c\/i\u003e: 2-3 rinses or gargles per day with 10 ml (1 scoop) of mouthwash. \u003ci\u003ePediatric population\u003c\/i\u003e Children over 12 years old: same as adults. Children under 12 years of age: Do not administer to children under 12 years of age (see section 4.3). \u003ci\u003eSpecial populations\u003c\/i\u003e \u003ci\u003eElderly\u003c\/i\u003e: The clinical data currently available are limited, therefore no recommendation regarding posology can be made. Elderly people are at greater risk of serious consequences in case of adverse reactions (see section 4.4). \u003ci\u003ePatients with liver failure\u003c\/i\u003e: A dosage reduction is not necessary in patients with mild to moderate hepatic impairment. Flurbiprofen is contraindicated in patients with severe hepatic impairment (see section 4.3). \u003ci\u003ePatients with renal failure\u003c\/i\u003e: A dosage reduction is not necessary in patients with mild to moderate renal impairment. Flurbiprofen is contraindicated in patients with severe hepatic impairment (see section 4.3).\u003cu\u003eMethod of administration\u003c\/u\u003e For oropharyngeal use. Rinse or keep in mouth while gargling for up to 1 minute. Do not ingest. The mouthwash can be used pure or diluted in half a glass of water. \u003cb\u003eBENACTIV THROAT Spray for oral mucosa\u003c\/b\u003e \u003cu\u003eDosage\u003c\/u\u003e \u003ci\u003eAdults\u003c\/i\u003e: apply one dose (2 sprays) 3 times a day, directed directly onto the affected part. Each spray delivers 0.2 ml of solution, equivalent to 0.5 mg of active ingredient. \u003ci\u003ePediatric population\u003c\/i\u003e Children over 12 years old: same as adults. Children under 12 years of age: Do not administer to children under 12 years of age (see section 4.3). \u003ci\u003eSpecial populations\u003c\/i\u003e \u003ci\u003eElderly\u003c\/i\u003e: The clinical data currently available are limited, therefore no recommendation regarding posology can be made. Elderly people are at greater risk of serious consequences in case of adverse reactions (see section 4.4). \u003ci\u003ePatients with liver failure\u003c\/i\u003e: A dosage reduction is not necessary in patients with mild to moderate hepatic impairment. Flurbiprofen is contraindicated in patients with severe hepatic impairment (see section 4.3). \u003ci\u003ePatients with renal failure\u003c\/i\u003e: A dosage reduction is not necessary in patients with mild to moderate renal impairment. Flurbiprofen is contraindicated in patients with severe hepatic impairment (see section 4.3).\u003cu\u003eMethod of administration\u003c\/u\u003e For oropharyngeal use. Direct the nozzle towards the back of the throat and spray on the affected part. \u003cb\u003eBENACTIV THROAT Lemon and Honey flavored lozenges\u003c\/b\u003e \u003cb\u003eBENACTIV GOLA Orange flavored sugar-free lozenges\u003c\/b\u003e \u003cu\u003eDosage\u003c\/u\u003e \u003ci\u003eAdults\u003c\/i\u003e: 1 tablet every 3-6 hours, as needed. Do not exceed the dose of 8 tablets in 24 hours. \u003ci\u003ePediatric population\u003c\/i\u003e Children over 12 years old: same as adults. Children under 12 years of age: Do not administer to children under 12 years of age (see section 4.3). \u003ci\u003eSpecial populations\u003c\/i\u003e \u003ci\u003eElderly\u003c\/i\u003e: The clinical data currently available are limited, therefore no recommendation regarding posology can be made. Elderly people are at greater risk of serious consequences in case of adverse reactions (see section 4.4). \u003ci\u003ePatients with liver failure\u003c\/i\u003e: A dosage reduction is not necessary in patients with mild to moderate hepatic impairment. Flurbiprofen is contraindicated in patients with severe hepatic impairment (see section 4.3). \u003ci\u003ePatients with renal failure\u003c\/i\u003e: A dosage reduction is not necessary in patients with mild to moderate renal impairment. Flurbiprofen is contraindicated in patients with severe hepatic impairment (see section 4.3).\u003cu\u003eMethod of administration\u003c\/u\u003e For oropharyngeal use. Dissolve slowly in your mouth. As with all lozenges, in order to avoid local irritation, flurbiprofen lozenges should also be moved inside the mouth during administration. If mouth irritation occurs, treatment should be discontinued.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eBenactiv Gola Orange flavored sugar-free lozenges and Benactiv Gola Lemon and Honey flavored lozenges: store at temperatures below 25°C.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAt the recommended doses, when using the medicine in its various pharmaceutical forms, any swallowing does not cause any harm to the patient, as the dose of flurbiprofen is significantly lower than that commonly used in systemic treatments. Elderly: Elderly patients have an increased frequency of adverse reactions to NSAIDs, especially gastrointestinal haemorrhage and perforation, which may be fatal. \u003ci\u003eRespiratory disorders \u003c\/i\u003e Cases of bronchospasm have been reported with flurbiprofen in patients with a history of bronchial asthma or allergies. Flurbiprofen should be used with caution in these patients. \u003ci\u003eOther NSAIDs \u003c\/i\u003e It is advisable not to combine the medicine with other NSAIDs (see section 4.5). \u003ci\u003eSystemic lupus erythematosus (SLE) and mixed connective tissue disease \u003c\/i\u003e Patients with systemic lupus erythematosus and mixed connective tissue disease may have an increased risk of aseptic meningitis (see section 4.8), however this effect is not usually seen with products intended for limited and short-term use such as flurbiprofen. \u003ci\u003eCardiac, hepatic and renal impairment \u003c\/i\u003e The medicine should be used with caution in patients with cardiac, renal or hepatic insufficiency. NSAIDs have been reported to cause various forms of nephrotoxicity, including interstitial nephritis, nephrotic syndrome, and renal failure. The administration of an NSAID can cause a dose-dependent reduction in the formation of prostaglandins and precipitate renal failure. Patients at highest risk of developing this reaction are those with impaired renal function, cardiac impairment, liver dysfunction, those on diuretic therapy and the elderly; however, this effect is not usually observed with products intended for limited and short-term use such as flurbiprofen. \u003ci\u003eCardiovascular and cerebrovascular effects \u003c\/i\u003e Before starting treatment in patients with a positive history of hypertension and\/or heart failure, caution is required (discuss with your doctor or pharmacist), since fluid retention, hypertension and edema have been reported in association with treatment with NSAIDs. Clinical studies and epidemiological data suggest that the use of some NSAIDs, especially at high doses and for long-term treatments, may be associated with a modest increase in the risk of arterial thrombotic events such as myocardial infarction or stroke. There are insufficient data to exclude a similar risk for flurbiprofen. Patients with uncontrolled hypertension, congestive heart failure, established ischemic heart disease, peripheral arterial disease and\/or cerebrovascular disease should be treated with flurbiprofen only after careful consideration. Similar considerations must be made before starting long-term treatment in patients with risk factors for cardiovascular disease (e.g. hypertension, hyperlipidemia, diabetes mellitus, smoking). \u003ci\u003eEffects on the central nervous system \u003c\/i\u003e Analgesic-induced headache. In case of prolonged or irregular use of analgesics, headache may occur, which must not be treated by increasing the dose of the medicine. \u003ci\u003eGastrointestinal effects\u003c\/i\u003e Flurbiprofen should be administered with caution to patients with a history of peptic ulcers and other gastrointestinal diseases as these conditions may be exacerbated. The risk of gastrointestinal haemorrhage, ulcer or perforation is higher with increasing dosage of flurbiprofen in patients with a history of ulcer, particularly if complicated by haemorrhage and perforation, and in the elderly. These patients should start treatment with the lowest available dose. Gastrointestinal bleeding, ulcer or perforation have been reported with all NSAIDs at any time during treatment. These adverse reactions can be fatal and can occur with or without warning symptoms or in case of a previous history of serious gastrointestinal reactions. Patients with a history of gastrointestinal disease, especially if elderly, should report any unusual abdominal symptoms (especially gastrointestinal bleeding) in the initial stages of treatment. Undesirable effects can be minimized by using the lowest effective dose for the shortest possible duration of treatment needed to control symptoms (see section 4.2). Caution should be advised in patients receiving concomitant medicinal products that may increase the risk of ulceration or bleeding, such as oral corticosteroids, anticoagulants such as warfarin, selective serotonin reuptake inhibitors or antiplatelet agents such as acetylsalicylic acid (see section 4.5). When gastrointestinal bleeding or ulceration occurs in patients taking flurbiprofen, treatment should be discontinued. \u003ci\u003eDermatological effects\u003c\/i\u003e The use of the medicine, especially if prolonged, can give rise to sensitization or local irritation phenomena. In such cases it is necessary to interrupt the treatment and consult a doctor to institute, if necessary, suitable therapy. Serious skin reactions, some of them fatal, including exfoliative dermatitis, Stevens-Johnson syndrome and toxic epidermal necrolysis, have been reported very rarely in association with the use of NSAIDs (see section 4.8). Flurbiprofen should be discontinued at the first appearance of skin rash, mucosal lesions or any other sign of hypersensitivity. \u003ci\u003eInfections\u003c\/i\u003e Since isolated cases of exacerbation of inflammation related to infections (e.g. development of necrotizing fasciitis) have been described in temporal association with the systemic use of drugs belonging to the NSAID class, patients are recommended to immediately consult a doctor in case of appearance or worsening of signs of a bacterial infection during flurbiprofen-based therapy. A possible indication for starting antibiotic therapy must be taken into consideration. If mouth irritation develops, treatment should be discontinued. BENACTIV GOLA Mouthwash and BENACTIV GOLA Spray contain para-hydroxybenzoates which can cause allergic reactions (even delayed). BENACTIV GOLA Mouthwash and BENACTIV GOLA Spray contain hydrogenated 40-polyoxyethylene castor oil which may cause localized skin reactions. BENACTIV GOLA Mouthwash and BENACTIV GOLA Spray contain an aroma which in turn contains d-limonene. D-limonene can cause allergic reactions. BENACTIV GOLA Mouthwash and BENACTIV GOLA Spray contain less than 1 mmol (23mg) sodium per 10 ml dose, i.e. essentially \"sodium-free\". BENACTIV GOLA Lemon and Honey flavored lozenges contain liquid glucose, liquid sucrose and honey (invert sugar). Patients suffering from rare problems of fructose intolerance, glucose-galactose malabsorption or sucrase isomaltase insufficiency should not take this medicine. To be taken into consideration in people with diabetes mellitus: this medicine contains 1.07 g of glucose and 1.41 g of sucrose per tablet. BENACTIV GOLA Lemon and Honey flavored lozenges contain sulphites. Rarely it can cause serious hypersensitivity reactions and bronchospasm. BENACTIV GOLA Lemon and Honey flavored lozenges contain only a very small amount of gluten (from wheat starch). This medicine is considered “gluten-free” and is very unlikely to cause problems for a celiac patient. One tablet contains no more than 21.38 micrograms of gluten. If a patient is allergic to wheat (condition other than celiac disease) he or she should not take this medicine. BENACTIV THROAT Lemon and Honey flavored lozenges contain an aroma which in turn contains citral, citronellol, d-limonene, farfalle, geraniol and linalool. Citral, citronellol, d-limonene, farfalle, geraniol and linalool can cause allergic reactions. BENACTIV THROAT Lemon and Honey flavored lozenges contain an aroma which in turn contains butylated hydroxyanisole which can cause localized skin reactions (e.g. contact dermatitis) or irritation to the eyes and mucous membranes. BENACTIV GOLA Sugar-Free Lozenges Orange flavor is instead indicated for those patients who need to control their intake of sugars and calories. BENACTIV GOLA Orange flavored sugar-free lozenges contain an aroma which in turn contains citral, citronellol, d-limonene, geraniol and linalool. Citral, citronellol, d-limonene, geraniol and linalool can cause allergic reactions. BENACTIV GOLA Orange flavored sugar-free lozenges contain liquid maltitol and isomalt. Patients with rare hereditary problems of fructose intolerance should not take this medicine. May have a mild laxative effect. The caloric value of maltitol and isomalt is 2.3 kcal\/g. Do not use for prolonged treatments beyond 7 days. If you do not notice appreciable results after 3 days of treatment, the cause could be a different pathological condition. In these cases it is advisable to consult your doctor.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eCaution should be exercised in patients treated with any of the medicines listed below, as interactions have been reported in some patients. However, inform your doctor if you are taking other medicines. Flurbiprofen should be avoided in association with: - Aspirin: unless the intake of low-dose aspirin (not exceeding 100 mg\/day or local prophylactic doses for cardiovascular protection) has been recommended by the doctor; As with other NSAID-containing medicinal products, concomitant administration of flurbiprofen and aspirin is generally not recommended due to the potential for increased side effects (see section 4.4). - Cox-2 inhibitors and other NSAIDs: concomitant use of other NSAIDs, including selective cyclooxygenase-2 inhibitors, should be avoided due to potential additive effects and an increased risk of adverse reactions (see section 4.4). Flurbiprofen should be used with caution in association with: - Anticoagulants: NSAIDs can potentiate the effects of anticoagulants such as warfarin (see section 4.4) - Antiaggregating agents: increased risk of gastrointestinal bleeding - Selective serotonin reuptake inhibitors (SSRIs): increased risk of gastrointestinal bleeding - Antihypertensives (diuretics, ACE inhibitors and angiotensin II antagonists): i NSAIDs can reduce the effect of diuretics. Other antihypertensive drugs may potentiate nephrotoxicity caused by inhibition of cyclooxygenase, especially in patients with impaired renal function (these patients must be adequately hydrated) - Alcohol: may increase the risk of adverse reactions, especially bleeding in the gastrointestinal tract - Cardiac glycosides: NSAIDs may exacerbate heart failure, reduce GFR (glomerular filtration rate) and increase plasma levels of glycosides - Cyclosporine: increased risk of nephrotoxicity - Corticosteroids: increased risk of gastrointestinal ulcer or haemorrhage with NSAIDs (see section 4.4) - Lithium: there is evidence for a possible increase in plasma lithium levels - Methotrexate: there may be an increase in plasma levels of methotrexate - Mifepristone: NSAIDs should not be used for 8-12 days after administration of mifepristone, as NSAIDs may reduce the effect of mifepristone - Quinolone antibiotics: data obtained in animals indicate that NSAIDs may increase the risk of convulsions associated with quinolone antibiotics. Patients taking NSAIDs and quinolones may have an increased risk of developing seizures - Tacrolimus: possible increased risk of nephrotoxicity when NSAIDs are administered together with tacrolimus - Zidovudine: increased risk of haematological toxicity when NSAIDs are administered with zidovudine.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity reactions to NSAIDs have been reported and these may consist of: (a) non-specific allergic reactions and anaphylaxis (b) respiratory tract reactivity, e.g. asthma, aggravated asthma, bronchospasm, dyspnoea (c) various skin disorders, including for example skin rashes of different types, pruritus, urticaria, purpura, angioedema and, more rarely, exfoliative and bullous dermatosis (including necrolysis epidermal and erythema multiforme). The most commonly observed adverse reactions are gastrointestinal in nature. Local use of the medicine, especially if prolonged, can give rise to local sensitization or irritation phenomena. The dissolution of the medicine in tablet form in the oral cavity may be accompanied by sensations of heat or tingling in the oropharynx. In such cases it is necessary to interrupt treatment and institute, if necessary, suitable therapy. The following side effects have been reported, particularly after the administration of formulations for systemic use. They refer to those detected with the use of flurbiprofen used short term and at doses compatible with the classification of self-medication medicines. When treating chronic conditions and for long periods of time, additional side effects may occur. The side effects associated with the use of flurbiprofen are divided below based on system organ classification and frequency. Frequency is defined as: very common (≥ 1\/10), common (≥1\/100, \u003c1\/10), uncommon (≥1\/1,000, \u003c1\/100), rare (≥1\/10,000, \u003c1\/1,000), very rare (\u003c1\/10,000) and not known (cannot be estimated from the available data). Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.\u003c\/p\u003e\n\u003cp\u003eDisorders of the blood and lymphatic system - Frequency: Not known. Adverse reactions: Anemia, thrombocytopenia, aplastic anemia and agranulocytosis.\u003c\/p\u003e\n\u003cp\u003eNervous system disorders - Frequency: Common. Adverse reactions: Dizziness, headache, paraesthesia.\u003c\/p\u003e\n\u003cp\u003eNervous system disorders - Frequency: Uncommon. Adverse reactions: Drowsiness.\u003c\/p\u003e\n\u003cp\u003eNervous system disorders - Frequency: Not known. Adverse reactions: Cerebrovascular accident, optic neuritis, migraine, confusional states, dizziness.\u003c\/p\u003e\n\u003cp\u003eImmune system disorders - Frequency: Rare. Adverse reactions: Anaphylactic reaction.\u003c\/p\u003e\n\u003cp\u003eImmune system disorders - Frequency: Not known. Adverse reactions: Angioedema, hypersensitivity\u003c\/p\u003e\n\u003cp\u003eEye disorders - Frequency: Not known. Adverse reactions: Vision impairment.\u003c\/p\u003e\n\u003cp\u003eEar and labyrinth disorders - Frequency: Not known. Adverse reactions: Tinnitus.\u003c\/p\u003e\n\u003cp\u003eCardiac disorders - Frequency: Not known. Adverse reactions: Heart failure, edema.\u003c\/p\u003e\n\u003cp\u003eVascular disorders - Frequency: Not known. Adverse reactions: Hypertension.\u003c\/p\u003e\n\u003cp\u003eRespiratory, thoracic and mediastinal disorders - Frequency: Common. Adverse reactions: Throat irritation.\u003c\/p\u003e\n\u003cp\u003eRespiratory, thoracic and mediastinal disorders - Frequency: Uncommon. Adverse reactions: Asthma, bronchospasm and dyspnea, oropharyngeal vesicular rash, oropharyngeal hypoesthesia.\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders - Frequency: Common. Adverse reactions: Diarrhoea, mouth ulceration, nausea, oral pain, oral paraesthesia, oropharyngeal pain, oral discomfort (hot or burning sensation, tingling in the mouth).\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders - Frequency: Uncommon. Adverse reactions: Abdominal distension, abdominal pain, constipation, dry mouth, dyspepsia, flatulence, glossodynia, dysgeusia, oral dysesthesia, vomiting.\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders - Frequency: Not known. Adverse reactions: Melena, haematemesis, gastrointestinal haemorrhage, colitis, exacerbation of Crohn's disease, gastritis, peptic ulcer, gastric perforation, ulcer haemorrhage.\u003c\/p\u003e\n\u003cp\u003eSkin and subcutaneous tissue disorders - Frequency: Uncommon. Adverse reactions: Skin rash, itching.\u003c\/p\u003e\n\u003cp\u003eSkin and subcutaneous tissue disorders - Frequency: Not known. Adverse reactions: Urticaria, purpura, bullous dermatitis (including Stevens-Johnson syndrome, toxic epidermal necrolysis and erythema multiforme).\u003c\/p\u003e\n\u003cp\u003eRenal and urinary disorders - Frequency: Not known. Adverse reactions: Toxic nephropathy, tubulointerstitial nephritis and nephrotic syndrome, renal failure (as with other NSAIDs).\u003c\/p\u003e\n\u003cp\u003eGeneral disorders and administration site conditions - Frequency: Uncommon. Adverse reactions: Pyrexia, pain.\u003c\/p\u003e\n\u003cp\u003eGeneral disorders and conditions relating to the administration site - Frequency: Not known. Adverse reactions: Discomfort, tiredness.\u003c\/p\u003e\n\u003cp\u003eHepatobiliary disorders - Frequency: Not known. Adverse reactions: Hepatitis.\u003c\/p\u003e\n\u003cp\u003ePsychiatric disorders - Frequency: Uncommon. Adverse reactions: Insomnia.\u003c\/p\u003e\n\u003cp\u003ePsychiatric disorders - Frequency: Not known. Adverse reactions: Depression, hallucination.\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eReporting of suspected adverse reactions\u003c\/u\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eGiven the reduced content of the active ingredient and its local use, it is unlikely that overdose situations may occur. \u003cb\u003eSymptoms\u003c\/b\u003e The majority of patients who ingest clinically large quantities of NSAIDs develop nausea, vomiting, gastrointestinal irritation, epigastric pain, or more rarely diarrhea. Tinnitus, headache and gastrointestinal bleeding are also possible. In more severe cases of NSAID intoxication, central nervous system toxicity is observed, manifested by drowsiness, occasionally excitability, blurred vision and disorientation or coma. Occasionally patients develop seizures. In case of severe NSAID intoxication, metabolic acidosis may occur and the prothrombin time\/INR may be prolonged, probably due to interference with the action of coagulation factors present in circulation. Acute renal failure and liver damage may occur. An exacerbation of asthma is possible in asthmatic subjects. \u003cb\u003eTreatment\u003c\/b\u003e Treatment should be symptomatic and supportive and should include maintaining a patent airway and monitoring cardiac function and vital signs until stabilization. Oral administration of activated charcoal and, if necessary, correction of serum electrolytes should be considered if the patient presents within one hour of ingesting a potentially toxic amount. Seizures should be treated with intravenous diazepam or lorazepam if they are frequent or prolonged. Administer bronchodilators for asthma. There is no specific antidote for flurbiprofen.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003ePregnancy\u003c\/u\u003e Flurbiprofen should not be administered during the first and second trimester of pregnancy unless strictly necessary. The use of flurbiprofen during the third trimester of pregnancy is contraindicated. \u003cu\u003eBreastfeeding\u003c\/u\u003e In a limited number of studies, flurbiprofen appears in breast milk in very low concentrations and is unlikely to have negative effects on the breastfed infant. However, administration of flurbiprofen is not recommended in breastfeeding mothers. \u003cu\u003eFertility\u003c\/u\u003e There is evidence to suggest that cyclooxygenase\/prostaglandin synthesis inhibitors may cause impairment of female fertility through an effect on ovulation. This is reversible upon discontinuation of treatment.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIt does not interfere with the ability to drive and use machinery.\u003c\/p\u003e","brand":"Reckitt Benckiser","offers":[{"title":"Default Title","offer_id":40720891445363,"sku":"033262027","price":12.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/products\/reckitt-benckiser-h-it-spa-benactiv-gola-miele-limone-16-pastiglie-farmacia-dottor-tili-1213792527.webp?v=1767131032"},{"product_id":"benexol-20-compresse-gastroresistenti","title":"Benexol 20 Gastro-resistant Tablets","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eVitamin B deficiency states\u003csub\u003e1\u003c\/sub\u003e, B\u003csub\u003e6\u003c\/sub\u003e and B\u003csub\u003e12\u003c\/sub\u003e and their different clinical forms (deficiency polyneuritis, neuritis during treatment with isoniazid and other vitamin B6 antagonists). Adjuvant therapy in non-deficient neuritis and during radiotherapy.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eBenexol gastro-resistant tablets\u003c\/i\u003e One gastro-resistant tablet contains: thiamine hydrochloride (Vit. B\u003csub\u003e1\u003c\/sub\u003e) 250 mg, pyridoxine hydrochloride (Vit. B\u003csub\u003e6\u003c\/sub\u003e) 250 mg, cyanocobalamin (Vit. B\u003csub\u003e12\u003c\/sub\u003e) 500 mcg. \u003ci\u003eBenexol low dosage powder and solvent \u003c\/i\u003e One vial of powder contains: vitamin B\u003csub\u003e1\u003c\/sub\u003e (as cocarboxylase) 38 mg, pyridoxine hydrochloride (Vit. B\u003csub\u003e6\u003c\/sub\u003e) 200 mg, hydroxocobalamin (Vit. B\u003csub\u003e12\u003c\/sub\u003e) 1000 mcg (as hydroxocobalamin acetate). \u003ci\u003eBenexol high dosage powder and solvent \u003c\/i\u003e One vial of powder contains: vitamin B\u003csub\u003e1\u003c\/sub\u003e (as cocarboxylase) 38 mg, pyridoxine hydrochloride (Vit. B\u003csub\u003e6\u003c\/sub\u003e) 300 mg, hydroxocobalamin (Vit. B\u003csub\u003e12\u003c\/sub\u003e) 5000 mcg (as hydroxocobalamin acetate). For the full list of excipients, see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eBenexol gastro-resistant tablets\u003c\/i\u003e hydrated colloidal silica, povidone, magnesium stearate, pregelatinized starch, mannitol, talc, methacrylic acid - ethyl acrylate copolymer (1:1), carmellose sodium, macrogol 6000, glycerol triacetate. \u003ci\u003eBenexol low dosage powder and solvent for solution for injection for intramuscular use\u003c\/i\u003e The powder vial contains: methyl parahydroxybenzoate, propyl parahydroxybenzoate, sodium hydroxide. One solvent vial contains: water for injections \u003ci\u003eBenexol high dosage powder and solvent for solution for injection for intramuscular use\u003c\/i\u003e The powder vial contains: methyl parahydroxybenzoate, propyl parahydroxybenzoate, sodium hydroxide. One solvent vial contains: water for injections\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e• Hypersensitivity to the active substances or to any of the excipients listed in paragraph 6.1. • Pregnancy and breastfeeding • Children under 12 years • Kidney or liver failure.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eBenexol is indicated in adults and adolescents from 12 years of age \u003cb\u003eDosage\u003c\/b\u003e \u003cb\u003eBenexol gastro-resistant tablets\u003c\/b\u003e 1 tablet per day. The product is generally prescribed for periods of one or more weeks. In some cases, the doctor can extend the treatment for up to a few months. \u003cb\u003eBenexol low dosage powder and solvent\u003c\/b\u003e Benexol low dosage is indicated when absorption is markedly reduced and for the treatment of hypovitaminosis. The dose is one vial per day, unless otherwise prescribed by a doctor. \u003cb\u003eBenexol high dosage powder and solvent\u003c\/b\u003e Benexol high dosage is indicated for the initial therapy of forms with particularly intense symptoms. The dose is one vial per day, unless otherwise prescribed by a doctor.\u003cb\u003eMethod of administration:\u003c\/b\u003e \u003cb\u003eBenexol gastro-resistant tablets\u003c\/b\u003e Benexol tablets should be swallowed with a sip of liquid, without chewing or dissolving them beforehand. \u003cb\u003eBenexol low dosage powder and solvent\u003c\/b\u003e The injection must be done deep intramuscularly by qualified and experienced personnel and the administration must take place as slowly as possible. The solution to be injected is prepared on the spot, dissolving the dry freeze-dried substance with the appropriate solvent contained in the package. \u003cb\u003eBenexol high dosage powder and solvent\u003c\/b\u003e The injection must be done deep intramuscularly by qualified and experienced personnel and the administration must take place as slowly as possible. The solution to be injected is prepared on the spot, dissolving the dry freeze-dried substance with the appropriate solvent contained in the package.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eBenexol low dosage powder and solvent for solution for injection for intramuscular use\u003c\/i\u003e This medicinal product does not require any special storage conditions. \u003ci\u003eBenexol high dosage powder and solvent for solution for injection for intramuscular use:\u003c\/i\u003e Do not store above 25°C \u003ci\u003eBenexol\u003c\/i\u003e gastro-resistant tablets: Do not store above 25°C\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDo not exceed the recommended dose and duration of treatment. The product should not be taken at higher doses or for longer periods than recommended, as overdose may be associated with serious neurotoxicity (see section 4.9). Particular caution must be used if the product is prescribed together with levodopa for the therapy of Parkinson's disease, as pyridoxine at high doses can antagonize its therapeutic effect (see section 4.5). Repeated administration of preparations containing vitamin B1 intramuscularly can in rare cases cause anaphylactic reactions. The clinical picture can in some respects simulate anaphylactic shock (see paragraph 4.8). In order to avoid these rare anaphylactic reactions, oral administration is always preferable, whenever possible. If this is not possible, the intramuscular injection must take place as slowly as possible and must be carried out by qualified and experienced personnel (see section 4.2). \u003cu\u003eImportant information about some excipients\u003c\/u\u003e \u003ci\u003eBenexol gastro-resistant tablets\u003c\/i\u003e This medicinal product contains less than 1 mmol (23 mg) sodium per dose, i.e. essentially 'sodium-free'. \u003ci\u003eBenexol low dosage powder and solvent for solution for injection for intramuscular use\u003c\/i\u003e This medicine contains parahydroxy benzoates. It can cause allergic reactions (even delayed) and, exceptionally, bronchospasm. This medicinal product contains less than 1 mmol (23 mg) sodium per dose, i.e. essentially 'sodium-free'. \u003ci\u003eBenexol high dosage powder and solvent for solution for injection for intramuscular use \u003c\/i\u003e This medicine contains parahydroxy benzoates. It can cause allergic reactions (even delayed) and, exceptionally, bronchospasm. This medicinal product contains less than 1 mmol (23 mg) sodium per dose, i.e. essentially 'sodium-free'.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eInteractions with other medicines:\u003c\/b\u003e \u003cb\u003eVitamin B\u003csub\u003e1\u003c\/sub\u003e (thiamine)\u003c\/b\u003e The medicines listed below inhibit the activity of thiamine: • Thiosemicarbazone • 5-fluorouracil \u003cb\u003eVitamin B6 (pyridoxine)\u003c\/b\u003e Several drugs interfere with pyridoxine and can reduce its plasma levels. Among these: • Cycloserine • Hydralazine • Isoniazid • Deoxypyridoxine • D-penicillamine • Oral contraceptives • Alcohol. Vitamin B6 can reduce the effectiveness of the following medicines: • Levodopa: pyridoxine enhances the metabolisation of levodopa into dopamine and therefore reduces its therapeutic antiparkinsonian effects at the doses usually used. This interaction, however, does not occur when carbidopa is used together with levodopa. • altretamine • Phenobarbital • Phenytoin • Amiodarone: co-administration may aggravate photosensitivity induced by amiodarone\u003ci\u003e.\u003c\/i\u003e \u003cb\u003eVitamin B12 (cyanocobalamin)\u003c\/b\u003e Aminoglycosides, antihistamines (anti-H\u003csub\u003e2\u003c\/sub\u003e), metformin and other related biguanides, oral contraceptives, aminosalicylic acid, and proton pump inhibitors may reduce the absorption of vitamin B\u003csub\u003e12\u003c\/sub\u003e from the gastrointestinal tract. Therefore, in patients taking these medicines, the requirement for vitamin B\u003csub\u003e12\u003c\/sub\u003e can be increased. Chloramphenicol can delay or interrupt the response of reticulocytes to vitamin B12. Therefore it is necessary to monitor the blood count in case of concomitant intake. \u003cb\u003eInteractions with laboratory tests:\u003c\/b\u003e \u003cb\u003eVitamin B\u003csub\u003e1\u003c\/sub\u003e (thiamine)\u003c\/b\u003e • Thiamine can give rise to false positives in the determination of urobilinogen with the Ehrlich reagent. • High doses of thiamine may interfere with the spectrophotometric determination of serum theophylline. \u003cb\u003eVitamin B6 (pyridoxine)\u003c\/b\u003e • Urobilinogen: Pyridoxine may cause a false positive in the Ehrlich reagent test.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe adverse reactions listed below are derived from spontaneous reports. Since these reactions are reported on a voluntary basis, it is not possible to estimate their frequency \u003cb\u003eGastrointestinal disorders\u003c\/b\u003e Diarrhoea, dyspepsia, nausea, vomiting, gastrointestinal and abdominal pain. \u003cb\u003eImmune system disorders\u003c\/b\u003e Allergic reaction and anaphylactic reaction. Hypersensitivity reactions with corresponding laboratory findings and clinical manifestations, which include asthma syndrome, mild to moderate intensity reactions affecting the skin and\/or the respiratory tract, the gastrointestinal tract and\/or the cardiovascular system. Symptoms may include facial edema (secondary mechanism), dyspnea, urticaria, angioedema, pruritus, and cardiorespiratory distress. If an allergic reaction occurs, stop treatment and consult a doctor. For solution for injection only: Serious reactions including anaphylactic shock with possible fatal outcome have been associated with parenteral use. \u003cb\u003eRenal and urinary disorders\u003c\/b\u003e Abnormal smelling urine \u003cb\u003eNervous system disorders\u003c\/b\u003e Peripheral neuropathy and polyneuropathy, paraesthesia \u003cb\u003ePathologies of the skin and subcutaneous tissue\u003c\/b\u003e Photosensitivity reaction, rash, erythema, pruritus, urticaria and bullous dermatitis. \u003cb\u003eReporting of suspected adverse reactions\u003c\/b\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAt recommended doses Benexol does not cause hypervitaminosis. Symptoms of overdose include sensory and\/or peripheral neuropathy and neuropathic syndromes, nausea, headache, paraesthesia, drowsiness, increased serum AST (SGOT) levels and decreased serum folic acid levels. These effects are generally reversible upon cessation of treatment.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003ePregnancy The product is contraindicated during pregnancy (see section 4.3) Breastfeeding The product is contraindicated during breastfeeding (see section 4.3) Women of childbearing potential Women of childbearing potential must use effective contraceptive methods during treatment.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eBenexol has no influence on the ability to drive or use machines, or its influence is negligible.\u003c\/p\u003e","brand":"Bayer","offers":[{"title":"Default Title","offer_id":40722366660723,"sku":"020213144","price":18.91,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/products\/bayer-spa-benexol-20-compresse-gastroresistenti-farmacia-dottor-tili-1213792525.webp?v=1767131079"},{"product_id":"fluimucil-mucolitico-sciroppo-espettorante-600-mg-15-ml","title":"Fluimucil Mucolytic Expectorant Syrup 600 Mg-15 Ml","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eTreatment of respiratory diseases characterized by dense and viscous hypersecretion.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eFLUIMUCIL MUCOLITIC 600 mg effervescent tablets\u003c\/i\u003e Each tablet contains: \u003cu\u003eActive ingredient\u003c\/u\u003e: N-acetylcysteine 600 mg. Excipients with known effects: aspartame, glucose, sodium. \u003ci\u003eFLUIMUCIL MUCOLITIC 600 mg granules for oral solution \u003c\/i\u003e Each sachet contains: \u003cu\u003eActive ingredient\u003c\/u\u003e: N-acetylcysteine 600 mg. Excipients with known effects: aspartame, glucose, lactose, sorbitol. \u003ci\u003eFLUIMUCIL MUCOLITIC 600 mg\/15 ml syrup\u003c\/i\u003e 15 ml of syrup contains: \u003cu\u003eActive ingredient\u003c\/u\u003e: N-acetylcysteine 600 mg. Excipients with known effects: propylene glycol, methyl parahydroxybenzoate, propyl parahydroxybenzoate, sodium, sorbitol. \u003ci\u003eFLUIMUCIL MUCOLITIC 200 mg, effervescent tablets\u003c\/i\u003e One tablet contains: \u003cu\u003eActive ingredient\u003c\/u\u003e: N-acetylcysteine 200 mg. Excipients with known effects: sodium, aspartame. \u003ci\u003eFLUIMUCIL MUCOLITIC 200 mg, buccal tablets:\u003c\/i\u003e One tablet contains: \u003cu\u003eActive ingredient\u003c\/u\u003e: N-acetylcysteine 200 mg. Excipients with known effects: sorbitol, sodium, aspartame. \u003ci\u003e FLUIMUCIL MUCOLITIC 200 mg, granules for oral solution\u003c\/i\u003e One sachet contains: \u003cu\u003eActive ingredient\u003c\/u\u003e: N-acetylcysteine 200 mg. Excipients with known effects: sucrose, glucose, sunset yellow (E110), lactose. \u003ci\u003eFLUIMUCIL MUCOLITIC 200 mg, granules for oral solution without sugar\u003c\/i\u003e One sachet contains: \u003cu\u003eActive ingredient\u003c\/u\u003e: N-acetylcysteine 200 mg. Excipients with known effects: sorbitol, aspartame. \u003ci\u003eFLUIMUCIL MUCOLITIC 100 mg, granules for oral solution\u003c\/i\u003e One sachet contains: \u003cu\u003eActive ingredient\u003c\/u\u003e: N-acetylcysteine 100 mg. Excipients with known effects: sucrose, sunset yellow (E110).\u003ci\u003eFLUIMUCIL MUCOLITIC 100 mg, granules for oral solution without sugar\u003c\/i\u003e One sachet contains: \u003cu\u003eActive ingredient\u003c\/u\u003e: N-acetylcysteine 100 mg. Excipients with known effects: sorbitol, aspartame. \u003ci\u003eFLUIMUCIL MUCOLITIC 100 mg\/5 ml, syrup\u003c\/i\u003e A 150 ml bottle contains: \u003cu\u003eActive ingredient\u003c\/u\u003e: N-acetylcysteine 3,000 g (corresponding to 100 mg\/5 ml of syrup). Excipients with known effects: ethanol, methyl parahydroxybenzoate, propylene glycol, sodium benzoate, sodium. A 200 ml bottle contains: \u003cu\u003e Active ingredient\u003c\/u\u003e: N-acetylcysteine 4,000 g (corresponding to 100 mg\/5 ml of syrup). Excipients with known effects: ethanol, methyl parahydroxybenzoate, propylene glycol, sodium benzoate, sodium. For the full list of excipients, see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eFLUIMUCIL MUCOLITIC 600 mg granules for oral solution \u003c\/i\u003e Aspartame, Orange flavor (containing glucose and lactose), Sorbitol. \u003ci\u003eFLUIMUCIL MUCOLITIC 600 mg effervescent tablets \u003c\/i\u003e Anhydrous citric acid, Lemon flavor (containing glucose), Aspartame, Sodium bicarbonate. \u003ci\u003eFLUIMUCIL MUCOLITIC 600 mg\/15 ml syrup 200 ml bottle\u003c\/i\u003eMethyl parahydroxybenzoate, Propyl parahydroxybenzoate, Sodium edetate, Carmellose, Sodium saccharin, Grenadine flavoring (containing propylene glycol), Strawberry flavoring (containing propylene glycol), Sorbitol, Sodium hydroxide, Purified water. \u003ci\u003eFLUIMUCIL MUCOLITIC 200 mg buccal tablets\u003c\/i\u003e Anhydrous citric acid, sorbitol, mannitol, polyethylene glycol 6000, povidone, sodium bicarbonate, lemon flavouring, mandarin flavouring, aspartame, magnesium stearate, microcrystalline cellulose. \u003ci\u003eFLUIMUCIL MUCOLITIC 200 mg granules for oral solution without sugar \u003c\/i\u003e Sorbitol, aspartame, orange flavouring. \u003ci\u003eFLUIMUCIL MUCOLITIC 200 mg granules for oral solution\u003c\/i\u003eOrange juice granules; Orange flavor (containing glucose and lactose); saccharin; sunset yellow (E 110); Sucrose. \u003ci\u003eFLUIMUCIL MUCOLITIC 200 mg effervescent tablets\u003c\/i\u003e \u003ci\u003eAnhydrous citric acid, sodium bicarbonate, lemon flavouring, aspartame.\u003c\/i\u003e \u003ci\u003eFLUIMUCIL MUCOLITIC 100 mg granules for oral solution\u003c\/i\u003eOrange juice granules; Orange flavour; Saccharin; E 110; Sucrose. \u003ci\u003eFLUIMUCIL MUCOLITIC 100 mg granules for oral solution without sugar\u003c\/i\u003e Sorbitol; Aspartame; Orange flavour. \u003ci\u003eFLUIMUCIL MUCOLITIC 100 mg\/5 ml syrup 150 ml bottle\u003c\/i\u003e Methyl parahydroxybenzoate, sodium benzoate, sodium edetate, sodium carboxymethyl cellulose, raspberry flavor (containing propylene glycol and ethanol), sodium saccharinate, sodium hydroxide, purified water. \u003ci\u003eFLUIMUCIL MUCOLITIC 100 mg\/5 ml syrup 200 ml bottle\u003c\/i\u003e Methyl parahydroxybenzoate, sodium benzoate, sodium edetate, sodium carboxymethylcellulose, sodium cyclamate, sucralose, raspberry flavor (containing propylene glycol and ethanol), sodium saccharinate, sodium hydroxide, purified water.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to the active substance or to any of the excipients listed in paragraph 6.1. Children under 2 years of age. Pregnancy and breast-feeding (see section 4.6).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eAdults\u003c\/u\u003e: 1 sachet of Mucolytic Fluimucil 200 mg granules for oral solution (with or without sugar) or 2 sachets of Mucolytic Fluimucil 100 mg (with or without sugar) 2-3 times a day. Fluimucil Mucolytic 200 mg, buccal tablets and effervescent tablets: 1 tablet 2-3 times a day. Fluimucil Mucolytic 100 mg\/5 ml, syrup: 10 ml of syrup (1 measuring spoon), equal to 200 mg of N-acetylcysteine, 2-3 times a day. Fluimucil Mucolytic 600 mg\/15 ml syrup, Fluimucil Mucolytic 600 mg effervescent tablets and Fluimucil Mucolytic 600 mg granules for solution: a 15 ml measuring spoon or an effervescent tablet or a sachet (preferably in the evening). Any dosage adjustments may concern the frequency of administration or the fractionation of the dose but must in any case be included within the maximum daily dosage of 600 mg. \u003cu\u003eChildren over 2 years old\u003c\/u\u003e: Fluimucil Mucolytic 100 mg granules for oral solution (with or without sugar): 1 sachet 2 to 4 times a day, depending on age. Fluimucil Mucolytic 100 mg\/5 ml, syrup: ½ scoop of syrup (5 ml), equal to 100 mg of N-acetylcysteine, 2 to 4 times a day depending on age. The duration of therapy is 5 to 10 days. \u003cb\u003eMethod of administration\u003c\/b\u003e \u003cu\u003eGranules for oral solution\u003c\/u\u003e: dissolve the contents of a sachet in a glass containing a little water, mixing as needed with a teaspoon. This results in a pleasant solution that can be drunk directly from the glass or, in the case of small children, given in teaspoons or in a bottle. The solution should be taken as soon as it is ready. \u003cu\u003eOral soluble tablets\u003c\/u\u003e: keep the tablet in the oral cavity until it has completely dissolved. \u003cu\u003eSyrup\u003c\/u\u003e: shake before use. Once opened, the syrup is valid for 15 days. Effervescent tablets: dissolve one tablet in a glass containing a little water, mixing as needed with a teaspoon. To facilitate the release of the tablet, we recommend tearing open the blister, using the side notches as indicated in the figure.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSachets of 100 and 200 granules for oral solution, 600 mg granules for oral solution, 200 mg granules for oral solution without sugar and 200 mg buccal tablets: store at a temperature not exceeding 30°C.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003ePatients suffering from bronchial asthma must be closely monitored during therapy; if bronchospasm appears, treatment with N-acetylcysteine ​​must be immediately suspended and appropriate treatment must be started. Mucolytics can induce bronchial obstruction in children under 2 years of age. In fact, the drainage capacity of bronchial mucus is limited in this age group, due to the physiological characteristics of the respiratory tract. They should therefore not be used in children under 2 years of age (see section 4.3). The use of the medicine in patients suffering from peptic ulcers or with a history of peptic ulcers requires particular attention, especially in case of simultaneous intake of other drugs with a known gastro-injurious effect. The possible presence of a sulphurous odor does not indicate alteration of the preparation but is specific to the active ingredient contained in it. The administration of N-acetylcysteine, especially at the beginning of treatment, can fluidize bronchial secretions and increase their volume at the same time. If the patient is unable to expectorate effectively, postural drainage and bronchoaspiration should be used to avoid retention of secretions. N-acetylcysteine ​​can affect histamine metabolism. Therefore, caution should be used when administering Fluimucil Mucolytic to patients with histamine intolerance, as hypersensitivity symptoms may occur. \u003ci\u003e \u003cu\u003eImportant information about some excipients\u003c\/u\u003e \u003c\/i\u003e Sodium benzoate The 100 mg\/5 ml syrup (150 ml and 200 ml) contains 15 mg of sodium benzoate for the 10 ml dose and 7.5 mg for the 5 ml dose.\u003ci\u003eParahydroxybenzoates\u003c\/i\u003e Syrups contain parahydroxybenzoates which can cause delayed allergic reactions. \u003ci\u003eSorbitol\u003c\/i\u003e The buccal tablets, 600 mg\/15 ml syrup, 600 mg granules for oral solution and 100 mg and 200 mg sugar-free granules for oral solution contain sorbitol. The sorbitol content in oral medicinal products may modify the bioavailability of other co-administered oral medicinal products. Patients with hereditary fructose intolerance should not be given these medicines. \u003ci\u003eAspartame\u003c\/i\u003e The buccal tablets, effervescent tablets, granules for oral solution 600 mg and granules for sugar-free oral solution 100 and 200 mg contain aspartame, a source of phenylalanine which may be harmful in patients with phenylketonuria. \u003ci\u003eGlucose\u003c\/i\u003e The 600 mg effervescent tablets, the 600 mg granules for oral solution and the 200 mg granules for oral solution contain glucose, patients suffering from rare problems of glucose-galactose malabsorption should not take this medicine. \u003ci\u003eSunset yellow (E110)\u003c\/i\u003e The granules for oral solution 100 mg and 200 mg contain sunset yellow (E110) which may cause allergic reactions. \u003ci\u003eSucrose\u003c\/i\u003e The granules for oral solution 100 and 200 mg contain sucrose. Patients suffering from rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase isomaltase insufficiency should not take this medicine. \u003ci\u003eSodium\u003c\/i\u003e The buccal tablets contain 26.9 mg sodium per tablet equivalent to 1.3% of the WHO recommended maximum daily intake of 2 g sodium for an adult. The 200 mg and 600 mg effervescent tablets contain 156.9 mg sodium per dose, equivalent to 7.8% of the WHO recommended maximum daily intake of 2 g sodium for an adult. The 100 mg\/5 ml (150 ml) syrup contains 36.7 mg of sodium per 10 ml dose, equivalent to 1.83% of the WHO recommended maximum daily intake of 2 g of sodium for an adult. The 100 mg\/5 ml (150 ml) syrup contains 18.4 mg sodium per 5 ml dose, equivalent to 0.9% of the WHO recommended maximum daily intake of 2 g sodium for an adult. The 100 mg\/5 ml (200 ml) syrup contains 38.2 mg of sodium per 10 ml dose, equivalent to 1.9% of the WHO recommended maximum daily intake of 2 g of sodium for an adult. The 100 mg\/5 ml (200 ml) syrup contains 19.1 mg sodium per 5 ml dose, equivalent to 0.9% of the WHO recommended maximum daily intake of 2 g sodium for an adult. The 600 mg\/15 ml syrup contains 98.31 mg of sodium per 15 ml dose equivalent to 4.9% of the maximum daily intake recommended by the WHO which corresponds to 2 g of sodium for an adult. \u003ci\u003eLactose\u003c\/i\u003e The 600 mg granules for oral solution and the 200 mg granules for oral solution contain lactose. Patients suffering from rare hereditary problems of galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption should not take this medicine. \u003ci\u003ePropylene glycol\u003c\/i\u003e The 100 mg\/5 ml syrup (150 ml and 200 ml) contains 23.4 mg of propylene glycol for the 10 ml dose and 11.7 mg for the 5 ml dose. The 600 mg\/15 ml syrup contains 168 mg of propylene glycol per dose (15 ml) equivalent to 11.2 mg\/ml. \u003ci\u003eEthanol\u003c\/i\u003e The 100 mg\/5 ml syrup (150 ml and 200 ml) contains 3.85 mg of alcohol (ethanol) in every 100 ml. The dose quantity of this medicine is equivalent to less than 1 ml of beer or 1 ml of wine. The small amount of alcohol in this medicine will not produce any noticeable effects.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eDrug-drug interaction\u003c\/u\u003e. Antitussive drugs and mucolytic agents, such as N-acetylcysteine, should not be taken at the same time as the reduction of the cough reflex could lead to an accumulation of bronchial secretions. Activated charcoal can reduce the effect of N-acetylcysteine. It is advisable not to mix other drugs with the Fluimucil Mucolytic solution. The information available regarding the antibiotic-N-acetylcysteine ​​interaction refers to in vitro tests, in which the two substances were mixed, which showed a decreased activity of the antibiotic. However, as a precaution, it is recommended to take oral antibiotics at least two hours after the administration of N-acetylcysteine, excluding loracarbef. It has been shown that the simultaneous intake of nitroglycerin and N-acetylcysteine ​​causes significant hypotension and causes dilation of the temporal artery with the possible onset of headache. If the simultaneous administration of nitroglycerin and N-acetylcysteine ​​is necessary, patients should be monitored for the appearance of hypotension which can even be severe and alerted to the possible onset of headache. \u003cu\u003ePediatric population\u003c\/u\u003e Interaction studies have only been carried out in adults. \u003cu\u003eDrug-laboratory test interactions\u003c\/u\u003e N-acetylcysteine may cause interference with the colorimetric assay method for the determination of salicylates. N-acetylcysteine ​​may interfere with urine ketone testing.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eSafety profile summary\u003c\/u\u003e The adverse events most frequently associated with the oral administration of N-acetylcysteine ​​are gastrointestinal in nature. Less frequently, hypersensitivity reactions including anaphylactic shock, anaphylactic\/anaphylactoid reactions, bronchospasm, angioedema, rash and pruritus have been reported. \u003cu\u003eTabular list of adverse reactions\u003c\/u\u003e The following table shows the adverse reactions listed according to the classification and frequency system: very common (≥ 1\/10), common (≥ 1\/100 to \u003c 1\/10), uncommon (≥ 1\/1,000 to \u003c 1\/100), rare (≥ 1\/10,000 to \u003c 1\/1,000), very rare (\u003c 1\/10,000) and not known (the frequency cannot be established on the basis of available data). Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.\u003c\/p\u003e\n\u003cp\u003eSystem organ class - Adverse reactions: Uncommon (≥1\/1,000; \u003c1\/100). Rare (≥1\/10,000; \u003c1\/1,000). Very rare (\u003c1\/10,000). Not known.\u003c\/p\u003e\n\u003cp\u003eImmune system disorders - Adverse reactions: Hypersensitivity. Anaphylactic shock, anaphylactic\/anaphylactoid reaction.\u003c\/p\u003e\n\u003cp\u003eNervous system disorders - Adverse reactions: Headache.\u003c\/p\u003e\n\u003cp\u003eEar and labyrinth disorders - Adverse reactions: Tinnitus.\u003c\/p\u003e\n\u003cp\u003eCardiac disorders - Adverse reactions: Tachycardia.\u003c\/p\u003e\n\u003cp\u003eVascular disorders - Haemorrhage.\u003c\/p\u003e\n\u003cp\u003eRespiratory, thoracic and mediastinal disorders - Bronchospasm, dyspnoea. Bronchial obstruction.\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders - Adverse reactions: Vomiting, diarrhea, stomatitis, abdominal pain, nausea. Dyspepsia.\u003c\/p\u003e\n\u003cp\u003eSkin and subcutaneous tissue disorders - Adverse reactions: Urticaria, rash, angioedema, pruritus.\u003c\/p\u003e\n\u003cp\u003eSystemic disorders and conditions relating to the administration site - Adverse reactions: Pyrexia. Edema of the face.\u003c\/p\u003e\n\u003cp\u003eDiagnostic tests - Adverse reactions: Reduced blood pressure.\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eDescription of some adverse reactions\u003c\/u\u003e In very rare cases, the appearance of serious skin reactions has occurred in temporal connection with the intake of N-acetylcysteine, such as Stevens-Johnson syndrome and Lyell syndrome. Although in most cases at least one other suspected drug has been identified which is more likely involved in the genesis of the aforementioned mucocutaneous syndromes, in case of mucocutaneous alterations it is advisable to contact your doctor and the intake of N-acetylcysteine ​​must be stopped immediately. Some studies have confirmed a reduction in platelet aggregation when taking N-acetylcysteine. The clinical significance of these findings has not yet been defined. \u003ci\u003eReporting of suspected adverse reactions\u003c\/i\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo cases of overdose have been found with oral administration of N-acetylcysteine. Healthy volunteers, who took a daily dose of 11.6 g of N-acetylcysteine ​​for three months, did not experience serious adverse reactions. Doses up to 500 mg NAC\/kg body weight, administered orally, were tolerated without any symptoms of intoxication. \u003ci\u003eSymptoms\u003c\/i\u003e Overdose can cause gastrointestinal symptoms such as nausea, vomiting and diarrhea. \u003ci\u003eTreatment\u003c\/i\u003e There are no specific antidotal treatments; Overdose therapy is based on symptomatic treatment.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAlthough the teratological studies conducted with Fluimucil Mucolytic on animals have not shown any teratogenic effect, however, as with other drugs, its administration during pregnancy and during the period of breastfeeding with breast milk should only be carried out in case of actual need.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eN-acetylcysteine does not influence the ability to drive and use machines.\u003c\/p\u003e","brand":"Zambon","offers":[{"title":"Default Title","offer_id":40723405013107,"sku":"034936157","price":12.09,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/products\/zambon-italia-srl-fluimucil-mucolitico-sciroppo-espettorante-600-mg-15-ml-farmacia-dottor-tili-1213792518.png?v=1767131129"},{"product_id":"fluimucil-mucolitico-200-mg-30-bustine-granulato-senza-zucchero","title":"Fluimucil Mucolitico 200 mg 30 Sachets Sugar-free Granules","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eTreatment of respiratory diseases characterized by dense and viscous hypersecretion.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eFLUIMUCIL MUCOLITIC 600 mg effervescent tablets\u003c\/i\u003e Each tablet contains: \u003cu\u003eActive ingredient\u003c\/u\u003e: N-acetylcysteine 600 mg. Excipients with known effects: aspartame, glucose, sodium. \u003ci\u003eFLUIMUCIL MUCOLITIC 600 mg granules for oral solution \u003c\/i\u003e Each sachet contains: \u003cu\u003eActive ingredient\u003c\/u\u003e: N-acetylcysteine 600 mg. Excipients with known effects: aspartame, glucose, lactose, sorbitol. \u003ci\u003eFLUIMUCIL MUCOLITIC 600 mg\/15 ml syrup\u003c\/i\u003e 15 ml of syrup contains: \u003cu\u003eActive ingredient\u003c\/u\u003e: N-acetylcysteine 600 mg. Excipients with known effects: propylene glycol, methyl parahydroxybenzoate, propyl parahydroxybenzoate, sodium, sorbitol. \u003ci\u003eFLUIMUCIL MUCOLITIC 200 mg, effervescent tablets\u003c\/i\u003e One tablet contains: \u003cu\u003eActive ingredient\u003c\/u\u003e: N-acetylcysteine 200 mg. Excipients with known effects: sodium, aspartame. \u003ci\u003eFLUIMUCIL MUCOLITIC 200 mg, buccal tablets:\u003c\/i\u003e One tablet contains: \u003cu\u003eActive ingredient\u003c\/u\u003e: N-acetylcysteine 200 mg. Excipients with known effects: sorbitol, sodium, aspartame. \u003ci\u003e FLUIMUCIL MUCOLITIC 200 mg, granules for oral solution\u003c\/i\u003e One sachet contains: \u003cu\u003eActive ingredient\u003c\/u\u003e: N-acetylcysteine 200 mg. Excipients with known effects: sucrose, glucose, sunset yellow (E110), lactose. \u003ci\u003eFLUIMUCIL MUCOLITIC 200 mg, granules for oral solution without sugar\u003c\/i\u003e One sachet contains: \u003cu\u003eActive ingredient\u003c\/u\u003e: N-acetylcysteine 200 mg. Excipients with known effects: sorbitol, aspartame. \u003ci\u003eFLUIMUCIL MUCOLITIC 100 mg, granules for oral solution\u003c\/i\u003e One sachet contains: \u003cu\u003eActive ingredient\u003c\/u\u003e: N-acetylcysteine 100 mg. Excipients with known effects: sucrose, sunset yellow (E110).\u003ci\u003eFLUIMUCIL MUCOLITIC 100 mg, granules for oral solution without sugar\u003c\/i\u003e One sachet contains: \u003cu\u003eActive ingredient\u003c\/u\u003e: N-acetylcysteine 100 mg. Excipients with known effects: sorbitol, aspartame. \u003ci\u003eFLUIMUCIL MUCOLITIC 100 mg\/5 ml, syrup\u003c\/i\u003e A 150 ml bottle contains: \u003cu\u003eActive ingredient\u003c\/u\u003e: N-acetylcysteine 3,000 g (corresponding to 100 mg\/5 ml of syrup). Excipients with known effects: ethanol, methyl parahydroxybenzoate, propylene glycol, sodium benzoate, sodium. A 200 ml bottle contains: \u003cu\u003e Active ingredient\u003c\/u\u003e: N-acetylcysteine 4,000 g (corresponding to 100 mg\/5 ml of syrup). Excipients with known effects: ethanol, methyl parahydroxybenzoate, propylene glycol, sodium benzoate, sodium. For the full list of excipients, see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eFLUIMUCIL MUCOLITIC 600 mg granules for oral solution \u003c\/i\u003e Aspartame, Orange flavor (containing glucose and lactose), Sorbitol. \u003ci\u003eFLUIMUCIL MUCOLITIC 600 mg effervescent tablets \u003c\/i\u003e Anhydrous citric acid, Lemon flavor (containing glucose), Aspartame, Sodium bicarbonate. \u003ci\u003eFLUIMUCIL MUCOLITIC 600 mg\/15 ml syrup 200 ml bottle\u003c\/i\u003eMethyl parahydroxybenzoate, Propyl parahydroxybenzoate, Sodium edetate, Carmellose, Sodium saccharin, Grenadine flavoring (containing propylene glycol), Strawberry flavoring (containing propylene glycol), Sorbitol, Sodium hydroxide, Purified water. \u003ci\u003eFLUIMUCIL MUCOLITIC 200 mg buccal tablets\u003c\/i\u003e Anhydrous citric acid, sorbitol, mannitol, polyethylene glycol 6000, povidone, sodium bicarbonate, lemon flavouring, mandarin flavouring, aspartame, magnesium stearate, microcrystalline cellulose. \u003ci\u003eFLUIMUCIL MUCOLITIC 200 mg granules for oral solution without sugar \u003c\/i\u003e Sorbitol, aspartame, orange flavouring. \u003ci\u003eFLUIMUCIL MUCOLITIC 200 mg granules for oral solution\u003c\/i\u003eOrange juice granules; Orange flavor (containing glucose and lactose); saccharin; sunset yellow (E 110); Sucrose. \u003ci\u003eFLUIMUCIL MUCOLITIC 200 mg effervescent tablets\u003c\/i\u003e \u003ci\u003eAnhydrous citric acid, sodium bicarbonate, lemon flavouring, aspartame.\u003c\/i\u003e \u003ci\u003eFLUIMUCIL MUCOLITIC 100 mg granules for oral solution\u003c\/i\u003eOrange juice granules; Orange flavour; Saccharin; E 110; Sucrose. \u003ci\u003eFLUIMUCIL MUCOLITIC 100 mg granules for oral solution without sugar\u003c\/i\u003e Sorbitol; Aspartame; Orange flavour. \u003ci\u003eFLUIMUCIL MUCOLITIC 100 mg\/5 ml syrup 150 ml bottle\u003c\/i\u003e Methyl parahydroxybenzoate, sodium benzoate, sodium edetate, sodium carboxymethyl cellulose, raspberry flavor (containing propylene glycol and ethanol), sodium saccharinate, sodium hydroxide, purified water. \u003ci\u003eFLUIMUCIL MUCOLITIC 100 mg\/5 ml syrup 200 ml bottle\u003c\/i\u003e Methyl parahydroxybenzoate, sodium benzoate, sodium edetate, sodium carboxymethylcellulose, sodium cyclamate, sucralose, raspberry flavor (containing propylene glycol and ethanol), sodium saccharinate, sodium hydroxide, purified water.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to the active substance or to any of the excipients listed in paragraph 6.1. Children under 2 years of age. Pregnancy and breast-feeding (see section 4.6).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eAdults\u003c\/u\u003e: 1 sachet of Mucolytic Fluimucil 200 mg granules for oral solution (with or without sugar) or 2 sachets of Mucolytic Fluimucil 100 mg (with or without sugar) 2-3 times a day. Fluimucil Mucolytic 200 mg, buccal tablets and effervescent tablets: 1 tablet 2-3 times a day. Fluimucil Mucolytic 100 mg\/5 ml, syrup: 10 ml of syrup (1 measuring spoon), equal to 200 mg of N-acetylcysteine, 2-3 times a day. Fluimucil Mucolytic 600 mg\/15 ml syrup, Fluimucil Mucolytic 600 mg effervescent tablets and Fluimucil Mucolytic 600 mg granules for solution: a 15 ml measuring spoon or an effervescent tablet or a sachet (preferably in the evening). Any dosage adjustments may concern the frequency of administration or the fractionation of the dose but must in any case be included within the maximum daily dosage of 600 mg. \u003cu\u003eChildren over 2 years old\u003c\/u\u003e: Fluimucil Mucolytic 100 mg granules for oral solution (with or without sugar): 1 sachet 2 to 4 times a day, depending on age. Fluimucil Mucolytic 100 mg\/5 ml, syrup: ½ scoop of syrup (5 ml), equal to 100 mg of N-acetylcysteine, 2 to 4 times a day depending on age. The duration of therapy is 5 to 10 days. \u003cb\u003eMethod of administration\u003c\/b\u003e \u003cu\u003eGranules for oral solution\u003c\/u\u003e: dissolve the contents of a sachet in a glass containing a little water, mixing as needed with a teaspoon. This results in a pleasant solution that can be drunk directly from the glass or, in the case of small children, given in teaspoons or in a bottle. The solution should be taken as soon as it is ready. \u003cu\u003eOral soluble tablets\u003c\/u\u003e: keep the tablet in the oral cavity until it has completely dissolved. \u003cu\u003eSyrup\u003c\/u\u003e: shake before use. Once opened, the syrup is valid for 15 days. Effervescent tablets: dissolve one tablet in a glass containing a little water, mixing as needed with a teaspoon. To facilitate the release of the tablet, we recommend tearing open the blister, using the side notches as indicated in the figure.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSachets of 100 and 200 granules for oral solution, 600 mg granules for oral solution, 200 mg granules for oral solution without sugar and 200 mg buccal tablets: store at a temperature not exceeding 30°C.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003ePatients suffering from bronchial asthma must be closely monitored during therapy; if bronchospasm appears, treatment with N-acetylcysteine ​​must be immediately suspended and appropriate treatment must be started. Mucolytics can induce bronchial obstruction in children under 2 years of age. In fact, the drainage capacity of bronchial mucus is limited in this age group, due to the physiological characteristics of the respiratory tract. They should therefore not be used in children under 2 years of age (see section 4.3). The use of the medicine in patients suffering from peptic ulcers or with a history of peptic ulcers requires particular attention, especially in case of simultaneous intake of other drugs with a known gastro-injurious effect. The possible presence of a sulphurous odor does not indicate alteration of the preparation but is specific to the active ingredient contained in it. The administration of N-acetylcysteine, especially at the beginning of treatment, can fluidize bronchial secretions and increase their volume at the same time. If the patient is unable to expectorate effectively, postural drainage and bronchoaspiration should be used to avoid retention of secretions. N-acetylcysteine ​​can affect histamine metabolism. Therefore, caution should be used when administering Fluimucil Mucolytic to patients with histamine intolerance, as hypersensitivity symptoms may occur. \u003ci\u003e \u003cu\u003eImportant information about some excipients\u003c\/u\u003e \u003c\/i\u003e Sodium benzoate The 100 mg\/5 ml syrup (150 ml and 200 ml) contains 15 mg of sodium benzoate for the 10 ml dose and 7.5 mg for the 5 ml dose.\u003ci\u003eParahydroxybenzoates\u003c\/i\u003e Syrups contain parahydroxybenzoates which can cause delayed allergic reactions. \u003ci\u003eSorbitol\u003c\/i\u003e The buccal tablets, 600 mg\/15 ml syrup, 600 mg granules for oral solution and 100 mg and 200 mg sugar-free granules for oral solution contain sorbitol. The sorbitol content in oral medicinal products may modify the bioavailability of other co-administered oral medicinal products. Patients with hereditary fructose intolerance should not be given these medicines. \u003ci\u003eAspartame\u003c\/i\u003e The buccal tablets, effervescent tablets, granules for oral solution 600 mg and granules for sugar-free oral solution 100 and 200 mg contain aspartame, a source of phenylalanine which may be harmful in patients with phenylketonuria. \u003ci\u003eGlucose\u003c\/i\u003e The 600 mg effervescent tablets, the 600 mg granules for oral solution and the 200 mg granules for oral solution contain glucose, patients suffering from rare problems of glucose-galactose malabsorption should not take this medicine. \u003ci\u003eSunset yellow (E110)\u003c\/i\u003e The granules for oral solution 100 mg and 200 mg contain sunset yellow (E110) which may cause allergic reactions. \u003ci\u003eSucrose\u003c\/i\u003e The granules for oral solution 100 and 200 mg contain sucrose. Patients suffering from rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase isomaltase insufficiency should not take this medicine. \u003ci\u003eSodium\u003c\/i\u003e The buccal tablets contain 26.9 mg sodium per tablet equivalent to 1.3% of the WHO recommended maximum daily intake of 2 g sodium for an adult. The 200 mg and 600 mg effervescent tablets contain 156.9 mg sodium per dose, equivalent to 7.8% of the WHO recommended maximum daily intake of 2 g sodium for an adult. The 100 mg\/5 ml (150 ml) syrup contains 36.7 mg of sodium per 10 ml dose, equivalent to 1.83% of the WHO recommended maximum daily intake of 2 g of sodium for an adult. The 100 mg\/5 ml (150 ml) syrup contains 18.4 mg sodium per 5 ml dose, equivalent to 0.9% of the WHO recommended maximum daily intake of 2 g sodium for an adult. The 100 mg\/5 ml (200 ml) syrup contains 38.2 mg of sodium per 10 ml dose, equivalent to 1.9% of the WHO recommended maximum daily intake of 2 g of sodium for an adult. The 100 mg\/5 ml (200 ml) syrup contains 19.1 mg sodium per 5 ml dose, equivalent to 0.9% of the WHO recommended maximum daily intake of 2 g sodium for an adult. The 600 mg\/15 ml syrup contains 98.31 mg of sodium per 15 ml dose equivalent to 4.9% of the maximum daily intake recommended by the WHO which corresponds to 2 g of sodium for an adult. \u003ci\u003eLactose\u003c\/i\u003e The 600 mg granules for oral solution and the 200 mg granules for oral solution contain lactose. Patients suffering from rare hereditary problems of galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption should not take this medicine. \u003ci\u003ePropylene glycol\u003c\/i\u003e The 100 mg\/5 ml syrup (150 ml and 200 ml) contains 23.4 mg of propylene glycol for the 10 ml dose and 11.7 mg for the 5 ml dose. The 600 mg\/15 ml syrup contains 168 mg of propylene glycol per dose (15 ml) equivalent to 11.2 mg\/ml. \u003ci\u003eEthanol\u003c\/i\u003e The 100 mg\/5 ml syrup (150 ml and 200 ml) contains 3.85 mg of alcohol (ethanol) in every 100 ml. The dose quantity of this medicine is equivalent to less than 1 ml of beer or 1 ml of wine. The small amount of alcohol in this medicine will not produce any noticeable effects.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eDrug-drug interaction\u003c\/u\u003e. Antitussive drugs and mucolytic agents, such as N-acetylcysteine, should not be taken at the same time as the reduction of the cough reflex could lead to an accumulation of bronchial secretions. Activated charcoal can reduce the effect of N-acetylcysteine. It is advisable not to mix other drugs with the Fluimucil Mucolytic solution. The information available regarding the antibiotic-N-acetylcysteine ​​interaction refers to in vitro tests, in which the two substances were mixed, which showed a decreased activity of the antibiotic. However, as a precaution, it is recommended to take oral antibiotics at least two hours after the administration of N-acetylcysteine, excluding loracarbef. It has been shown that the simultaneous intake of nitroglycerin and N-acetylcysteine ​​causes significant hypotension and causes dilation of the temporal artery with the possible onset of headache. If the simultaneous administration of nitroglycerin and N-acetylcysteine ​​is necessary, patients should be monitored for the appearance of hypotension which can even be severe and alerted to the possible onset of headache. \u003cu\u003ePediatric population\u003c\/u\u003e Interaction studies have only been carried out in adults. \u003cu\u003eDrug-laboratory test interactions\u003c\/u\u003e N-acetylcysteine may cause interference with the colorimetric assay method for the determination of salicylates. N-acetylcysteine ​​may interfere with urine ketone testing.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eSafety profile summary\u003c\/u\u003e The adverse events most frequently associated with the oral administration of N-acetylcysteine ​​are gastrointestinal in nature. Less frequently, hypersensitivity reactions including anaphylactic shock, anaphylactic\/anaphylactoid reactions, bronchospasm, angioedema, rash and pruritus have been reported. \u003cu\u003eTabular list of adverse reactions\u003c\/u\u003e The following table shows the adverse reactions listed according to the classification and frequency system: very common (≥ 1\/10), common (≥ 1\/100 to \u003c 1\/10), uncommon (≥ 1\/1,000 to \u003c 1\/100), rare (≥ 1\/10,000 to \u003c 1\/1,000), very rare (\u003c 1\/10,000) and not known (the frequency cannot be established on the basis of available data). Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.\u003c\/p\u003e\n\u003cp\u003eSystem organ class - Adverse reactions: Uncommon (≥1\/1,000; \u003c1\/100). Rare (≥1\/10,000; \u003c1\/1,000). Very rare (\u003c1\/10,000). Not known.\u003c\/p\u003e\n\u003cp\u003eImmune system disorders - Adverse reactions: Hypersensitivity. Anaphylactic shock, anaphylactic\/anaphylactoid reaction.\u003c\/p\u003e\n\u003cp\u003eNervous system disorders - Adverse reactions: Headache.\u003c\/p\u003e\n\u003cp\u003eEar and labyrinth disorders - Adverse reactions: Tinnitus.\u003c\/p\u003e\n\u003cp\u003eCardiac disorders - Adverse reactions: Tachycardia.\u003c\/p\u003e\n\u003cp\u003eVascular disorders - Haemorrhage.\u003c\/p\u003e\n\u003cp\u003eRespiratory, thoracic and mediastinal disorders - Bronchospasm, dyspnoea. Bronchial obstruction.\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders - Adverse reactions: Vomiting, diarrhea, stomatitis, abdominal pain, nausea. Dyspepsia.\u003c\/p\u003e\n\u003cp\u003eSkin and subcutaneous tissue disorders - Adverse reactions: Urticaria, rash, angioedema, pruritus.\u003c\/p\u003e\n\u003cp\u003eSystemic disorders and conditions relating to the administration site - Adverse reactions: Pyrexia. Edema of the face.\u003c\/p\u003e\n\u003cp\u003eDiagnostic tests - Adverse reactions: Reduced blood pressure.\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eDescription of some adverse reactions\u003c\/u\u003e In very rare cases, the appearance of serious skin reactions has occurred in temporal connection with the intake of N-acetylcysteine, such as Stevens-Johnson syndrome and Lyell syndrome. Although in most cases at least one other suspected drug has been identified which is more likely involved in the genesis of the aforementioned mucocutaneous syndromes, in case of mucocutaneous alterations it is advisable to contact your doctor and the intake of N-acetylcysteine ​​must be stopped immediately. Some studies have confirmed a reduction in platelet aggregation when taking N-acetylcysteine. The clinical significance of these findings has not yet been defined. \u003ci\u003eReporting of suspected adverse reactions\u003c\/i\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo cases of overdose have been found with oral administration of N-acetylcysteine. Healthy volunteers, who took a daily dose of 11.6 g of N-acetylcysteine ​​for three months, did not experience serious adverse reactions. Doses up to 500 mg NAC\/kg body weight, administered orally, were tolerated without any symptoms of intoxication. \u003ci\u003eSymptoms\u003c\/i\u003e Overdose can cause gastrointestinal symptoms such as nausea, vomiting and diarrhea. \u003ci\u003eTreatment\u003c\/i\u003e There are no specific antidotal treatments; Overdose therapy is based on symptomatic treatment.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAlthough the teratological studies conducted with Fluimucil Mucolytic on animals have not shown any teratogenic effect, however, as with other drugs, its administration during pregnancy and during the period of breastfeeding with breast milk should only be carried out in case of actual need.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eN-acetylcysteine does not influence the ability to drive and use machines.\u003c\/p\u003e","brand":"Zambon","offers":[{"title":"Default Title","offer_id":40731897430131,"sku":"034936106","price":11.63,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/zambon-italia-srl-fluimucil-mucolitico-200-mg-30-bustine-granulato-senza-zucchero-farmacia-dottor-tili-1213792517.webp?v=1767131148"}],"url":"https:\/\/www.dottortili.com\/en-eu\/collections\/farmaci.oembed?page=24","provider":"Farmacia Dottor Tili","version":"1.0","type":"link"}